METHODS OF USING BISPECIFIC ANTIGEN-BINDING CONSTRUCTS TARGETING HER2

Abstract

Described herein methods of using antigen-binding constructs to treat HER2+ tumors in a subject such as breast, lung, or head and neck tumors. In some aspects, the tumor volume in the subject after receiving at least seven doses of the antigen binding construct is less than the tumor volume of a control subject receiving an equivalent amount of trastuzumab. In some aspects, the survival of the subject receiving the antigen binding construct is increased as compared to a control subject receiving an equivalent amount of a non-specific control antibody or as compared to a control subject not receiving treatment.

Description

CROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of PCT/CA2014/051140, filed Nov. 27, 2014, and 62/166,844, filed May 27, 2015; each of which is herein incorporated by reference, in its entirety, for all purposes.

SEQUENCE LISTING

[0002] The instant application contains a Sequence Listing which will be submitted via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Nov. 24, 2015, is named 32565PCT_sequencelisting.txt, and is 275,091 bytes in size.

BACKGROUND

[0003] The majority of current marketed antibody therapeutics are bivalent monospecific antibodies optimized and selected for high affinity binding and avidity conferred by the two antigen-binding domains. Afucosylation or enhancement of FcgR binding by mutagenesis have been employed to render antibodies more efficacious via antibody Fc dependent cell cytotoxicity mechanisms. Afucyosylated antibodies or antibodies with enhanced FcgR binding still suffer from incomplete therapeutic efficacy in clinical testing and marketed drug status has yet to be achieved for any of these antibodies. Typical bivalent antibodies conjugated to toxins (antibody drug conjugates) are more efficacious but broader clinical utility is limited by dose-limiting toxicity.

[0004] Therapeutic antibodies would ideally possess certain minimal characteristics, including target specificity, biostability, bioavailability and biodistribution following administration to a subject patient, and sufficient target binding affinity and high target occupancy to maximize antibody dependent therapeutic effects. Typically therapeutic antibodies are monospecific. Monospecific targeting however does not address other target epitopes that may be relevant in signaling and disease pathogenesis, allowing for drug resistance and escape mechanism. Some of the current therapeutic paradigms call for the use of combination of two therapeutic monospecific antibodies targeting two different epitopes of the same target antigen. One example is the use of a combination of Trastuzumab and Pertuzumab, both targeting the HER2 receptor protein on the surface of some cancer cells, but patients still progress with disease while others with lower HER2 receptor levels (HER2 <3+ by Hercept test) show no therapeutic benefit. Therapeutic antibodies targeting HER2 are disclosed in WO 2012/143523 to GenMab and WO 2009/154651 to Genentech. Antibodies are also described in WO 2009/068625 and WO 2009/068631.

[0005] Co-owned patent application number PCT/CA2014/051140 describes HER2 antibodies. Co-owned patent application number PCT/US2014/037401 (WO 2014/182970) describes HER2 antibodies. Co-owned patent application number PCT/CA2013/050358 (WO 2013/166604) describes single arm monovalent antibodies. Co-owned patent applications PCT/CA2011/001238, filed Nov. 4, 2011, PCT/CA2012/050780, filed Nov. 2, 2012, PCT/CA2013/00471, filed May 10, 2013, and PCT/CA2013/050358, filed May 8, 2013 describe therapeutic antibodies. Each is hereby incorporated by reference in their entirety for all purposes.

SUMMARY

[0006] Described herein are methods of using one or more antigen-binding constructs to treat tumors in a subject, e.g., such as gastric, pancreatic, breast, lung, or head and neck tumors. The one or more antigen-binding constructs can comprise a first antigen-binding polypeptide construct which monovalently and specifically binds a HER2 (human epidermal growth factor receptor 2) ECD2 (extracellular domain 2) antigen on a HER2-expressing cell and a second antigen-binding polypeptide construct which monovalently and specifically binds a HER2 ECD4 (extracellular domain 4) antigen on a HER2-expressing cell, first and second linker polypeptides, wherein the first linker polypeptide is operably linked to the first antigen-binding polypeptide construct, and the second linker polypeptide is operably linked to the second antigen-binding polypeptide construct; wherein the linker polypeptides are capable of forming a covalent linkage with each other, wherein at least one of the ECD2- or the ECD4-binding polypeptide constructs is an scFv. In certain embodiments, the ECD2-binding polypeptide construct is an scFv, and the ECD2-binding polypeptide construct is a Fab. In certain embodiments, the ECD2-binding polypeptide construct is a Fab and the ECD4 binding polypeptide construct is an scFv. In some embodiments, both the ECD2- and ECD4-binding polypeptide constructs are scFvs. In some embodiments, the antigen-binding constructs have a dimeric Fc comprising a CH3 sequence. In some embodiments, the Fc is a heterodimer having one or more modifications in the CH3 sequence that promote the formation of a heterodimer with stability comparable to a wild-type homodimeric Fc. In some embodiments, the heterodimeric CH3 sequence has a melting temperature (Tm) of 68.degree. C. or higher.

BRIEF DESCRIPTION OF THE DRAWINGS

[0007] FIG. 1A depicts the structure of a biparatopic antibody in a Fab-Fab format. FIGS. 1B to 1E depict the structure of possible versions of a biparatopic antibody in an scFv-Fab format. In FIG. 1B, antigen-binding domain 1 is an scFv, fused to Chain A, while antigen-binding domain 2 is a Fab, fused to Chain B. In FIG. 1C, antigen-binding domain 1 is a Fab, fused to Chain A, while antigen-binding domain 2 is an scFv, fused to Chain B. In FIG. 1D, antigen-binding domain 2 is a Fab, fused to Chain A, while antigen-binding domain 1 is an scFv, fused to Chain B. In FIG. 1E, antigen-binding domain 2 is an scFv, fused to Chain A, while antigen-binding domain 1 is a Fab, fused to Chain B. In FIG. 1F, both antigen-binding domains are scFvs.

[0008] FIG. 2 depicts the characterization of expression and purification of exemplary anti-HER2 biparatopic antibodies. FIG. 2A and FIG. 2B depict the SEC chromatograph of the protein A purified antibody, and non-reducing SDS-PAGE analysis of 10 L expression and purification of v5019. FIG. 2C depicts the SDS-PAGE analysis of a 25 L expression and purification of v10000.

[0009] FIG. 3 depicts the results of UPLC-SEC analysis of exemplary anti-HER2 biparatopic antibodies purified by protein A and SEC. FIG. 3A shows the results for v5019, where the upper panel shows the results of the purification and the lower panel shows the same result with an expanded scale for the y-axis. A summary of the data obtained is provided below the UPLC-SEC results. FIG. 3B shows the results for v10000.

[0010] FIG. 4 depicts LCMS analysis of the heterodimer purity of exemplary anti-HER2 biparatopic antibodies. FIG. 4A depicts results from LC-MS analysis of the pooled SEC fractions of v5019. FIG. 4B depicts the results from LC-MS analysis of the pooled protein A fractions of v10000.

[0011] FIG. 5 depicts analysis of a 25 L-scale preparation of an exemplary anti-HER2 biparatopic antibody. FIG. 5A depicts the SDS-PAGE profile of an exemplary anti-HER2 biparatopic following MabSelect.TM. and HiTrap.TM. SP FF purification. FIG. 5B depicts LCMS analysis of the purified antibody.

[0012] FIG. 6 compares the ability of an exemplary biparatopic anti-HER2 antibodies to bind to HER2+ whole cells displaying different HER2 receptor density compared to control antibodies, as measured by FACS. FIG. 6A and FIG. 6E depict binding to SKOV3 cells;

[0013] FIG. 6B depicts binding to JIMT1 cells; FIG. 6C and FIG. 6F depict binding to MCF7 cells; FIG. 6D depicts binding to MDA-MB-231 cells; and FIG. 6G depicts binding to WI-38 cells.

[0014] FIG. 7 depicts the ability of exemplary anti-HER2 biparatopic antibodies to inhibit the growth of HER2+ cells. FIG. 7A and FIG. 7D shows growth inhibition in SKOV3 cells; FIG. 7B shows growth inhibition in BT-474 cells; FIG. 7C shows growth inhibition in SKBR3 cells, and FIG. 7E shows growth inhibition in JIMT-1 cells.

[0015] FIG. 8 depicts the SPR binding data relating to the paratopes of an exemplary anti-HER2 biparatopic antibodies. FIG. 8A illustrates the K.sub.D values (nM) of a monovalent anti-Her2 antibody (v1040; representing the antigen-binding domain on CH--B of exemplary anti-Her2 biparatopic antibody), for binding to immobilized Her2 ECD or dimeric Her2-Fc. FIG. 8B illustrates the K.sub.D values (nM) of a monovalent anti-Her2 antibody (v4182; representing the antigen-binding domain on CH-A of exemplary anti-Her2 biparatopic antibody) for binding to immobilized Her2 ECD or dimeric Her2-Fc.

[0016] FIG. 9 depicts the ability of exemplary anti-HER2 biparatopic antibody to internalize in HER2+ cells. FIG. 9A depicts internalization in BT-474 cells, while FIG. 9b depicts internalization in JIMT-1 cells.

[0017] FIG. 10 depicts surface binding and internalization of exemplary anti-HER2 biparatopic antibodies. FIG. 10A (v5019) depicts the result in BT-474 cells; FIG. 10B (v5019) and FIG. 10F (v5019 and v10000) depict the result in JIMT1 cells; FIG. 10C (v5019) and FIG. 10E (v5019 and v10000) depict the result in SKOV3 cells, and FIG. 10D (v5019) depicts the result in MCF7 cells.

[0018] FIG. 11 depicts the ability of an exemplary anti-HER2 biparatopic antibody to mediate ADCC in SKOV3 cells. In FIG. 11A, the assay was carried out using an effector to target cell ratio of 5:1; in FIG. 11B, the assay was carried out using an effector to target cell ratio of 3:1; and in FIG. 11C, the assay was carried out using an effector to target cell ratio of 1.1.

[0019] FIG. 12 depicts the characterization of affinity and binding kinetics of monovalent anti-HER2 (v630 and v4182) and an exemplary biparatopic anti-Her2 antibody (v5019) to recombinant human HER2. FIG. 12A shows the measurement of ka (1/Ms). FIG. 12B shows the measurement of kd (1/s). FIG. 12C shows the measurement of K.sub.D (M).

[0020] FIG. 13 depicts affinity and binding characteristics of an exemplary biparatopic anti-HER2 antibody to recombinant human HER2 over a range of antibody capture levels. FIG. 13A depicts the measurement of kd (1/s) to HER2 ECD determined over a range of antibody capture levels for exemplary biparatopic anti-Her2 antibody (v5019). FIG. 13B depicts the measurement of kd (1/s) to HER2 ECD determined over a range of antibody capture levels for monovalent anti-Her2 antibody (v4182). FIG. 13C depicts the measurement of kd (1/s) to HER2 ECD determined over a range of antibody capture levels for monovalent anti-Her2 antibody (v630).

[0021] FIG. 14 shows a comparison of the mechanism of binding of a monospecific anti-ECD4 HER2 antibody (left), and a Fab-scFv biparatopic anti-ECD2.times.ECD4 HER2 antibody (right). The monospecific anti-ECD4 HER2 antibody is capable of binding one antibody molecule to two HER2 molecules; whereas the biparatopic anti-ECD2.times.ECD4 HER2 antibody is capable of binding one antibody to two HER2 molecule, as well as 2 antibodies to one HER2 molecule and combinations therein which results in HER2 receptor cross-linking and lattice formation followed by downstream biological effects such as internalization and/or growth inhibition as indicated by the arrows. IEC represents "immune effector cells." The four extracellular domains of HER2 are numbered as 1, 2, 3, or 4 where 1=ECD1, 2=ECD2, 3=ECD3, and 4=ECD4.

[0022] FIG. 15 depicts the effect of an exemplary anti-HER2 biparatopic antibody on AKT phosphorylation in BT-474 cells.

[0023] FIG. 16 depicts the effect of an exemplary anti-HER2 biparatopic antibody on cardiomyocyte viability. FIG. 16A depicts the effect of v5019 and the corresponding ADC v6363 on cardiomyocyte viability; FIG. 16B depicts the effect of v5019, v7091, and v10000 and corresponding ADCs v6363, 7148, 10553 on cardiomyocyte viability, and FIG. 16C depicts the effect of v5019, v7091, and v10000 and corresponding ADCs v6363, 7148, 10553 on the viability of doxorubicin-pretreated cardiomyocytes.

[0024] FIG. 17 depicts the ability of exemplary anti-HER2 biparatopic antibody drug conjugates to inhibit the growth of HER2+ cells. FIG. 17A shows the ability of the ADC v6363 to inhibit the growth of JIMT1 cells. FIG. 17B shows the ability of the ADC v6363 to inhibit the growth of SKOV3 cells. FIG. 17C shows the ability of the ADC v6363 to inhibit the growth of MCF7 cells. FIG. 17D shows the ability of the ADC v6363 to inhibit the growth of MDA-MB-231 cells. FIG. 17E shows the ability of ADCs v6363, v10553, and v1748 to inhibit the growth of SKOV3 cells. FIG. 17F shows the ability of ADCs v6363, v10553, and v1748 to inhibit the growth of JIMT-1 cells. FIG. 17G shows the ability of ADCs v6363, v10553, and v1748 to inhibit the growth of NCI-N87 cells.

[0025] FIG. 18 depicts the effect of a biparatopic anti-HER2 antibody in a human ovarian cancer line xenograft model (SKOV3). FIG. 18A shows the effect of the antibody on mean tumor volume. FIG. 18B shows the effect of the antibody on percent survival of the animals.

[0026] FIG. 19 depicts the effect of a biparatopic anti-HER2 antibody drug conjugate (ADC) in a human ovarian cancer line xenograft model (SKOV3). FIG. 19A shows the effect of the antibody on mean tumor volume. FIG. 19B shows the effect of the antibody on percent survival of the animals.

[0027] FIG. 20 depicts the effect of a biparatopic anti-HER2 antibody drug conjugate (ADC) on mean tumour volume in a human breast primary cell xenograft model (HBCx-13b).

[0028] FIG. 21 depicts the effect of a biparatopic anti-HER2 antibody drug conjugate (ADC) on mean tumour volume in a human breast primary cell xenograft model (T226).

[0029] FIG. 22 depicts the effect of a biparatopic anti-HER2 antibody drug conjugate (ADC) on mean tumour volume in a human breast primary cell xenograft model (HBCx-5).

[0030] FIG. 23 depicts the effect of a biparatopic anti-HER2 antibody drug conjugate (ADC) on anti-HER2 treatment resistant tumors in a human cell line xenograft model (SKOV3).

[0031] FIG. 24 depicts the effect of a biparatopic anti-HER2 antibody drug conjugate (ADC) to anti-HER2 treatment resistant tumors in human primary cell xenograft model (HBCx-13b).

[0032] FIG. 25 depicts the thermal stability of exemplary anti-HER2 biparatopic antibodies. FIG. 25A depicts the thermal stability of v5019. FIG. 25B depicts the thermal stability of v10000. FIG. 25C depicts the thermal stability of v7091.

[0033] FIG. 26 depicts the thermal stability of exemplary anti-HER2 biparatopic antibody drug conjugates. FIG. 26A depicts the thermal stability of v6363. FIG. 26B depicts the thermal stability of v10553. FIG. 26C depicts the thermal stability of v7148.

[0034] FIG. 27 depicts the ability of anti-HER2 biparatopic antibodies to mediate ADCC in HER2+ cells. The legend shown in FIG. 27C applies to FIG. 27A and FIG. 27B. FIG. 27A depicts this ability in SKBR3 cells; FIG. 27B depicts this ability in JIMT-1 cells; FIG. 27C depicts this ability in MDA-MB-231 cells; and FIG. 27D depicts this ability in WI-38 cells.

[0035] FIG. 28 depicts the effect of afucosylation on the ability of anti-HER2 biparatopic antibodies to mediate ADCC. The legend shown in FIG. 28B applies to FIG. 28A as well. FIG. 28A compares the ability of an afucosylated version of v5019 to mediate ADCC to that of Herceptin.TM. in SKOV3 cells. FIG. 28B compares the ability of an afucosylated version of v5019 to mediate ADCC to that of Herceptin.TM. in MDA-MB-231 cells.

[0036] FIG. 28C compares the ability of v10000 and an afucosylated version of v10000 to mediate ADCC against that of Herceptin.TM. in ZR-75-1 cells.

[0037] FIG. 29 depicts the ability of v5019 to inhibit growth of BT-474 cells in the presence or absence of growth-stimulatory ligands.

[0038] FIG. 30 depicts the effect of an afucosylated version of v5019 (v7187) on tumor volume in a human breast cancer xenograft model (HBCx13B).

[0039] FIG. 31 depicts the ability of anti-HER2 biparatopic antibodies and anti-HER2 biparatopic-ADCs to bind to HER2+ tumor cells. FIG. 31A compares the binding of v6363 to a T-DM1 analog, v6246, in SKOV3 cells. FIG. 31B compares the binding of v6363 to a T-DM1 analog, v6246, in JIMT-1 cells. FIG. 31C compares the binding of several exemplary anti-HER2 biparatopic antibodies and anti-HER2 biparatopic-ADCs to controls, in SKOV3 cells. FIG. 31D compares the binding of several exemplary anti-HER2 biparatopic antibodies and anti-HER2 biparatopic-ADCs to controls, in JIMT-1 cells.

[0040] FIG. 32 depicts Dose-Dependent Tumour Growth Inhibition of an exemplary anti-HER2 biparatopic-ADC in a HER2 3+ (ER-PR negative) patient derived xenograft model (HBCx13b). FIG. 32A shows the effect of v6363 on tumor volume, while FIG. 32B shows the effect on percent survival.

[0041] FIG. 33 depicts the effect of Biparatopic anti-HER2-ADC v6363 compared to Standard of Care Combinations in a Trastuzumab Resistant PDX HBCx-13b xenograft model. FIG. 33A depicts the effect of treatment on tumor volume, while FIG. 33B depicts the effect of treatment on survival.

[0042] FIG. 34 depicts the efficacy of a biparatopic anti-HER2-ADC in HER2+ trastuzumab-resistant breast cancer cell derived tumour xenograft model (JIMT-1).

[0043] FIG. 35 depicts the efficacy of exemplary anti-HER2 biparatopic antibodies in vivo in a trastuzumab sensitive ovarian cancer cell derived tumour xenograft model (SKOV3). FIG. 35A depicts the effect of treatment on tumor volume, while FIG. 35B depicts the effect of treatment on survival.

[0044] FIG. 36 depicts the dose-dependent efficacy of exemplary anti-HER2 biparatopic antibodies in vivo in a trastuzumab sensitive ovarian cancer cell derived tumour xenograft model (SKOV3).

[0045] FIG. 37 depicts the ability of an anti-HER2 biparatopic antibody and an anti-HER2 biparatopic-ADC to inhibit growth of cell lines expressing HER2, and EGFR and/or HER3 at the 3+, 2+ or 1+ levels. FIG. 37A depicts the ability of v10000 to inhibit growth selected cell lines. FIG. 37B depicts the ability of v10553 to inhibit growth of selected cell lines.

[0046] FIG. 38 depicts a summary of the ability of v10000 and v10553 to inhibit growth in a panel of cell lines. Hyphenated values (e.g. 1/2) indicate discrepant erbb receptor levels as reported in the literature; Erbb IHC values were obtained internally or from the literature. Where no value is reported the receptor quantities are unknown and/or not reported. * IHC level estimate based on erBb2 gene expression data (Crown BioSciences). Numbered references are described below.

[0047] FIG. 39 depicts the ability of v10000 to mediate ADCC in HER2+ cells. FIG. 39A depicts the results in FaDu cells. FIG. 39B depicts the results in A549 cells. FIG. 39C depicts the results in BxPC3 cells. FIG. 39D depicts the results in MiaPaca2 cells.

[0048] FIG. 40 depicts the ability of anti-HER2 biparatopic antibodies to mediate ADCC in HER2+ cells. FIG. 40A depicts the results in A549 cells. FIG. 40B depicts the results in NCI-N87 cells. FIG. 40C depicts the results in HCT-116 cells.

[0049] FIG. 41 depicts the effect of anti-HER2 biparatopic antibody format on binding HER2+ cells. FIG. 41A depicts the effect of format on binding to BT-474 cells. FIG. 41B depicts the effect of format on binding to JIMT-1 cells. FIG. 41C depicts the effect of format on binding to MCF7 cells. FIG. 41D depicts the effect of format on binding to MDA-MB-231 cells.

[0050] FIG. 42 depicts the effect of anti-HER2 biparatopic antibody format on internalization of antibody in HER2+ cells. FIG. 42A depicts the effect on internalization in BT-474 cells. FIG. 42B depicts the effect on internalization in JIMT-1 cells. FIG. 42C depicts the effect on internalization in MCF7 cells.

[0051] FIG. 43 depicts the effect of anti-HER2 biparatopic antibody format on the ability to mediate ADCC in HER2+ cells. FIG. 43A depicts the effect in JIMT-1 cells. FIG. 43B depicts the effect in MCF7 cells. FIG. 43C depicts the effect in HER2 0/1+ MDA-MB-231 breast tumor cells.

[0052] FIG. 44 depicts the effect of anti-HER2 biparatopic antibody format on the ability of the antibodies to inhibit HER2+ tumor cell growth in BT-474 cells in the presence or absence of growth-stimulatory ligands.

[0053] FIG. 45 depicts the effect of anti-HER2 biparatopic antibody format on the ability of the antibodies to inhibit growth of SKBR3 cells.

[0054] FIG. 46 depicts the effect of anti-HER2 biparatopic antibody format on the ability of antibodies to inhibit growth of HER2+ tumor cells. FIG. 46A depicts growth inhibition in SKOV3 cells. FIG. 46B depicts growth inhibition in JIMT-1 cells. FIG. 46C depicts growth inhibition in MCF7 cells.

[0055] FIG. 47 depicts a comparison of binding characteristics of anti-HER2 biparatopic antibodies of differing format as measured by SPR. FIG. 47A depicts the plot and linear regression analysis for the kd (1/s) at different antibody capture levels with v6903 and v7091. FIG. 47B depicts the plot and linear regression analysis for the KD (M) at different antibody capture levels with v6903 and v7091.

[0056] References found in FIG. 38 are as follows: 1. Labouret et al. 2012, Neoplasia 14:121-130; 2. Ghasemi et al. 2014, Oncogenesis doi:10.1038/oncsis.2014.31; 3. Gaborit et al. 2011 J Bio Chem, 286:1133-11345; 4. Kimura et al. 2006, Clin Cancer Res; 12:4925-4932; 5. Komoto et al. 2009, Canc Sci; 101:468-473; 6. Cretella et al. 2014, Molecular Cancer 13:143-155; 7. Bunn et al. 2001, Clin Cancer Res; 7:3239-3250; 8. Lewis Phillips et al. 2013, Clin Cancer Res, 20:456-468; 9. McDonagh et al. 2012, 11:582-593; 10. Coldren et al. 2006, Mol Cancer Res: 521-528; 11. Cavazzoni et al. 2012 Mol Cancer, 11:91-115; 12. Li et al. 2014, Mol Cancer Res, doi:10.1158/1541-7786.MCR-13-0396; 13. Chmielewski et al. 2004, Immunology, 173:7647-7653; 14. Kuwada et al. 2004, Int J Cancer, 109:291-301; 15. Fujimoto-Ouchi et al. 2007, Clin Chemother Pharmacol, 59:795-805; 16. Chavez-Blanco et al. 2004, BMC Cancer, 4:59; 17. Campiglio et al. 2004, J Cellular Physiology. 198:259-268; 18. Lehmann et al. 2011, J Clin Investigation, 121:2750-2767; 19. Collins et al. 2011, Annals Oncology, 23:1788-1795; 20. Takai et al. 2005, Cancer, 104:2701-2708; 21. Rusnack et al. 2007, Cell Prolif, 40:580-594; 22. Ma et al. 2013, PLOS ONE, 8:e73261-e73261; 23. Meira et al. 2009, British J Cancer, 101:782-791; 24. Hayashi MP28-14 poster; 25. Wang et al. 2005 J Huazhong Univ Sci Technolog Med Sci. 25:326-8; 26. Makhja et al. 2010. J Clinc Oncolo 28:1215-1223.

[0057] FIG. 48A-B depicts the effect of a biparatopic anti-HER2 antibody in a xenograft model of HER2-low, non-small cell lung cancer. FIG. 48A shows the effect of the antibody on tumor volume. FIG. 48B shows the effect of the antibody on percent survival of the animals.

[0058] FIG. 49A-B depicts the effect of a biparatopic anti-HER2 antibody in a xenograft model of HER2-low, head and neck squamous cell carcinoma. FIG. 49A shows the effect of the antibody on tumor volume. FIG. 49B shows the effect of the antibody on percent survival of the animals.

[0059] FIG. 50A-B depicts the effect of a biparatopic anti-HER2 antibody in a xenograft model of HER2-low, ER+ breast cancer. FIG. 50A shows the effect of the antibody on tumor volume. FIG. 50B shows the effect of the antibody on percent survival of the animals.

[0060] FIG. 51A-B shows tumor volume and survival in a xenograft model of pancreatic cancer.

[0061] FIG. 52 shows tumor volume in a xenograft model of gastric cancer.

DETAILED DESCRIPTION

[0062] Described herein are methods of using bispecific antigen-binding constructs that bind HER2.

Antigen-Binding Constructs

[0063] Provided herein are antigen-binding constructs, e.g., antibodies, that bind HER2. The antigen-binding constructs include at least one antigen-binding polypeptide construct binding a HER2 ECD2 antigen. In some embodiments, antigen-binding constructs include a second antigen-binding polypeptide construct binding a second antigen, e.g., a HER2 ECD4 antigen or the HER2 ECD2 antigen. As described in more detail below, the antigen-binding polypeptide constructs can be, but are not limited to, protein constructs such as Fab (fragment antigen-binding), scFv (single chain Fv) and sdab (single domain antibody). In some embodiments, the antigen-binding construct includes a scaffold, e.g, an Fc.

[0064] The term "antigen-binding construct" refers to any agent, e.g., polypeptide or polypeptide complex capable of binding to an antigen. In some aspects an antigen-binding construct is a polypeptide that specifically binds to an antigen of interest. An antigen-binding construct can be a monomer, dimer, multimer, a protein, a peptide, or a protein or peptide complex; an antibody, an antibody fragment, or an antigen-binding fragment thereof; an scFv and the like. An antigen-binding construct can be monospecific, bispecific, or multispecific. In some aspects, an antigen-binding construct can include, e.g., one or more antigen-binding polypeptide constructs (e.g., Fabs or scFvs) linked to one or more Fc. Further examples of antigen-binding constructs are described below and provided in the Examples.

[0065] In some embodiments, the antigen-binding construct is monospecific. A monospecific antigen-binding construct refers to an antigen-binding construct with one binding specificity. In other words, the antigen-binding polypeptide construct binds to the same epitope on the same antigen. Examples of monospecific antigen-binding constructs include trastuzumab and pertuzumab.

[0066] A bispecific antigen binding construct has two antigen binding polypeptide constructs, each with a unique binding specificity. For example, a first antigen binding polypeptide construct binds to an epitope on a first antigen, and a second antigen binding polypeptide construct binds to an epitope on a second antigen. The term "biparatopic" as used herein, refers to a bispecific antibody where the first antigen binding moiety and the second antigen binding moiety bind to different epitopes on the same antigen.

[0067] An antigen-binding construct can be an antibody or antigen-binding portion thereof. As used herein, an "antibody" or "immunoglobulin" refers to a polypeptide substantially encoded by an immunoglobulin gene or immunoglobulin genes, or fragments thereof, which specifically bind and recognize an analyte (e.g., antigen). The recognized immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon and mu constant region genes, as well as the myriad immunoglobulin variable region genes. Light chains are classified as either kappa or lambda. The "class" of an antibody or immunoglobulin refers to the type of constant domain or constant region possessed by its heavy chain. There are five major classes of antibodies: IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into subclasses (isotypes), e.g., IgG1, IgG.sub.2, IgG.sub.3, IgG.sub.4, IgA1, and IgA.sub.2. The heavy chain constant domains that correspond to the different classes of immunoglobulins are called .alpha., .delta., .epsilon., .gamma., and respectively.

[0068] An exemplary immunoglobulin (antibody) structural unit is composed of two pairs of polypeptide chains, each pair having one "light" (about 25 kD) and one "heavy" chain (about 50-70 kD). The N-terminal domain of each chain defines a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition. The terms variable light chain (VL) and variable heavy chain (VH) refer to these light and heavy chain domains respectively. The IgG1 heavy chain comprises of the VH, CH1, CH2 and CH3 domains respectively from the N to C-terminus. The light chain comprises of the VL and CL domains from N to C terminus. The IgG1 heavy chain comprises a hinge between the CH1 and CH2 domains.

[0069] The term "hypervariable region" or "HVR", as used herein, refers to each of the regions of an antibody variable domain which are hypervariable in sequence and/or form structurally defined loops ("hypervariable loops"). Generally, native four-chain antibodies comprise six HVRs; three in the VH (H1, H2, H3), and three in the VL (L1, L2, L3). HVRs generally comprise amino acid residues from the hypervariable loops and/or from the complementarity determining regions (CDRs), the latter being of highest sequence variability and/or involved in antigen recognition. With the exception of CDR1 in VH, CDRs generally comprise the amino acid residues that form the hypervariable loops. Hypervariable regions (HVRs) are also referred to as "complementarity determining regions" (CDRs), and these terms are used herein interchangeably in reference to portions of the variable region that form the antigen-binding regions. This particular region has been described by Kabat et al., U.S. Dept. of Health and Human Services, Sequences of Proteins of Immunological Interest (1983) and by Chothia et al., J Mol Biol 196:901-917 (1987), where the definitions include overlapping or subsets of amino acid residues when compared against each other. Nevertheless, application of either definition to refer to a CDR of an antibody or variants thereof is intended to be within the scope of the term as defined and used herein. The exact residue numbers which encompass a particular CDR will vary depending on the sequence and size of the CDR. Those skilled in the art can routinely determine which residues comprise a particular CDR given the variable region amino acid sequence of the antibody.

[0070] "Humanized" forms of non-human (e.g., rodent) antibodies are chimeric antibodies that contain minimal sequence derived from non-human immunoglobulin. For the most part, humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a hypervariable region of the recipient are replaced by residues from a hypervariable region of a non-human species (donor antibody) such as mouse, rat, rabbit or nonhuman primate having the desired specificity, affinity, and capacity. In some instances, framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, humanized antibodies may comprise residues that are not found in the recipient antibody or in the donor antibody. These modifications are made to further refine antibody performance. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable loops correspond to those of a non-human immunoglobulin and all or substantially all of the FRs are those of a human immunoglobulin sequence. The humanized antibody optionally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. For further details, see Jones et al., Nature 321:522-525 (1986); Riechmann et al., Nature 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol. 2:593-596 (1992).

[0071] Humanized HER2 antibodies include huMAb4D5-1, huMAb4D5-2, huMAb4D5-3, huMAb4D5-4, huMAb4D5-5, huMAb4D5-6, huMAb4D5-7 and huMAb4D5-8 or Trastuzumab (HERCEPTIN.RTM.) as described in Table 3 of U.S. Pat. No. 5,821,337 expressly incorporated herein by reference; humanized 520C9 (WO93/21319) and humanized 2C4 antibodies as described in US Patent Publication No. 2006/0018899.

Antigen-Binding Polypeptide Construct

[0072] The antigen-binding constructs described herein comprise at least one antigen-binding polypeptide construct that each binds to a HER2 ECD2 antigen. In some embodiments, the antigen-binding constructs described herein include a second antigen-binding polypeptide construct that binds to, e.g., a HER2 ECD2 antigen or a HER2 ECD4 antigen. In some embodiments the antigen-binding polypeptide construct comprises a sequence that is disclosed in the examples below, e.g., the VH or VL or CDRs of v5019, v5020, v7091, v10000, or v6717.

[0073] The antigen-binding polypeptide construct is typically monovalent, i.e. can bind only one epitope. In some embodiments, however, the antigen-binding polypeptide construct can be bivalent (binding to two epitopes) or multivalent.

[0074] Either antigen-binding polypeptide construct can be, e.g., a Fab, or an scFv, depending on the application. In some embodiments, the antigen binding construct includes two antigen-binding polypeptide constructs. The format of the antigen-binding construct may be Fab-Fab, scFv-scFv, or Fab-scFv or scFv-Fab (first antigen-binding polypeptide construct-second antigen-binding polypeptide respectively).

[0075] A Fab (also referred to as fragment antigen-binding) contains the constant domain (CL) of the light chain and the first constant domain (CH1) of the heavy chain along with the variable domains VL and VH on the light and heavy chains respectively. The variable domains comprise the complementarity determining loops (CDR, also referred to as hypervariable region) that are involved in antigen-binding. Fab' fragments differ from Fab fragments by the addition of a few residues at the carboxy terminus of the heavy chain CH1 domain including one or more cysteines from the antibody hinge region.

[0076] A "single-chain Fv" or "scFv" includes the VH and VL domains of an antibody, wherein these domains are present in a single polypeptide chain. In one embodiment, the Fv polypeptide further comprises a polypeptide linker between the VH and VL domains which enables the scFv to form the desired structure for antigen-binding. For a review of scFv see Pluckthun in The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds., Springer-Verlag, New York, pp. 269-315 (1994). HER2 antibody scFv fragments are described in WO93/16185; U.S. Pat. No. 5,571,894; and U.S. Pat. No. 5,587,458.

[0077] A "single domain antibody" or "sdAb" format is an individual immunoglobulin domain. SdAbs are fairly stable and easy to express as fusion partner with the Fc chain of an antibody (Harmsen MM, De Haard HJ (2007). "Properties, production, and applications of camelid single-domain antibody fragments". Appl. Microbiol Biotechnol. 77(1): 13-22).

[0078] In some embodiments the antigen binding polypeptide construct is derived from an antibody, a fibronectin, an affibody, anticalin, cysteine knot protein, DARPin, avimer, Kunitz domain or variant or derivative thereof.

[0079] The antigen binding polypeptide constructs described herein can be converted to different formats. For example, a Fab can be converted to an scFv or an scFv can be converted to a Fab. Methods of converting between types of antigen-binding domains are known in the art (see for example methods for converting an scFv to a Fab format described at, e.g., Zhou et al (2012) Mol Cancer Ther 11:1167-1476. The methods described therein are incorporated by reference.).

[0080] The antigen binding constructs described herein specifically bind HER2. "Specifically binds", "specific binding" or "selective binding" means that the binding is selective for the antigen and can be discriminated from unwanted or non-specific interactions. The ability of an antigen-binding construct to bind to a specific antigenic determinant can be measured either through an enzyme-linked immunosorbent assay (ELISA) or other techniques familiar to one of skill in the art, e.g. surface plasmon resonance (SPR) technique (analyzed on a BIAcore instrument) (Liljeblad et al, Glyco J 17, 323-329 (2000)), and traditional binding assays (Heeley, Endocr Res 28, 217-229 (2002)).

[0081] In one embodiment, the extent of binding of an antigen-binding moiety to an unrelated protein is less than about 10% of the binding of the antigen-binding construct to the antigen as measured, e.g., by SPR.

HER2

[0082] The antigen-binding constructs described herein include an antigen-binding polypeptide construct that binds to the ECD2 of HER2.

[0083] The expressions "ErbB2" and "HER2" are used interchangeably herein and refer to human HER2 protein described, for example, in Semba et al., PNAS (USA) 82:6497-6501 (1985) and Yamamoto et al. Nature 319:230-234 (1986) (Genebank accession number X03363). The term "erbB2" and "neu" refers to the gene encoding human ErbB2 protein. p185 or p185neu refers to the protein product of the neu gene.

[0084] HER2 is a HER receptor. A "HER receptor" is a receptor protein tyrosine kinase which belongs to the human epidermal growth factor receptor (HER) family and includes EGFR, HER2, HER3 and HER4 receptors. A HER receptor will generally comprise an extracellular domain, which may bind an HER ligand; a lipophilic transmembrane domain; a conserved intracellular tyrosine kinase domain; and a carboxyl-terminal signaling domain harboring several tyrosine residues which can be phosphorylated. By "HER ligand" is meant a polypeptide which binds to and/or activates an HER receptor.

[0085] The extracellular (ecto) domain of HER2 comprises four domains, Domain I (ECD1, amino acid residues from about 1-195), Domain II (ECD2, amino acid residues from about 196-319), Domain III (ECD3, amino acid residues from about 320-488), and Domain IV (ECD4, amino acid residues from about 489-630) (residue numbering without signal peptide). See Garrett et al. Mol. Cell. 11: 495-505 (2003), Cho et al. Nature 421: 756-760 (2003), Franklin et al. Cancer Cell 5:317-328 (2004), Tse et al. Cancer Treat Rev. 2012 April; 38(2):133-42 (2012), or Plowman et al. Proc. Natl. Acad. Sci. 90:1746-1750 (1993).

[0086] The sequence of HER2 is as follows; ECD boundaries are Domain I: 1-165; Domain II: 166-322; Domain III: 323-488; Domain IV: 489-607.

TABLE-US-00001 (SEQ ID NO: 349) 1 tqvctgtdmk lrlpaspeth ldmlrhlyqg cqvvqgnlel tylptnasls flgdigevqg 61 yvliahnqvr qvplqrlriv rgtqlfedny alavldngdp lnnttpvtga spgglrelql 121 rslteilkgg vliqrnpq1c yqdtilwkdi fhknnqlalt lidtnrsrac hpcspmckgs 181 rcwgessedc qsltrtvcag gcarckgplp tdccheqcaa gctgpkhsdc laclhfnhsg 241 icelhcpalv tyntdtfesm pnpegrytfg ascvtacpyn ylstdvgsct lvcplhnqev 301 taedgtqrce kcskpcarvc yglgmehlre vravtsaniq efagckkifg slaflpesfd 361 gdpasntapl gpeqlqvfet leeitgylyi sawpdslpdl svfqnlqvir grilhngays 421 ltlqglgisw lglrslrelg sglalihhnt hlcfvhtvpw dqlfrnphqa llhtanrped 481 ecvgeglach qlcarghcwg pgptqcvncs qflrggecve ecrvlqglpr eyvnarhclp 541 chpecqpqng svtcfgpead qcvacahykd ppfcvarcps gvkpdlsymp iwkfpdeega 601 cqpcpin

[0087] The "epitope 2C4" is the region in the extracellular domain of HER2 to which the antibody 2C4 binds. Epitope 2C4 comprises residues from domain II in the extracellular domain of HER2. 2C4 and Pertuzumab bind to the extracellular domain of HER2 at the junction of domains I, II and III. Franklin et al. Cancer Cell 5:317-328 (2004). In order to screen for antibodies which bind to the 2C4 epitope, a routine cross-blocking assay such as that described in Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory, Ed Harlow and David Lane (1988), can be performed. Alternatively, epitope mapping can be performed to assess whether the antibody binds to the 2C4 epitope of HER2 using methods known in the art and/or one can study the antibody-HER2 structure (Franklin et al. Cancer Cell 5:317-328 (2004)) to see what domain(s) of HER2 is/are bound by the antibody.

[0088] The "epitope 4D5" is the region in the extracellular domain of HER2 to which the antibody 4D5 (ATCC CRL 10463) and Trastuzumab bind. This epitope is close to the transmembrane domain of HER2, and within Domain IV of HER2. To screen for antibodies which bind to the 4D5 epitope, a routine cross-blocking assay such as that described in Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory, Ed Harlow and David Lane (1988), can be performed. Alternatively, epitope mapping can be performed to assess whether the antibody binds to the 4D5 epitope of HER2 (e.g. any one or more residues in the region from about residue 529 to about residue 625, inclusive, see FIG. 1 of US Patent Publication No. 2006/0018899).

Exemplary Anti-HER2 Antigen Binding Constructs

[0089] Exemplary anti-HER2 antibodies (or antigen-binding constructs) and controls are provided herein. Representations of exemplary biparatopic formats are shown in FIG. 1. In all of the formats shown in FIG. 1, the heterodimeric Fc is depicted with one chain (Chain A) shown in black and the other (Chain B) shown in grey, while one antigen-binding domain (1) is shown in hatched fill and the other antigen-binding domain (2) is shown in white.

[0090] FIG. 1A depicts the structure of a biparatopic antibody in a Fab-Fab format. FIGS. 1B to 1E depict the structure of possible versions of a biparatopic antibody in an scFv-Fab format. In FIG. 1B, antigen-binding domain 1 is an scFv, fused to Chain A, while antigen-binding domain 2 is a Fab, fused to Chain B. In FIG. 1C, antigen-binding domain 1 is a Fab, fused to Chain A, while antigen-binding domain 2 is an scFv, fused to Chain B. In FIG. 1D, antigen-binding domain 2 is a Fab, fused to Chain A, while antigen-binding domain 1 is an scFv, fused to Chain B. In FIG. 1E, antigen-binding domain 2 is an scFv, fused to Chain A, while antigen-binding domain 1 is a Fab, fused to Chain B. In FIG. 1F, both antigen-binding domains are scFvs.

[0091] The sequences of the following variants are provided in the Sequence Table found after the Examples. CDR regions were identified using a combination of the Kabat and Chothia methods. Regions may vary slightly based on method used for identification.

[0092] Exemplary Anti-HER2 Biparatopic Antibodies

[0093] Exemplary anti-HER2 biparatopic antibodies are shown in Table 1.

TABLE-US-00002 TABLE 1 Exemplary anti-HER2 biparatbopic antibodies Variant Chain A Chain B 5019 domain ECD2 ECD4 containing the epitope Format Fab scFv Antibody Pertuzumab Trastuzumab name CH3 T350V_L351Y_F405A_Y407V T366I_N390R_K392M_T394W sequence substitutions 5020 domain ECD4 ECD2 containing the epitope format scFv Fab Antibody Trastuzumab Pertuzumab name CH3 L351Y_S400E_F405A_Y407V T350V_T366L_K392L_T394W sequence substitutions 7091 domain ECD2 ECD4 containing the epitope format Fab scFv Antibody Pertuzumab Trastuzumab name CH3 T350V_L351Y_F405A_Y407V T350V_T366L_K392L_T394W sequence substitutions 10000 domain ECD2 ECD4 containing the epitope format Fab scFv Antibody Pertuzumab - with Y96A in VL Trastuzumab name region and T30A/A49G/L69F in VH region CH3 T350V_L351Y_F405A_Y407V T350V_T366L_K392L_T394W sequence substitutions 6902 domain ECD2 ECD4 containing the epitope format Fab Fab Antibody Trastuzumab Pertuzumab name Fab HC: L143E_K145T HC: D146G_Q179K substitutions LC: Q124R LC: Q124E_Q160E_T180E CH3 T350V_L351Y_F405A_Y407V T350V_T366L_K392L_T394W sequence substitutions 6903 domain ECD2 ECD4 containing the epitope format Fab Fab Fab HC: L143E_K145T HC: D146G_Q179K substitutions LC: Q124R_Q1160K_T178R LC: Q124E_Q160E_T180E Antibody Trastuzumab Pertuzumab name CH3 T350V_L351Y_F405A_Y407V T350V_T366L_K392L_T394W sequence substitutions 6717 domain ECD4 ECD2 containing the epitope format scFv scFv Antibody Pertuzumab Trastuzumab name CH3 T350V_L351Y_F405A_Y407V T366I_N390R_K392M_T394W sequence substitutions Notes: CH3 numbering according to EU index as in Kabat referring to the numbering of the EU antibody (Edelman et al., 1969, Proc Natl Acad Sci USA 63: 78-85); Fab or variable domain numbering according to Kabat (Kabat and Wu, 1991; Kabat et al, Sequences of proteins of immunological interest. 5th Edition - US Department of Health and Human Services, NIH publication n.sup.o 91-3242, p 647 (1991)) "domain containing the epitope" = domain of HER2 to which antigen-binding moiety binds; "Antibody name" = antibody from which antigen-binding moiety is derived, includes substitutions compared to wild-type when present; "Fab substitutions" = substitutions in Fab that promote correct light chain pairing; "CH3 sequence substitutions" = substitutions in CH3 domain that promote formation of heterodimeric Fc

[0094] Exemplary Anti-HER2 Monovalent Control Antibodies

[0095] v1040: a monovalent anti-HER2 antibody, where the HER2 binding domain is a Fab derived from trastuzumab on chain A, and the Fc region is a heterodimer having the mutations T350V_L351Y_F405A_Y407V in Chain A, T350V_T366L_K392L_T394W in Chain B, and the hinge region of Chain B having the mutation C226S; the antigen-binding domain binds to domain 4 of HER2.

[0096] v630--a monovalent anti-HER2 antibody, where the HER2 binding domain is an scFv derived from trastuzumab on Chain A, and the Fc region is a heterodimer having the mutations L351Y_S400E_F405A_Y407V in Chain A, T366I_N390R_K392M_T394W in Chain B; and the hinge region having the mutation C226S (EU numbering) in both chains; the antigen-binding domain binds to domain 4 of HER2.

[0097] v4182: a monovalent anti-HER2 antibody, where the HER2 binding domain is a Fab derived from pertuzumab on chain A, and the Fc region is a heterodimer having the mutations T350V_L351Y_F405A_Y407V in Chain A, T350V_T366L_K392L_T394W in Chain B, and the hinge region of Chain B having the mutation C226S; the antigen-binding domain binds to domain 2 of HER2.

[0098] Exemplary Anti-HER2 Monospecific Bivalent Antibody Controls (Full-Sized Antibodies, FSAs)

[0099] v506 is a wild-type anti HER2 produced in-house in Chinese Hamster Ovary (CHO) cells, as a control. Both HER2 binding domains are derived from trastuzumab in the Fab format and the Fc is a wild type homodimer; the antigen-binding domain binds to domain 4 of HER2. This antibody is also referred to as a trastuzumab analog.

[0100] v792, is wild-type trastuzumab with a IgG1 hinge, where both HER2 binding domains are derived from trastuzumab in the Fab format, and the and the Fc region is a heterodimer having the mutations T350V_L351Y_F405A_Y407V in Chain A, and T350V_T366L_K392L_T394W Chain B; the antigen-binding domain binds to domain 4 of HER2. This antibody is also referred to as a trastuzumab analog.

[0101] v4184, a bivalent anti-HER2 antibody, where both HER2 binding domains are derived from pertuzumab in the Fab format, and the Fc region is a heterodimer having the mutations T350V_L351Y_F405A_Y407V in Chain A, and T350V_T366L_K392L_T394W Chain B. The antigen-binding domain binds to domain 2 of HER2. This antibody is also referred to as a pertuzumab analog.

[0102] Exemplary Anti-HER2 Biparatopic Antibody Drug Conjugates (ADCs)

[0103] The following are exemplary anti-HER2 biparatopic antibody drug conjugates (anti-HER2 biparatopic-ADCs). ADCs of variants 5019, 7091, 10000 and 506 are identified as follows:

[0104] v6363 (v5019 conjugated to DM1)

[0105] v7148 (v7091 conjugated to DM1)

[0106] v10553 (v10000 conjugated to DM1)

[0107] v6246 (v506 conjugated to DM1, analogous to T-DM1, trastuzumab-emtansine)

[0108] v6249 (human IgG conjugated to DM1)

Fc of Antigen-Binding Constructs.

[0109] In some embodiments, the antigen-binding constructs described herein comprise an Fc, e.g., a dimeric Fc. A dimeric Fc can be homodimeric or heterodimeric

[0110] The term "Fc domain" or "Fc region" herein is used to define a C-terminal region of an immunoglobulin heavy chain that contains at least a portion of the constant region. The term includes native sequence Fc regions and variant Fc regions. Unless otherwise specified herein, numbering of amino acid residues in the Fc region or constant region is according to the EU numbering system, also called the EU index, as described in Kabat et al, Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md., 1991. An "Fc polypeptide" of a dimeric Fc as used herein refers to one of the two polypeptides forming the dimeric Fc domain, i.e. a polypeptide comprising C-terminal constant regions of an immunoglobulin heavy chain, capable of stable self-association. For example, an Fc polypeptide of a dimeric IgG Fc comprises an IgG CH2 and an IgG CH3 constant domain sequence.

[0111] An Fc domain comprises either a CH3 domain or a CH3 and a CH2 domain. The CH3 domain comprises two CH3 sequences, one from each of the two Fc polypeptides of the dimeric Fc. The CH2 domain comprises two CH2 sequences, one from each of the two Fc polypeptides of the dimeric Fc.

[0112] In some aspects, the Fc comprises at least one or two CH3 sequences. In some aspects, the Fc is coupled, with or without one or more linkers, to a first antigen-binding construct and/or a second antigen-binding construct. In some aspects, the Fc is a human Fc. In some aspects, the Fc is a human IgG or IgG1 Fc. In some aspects, the Fc is a heterodimeric Fc. In some aspects, the Fc comprises at least one or two CH2 sequences.

[0113] In some aspects, the Fc comprises one or more modifications in at least one of the CH3 sequences. In some aspects, the Fc comprises one or more modifications in at least one of the CH2 sequences. In some aspects, an Fc is a single polypeptide. In some aspects, an Fc is multiple peptides, e.g., two polypeptides.

[0114] In some aspects, an Fc is an Fc described in patent applications PCT/CA2011/001238, filed Nov. 4, 2011 or PCT/CA2012/050780, filed Nov. 2, 2012, the entire disclosure of each of which is hereby incorporated by reference in its entirety for all purposes.

[0115] Modified CH3 Domains

[0116] In some aspects, the antigen-binding construct described herein comprises a heterodimeric Fc comprising a modified CH3 domain that has been asymmetrically modified. The heterodimeric Fc can comprise two heavy chain constant domain polypeptides: a first Fc polypeptide and a second Fc polypeptide, which can be used interchangeably provided that Fc comprises one first Fc polypeptide and one second Fc polypeptide. Generally, the first Fc polypeptide comprises a first CH3 sequence and the second Fc polypeptide comprises a second CH3 sequence.

[0117] Two CH3 sequences that comprise one or more amino acid modifications introduced in an asymmetric fashion generally results in a heterodimeric Fc, rather than a homodimer, when the two CH3 sequences dimerize. As used herein, "asymmetric amino acid modifications" refers to any modification where an amino acid at a specific position on a first CH3 sequence is different from the amino acid on a second CH3 sequence at the same position, and the first and second CH3 sequence preferentially pair to form a heterodimer, rather than a homodimer. This heterodimerization can be a result of modification of only one of the two amino acids at the same respective amino acid position on each sequence; or modification of both amino acids on each sequence at the same respective position on each of the first and second CH3 sequences. The first and second CH3 sequence of a heterodimeric Fc can comprise one or more than one asymmetric amino acid modification.

[0118] Table A provides the amino acid sequence of the human IgG1 Fc sequence, corresponding to amino acids 231 to 447 of the full-length human IgG1 heavy chain. The CH3 sequence comprises amino acid 341-447 of the full-length human IgG1 heavy chain.

[0119] Typically an Fc can include two contiguous heavy chain sequences (A and B) that are capable of dimerizing. In some aspects, one or both sequences of an Fc include one or more mutations or modifications at the following locations: L351, F405, Y407, T366, K392, T394, T350, S400, and/or N390, using EU numbering. In some aspects, an Fc includes a mutant sequence shown in Table X. In some aspects, an Fc includes the mutations of Variant 1 A-B. In some aspects, an Fc includes the mutations of Variant 2 A-B. In some aspects, an Fc includes the mutations of Variant 3 A-B. In some aspects, an Fc includes the mutations of Variant 4 A-B. In some aspects, an Fc includes the mutations of Variant 5 A-B.

TABLE-US-00003 TABLE A IgG1 Fc sequences Human IgG1 Fc APELLGGPSVFLFPPKPKDTLMISRTP sequence 231-447 EVTCVVVDVSHEDPEVKFNWYVDGVEV (EU-numbering) HNAKTKPREEQYNSTYRVVSVLTVLHQ DWLNGKEYKCKVSNKALPAPIEKTISK AKGQPREPQVYTLPPSRDELTKNQVSL TCLVKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFLYSKLTVDKSRWQQ GNVFSCSVMHEALHNHYTQKSLSLSPG K (SEQ ID NO: 350) Variant IgG1 Fc sequence (231-447) Chain Mutations 1 A L351Y_F405A_Y407V 1 B T366L_K392M_T394W 2 A L351Y_F405A_Y407V 2 B T366L_K392L_T394W 3 A T350V_L351Y_F405A_Y407V 3 B T350V_T366L_K392L_T394W 4 A T350V_L351Y_F405A_Y407V 4 B T350V_T366L_K392M_T394W 5 A T350V_L351Y_S400E_F405A_ Y407V 5 B T350V_T366L_N390R_K392M_ T394W

[0120] The first and second CH3 sequences can comprise amino acid mutations as described herein, with reference to amino acids 231 to 447 of the full-length human IgG1 heavy chain. In one embodiment, the heterodimeric Fc comprises a modified CH3 domain with a first CH3 sequence having amino acid modifications at positions F405 and Y407, and a second CH3 sequence having amino acid modifications at position T394. In one embodiment, the heterodimeric Fc comprises a modified CH3 domain with a first CH3 sequence having one or more amino acid modifications selected from L351Y, F405A, and Y407V, and the second CH3 sequence having one or more amino acid modifications selected from T366L, T366I, K392L, K392M, and T394W.

[0121] In one embodiment, a heterodimeric Fc comprises a modified CH3 domain with a first CH3 sequence having amino acid modifications at positions L351, F405 and Y407, and a second CH3 sequence having amino acid modifications at positions T366, K392, and T394, and one of the first or second CH3 sequences further comprising amino acid modifications at position Q347, and the other CH3 sequence further comprising amino acid modification at position K360. In another embodiment, a heterodimeric Fc comprises a modified CH3 domain with a first CH3 sequence having amino acid modifications at positions L351, F405 and Y407, and a second CH3 sequence having amino acid modifications at position T366, K392, and T394, one of the first or second CH3 sequences further comprising amino acid modifications at position Q347, and the other CH3 sequence further comprising amino acid modification at position K360, and one or both of said CH3 sequences further comprise the amino acid modification T350V.

[0122] In one embodiment, a heterodimeric Fc comprises a modified CH3 domain with a first CH3 sequence having amino acid modifications at positions L351, F405 and Y407, and a second CH3 sequence having amino acid modifications at positions T366, K392, and T394 and one of said first and second CH3 sequences further comprising amino acid modification of D399R or D399K and the other CH3 sequence comprising one or more of T411E, T411D, K409E, K409D, K392E and K392D. In another embodiment, a heterodimeric Fc comprises a modified CH3 domain with a first CH3 sequence having amino acid modifications at positions L351, F405 and Y407, and a second CH3 sequence having amino acid modifications at positions T366, K392, and T394, one of said first and second CH3 sequences further comprises amino acid modification of D399R or D399K and the other CH3 sequence comprising one or more of T411E, T411D, K409E, K409D, K392E and K392D, and one or both of said CH3 sequences further comprise the amino acid modification T350V.

[0123] In one embodiment, a heterodimeric Fc comprises a modified CH3 domain with a first CH3 sequence having amino acid modifications at positions L351, F405 and Y407, and a second CH3 sequence having amino acid modifications at positions T366, K392, and T394, wherein one or both of said CH3 sequences further comprise the amino acid modification of T350V.

[0124] In one embodiment, a heterodimeric Fc comprises a modified CH3 domain comprising the following amino acid modifications, where "A" represents the amino acid modifications to the first CH3 sequence, and "B" represents the amino acid modifications to the second CH3 sequence: A:L351Y_F405A_Y407V, B:T366L_K392M_T394W, A:L351Y_F405A_Y407V, B:T366L_K392L_T394W, A:T350V_L351Y_F405A_Y407V, B:T350V_T366L_K392L_T394W, A:T350V_L351Y_F405A_Y407V, B:T350V_T366L_K392M_T394W, A:T350V_L351Y_S400E_F405A_Y407V, and/or B:T350V_T366L_N390R_K392M_T394W.

[0125] The one or more asymmetric amino acid modifications can promote the formation of a heterodimeric Fc in which the heterodimeric CH3 domain has a stability that is comparable to a wild-type homodimeric CH3 domain. In an embodiment, the one or more asymmetric amino acid modifications promote the formation of a heterodimeric Fc domain in which the heterodimeric Fc domain has a stability that is comparable to a wild-type homodimeric Fc domain. In an embodiment, the one or more asymmetric amino acid modifications promote the formation of a heterodimeric Fc domain in which the heterodimeric Fc domain has a stability observed via the melting temperature (Tm) in a differential scanning calorimetry study, and where the melting temperature is within 4.degree. C. of that observed for the corresponding symmetric wild-type homodimeric Fc domain. In some aspects, the Fc comprises one or more modifications in at least one of the C.sub.H3 sequences that promote the formation of a heterodimeric Fc with stability comparable to a wild-type homodimeric Fc.

[0126] In one embodiment, the stability of the CH3 domain can be assessed by measuring the melting temperature of the CH3 domain, for example by differential scanning calorimetry (DSC). Thus, in a further embodiment, the CH3 domain has a melting temperature of about 68.degree. C. or higher. In another embodiment, the CH3 domain has a melting temperature of about 70.degree. C. or higher. In another embodiment, the CH3 domain has a melting temperature of about 72.degree. C. or higher. In another embodiment, the CH3 domain has a melting temperature of about 73.degree. C. or higher. In another embodiment, the CH3 domain has a melting temperature of about 75.degree. C. or higher. In another embodiment, the CH3 domain has a melting temperature of about 78.degree. C. or higher. In some aspects, the dimerized CH3 sequences have a melting temperature (Tm) of about 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 77.5, 78, 79, 80, 81, 82, 83, 84, or 85.degree. C. or higher.

[0127] In some embodiments, a heterodimeric Fc comprising modified CH3 sequences can be formed with a purity of at least about 75% as compared to homodimeric Fc in the expressed product. In another embodiment, the heterodimeric Fc is formed with a purity greater than about 80%. In another embodiment, the heterodimeric Fc is formed with a purity greater than about 85%. In another embodiment, the heterodimeric Fc is formed with a purity greater than about 90%. In another embodiment, the heterodimeric Fc is formed with a purity greater than about 95%. In another embodiment, the heterodimeric Fc is formed with a purity greater than about 97%. In some aspects, the Fc is a heterodimer formed with a purity greater than about 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% when expressed. In some aspects, the Fc is a heterodimer formed with a purity greater than about 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% when expressed via a single cell.

[0128] Additional methods for modifying monomeric Fc polypeptides to promote heterodimeric Fc formation are described in International Patent Publication No. WO 96/027011 (knobs into holes), in Gunasekaran et al. (Gunasekaran K. et al. (2010) J Biol Chem. 285, 19637-46, electrostatic design to achieve selective heterodimerization), in Davis et al. (Davis, J H. et al. (2010) Prot Eng Des Sel; 23(4): 195-202, strand exchange engineered domain (SEED) technology), and in Labrijn et al [Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. Labrijn A F, Meesters J I, de Goeij B E, van den Bremer E T, Neijssen J, van Kampen M D, Strumane K, Verploegen S, Kundu A, Gramer M J, van Berkel P H, van de Winkel J G, Schuurman J, Parren P W. Proc Natl Acad Sci USA. 2013 Mar. 26; 110(13):5145-50.

[0129] CH2 Domains

[0130] In some embodiments, the Fc of the antigen-binding construct comprises a CH2 domain. One example of an CH2 domain of an Fc is amino acid 231-340 of the sequence shown in Table A. Several effector functions are mediated by Fc receptors (FcRs), which bind to the Fc of an antibody.

[0131] The terms "Fc receptor" and "FcR" are used to describe a receptor that binds to the Fc region of an antibody. For example, an FcR can be a native sequence human FcR. Generally, an FcR is one which binds an IgG antibody (a gamma receptor) and includes receptors of the Fc.gamma.RI, Fc.gamma.RII, and Fc.gamma.RIII subclasses, including allelic variants and alternatively spliced forms of these receptors. Fc.gamma.RII receptors include Fc.gamma.RIIA (an "activating receptor") and Fc.gamma.RIIB (an "inhibiting receptor"), which have similar amino acid sequences that differ primarily in the cytoplasmic domains thereof. Immunoglobulins of other isotypes can also be bound by certain FcRs (see, e.g., Janeway et al., Immuno Biology: the immune system in health and disease, (Elsevier Science Ltd., NY) (4th ed., 1999)). Activating receptor Fc.gamma.RIIA contains an immunoreceptor tyrosine-based activation motif (ITAM) in its cytoplasmic domain. Inhibiting receptor Fc.gamma.RIIB contains an immunoreceptor tyrosine-based inhibition motif (ITIM) in its cytoplasmic domain (reviewed in Daeron, Annu. Rev. Immunol. 15:203-234 (1997)). FcRs are reviewed in Ravetch and Kinet, Annu. Rev. Immunol 9:457-92 (1991); Capel et al., Immunomethods 4:25-34 (1994); and de Haas et al., J. Lab. Clin. Med. 126:330-41 (1995). Other FcRs, including those to be identified in the future, are encompassed by the term "FcR" herein. The term also includes the neonatal receptor, FcRn, which is responsible for the transfer of maternal IgGs to the fetus (Guyer et al., J. Immunol. 117:587 (1976); and Kim et al., J. Immunol. 24:249 (1994)).

[0132] Modifications in the CH2 domain can affect the binding of FcRs to the Fc. A number of amino acid modifications in the Fc region are known in the art for selectively altering the affinity of the Fc for different Fcgamma receptors. In some aspects, the Fc comprises one or more modifications to promote selective binding of Fc-gamma receptors.

[0133] Exemplary mutations that alter the binding of FcRs to the Fc are listed below:

[0134] S298A/E333A/K334A, S298A/E333A/K334A/K326A (Lu Y, Vernes J M, Chiang N, et al. J Immunol Methods. 2011 Feb. 28; 365(1-2):132-41);

[0135] F243L/R292P/Y300L/V305I/P396L, F243L/R292P/Y300L/L235V/P396L (Stavenhagen J B, Gorlatov S, Tuaillon N, et al. Cancer Res. 2007 Sep. 15; 67(18):8882-90; Nordstrom J L, Gorlatov S, Zhang W, et al. Breast Cancer Res. 2011 Nov. 30; 13(6):R123);

[0136] F243L (Stewart R, Thom G, Levens M, et al. Protein Eng Des Sel. 2011 September; 24(9):671-8.), S298A/E333A/K334A (Shields R L, Namenuk A K, Hong K, et al. J Biol Chem. 2001 Mar. 2; 276(9):6591-604);

[0137] S239D/I332E/A330L, S239D/I332E (Lazar G A, Dang W, Karki S, et al. Proc Natl Acad Sci USA. 2006 Mar. 14; 103(11):4005-10);

[0138] S239D/S267E, S267E/L328F (Chu S Y, Vostiar I, Karki S, et al. Mol Immunol. 2008 September; 45(15):3926-33);

[0139] S239D/D265S/S298A/I332E, S239E/S298A/K326A/A327H, G237F/S298A/A33 0L/I332E, S239D/I332E/S298A, S239D/K326E/A330L/I332E/S298A, G236A/S239D/D270L/I3 32E, S239E/S267E/H268D, L234F/S267E/N325L, G237F/V266L/S267D and other mutations listed in WO2011/120134 and WO2011/120135, herein incorporated by reference. Therapeutic Antibody Engineering (by William R. Strohl and Lila M. Strohl, Woodhead Publishing series in Biomedicine No 11, ISBN 1 907568 37 9, October 2012) lists mutations on page 283.

[0140] In some embodiments an antigen-binding construct described herein comprises an antigen-binding polypeptide construct which binds an antigen; and a dimeric Fc that has superior biophysical properties like stability and ease of manufacture relative to an antigen-binding construct which does not include the same dimeric Fc. In some embodiments a CH2 domain comprises one or more asymmetric amino acid modifications. Exemplary asymmetric mutations are described in International Patent Application No. PCT/CA2014/050507.

[0141] Additional Modifications to Improve Effector Function.

[0142] In some embodiments an antigen-binding construct described herein includes modifications to improve its ability to mediate effector function. Such modifications are known in the art and include afucosylation, or engineering of the affinity of the Fc towards an activating receptor, mainly FCGR3a for ADCC, and towards C1q for CDC. The following Table B summarizes various designs reported in the literature for effector function engineering.

[0143] Methods of producing antigen-binding constructs with little or no fucose on the Fc glycosylation site (Asn 297 EU numbering) without altering the amino acid sequence are well known in the art. The GlymaX.RTM. technology (ProBioGen AG) is based on the introduction of a gene for an enzyme which deflects the cellular pathway of fucose biosynthesis into cells used for antigen-binding construct production. This prevents the addition of the sugar "fucose" to the N-linked antibody carbohydrate part by antigen-binding construct-producing cells. (von Horsten et al. (2010) Glycobiology. 2010 December; 20 (12):1607-18. Another approach to obtaining antigen-binding constructs with lowered levels of fucosylation can be found in U.S. Pat. No. 8,409,572, which teaches selecting cell lines for antigen-binding construct production for their ability to yield lower levels of fucosylation on antigen-binding constructs Antigen-binding constructs can be fully afucosylated (meaning they contain no detectable fucose) or they can be partially afucosylated, meaning that the isolated antibody contains less than 95%, less than 85%, less than 75%, less than 65%, less than 55%, less than 45%, less than 35%, less than 25%, less than 15% or less than 5% of the amount of fucose normally detected for a similar antibody produced by a mammalian expression system.

[0144] Thus, in one embodiment, an antigen-binding construct described herein can include a dimeric Fc that comprises one or more amino acid modifications as noted in Table B that confer improved effector function. In another embodiment, the antigen-binding construct can be afucosylated to improve effector function.

TABLE-US-00004 TABLE B CH2 domains and effector function engineering. Reference Mutations Effect Lu, 2011, Afucosylated Increased ADCC Ferrara 2011, Mizushima 2011 Lu, 2011 S298A/E333A/K334A Increased ADCC Lu, 2011 S298A/E333A/K334A/K326A Increased ADCC Stavenhagen, F243L/R292P/Y300L/V305I/ Increased ADCC 2007 P396L Nordstrom, 2011 F243L/R292P/Y300L/L235V/ Increased ADCC P396L Stewart, 2011 F243L Increased ADCC Shields, 2001 S298A/E333A/K334A Increased ADCC Lazar, 2006 S239D/I332E/A330L Increased ADCC Lazar, 2006 S239D/I332E Increased ADCC Bowles, 2006 AME-D, not specified mutations Increased ADCC Heider, 2011 37.1, mutations not disclosed Increased ADCC Moore, 2010 S267E/H268F/S324T Increased CDC

[0145] Fc modifications reducing Fc.gamma.R and/or complement binding and/or effector function are known in the art. Recent publications describe strategies that have been used to engineer antibodies with reduced or silenced effector activity (see Strohl, W R (2009), Curr Opin Biotech 20:685-691, and Strohl, W R and Strohl L M, "Antibody Fc engineering for optimal antibody performance" In Therapeutic Antibody Engineering, Cambridge: Woodhead Publishing (2012), pp 225-249). These strategies include reduction of effector function through modification of glycosylation, use of IgG2/IgG4 scaffolds, or the introduction of mutations in the hinge or CH2 regions of the Fc. For example, US Patent Publication No. 2011/0212087 (Strohl), International Patent Publication No. WO 2006/105338 (Xencor), US Patent Publication No. 2012/0225058 (Xencor), US Patent Publication No. 2012/0251531 (Genentech), and Strop et al ((2012) J. Mol. Biol. 420: 204-219) describe specific modifications to reduce Fc.gamma.R or complement binding to the Fc.

[0146] Specific, non-limiting examples of known amino acid modifications to reduce Fc.gamma.R or complement binding to the Fc include those identified in the following table:

TABLE-US-00005 TABLE C modifications to reduce Fc.gamma.R or complement binding to the Fc Company Mutations GSK N297A Ortho Biotech L234A/L235A Protein Design labs IGG2 V234A/G237A Wellcome Labs IGG4 L235A/G237A/E318A GSK IGG4 S228P/L236E Alexion IGG2/IGG4combo Merck IGG2 H268Q/V309L/A330S/A331S Bristol-Myers C220S/C226S/C229S/P238S Seattle Genetics C226S/C229S/E3233P/L235V/L235A Amgen E. coli production, non glyco Medimune L234F/L235E/P331S Trubion Hinge mutant, possibly C226S/P230S

[0147] In one embodiment, the Fc comprises at least one amino acid modification identified in the above table. In another embodiment the Fc comprises amino acid modification of at least one of L234, L235, or D265. In another embodiment, the Fc comprises amino acid modification at L234, L235 and D265. In another embodiment, the Fc comprises the amino acid modification L234A, L235A and D265S.

Linkers and Linker Polypeptides

[0148] In some embodiments, the antigen-binding constructs described herein include two antigen-binding polypeptide constructs. In these embodiments, the antigen-binding polypeptide constructs are each operatively linked to a linker polypeptide wherein the linker polypeptides are capable of forming a complex or interface with each other. In some embodiments, the linker polypeptides are capable of forming a covalent linkage with each other. The spatial conformation of the antigen-binding construct comprising a first and second antigen-binding polypeptide constructs with the linker polypeptides is similar to the relative spatial conformation of the paratopes of a F(ab')2 fragment generated by papain digestion, albeit in the context of an antigen-binding construct with 2 antigen-binding polypeptide constructs.

[0149] In some embodiments, the linker polypeptides are selected such that they maintain the relative spatial conformation of the paratopes of a F(ab') fragment, and are capable of forming a covalent bond equivalent to the disulphide bond in the core hinge of IgG. Suitable linker polypeptides include IgG hinge regions such as, for example those from IgG1, IgG2, or IgG4. Modified versions of these exemplary linkers can also be used. For example, modifications to improve the stability of the IgG4 hinge are known in the art (see for example, Labrijn et al. (2009) Nature Biotechnology 27, 767-771).

[0150] In one embodiment, the linker polypeptides are operatively linked to a scaffold as described here, for example an Fc. In some aspects, an Fc is coupled to the one or more antigen-binding polypeptide constructs with one or more linkers. In some aspects, Fc is coupled to the heavy chain of each antigen-binding polypeptide by a linker.

[0151] In other embodiments, the linker polypeptides are operatively linked to scaffolds other than an Fc. A number of alternate protein or molecular domains are know in the art and can be used to form selective pairs of two different antigen-binding polypeptides. An example is the leucine zipper domains such as Fos and Jun that selectively pair together [S A Kostelny, M S Cole, and J Y Tso. Formation of a bispecific antibody by the use of leucine zippers. J Immunol 1992 148:1547-53; Bernd J. Wranik, Erin L. Christensen, Gabriele Schaefer, Janet K. Jackman, Andrew C. Vendel, and Dan Eaton. LUZ-Y, a Novel Platform for the Mammalian Cell Production of Full-length IgG-bispecific AntibodiesJ. Biol. Chem. 2012 287: 43331-43339]. Alternately, other selectively pairing molecular pairs such as the barnase barstar pair [Deyev, S. M., Waibel, R., Lebedenko, E. N., Schubiger, A. P., and Pluckthun, A. (2003). Design of multivalent complexes using the barnase*barstar module. Nat Biotechnol 21, 1486-1492], DNA strand pairs [Zahida N. Chaudri, Michael Bartlet-Jones, George Panayotou, Thomas Klonisch, Ivan M. Roitt, Torben Lund, Peter J. Delves, Dual specificity antibodies using a double-stranded oligonucleotide bridge, FEBS Letters, Volume 450, Issues 1-2, 30 Apr. 1999, Pages 23-26], split fluorescent protein pairs [Ulrich Brinkmann, Alexander Haas. Fluorescent antibody fusion protein, its production and use, WO 2011135040 A1] can also be employed.

Affinity

[0152] In some embodiments, affinity is determined by SPR (surface plasmon resonance) and/or FACS (fluorescence activated cell sorting). In some embodiments, affinity is determined by SPR and/or FACS as described below.

Dissociation Constant (K) and Maximal Binding (Bmax)

[0153] In some embodiments, an antigen-binding construct is described by functional characteristics including but not limited to a dissociation constant and a maximal binding.

[0154] The term "dissociation constant (K.sub.D)" as used herein, is intended to refer to the equilibrium dissociation constant of a particular ligand-protein interaction. As used herein, ligand-protein interactions refer to, but are not limited to protein-protein interactions or antibody-antigen interactions. The K.sub.D measures the propensity of two proteins (e.g. AB) to dissociate reversibly into smaller components (A+B), and is define as the ratio of the rate of dissociation, also called the "off-rate (k.sub.off)", to the association rate, or "on-rate (k.sub.on)". Thus, K.sub.D equals k.sub.off/k.sub.on and is expressed as a molar concentration (M). It follows that the smaller the K.sub.D, the stronger the affinity of binding. Therefore, a K.sub.D of 1 mM indicates weak binding affinity compared to a K.sub.D of 1 nM. K.sub.D values for antigen-binding constructs can be determined using methods well established in the art. One method for determining the K.sub.D of an antigen-binding construct is by using surface plasmon resonance (SPR), typically using a biosensor system such as a Biacore.RTM. system. Isothermal titration calorimetry (ITC) is another method that can be used to determine.

[0155] The binding characteristics of an antigen-binding construct can be determined by various techniques. One of which is the measurement of binding to target cells expressing the antigen by flow cytometry (FACS, Fluorescence-activated cell sorting). Typically, in such an experiment, the target cells expressing the antigen of interest are incubated with antigen-binding constructs at different concentrations, washed, incubated with a secondary agent for detecting the antigen-binding construct, washed, and analyzed in the flow cytometer to measure the median fluorescent intensity (MFI) representing the strength of detection signal on the cells, which in turn is related to the number of antigen-binding constructs bound to the cells. The antigen-binding construct concentration vs. MFI data is then fitted into a saturation binding equation to yield two key binding parameters, Bmax and apparent K.sub.D.

[0156] Apparent K.sub.D, or apparent equilibrium dissociation constant, represents the antigen-binding construct concentration at which half maximal cell binding is observed. Evidently, the smaller the K.sub.D value, the smaller antigen-binding construct concentration is required to reach maximum cell binding and thus the higher is the affinity of the antigen-binding construct. The apparent K.sub.D is dependent on the conditions of the cell binding experiment, such as different receptor levels expressed on the cells and incubation conditions, and thus the apparent K.sub.D is generally different from the K.sub.D values determined from cell-free molecular experiments such as SPR and ITC. However, there is generally good agreement between the different methods.

[0157] The term "Bmax", or maximal binding, refers to the maximum antigen-binding construct binding level on the cells at saturating concentrations of antigen-binding construct. This parameter can be reported in the arbitrary unit MFI for relative comparison, or converted into an absolute value corresponding to the number of antigen-binding constructs bound to the cell with the use of a standard curve.

Testing of Antigen-Binding Constructs: HER2 Binding

[0158] The antigen-binding constructs or pharmaceutical compositions described herein are tested in vitro, and then in vivo for the desired therapeutic or prophylactic activity, prior to use in humans. For example, in vitro assays to demonstrate the therapeutic or prophylactic utility of a compound or pharmaceutical composition include, the effect of a compound on a cell line or a patient tissue sample. The effect of the compound or composition on the cell line and/or tissue sample can be determined utilizing techniques known to those of skill in the art including, but not limited to, rosette formation assays and cell lysis assays. In accordance with the invention, in vitro assays which can be used to determine whether administration of a specific antigen-binding construct is indicated, include in vitro cell culture assays, or in vitro assays in which a patient tissue sample is grown in culture, and exposed to or otherwise administered antigen-binding construct, and the effect of such antigen-binding construct upon the tissue sample is observed.

[0159] Candidate antigen-binding constructs can be assayed using cells, e.g., breast cancer cell lines, expressing HER2. The following Table D describes the expression level of HER2 in several representative cancer cell lines.

TABLE-US-00006 TABLE D Relative expression levels of HER2 in cell lines of interest. IHC HER2 Cell Line Description scoring receptors/cell NCI-N87 Human gastric carcinoma 3+ Not assessed A549 Human lung alveolar 0/1+ Not assessed carcinoma (non-small cell lung cancer) BxPC-3 Human pancreatic 1+ Not assessed adenocarcinoma MIA Human pancreatic ductal 2+ Not assessed PaCa-2 adenocarcinoma FaDu Human pharyngeal 2+ Not assessed squamous cell carcinoma HCT-116 Human colorectal 1+ Not assessed epithelial carcinoma WI-38 Normal fetal lung 0 1.0 .times. 10E4 MDA- Human triple negative 0/1+ 1.7 .times. 10E4-2.3 .times. 10E4 MB-231 breast epithelial adenocarcinoma MCF-7 Human estrogen receptor 1+ 4 .times. 10E4-7 .times. 10E4 positive breast epithelial adenocarcinoma JIMT-1 Trastuzumab resistant 2+ 2 .times. 10E5-8 .times. 10E5 breast epithelial carcinoma, amplified HER2 oncogene, insensitive to HER2-inhibiting drugs (i.e. Herceptin .TM.) ZR-75-1 Estrogen receptor 2+ 3 .times. 10E5 positive breast ductal carcinoma SKOV-3 Human ovarian epithelial 2/3+ 5 .times. 10E5-1 .times. 10E6 adenocarcinoma, HER2 gene amplified SK-BR-3 Human breast epithelial 3+ >1 .times. 10E6 adenocarcinoma BT-474 Human breast epithelial 3+ >1 .times. 10E6 ductal carcinoma,

[0160] McDonagh et al Mol Cancer Ther. 2012 March; 11(3):582-93; Subik et al. (2010) Breast Cancer: Basic Clinical Research: 4; 35-41; Carter et al. PNAS, 1994:89; 4285-4289; Yarden 2000, HER2: Basic Research, Prognosis and Therapy; Hendricks et al Mol Cancer Ther 2013; 12:1816-28.

[0161] As is known in the art, a number of assays may be employed in order to identify antigen-binding constructs suitable for use in the methods described herein. These assays can be carried out in cancer cells expressing HER2. Examples of suitable cancer cells are identified in Table A5. Examples of assays that may be carried out are described as follows.

[0162] For example, to identify growth inhibitory candidate antigen-binding constructs that bind HER2, one may screen for antibodies which inhibit the growth of cancer cells which express HER2. In one embodiment, the candidate antigen-binding construct of choice is able to inhibit growth of cancer cells in cell culture by about 20-100% and preferably by about 50-100% at compared to a control antigen-binding construct.

[0163] To select for candidate antigen-binding constructs which induce cell death, loss of membrane integrity as indicated by, e.g., PI (phosphatidylinositol), trypan blue or 7AAD uptake may be assessed relative to control.

[0164] In order to select for candidate antigen-binding constructs which induce apoptosis, an annexin binding assay may be employed. In addition to the annexin binding assay, a DNA staining assay may also be used.

[0165] In one embodiment, the candidate antigen-binding construct of interest may block heregulin dependent association of ErbB2 with ErbB3 in both MCF7 and SK-BR-3 cells as determined in a co-immunoprecipitation experiment substantially more effectively than monoclonal antibody 4D5, and preferably substantially more effectively than monoclonal antibody 7F3.

[0166] To screen for antigen-binding constructs which bind to an epitope on ErbB2 bound by an antibody of interest, a routine cross-blocking assay such as that described in Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory, Ed Harlow and David Lane (1988), can be performed. Alternatively, or additionally, epitope mapping can be performed by methods known in the art.

[0167] Competition between antigen-binding constructs can be determined by an assay in which an antigen-binding construct under test inhibits or blocks specific binding of a reference antigen-binding construct to a common antigen (see, e.g., Junghans et al., Cancer Res. 50:1495, 1990; Fendly et al. Cancer Research 50: 1550-1558; U.S. Pat. No. 6,949,245). A test antigen-binding construct competes with a reference antigen-binding construct if an excess of a test antigen-binding construct (e.g., at least 2.times., 5.times., 10.times., 20.times., or 100.times.) inhibits or blocks binding of the reference antigen-binding construct by, e.g., at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% as measured in a competitive binding assay. Antigen-binding constructs identified by competition assay (competing antigen-binding construct) include antigen-binding constructs binding to the same epitope as the reference antigen-binding construct and antigen-binding constructs binding to an adjacent epitope sufficiently proximal to the epitope bound by the reference antigen-binding construct for steric hindrance to occur. For example, a second, competing antigen-binding construct can be identified that competes for binding to HER2 with a first antigen-binding construct described herein. In certain instances, the second construct can block or inhibit binding of the first construct by, e.g., at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% as measured in a competitive binding assay. In certain instances, the second construct can displace the first construct by greater than 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, or 99%.

[0168] In some embodiments, antigen-binding constructs described herein are assayed for function in vivo, e.g., in animal models. In some embodiments, the animal models are those described in Table E. In some embodiments, the animal models are those described in the Examples. In some embodiments, the antigen-binding constructs display an increase in efficacy of treatment in an animal model compared to a reference antigen-binding construct.

TABLE-US-00007 TABLE E Animal models for testing HER2 binding antigen-binding constructs Xenograft Model Description Reference SKOV3 human HER2+/3+, gene amplified, Rhodes et al. 2002. American Journal of ovarian cancer moderately sensitive to trastuzumab Pathology 118: 408-417; Sims et al. 2012. British Journal of Cancer 106: 1779-1789 HBCx-13b human HER2 3+, estrogen receptor negative, Marangoni et al. 2007. Clinical Cancer metastatic progesterone receptor negative; Research 13: 3989-3998; Reyal et al. 2012. breast cancer Invasive ductal breast carcinoma; Breast Cancer Research 14: R11 Chemotherapy resistant, Trastuzumab resistant T226 human HER2 3+, estrogen receptor negative, breast cancer progesterone receptor negative; Inflammatory breast cancer; Trastuzumab resistant, Docetaxel and capecitabine moderately sensitive, Adriamycin/cyclophosphamide sensitive HBCx-5 human HER2 3+, estrogen receptor negative, Marangoni et al. 2007. Clinical Cancer breast cancer progesterone receptor negative; Research 13: 3989-3998; Reyal et al. 2012. Invasive ductal carcinoma, luminal B; Breast Cancer Research 14: R11 Trastuzumab resistant, Docetaxel moderately sensitive, Capecitabine, Adriamycin/Cyclophosphamide sensitive JIMT-1 human HER2 2+, HER2 gene amplified, Tanner et al. 2004. Molecular Cancer breast cancer Trastuzumab and pertuzumab Therapeutics 3: 1585-1592 resistant

Reference Antigen-Binding Construct

[0169] In some embodiments, the functional characteristics of the antigen-binding constructs described herein are compared to those of a reference antigen-binding construct. The identity of the reference antigen-binding construct depends on the functional characteristic being measured or the distinction being made. For example, when comparing the functional characteristics of antigen-binding constructs described herein, the reference antigen-binding construct may be a trastuzumab (for example v6336), or analog thereof, or may be a control IgG, for example a non-specific polyclonal human antibody.

Antigen-Binding Constructs and Antibody Drug Conjugates (ADC)

[0170] In certain embodiments an antigen-binding construct is conjugated to a drug, e.g., a toxin, a chemotherapeutic agent, an immune modulator, or a radioisotope. Several methods of preparing ADCs (antibody drug conjugates or antigen-binding construct drug conjugates) are known in the art and are described below.

[0171] In some embodiments, the drug is selected from a maytansine, auristatin, calicheamicin, or derivative thereof. In other embodiments, the drug is a maytansine selected from DM1 and DM4. Further examples are described below.

[0172] In some embodiments the drug is conjugated to the isolated antigen-binding construct with an SMCC linker (DM1), or an SPDB linker (DM4). Additional examples are described below. The drug-to-antigen-binding protein ratio (DAR) can be, e.g., 1.0 to 6.0 or 3.0 to 5.0 or 3.5-4.2.

[0173] In some embodiments the antigen-binding construct is conjugated to a cytotoxic agent. The term "cytotoxic agent" as used herein refers to a substance that inhibits or prevents the function of cells and/or causes destruction of cells. The term is intended to include radioactive isotopes (e.g. At211, I131, I125, Y90, Re186, Re188, Sm153, Bi212, P32, and Lu177), chemotherapeutic agents, and toxins such as small molecule toxins or enzymatically active toxins of bacterial, fungal, plant or animal origin, including fragments and/or variants thereof. Further examples are described below.

[0174] Drugs

[0175] Non-limiting examples of drugs or payloads used in various embodiments of ADCs include DM1 (maytansine, N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)- or N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine), mc-MMAD (6-maleimidocaproyl-monomethylauristatin-D or N-methyl-L-valyl-N-[(1S,2R)-2-methoxy-4-[(2S)-2-[(1R,2R)-1-methoxy-2-meth- yl-3-oxo-3-[[(1S)-2-phenyl-1-(2-thiazolyl)ethyl]amino]propyl]-1-pyrrolidin- yl]-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-(9Cl)-L-valinamide), mc-MMAF (maleimidocaproyl-monomethylauristatin F or N-[6-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxohexyl]-N-methyl-L-valyl-- L-valyl-(3R,4S,5S)-3-methoxy-5-methyl-4-(methylamino)heptanoyl-(.alpha.R, .beta.R,2S)-.beta.-methoxy-.alpha.-methyl-2-pyrrolidinepropanoyl-L-phenyl- alanine) and mc-Val-Cit-PABA-MMAE (6-maleimidocaproyl-ValcCit-(p-aminobenzyloxycarbonyl)-monomethylauristat- in E or N-[[[4-[[N-[6-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxohexyl]-L- -valyl-N5-(aminocarbonyl)-L-ornithyl]amino]phenyl]methoxy]carbonyl]-N-meth- yl-L-valyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[[(1R,2S)-2-hydroxy-1-methyl-2-- phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]-1-pyrrolidinyl]-2-metho- xy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide). DM1 is a derivative of the tubulin inhibitor maytansine while MMAD, MMAE, and MMAF are auristatin derivatives.

[0176] Maytansinoid Drug Moieties

[0177] As indicated above, in some embodiments the drug is a maytansinoid. Exemplary maytansinoids include DM1, DM3 (N.sup.2'-deacetyl-N.sup.2'-(4-mercapto-1-oxopentyl) maytansine), and DM4 (N.sup.2'-deacetyl-N.sup.2'-(4-methyl-4-mercapto-1-oxopentyl)methylmaytan- sine) (see US20090202536).

[0178] Many positions on maytansine compounds are known to be useful as the linkage position, depending upon the type of link. For example, for forming an ester linkage, the C-3 position having a hydroxyl group, the C-14 position modified with hydroxymethyl, the C-15 position modified with a hydroxyl group and the C-20 position having a hydroxyl group are all suitable.

[0179] All stereoisomers of the maytansinoid drug moiety are contemplated for the ADCs described herein, i.e. any combination of R and S configurations at the chiral carbons of D.

[0180] Auristatins

[0181] In some embodiments, the drug is an auristatin, such as auristatin E (also known in the art as a derivative of dolastatin-10) or a derivative thereof. The auristatin can be, for example, an ester formed between auristatin E and a keto acid. For example, auristatin E can be reacted with paraacetyl benzoic acid or benzoylvaleric acid to produce AEB and AEVB, respectively. Other typical auristatins include AFP, MMAF, and MMAE. The synthesis and structure of exemplary auristatins are described in U.S. Pat. Nos. 6,884,869, 7,098,308, 7,256,257, 7,423,116, 7,498,298 and 7,745,394, each of which is incorporated by reference herein in its entirety and for all purposes.

[0182] Chemotherapeutic Agents

[0183] In some embodiments the antigen-binding construct is conjugated to a chemotherapeutic agent. Examples include but are not limited to Cisplantin and Lapatinib. A "chemotherapeutic agent" is a chemical compound useful in the treatment of cancer.

[0184] Examples of chemotherapeutic agents include alkylating agents such as thiotepa and cyclosphosphamide (CYTOXAN.TM.); alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelamines including altretamine, triethylenemelamine, trietylenephosphoramide, triethylenethiophosphaoramide and trimethylolomelamine; nitrogen mustards such as chlorambucil, chlomaphazine, cholophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard; nitrosureas such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, ranimustine; antibiotics such as aclacinomysins, actinomycin, authramycin, azaserine, bleomycins, cactinomycin, calicheamicin, carabicin, carminomycin, carzinophilin, chromomycins, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin, epirubicin, esorubicin, idarubicin, marcellomycin, mitomycins, mycophenolic acid, nogalamycin, olivomycins, peplomycin, potfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin; anti-metabolites such as methotrexate and 5-fluorouracil (5-FU); folic acid analogues such as denopterin, methotrexate, pteropterin, trimetrexate; purine analogs such as fludarabine, 6-mercaptopurine, thiamiprine, thioguanine; pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine, 5-FU; androgens such as calusterone, dromostanolone propionate, epitiostanol, mepitiostane, testolactone; anti-adrenals such as aminoglutethimide, mitotane, trilostane; folic acid replenisher such as frolinic acid; aceglatone; aldophosphamide glycoside; aminolevulinic acid; amsacrine; bestrabucil; bisantrene; edatraxate; defofamine; demecolcine; diaziquone; elfornithine; elliptinium acetate; etoglucid; gallium nitrate; hydroxyurea; lentinan; lonidamine; mitoguazone; mitoxantrone; mopidamol; nitracrine; pentostatin; phenamet; pirarubicin; podophyllinic acid; 2-ethylhydrazide; procarbazine; PSK7; razoxane; sizofiran; spirogermanium; tenuazonic acid; triaziquone; 2, 2',2'=-trichlorotriethylamine; urethan; vindesine; dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside ("Ara-C"); cyclophosphamide; thiotepa; taxanes, e.g. paclitaxel (TAXOL.RTM., Bristol-Myers Squibb Oncology, Princeton, N.J.) and doxetaxel (TAXOTERE.RTM., Rhone-Poulenc Rorer, Antony, France); chlorambucil; gemcitabine; 6-thioguanine; mercaptopurine; methotrexate; platinum analogs such as cisplatin and carboplatin; vinblastine; platinum; etoposide (VP-16); ifosfamide; mitomycin C; mitoxantrone; vincristine; vinorelbine; navelbine; novantrone; teniposide; daunomycin; aminopterin; xeloda; ibandronate; CPT-11; topoisomerase inhibitor RFS 2000; difluoromethylornithine (DMFO); retinoic acid; esperamicins; capecitabine; and pharmaceutically acceptable salts, acids or derivatives of any of the above. Also included in this definition are anti-hormonal agents that act to regulate or inhibit hormone action on tumors such as anti-estrogens including for example tamoxifen, raloxifene, aromatase inhibiting 4(5)-imidazoles, 4-hydroxytamoxifen, trioxifene, keoxifene, LY117018, onapristone, and toremifene (Fareston); and anti-androgens such as flutamide, nilutamide, bicalutamide, leuprolide, and goserelin; and pharmaceutically acceptable salts, acids or derivatives of any of the above.

[0185] Conjugate Linkers

[0186] In some embodiments, the drug is linked to the antigen-binding construct, e.g., antibody, by a linker. Attachment of a linker to an antibody can be accomplished in a variety of ways, such as through surface lysines, reductive-coupling to oxidized carbohydrates, and through cysteine residues liberated by reducing interchain disulfide linkages. A variety of ADC linkage systems are known in the art, including hydrazone-, disulfide- and peptide-based linkages.

[0187] Suitable linkers include, for example, cleavable and non-cleavable linkers. A cleavable linker is typically susceptible to cleavage under intracellular conditions. Suitable cleavable linkers include, for example, a peptide linker cleavable by an intracellular protease, such as lysosomal protease or an endosomal protease. In exemplary embodiments, the linker can be a dipeptide linker, such as a valine-citrulline (val-cit), a phenylalanine-lysine (phe-lys) linker, or maleimidocapronic-valine-citruline-p-aminobenzyloxycarbonyl (mc-Val-Cit-PABA) linker. Another linker is Sulfosuccinimidyl-4-[N-maleimidomethyl]cyclohexane-1-carboxylate (SMCC). Sulfo-smcc conjugation occurs via a maleimide group which reacts with sulfhydryls (thiols, --SH), while its Sulfo-NHS ester is reactive toward primary amines (as found in Lysine and the protein or peptide N-terminus). Yet another linker is maleimidocaproyl (MC). Other suitable linkers include linkers hydrolyzable at a specific pH or a pH range, such as a hydrazone linker. Additional suitable cleavable linkers include disulfide linkers. The linker may be covalently bound to the antibody to such an extent that the antibody must be degraded intracellularly in order for the drug to be released e.g. the MC linker and the like.

[0188] Preparation of ADCs

[0189] The ADC may be prepared by several routes, employing organic chemistry reactions, conditions, and reagents known to those skilled in the art, including: (1) reaction of a nucleophilic group or an electrophilic group of an antibody with a bivalent linker reagent, to form antibody-linker intermediate Ab-L, via a covalent bond, followed by reaction with an activated drug moiety D; and (2) reaction of a nucleophilic group or an electrophilic group of a drug moiety with a linker reagent, to form drug-linker intermediate D-L, via a covalent bond, followed by reaction with the nucleophilic group or an electrophilic group of an antibody. Conjugation methods (1) and (2) may be employed with a variety of antibodies, drug moieties, and linkers to prepare the antibody-drug conjugates described here.

[0190] Several specific examples of methods of preparing ADCs are known in the art and are described in U.S. Pat. No. 8,624,003 (pot method), U.S. Pat. No. 8,163,888 (one-step), and U.S. Pat. No. 5,208,020 (two-step method).

Methods of Preparation of Antigen-Binding Constructs

[0191] Antigen-binding constructs described herein may be produced using recombinant methods and compositions, e.g., as described in U.S. Pat. No. 4,816,567.

[0192] In one embodiment, isolated nucleic acid encoding an antigen-binding construct described herein is provided. Such nucleic acid may encode an amino acid sequence comprising the VL and/or an amino acid sequence comprising the VH of the antigen-binding construct (e.g., the light and/or heavy chains of the antigen-binding construct). In a further embodiment, one or more vectors (e.g., expression vectors) comprising such nucleic acid are provided. In one embodiment, the nucleic acid is provided in a multicistronic vector. In a further embodiment, a host cell comprising such nucleic acid is provided. In one such embodiment, a host cell comprises (e.g., has been transformed with): (1) a vector comprising a nucleic acid that encodes an amino acid sequence comprising the VL of the antigen-binding construct and an amino acid sequence comprising the VH of the antigen-binding polypeptide construct, or (2) a first vector comprising a nucleic acid that encodes an amino acid sequence comprising the VL of the antigen-binding polypeptide construct and a second vector comprising a nucleic acid that encodes an amino acid sequence comprising the VH of the antigen-binding polypeptide construct. In one embodiment, the host cell is eukaryotic, e.g. a Chinese Hamster Ovary (CHO) cell, or human embryonic kidney (HEK) cell, or lymphoid cell (e.g., Y0, NS0, Sp20 cell). In one embodiment, a method of making an antigen-binding construct is provided, wherein the method comprises culturing a host cell comprising nucleic acid encoding the antigen-binding construct, as provided above, under conditions suitable for expression of the antigen-binding construct, and optionally recovering the antigen-binding construct from the host cell (or host cell culture medium).

[0193] For recombinant production of the antigen-binding construct, nucleic acid encoding an antigen-binding construct, e.g., as described above, is isolated and inserted into one or more vectors for further cloning and/or expression in a host cell. Such nucleic acid may be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of the antigen-binding construct).

[0194] The term "substantially purified" refers to a construct described herein, or variant thereof that may be substantially or essentially free of components that normally accompany or interact with the protein as found in its naturally occurring environment, i.e. a native cell, or host cell in the case of recombinantly produced heteromultimer that in certain embodiments, is substantially free of cellular material includes preparations of protein having less than about 30%, less than about 25%, less than about 20%, less than about 15%, less than about 10%, less than about 5%, less than about 4%, less than about 3%, less than about 2%, or less than about 1% (by dry weight) of contaminating protein. When the heteromultimer or variant thereof is recombinantly produced by the host cells, the protein in certain embodiments is present at about 30%, about 25%, about 20%, about 15%, about 10%, about 5%, about 4%, about 3%, about 2%, or about 1% or less of the dry weight of the cells. When the heteromultimer or variant thereof is recombinantly produced by the host cells, the protein, in certain embodiments, is present in the culture medium at about 5 g/L, about 4 g/L, about 3 g/L, about 2 g/L, about 1 g/L, about 750 mg/L, about 500 mg/L, about 250 mg/L, about 100 mg/L, about 50 mg/L, about 10 mg/L, or about 1 mg/L or less of the dry weight of the cells. In certain embodiments, "substantially purified" heteromultimer produced by the methods described herein, has a purity level of at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, specifically, a purity level of at least about 75%, 80%, 85%, and more specifically, a purity level of at least about 90%, a purity level of at least about 95%, a purity level of at least about 99% or greater as determined by appropriate methods such as SDS/PAGE analysis, RP-HPLC, SEC, and capillary electrophoresis.

[0195] Suitable host cells for cloning or expression of antigen-binding construct-encoding vectors include prokaryotic or eukaryotic cells described herein.

[0196] A "recombinant host cell" or "host cell" refers to a cell that includes an exogenous polynucleotide, regardless of the method used for insertion, for example, direct uptake, transduction, f-mating, or other methods known in the art to create recombinant host cells. The exogenous polynucleotide may be maintained as a nonintegrated vector, for example, a plasmid, or alternatively, may be integrated into the host genome.

[0197] As used herein, the term "eukaryote" refers to organisms belonging to the phylogenetic domain Eucarya such as animals (including but not limited to, mammals, insects, reptiles, birds, etc.), ciliates, plants (including but not limited to, monocots, dicots, algae, etc.), fungi, yeasts, flagellates, microsporidia, protists, etc.

[0198] As used herein, the term "prokaryote" refers to prokaryotic organisms. For example, a non-eukaryotic organism can belong to the Eubacteria (including but not limited to, Escherichia coli, Thermus thermophilus, Bacillus stearothermophilus, Pseudomonas fluorescens, Pseudomonas aeruginosa, Pseudomonas putida, etc.) phylogenetic domain, or the Archaea (including but not limited to, Methanococcus jannaschii, Methanobacterium thermoautotrophicum, Halobacterium such as Haloferax volcanii and Halobacterium species NRC-1, Archaeoglobus fulgidus, Pyrococcus furiosus, Pyrococcus horikoshii, Aeuropyrum pemix, etc.) phylogenetic domain.

[0199] For example, antigen-binding construct may be produced in bacteria, in particular when glycosylation and Fc effector function are not needed. For expression of antigen-binding construct fragments and polypeptides in bacteria, see, e.g., U.S. Pat. Nos. 5,648,237, 5,789,199, and 5,840,523. (See also Charlton, Methods in Molecular Biology, Vol. 248 (B.K.C. Lo, ed., Humana Press, Totowa, N.J., 2003), pp. 245-254, describing expression of antibody fragments in E. coli.) After expression, the antigen-binding construct may be isolated from the bacterial cell paste in a soluble fraction and can be further purified.

[0200] In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for antigen-binding construct-encoding vectors, including fungi and yeast strains whose glycosylation pathways have been "humanized," resulting in the production of an antigen-binding construct with a partially or fully human glycosylation pattern. See Gerngross, Nat. Biotech. 22:1409-1414 (2004), and Li et al., Nat. Biotech. 24:210-215 (2006).

[0201] Suitable host cells for the expression of glycosylated antigen-binding constructs are also derived from multicellular organisms (invertebrates and vertebrates). Examples of invertebrate cells include plant and insect cells. Numerous baculoviral strains have been identified which may be used in conjunction with insect cells, particularly for transfection of Spodoptera frugiperda cells.

[0202] Plant cell cultures can also be utilized as hosts. See, e.g., U.S. Pat. Nos. 5,959,177, 6,040,498, 6,420,548, 7,125,978, and 6,417,429 (describing PLANTIBODIES.TM. technology for producing antigen-binding constructs in transgenic plants).

[0203] Vertebrate cells may also be used as hosts. For example, mammalian cell lines that are adapted to grow in suspension may be useful. Other examples of useful mammalian host cell lines are monkey kidney CV1 line transformed by SV40 (COS-7); human embryonic kidney line (293 or 293 cells as described, e.g., in Graham et al., J Gen Virol. 36:59 (1977)); baby hamster kidney cells (BHK); mouse sertoli cells (TM4 cells as described, e.g., in Mather, Biol. Reprod. 23:243-251 (1980)); monkey kidney cells (CV1); African green monkey kidney cells (VERO-76); human cervical carcinoma cells (HELA); canine kidney cells (MDCK; buffalo rat liver cells (BRL 3A); human lung cells (W138); human liver cells (Hep G2); mouse mammary tumor (MMT 060562); TRI cells, as described, e.g., in Mather et al., Annals N.Y. Acad. Sci. 383:44-68 (1982); MRC 5 cells; and FS4 cells. Other useful mammalian host cell lines include Chinese hamster ovary (CHO) cells, including DHFR CHO cells (Urlaub et al., Proc. Natl. Acad. Sci. USA 77:4216 (1980)); and myeloma cell lines such as Y0, NS0 and Sp2/0. For a review of certain mammalian host cell lines suitable for antigen-binding construct production, see, e.g., Yazaki and Wu, Methods in Molecular Biology, Vol. 248 (B.K.C. Lo, ed., Humana Press, Totowa, N.J.), pp. 255-268 (2003).

[0204] In one embodiment, the antigen-binding constructs described herein are produced in stable mammalian cells, by a method comprising: transfecting at least one stable mammalian cell with: nucleic acid encoding the antigen-binding construct, in a predetermined ratio; and expressing the nucleic acid in the at least one mammalian cell. In some embodiments, the predetermined ratio of nucleic acid is determined in transient transfection experiments to determine the relative ratio of input nucleic acids that results in the highest percentage of the antigen-binding construct in the expressed product.

[0205] In some embodiments is the method of producing a antigen-binding construct in stable mammalian cells as described herein wherein the expression product of the at least one stable mammalian cell comprises a larger percentage of the desired glycosylated antigen-binding construct as compared to the monomeric heavy or light chain polypeptides, or other antibodies.

[0206] In some embodiments is the method of producing a glycosylated antigen-binding construct in stable mammalian cells described herein, said method comprising identifying and purifying the desired glycosylated antigen-binding construct. In some embodiments, the said identification is by one or both of liquid chromatography and mass spectrometry.

[0207] If required, the antigen-binding constructs can be purified or isolated after expression. Proteins may be isolated or purified in a variety of ways known to those skilled in the art. Standard purification methods include chromatographic techniques, including ion exchange, hydrophobic interaction, affinity, sizing or gel filtration, and reversed-phase, carried out at atmospheric pressure or at high pressure using systems such as FPLC and HPLC. Purification methods also include electrophoretic, immunological, precipitation, dialysis, and chromatofocusing techniques. Ultrafiltration and diafiltration techniques, in conjunction with protein concentration, are also useful. As is well known in the art, a variety of natural proteins bind Fc and antibodies, and these proteins can find use in the present invention for purification of antigen-binding constructs. For example, the bacterial proteins A and G bind to the Fc region. Likewise, the bacterial protein L binds to the Fab region of some antibodies. Purification can often be enabled by a particular fusion partner. For example, antibodies may be purified using glutathione resin if a GST fusion is employed, Ni.sup.+2 affinity chromatography if a His-tag is employed, or immobilized anti-flag antibody if a flag-tag is used. For general guidance in suitable purification techniques, see, e.g. incorporated entirely by reference Protein Purification: Principles and Practice, 3.sup.rd Ed., Scopes, Springer-Verlag, N.Y., 1994, incorporated entirely by reference. The degree of purification necessary will vary depending on the use of the antigen-binding constructs. In some instances no purification is necessary.

[0208] In certain embodiments the antigen-binding constructs are purified using Anion Exchange Chromatography including, but not limited to, chromatography on Q-sepharose, DEAE sepharose, poros HQ, poros DEAF, Toyopearl Q, Toyopearl QAE, Toyopearl DEAE, Resource/Source Q and DEAE, Fractogel Q and DEAE columns.

[0209] In specific embodiments the proteins described herein are purified using Cation Exchange Chromatography including, but not limited to, SP-sepharose, CM sepharose, poros HS, poros CM, Toyopearl SP, Toyopearl CM, Resource/Source S and CM, Fractogel S and CM columns and their equivalents and comparables.

[0210] In addition, antigen-binding constructs described herein can be chemically synthesized using techniques known in the art (e.g., see Creighton, 1983, Proteins: Structures and Molecular Principles, W. H. Freeman & Co., N.Y and Hunkapiller et al., Nature, 310:105-111 (1984)). For example, a polypeptide corresponding to a fragment of a polypeptide can be synthesized by use of a peptide synthesizer. Furthermore, if desired, nonclassical amino acids or chemical amino acid analogs can be introduced as a substitution or addition into the polypeptide sequence. Non-classical amino acids include, but are not limited to, to the D-isomers of the common amino acids, 2,4diaminobutyric acid, alpha-amino isobutyric acid, 4aminobutyric acid, Abu, 2-amino butyric acid, g-Abu, e-Ahx, 6amino hexanoic acid, Aib, 2-amino isobutyric acid, 3-amino propionic acid, ornithine, norleucine, norvaline, hydroxyproline, sarcosine, citrulline, homocitrulline, cysteic acid, t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine, .quadrature.-alanine, fluoro-amino acids, designer amino acids such as .quadrature.-methyl amino acids, C.quadrature.-methyl amino acids, N.quadrature.-methyl amino acids, and amino acid analogs in general. Furthermore, the amino acid can be D (dextrorotary) or L (levorotary).

[0211] Post-Translational Modifications:

[0212] In certain embodiments antigen-binding constructs described herein are differentially modified during or after translation.

[0213] The term "modified," as used herein refers to any changes made to a given polypeptide, such as changes to the length of the polypeptide, the amino acid sequence, chemical structure, co-translational modification, or post-translational modification of a polypeptide. The form "(modified)" term means that the polypeptides being discussed are optionally modified, that is, the polypeptides under discussion can be modified or unmodified.

[0214] The term "post-translationally modified" refers to any modification of a natural or non-natural amino acid that occurs to such an amino acid after it has been incorporated into a polypeptide chain. The term encompasses, by way of example only, co-translational in vivo modifications, co-translational in vitro modifications (such as in a cell-free translation system), post-translational in vivo modifications, and post-translational in vitro modifications.

[0215] In some embodiments, the modification is at least one of: glycosylation, acetylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage and linkage to an antibody molecule or antigen-binding construct or other cellular ligand. In some embodiments, the antigen-binding construct is chemically modified by known techniques, including but not limited, to specific chemical cleavage by cyanogen bromide, trypsin, chymotrypsin, papain, V8 protease, NaBH.sub.4; acetylation, formylation, oxidation, reduction; and metabolic synthesis in the presence of tunicamycin.

[0216] Additional post-translational modifications of antigen-binding constructs described herein include, for example, N-linked or O-linked carbohydrate chains, processing of N-terminal or C-terminal ends), attachment of chemical moieties to the amino acid backbone, chemical modifications of N-linked or O-linked carbohydrate chains, and addition or deletion of an N-terminal methionine residue as a result of procaryotic host cell expression. The antigen-binding constructs described herein are modified with a detectable label, such as an enzymatic, fluorescent, isotopic or affinity label to allow for detection and isolation of the protein. In certain embodiments, examples of suitable enzyme labels include horseradish peroxidase, alkaline phosphatase, beta-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin; and examples of suitable radioactive material include iodine, carbon, sulfur, tritium, indium, technetium, thallium, gallium, palladium, molybdenum, xenon, fluorine.

[0217] In specific embodiments, antigen-binding constructs described herein are attached to macrocyclic chelators that associate with radiometal ions.

[0218] In some embodiments, the antigen-binding constructs described herein are modified by either natural processes, such as post-translational processing, or by chemical modification techniques which are well known in the art. In certain embodiments, the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. In certain embodiments, polypeptides from antigen-binding constructs described herein are branched, for example, as a result of ubiquitination, and in some embodiments are cyclic, with or without branching. Cyclic, branched, and branched cyclic polypeptides are a result from posttranslation natural processes or made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphotidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristylation, oxidation, pegylation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. (See, for instance, PROTEINS--STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York (1993); POST-TRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B. C. Johnson, Ed., Academic Press, New York, pgs. 1-12 (1983); Seifter et al., Meth. Enzymol. 182:626-646 (1990); Rattan et al., Ann. N.Y. Acad. Sci. 663:48-62 (1992)).

[0219] In certain embodiments, antigen-binding constructs described herein are attached to solid supports, which are particularly useful for immunoassays or purification of polypeptides that are bound by, that bind to, or associate with proteins described herein. Such solid supports include, but are not limited to, glass, cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride or polypropylene.

Pharmaceutical Compositions

[0220] Also provided herein are pharmaceutical compositions comprising an antigen-binding construct described herein. Pharmaceutical compositions comprise the construct and a pharmaceutically acceptable carrier.

[0221] The term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which the therapeutic is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. In some aspects, the carrier is a man-made carrier not found in nature. Water can be used as a carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. These compositions can take the form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, sustained-release formulations and the like. The composition can be formulated as a suppository, with traditional binders and carriers such as triglycerides. Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Examples of suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E. W. Martin. Such compositions will contain a therapeutically effective amount of the compound, preferably in purified form, together with a suitable amount of carrier so as to provide the form for proper administration to the patient. The formulation should suit the mode of administration.

[0222] In certain embodiments, the composition comprising the construct is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to human beings. Typically, compositions for intravenous administration are solutions in sterile isotonic aqueous buffer. Where necessary, the composition may also include a solubilizing agent and a local anesthetic such as lignocaine to ease pain at the site of the injection. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the composition is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.

[0223] In certain embodiments, the compositions described herein are formulated as neutral or salt forms. Pharmaceutically acceptable salts include those formed with anions such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., and those formed with cations such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxide isopropylamine, triethylamine, 2-ethylamino ethanol, histidine, procaine, etc.

Methods of Treatment

[0224] In certain embodiments, provided is a method of treating a disease or disorder comprising administering to a subject in which such treatment, prevention or amelioration is desired, an antigen-binding construct described herein, in an amount effective to treat, prevent or ameliorate the disease or disorder.

[0225] "Disorder" refers to any condition that would benefit from treatment with an antigen-binding construct or method described herein. This includes chronic and acute disorders or diseases including those pathological conditions which predispose the mammal to the disorder in question. In some embodiments, the disorder is cancer, as described in more detail below.

[0226] The term "subject" refers to an animal, in some embodiments a mammal, which is the object of treatment, observation or experiment. An animal may be a human, a non-human primate, a companion animal (e.g., dogs, cats, and the like), farm animal (e.g., cows, sheep, pigs, horses, and the like) or a laboratory animal (e.g., rats, mice, guinea pigs, and the like).

[0227] The term "mammal" as used herein includes but is not limited to humans, non-human primates, canines, felines, murines, bovines, equines, and porcines.

[0228] "Treatment" refers to clinical intervention in an attempt to alter the natural course of the individual or cell being treated, and can be performed either for prophylaxis or during the course of clinical pathology. Desirable effects of treatment include preventing occurrence or recurrence of disease, alleviation of symptoms, diminishing of any direct or indirect pathological consequences of the disease, preventing metastasis, decreasing the rate of disease progression, amelioration or palliation of the disease state, and remission or improved prognosis. In some embodiments, antigen-binding constructs described herein are used to delay development of a disease or disorder. In one embodiment, antigen-binding constructs and methods described herein effect tumor regression. In one embodiment, antigen-binding constructs and methods described herein effect inhibition of tumor/cancer growth.

[0229] Desirable effects of treatment include, but are not limited to, preventing occurrence or recurrence of disease, alleviation of symptoms, diminishment of any direct or indirect pathological consequences of the disease, preventing metastasis, decreasing the rate of disease progression, amelioration or palliation of the disease state, improved survival, and remission or improved prognosis. In some embodiments, antigen-binding constructs described herein are used to delay development of a disease or to slow the progression of a disease.

[0230] The term "effective amount" as used herein refers to that amount of construct being administered, which will accomplish the goal of the recited method, e.g., relieve to some extent one or more of the symptoms of the disease, condition or disorder being treated. The amount of the composition described herein which will be effective in the treatment, inhibition and prevention of a disease or disorder associated with aberrant expression and/or activity of a therapeutic protein can be determined by standard clinical techniques. In addition, in vitro assays may optionally be employed to help identify optimal dosage ranges. The precise dose to be employed in the formulation will also depend on the route of administration, and the seriousness of the disease or disorder, and should be decided according to the judgment of the practitioner and each patient's circumstances. Effective doses are extrapolated from dose-response curves derived from in vitro or animal model test systems.

[0231] The antigen-binding construct is administered to the subject. Various delivery systems are known and can be used to administer an antigen-binding construct formulation described herein, e.g., encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing the compound, receptor-mediated endocytosis (see, e.g., Wu and Wu, J. Biol. Chem. 262:4429-4432 (1987)), construction of a nucleic acid as part of a retroviral or other vector, etc. Methods of introduction include but are not limited to intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. The compounds or compositions may be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents. Administration can be systemic or local. In addition, in certain embodiments, it is desirable to introduce the antigen-binding construct compositions described herein into the central nervous system by any suitable route, including intraventricular and intrathecal injection; intraventricular injection may be facilitated by an intraventricular catheter, for example, attached to a reservoir, such as an Ommaya reservoir. Pulmonary administration can also be employed, e.g., by use of an inhaler or nebulizer, and formulation with an aerosolizing agent.

[0232] In a specific embodiment, it is desirable to administer the antigen-binding constructs, or compositions described herein locally to the area in need of treatment; this may be achieved by, for example, and not by way of limitation, local infusion during surgery, topical application, e.g., in conjunction with a wound dressing after surgery, by injection, by means of a catheter, by means of a suppository, or by means of an implant, said implant being of a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers. Preferably, when administering a protein, including an antigen-binding construct, described herein, care must be taken to use materials to which the protein does not absorb.

[0233] In another embodiment, the antigen-binding constructs or composition can be delivered in a vesicle, in particular a liposome (see Langer, Science 249:1527-1533 (1990); Treat et al., in Liposomes in the Therapy of Infectious Disease and Cancer, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 353-365 (1989); Lopez-Berestein, ibid., pp. 317-327; see generally ibid.)

[0234] In yet another embodiment, the antigen-binding constructs or composition can be delivered in a controlled release system. In one embodiment, a pump may be used (see Langer, supra; Sefton, CRC Crit. Ref. Biomed. Eng. 14:201 (1987); Buchwald et al., Surgery 88:507 (1980); Saudek et al., N. Engl. J. Med. 321:574 (1989)). In another embodiment, polymeric materials can be used (see Medical Applications of Controlled Release, Langer and Wise (eds.), CRC Pres., Boca Raton, Fla. (1974); Controlled Drug Bioavailability, Drug Product Design and Performance, Smolen and Ball (eds.), Wiley, New York (1984); Ranger and Peppas, J., Macromol. Sci. Rev. Macromol. Chem. 23:61 (1983); see also Levy et al., Science 228:190 (1985); During et al., Ann. Neurol. 25:351 (1989); Howard et al., J. Neurosurg. 71:105 (1989)). In yet another embodiment, a controlled release system can be placed in proximity of the therapeutic target, e.g., the brain, thus requiring only a fraction of the systemic dose (see, e.g., Goodson, in Medical Applications of Controlled Release, vol. 2, pp. 115-138 (1984)).

[0235] In a specific embodiment comprising a nucleic acid encoding antigen-binding constructs decribed herein, the nucleic acid can be administered in vivo to promote expression of its encoded protein, by constructing it as part of an appropriate nucleic acid expression vector and administering it so that it becomes intracellular, e.g., by use of a retroviral vector (see U.S. Pat. No. 4,980,286), or by direct injection, or by use of microparticle bombardment (e.g., a gene gun; Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, or by administering it in linkage to a homeobox-like peptide which is known to enter the nucleus (see e.g., Joliot et al., Proc. Natl. Acad. Sci. USA 88:1864-1868 (1991)), etc. Alternatively, a nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination.

[0236] In certain embodiments an antigen-binding construct described herein is administered as a combination with antigen-binding constructs with non-overlapping binding target epitopes.

[0237] The amount of the antigen-binding construct which will be effective in the treatment, inhibition and prevention of a disease or disorder can be determined by standard clinical techniques. In addition, in vitro assays may optionally be employed to help identify optimal dosage ranges. The precise dose to be employed in the formulation will also depend on the route of administration, and the seriousness of the disease or disorder, and should be decided according to the judgment of the practitioner and each patient's circumstances. Effective doses are extrapolated from dose-response curves derived from in vitro or animal model test systems.

[0238] The antigen-binding constructs described herein may be administered alone or in combination with other types of treatments (e.g., radiation therapy, chemotherapy, hormonal therapy, immunotherapy and anti-tumor agents). Generally, administration of products of a species origin or species reactivity (in the case of antibodies) that is the same species as that of the patient is preferred. Thus, in an embodiment, human antigen-binding constructs, fragments derivatives, analogs, or nucleic acids, are administered to a human patient for therapy or prophylaxis.

Methods of Treating Cancers

[0239] Described herein are methods of treating a HER2+ cancer or a tumor in a subject, and methods of inhibiting the growth of a HER2+ tumor cell or killing a HER2+ tumor cell using the antigen-binding constructs described herein.

[0240] By a HER2+ cancer is meant a cancer that expresses HER2 such that the antigen-binding constructs described herein are able to bind to the cancer. As is known in the art, HER2+ cancers express HER2 at varying levels. To determine ErbB, e.g. ErbB2 (HER2) expression in the cancer, various diagnostic/prognostic assays are available. In one embodiment, ErbB2 overexpression may be analyzed by IHC, e.g. using the HERCEPTEST.RTM. (Dako). Paraffin embedded tissue sections from a tumor biopsy may be subjected to the IHC assay and accorded a ErbB2 protein staining intensity criteria as follows:

[0241] Score 0 no staining is observed or membrane staining is observed in less than 10% of tumor cells.

[0242] Score 1+ a faint/barely perceptible membrane staining is detected in more than 10% of the tumor cells. The cells are only stained in part of their membrane.

[0243] Score 2+ a weak to moderate complete membrane staining is observed in more than 10% of the tumor cells.

[0244] Score 3+ a moderate to strong complete membrane staining is observed in more than 10% of the tumor cells.

[0245] Those tumors with 0 or 1+ scores for ErbB2 overexpression assessment may be characterized as not overexpressing ErbB2, whereas those tumors with 2+ or 3+ scores may be characterized as overexpressing ErbB2.

[0246] Alternatively, or additionally, fluorescence in situ hybridization (FISH) assays such as the INFORM.TM. (sold by Ventana, Ariz.) or PATHVISION.TM. (Vysis, Ill.) may be carried out on formalin-fixed, paraffin-embedded tumor tissue to determine the extent (if any) of ErbB2 overexpression in the tumor. In comparison with IHC assay, the FISH assay, which measures HER2 gene amplification, seems to correlate better with response of patients to treatment with HERCEPTIN.RTM., and is currently considered to be the preferred assay to identify patients likely to benefit from HERCEPTIN.RTM. treatment.

[0247] Table D describes the expression level of HER2 on several representative breast cancer and other cancer cell lines (Subik et al. (2010) Breast Cancer: Basic Clinical Research: 4; 35-41; Prang et a. (2005) British Journal of Cancer Research: 92; 342-349). As shown in the table, MCF-7 and MDA-MB-231 cells are considered to be low HER2 expressing cells; JIMT-1, and ZR-75-1 cells are considered to be medium HER2 expressing cells, and SKBR3 and BT-474 cells are considered to be high HER2 expressing cells. SKOV3 (ovarian cancer) cells are considered to be medium HER2 expressing cells.

[0248] Described herein are methods of treating a subject having a HER2+ cancer or a tumor comprising providing to the subject an effective amount of a pharmaceutical composition comprising an antigen-binding construct described herein.

[0249] Also described herein is the use of an HER2 antigen-binding construct described herein for the manufacture of a medicament for treating a cancer or a tumor. Also described herein are HER2 antigen-binding constructs for use in the treatment of cancer or a tumor.

[0250] In some embodiments, the subject being treated has pancreatic cancer, head and neck cancer, gastric cancer, colorectal cancer, breast cancer, renal cancer, cervical cancer, ovarian cancer, brain cancer, endometrial cancer, bladder cancer, non-small cell lung cancer or an epidermal-derived cancer. In some embodiments, the tumor is metastatic.

[0251] In general, the tumor in the subject being treated expresses an average of 10,000 or more copies of HER2 per tumor cell. In certain embodiments the tumor is HER2 0-1+, 1+, HER2 2+ or HER2 3+ as determined by IHC. In some embodiments the tumor is HER2 2+ or lower, or HER2 1+ or lower. In some embodiments, the tumor has an amplified HER2 gene. In some embodiments the HER2 gene is non-amplified.

[0252] In some embodiments, the tumor of the subject being treated with the antigen-binding constructs is a breast cancer. In some embodiments, the breast cancer expresses HER2 at a 3+ level. In some embodiments the breast cancer expresses HER2 at less than a 3+ level. In a specific embodiment, the breast cancer expresses HER2 at a 2+ level or lower. In a specific embodiment, the breast cancer expresses HER2 at a 1+ level or lower. In some embodiments, the breast cancer expresses estrogen receptors (ER+) and/or progesterone receptors (PR+). In some embodiments, the breast cancer is ER- and or PR-. In some embodiments the breast cancer has an amplified HER2 gene. In some embodiments the HER2 gene is non-amplified. In some embodiments, the breast cancer is a HER2 3+ estrogen receptor negative (ER-), progesterone receptor negative (PR-), trastuzumab resistant, chemotherapy resistant invasive ductal breast cancer. In another embodiment, the breast cancer is a HER2 3+ER-, PR-, trastuzumab resistant inflammatory breast cancer. In another embodiment, the breast cancer is a HER2 3+, ER-, PR-, invasive ductal carcinoma. In another embodiment, the breast cancer is a HER2 2+ HER2 gene amplified trastuzumab and pertuzumab resistant breast cancer. In some embodiments, the breast cancer is triple negative (ER-, PR- and low HER2-expressing). In some embodiments the breast cancer is resistant or refractory to trastuzumab, pertuzumab and/or trastuzumab conjugated to DM1 (ado-trastuzumab emtansine or T-DM1).

[0253] In one embodiment, the tumor is an HER2 2/3+ ovarian epithelial adenocarcinoma having an amplified HER2 gene.

[0254] Provided herein are methods for treating a subject having a HER2+ tumor that is resistant or becomes resistant to other standard-of-care therapies comprising administering to the subject a pharmaceutical composition comprising the antigen-binding constructs described herein. In certain embodiments the antigen-binding constructs described herein are provided to subjects that are unresponsive to current therapies, optionally in combination with one or more current anti-HER2 therapies. In some embodiments the current anti-HER2 therapies include, but are not limited to, anti-HER2 or anti-HER3 monospecific bivalent antibodies, trastuzumab, pertuzumab, T-DM1, a bi-specific HER2/HER3 scFv, or combinations thereof. In some embodiments, the cancer is resistant to various chemotherapeutic agents such as taxanes. In some embodiments the cancer is resistant to trastuzumab. In some embodiment the cancer is resistant to pertuzumab. In one embodiment, the cancer is resistant or refractory to TDM1 (trastuzumab conjugated to DM1). In some embodiments, the subject has previously been treated with an anti-HER2 antibody such as trastuzumab, pertuzumab or DM1. In some embodiments, the subject has not been previously treated with an anti-HER2 antibody. In one embodiment, the antigen-binding construct is provided to a subject for the treatment of metastatic cancer when the patient has progressed on previous anti-HER2 therapy.

[0255] Provided herein are methods of treating a subject having a HER2+ tumor comprising providing an effective amount of a pharmaceutical composition comprising an antigen-binding construct described herein in conjunction with an additional anti-tumor agent. The additional anti-tumor agent may be a therapeutic antibody as noted above, or a chemotherapeutic agent. Chemotherapeutic agents useful for use in combination with the antigen-binding constructs of the invention include cisplatin, carboplatin, paclitaxel, albumin-bound paclitaxel, nab-paclitaxel, docetaxel, gemcitabine, vinorelbine, irinotecan, etoposide, vinblastine, pemetrexed, 5-fluorouracil (with or without folinic acid), capecitabine, carboplatin, epirubicin, oxaliplatin, folfirinox, abraxane, navelbine and cyclophosphamide, capecitabine, gemcitabine, navelbine, paclitaxel, nab-paclitaxel.

[0256] In some embodiments, the tumor is non-small cell lung cancer, and the additional agent is one or more of cisplatin, carboplatin, paclitaxel, albumin-bound paclitaxel, nab-paclitaxel, capecitabine, navelbine, docetaxel, gemcitabine, vinorelbine, irinotecan, etoposide, vinblastine or pemetrexed. In embodiments, the tumor is gastric or stomach cancer, and the additional agent is one or more of 5-fluorouracil (with or without folinic acid), capecitabine, carboplatin, cisplatin, docetaxel, epirubicin, irinotecan, oxaliplatin, nab-paclitaxel or paclitaxel. In other embodiments the tumor is pancreatic cancer, and the additional agent is one or more of nab-paclitaxel, capecitabine, navelbine, gemcitabine, folfirinox, abraxane, or 5-fluorouracil. In other embodiments the tumor is a estrogen and/or progesterone positive breast cancer, and the additional agent is one or more of paclitaxel, capecitabine, navelbine, gemcitabine, paclitaxel or nab-paclitaxel or a combination of (a) doxorubicin and epirubicin, (b) a combination of paclitaxel and docetaxel, or (c) a combination of 5-fluorouracil, cyclophosphamide and carboplatin. In other embodiments, the tumor is head and neck cancer, and the additional agent is one or more of paclitaxel, capecitabine, navelbine, gemcitabine or nab-paclitaxel carboplatin, doxorubicin or cisplatin. In other embodiments, the tumor is ovarian cancer and the additional agent may be one or more of capecitabine, navelbine, gemcitabine, nab-paclitaxel, cisplatin, carboplatin, or a taxane such as paclitaxel or docetaxel.

[0257] The additional agents may be administered to the subject being treated concurrently with the antigen-binding constructs or sequentially.

[0258] The subject being treated with the antigen-binding constructs may be a human, a non-human primate or other mammal such as a mouse.

[0259] In some embodiments, the result of providing an effective amount of the antigen-binding construct to a subject having a tumor is shrinking the tumor, inhibiting growth of the tumor, increasing time to progression of the tumor, prolonging disease-free survival of the subject, decreasing metastases, increasing the progression-free survival of the subject, or increasing overall survival of the subject or increasing the overall survival of a group of subjects receiving the treatment.

[0260] Also described herein are methods of killing or inhibiting the growth of a HER2-expressing tumor cell comprising contacting the cell with the antigen-binding construct provided herein.

[0261] In various embodiments, a tumor cell may be a HER2 1+ or 2+ human pancreatic carcinoma cell, a HER2 3+ human lung carcinoma cell, a HER2 2+ human Caucasian bronchioaveolar carcinoma cell, a human pharyngeal carcinoma cell, a HER2 2+ human tongue squamous cell carcinoma cell, a HER2 2+ squamous cell carcinoma cell of the pharynx, a HER2 1+ or 2+ human colorectal carcinoma cell, a HER2 3+ human gastric carcinoma cell, a HER2 1+ human breast ductal ER+ (estrogen receptor-positive) carcinoma cell, a HER2 2+/3+ human ER+, HER2-amplified breast carcinoma cell, a HER2 0+/1+ human triple negative breast carcinoma cell, a HER2 2+ human endometrioid carcinoma cell, a HER2 1+ lung-metastatic malignant melanoma cell, a HER2 1+ human cervix carcinoma cell, Her2 1+ human renal cell carcinoma cell, or a HER2 1+ human ovary carcinoma cell.

[0262] In embodiments in which the antigen-binding constructs are conjugated to DM1, the tumor cell may be a HER2 1+ or 2+ or 3+ human pancreatic carcinoma cell, a HER2 2+ metastatic pancreatic carcinoma cell, a HER2 0+/1+, +3+ human lung carcinoma cell, a HER2 2+ human Caucasian bronchioaveolar carcinoma cell, a HER2 0+ anaplastic lung carcinoma, a human non-small cell lung carcinoma cell, a human pharyngeal carcinoma cell, a HER2 2+ human tongue squamous cell carcinoma cell, a HER2 2+ squamous cell carcinoma cell of the pharynx, a HER2 1+ or 2+ human colorectal carcinoma cell, a HER2 0+, 1+ or 3+ human gastric carcinoma cell, a HER2 1+ human breast ductal ER+ (estrogen receptor-positive) carcinoma cell, a HER2 2+/3+ human ER+, HER2-amplified breast carcinoma cell, a HER2 0+/1+ human triple negative breast carcinoma cell, a HER2 0+ human breast ductal carcinoma (Basal B, Mesenchymal-like triple negative) cell, a HER2 2+ER+ breast carcinoma, a HER2 0+ human metastatic breast carcinoma cell (ER-, HER2-amplified, luminal A, TN), a human uterus mesodermal tumor (mixed grade III) cell, a 2+ human endometrioid carcinoma cell, a HER2 1+ human skin epidermoid carcinoma cell, a HER2 1+ lung-metastatic malignant melanoma cell, a HER2 1+ malignant melanoma cell, a human cervix epidermoid carcinoma vcell, a HER2 1+ human urinary bladder carcinoma cell, a HER2 1+ human cervix carcinoma cell, Her2 1+ human renal cell carcinoma cell, or a HER2 1+, 2+ or 3+ human ovary carcinoma cell.

[0263] In some embodiments the tumor cell may be one or more of the following cell lines: pancreatic tumor cell lines BxPC3, Capan-1, MiaPaca2; lung tumor cell lines Calu-3, NCI-H322; head and neck tumor cells lines Detroit 562, SCC-25, FaDu; colorectal tumor cell lines HT29, SNU-C2B; gastric tumor cell line NCI-N87; breast tumor cell lines MCF-7, MDA-MB-175, MDA-MB-361, MDA-MB-231, BT-20, JIMT-1, SkBr3, BT-474; uterine tumor cell line TOV-112D; skin tumor cell line Malme-3M; cervical tumor cell lines Caski, MS751; bladder tumor cell line T24, ovarian tumor cell lines CaOV3, and SKOV3.

[0264] In some embodiments in which the antigen-binding constructs are conjugated to DM1, the tumor cell may be one or more of the following cell lines: pancreatic tumor cell lines BxPC3, Capan-1, MiaPaca2, SW 1990, Pancl; lung tumor cell lines A549, Calu-3, Calu-6, NCI-H2126, NCI-H322; head and neck tumor cells lines Detroit 562, SCC-15, SCC-25, FaDu; colorectal tumor cell lines Colo201, DLD-1, HCT116, HT29, SNU-C2B; gastric tumor cell lines SNU-1, SNU-16, NCI-N87; breast tumor cell lines SkBr3, MCF-7, MDA-MB-175, MDA-MB-361, MDA-MB-231, ZR-75-1, BT-20, BT549, BT-474, CAMA-1, MDA-MB-453, JIMT-1, T47D; Uterine tumor cell lines SK-UT-1, TOV-112D; skin tumor cell lines A431, Malme-3M, SKEMEL28; cervical tumor cell lines Caski, MS751; bladder tumor cell line T24, renal tumor cell line ACHN; ovarian tumor cell lines CaOV3, Ovar-3, and SKOV3.

[0265] Also described herein are methods of treating a subject having a HER2 expressing (HER2+) tumor such as a HER2+ lung, head and neck, or breast tumor by administering an antigen binding construct disclosed herein. In some aspects, the tumor volume in the subject after receiving at least seven doses of the antigen binding construct is less than the tumor volume of a control subject receiving an equivalent amount of trastuzumab. In some aspects, the survival of the subject receiving the antigen binding construct is increased as compared to a control subject receiving an equivalent amount of a non-specific control antibody or as compared to a control subject not receiving treatment.

[0266] In some aspects, the tumor is a lung tumor, optionally wherein the tumor is a non-squamous non-small cell lung tumor that is HER2-low, non-HER2 gene amplified. In some aspects, the tumor is HER3+. In some aspects, the tumor is EGFR low. In some aspects, the tumor is moderately sensitive to Cisplatin at the MTD.

[0267] In some aspects, the tumor is a head and neck tumor, optionally wherein the tumor is a squamous cell tumor of the head and neck that is HER2 low, non-HER2 gene amplified. In some aspects, the tumor is HER3+ low. In some aspects, the tumor is EGFR+. In some aspects, the tumor is highly sensitive to Cisplatin at the MTD.

[0268] In some aspects, the tumor is a breast tumor, optionally wherein the tumor is a ER+/PR- breast cancer with a luminal B molecular classification.

[0269] In some aspects, the subject is administered at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 doses. In some aspects, the amount of at least one of the plurality of doses is at least 0.3, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 mg/kg. In some aspects, the amount of each of the plurality of doses is at least 0.3, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 mg/kg. In some aspects, each dose is administered at least daily, weekly, or monthly. In some aspects, each dose is administered at least every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, or 31 days. In some aspects, treatment continues for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, or 31 days; at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 weeks; or at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 months.

[0270] In some aspects, the mean tumor volume in the subject after receiving at least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 doses is less than the mean tumor volume of a control subject receiving an equivalent amount of trastuzumab.

[0271] In some aspects, overall survival of the subject is significantly increased as compared to a control subject receiving an equivalent amount of a non-specific control antibody or as compared to a control subject not receiving treatment. In some aspects, the significance is measured by a log rank test. In some aspects, the p value is less than 0.5, 0.01, or 0.001.

[0272] In some aspects, overall survival of the subject is more significantly increased as compared to a control subject receiving an equivalent amount of trastuzumab. In some aspects, the antigen-binding construct p value is less than 0.001 and wherein the trastuzumab p value is greater than 0.001.

[0273] In some aspects, the p value of the significance of the increase relative to the control subject receiving an equivalent amount of a non-specific control antibody is less than the p value of an increase in survival of a second control receiving an equivalent amount of trastuzumab as compared to the control subject receiving an equivalent amount of a non-specific control antibody. In some aspects, the antigen-binding construct p value is less than 0.001 and wherein the trastuzumab p value is greater than 0.001.

[0274] In some aspects, overall survival of the subject after receiving a combination of the antigen-binding construct and an additional agent is significantly increased as compared to a control subject receiving an equivalent amount of trastuzumab alone.

[0275] In some aspects, overall survival of the subject is significantly increased as compared to a control subject receiving a lesser amount of trastuzumab.

Kits and Articles of Manufacture

[0276] Also described herein are kits comprising one or more antigen-binding construct described herein. Individual components of the kit would be packaged in separate containers and, associated with such containers, can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale. The kit may optionally contain instructions or directions outlining the method of use or administration regimen for the antigen-binding construct.

[0277] When one or more components of the kit are provided as solutions, for example an aqueous solution, or a sterile aqueous solution, the container means may itself be an inhalant, syringe, pipette, eye dropper, or other such like apparatus, from which the solution may be administered to a subject or applied to and mixed with the other components of the kit.

[0278] The components of the kit may also be provided in dried or lyophilized form and the kit can additionally contain a suitable solvent for reconstitution of the lyophilized components. Irrespective of the number or type of containers, the kits described herein also may comprise an instrument for assisting with the administration of the composition to a patient. Such an instrument may be an inhalant, nasal spray device, syringe, pipette, forceps, measured spoon, eye dropper or similar medically approved delivery vehicle.

[0279] In another aspect described herein, an article of manufacture containing materials useful for the treatment, prevention and/or diagnosis of the disorders described above is provided. The article of manufacture comprises a container and a label or package insert on or associated with the container. Suitable containers include, for example, bottles, vials, syringes, IV solution bags, etc. The containers may be formed from a variety of materials such as glass or plastic. The container holds a composition which is by itself or combined with another composition effective for treating, preventing and/or diagnosing the condition and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). At least one active agent in the composition is a T cell activating antigen-binding construct described herein. The label or package insert indicates that the composition is used for treating the condition of choice. Moreover, the article of manufacture may comprise (a) a first container with a composition contained therein, wherein the composition comprises an antigen-binding construct described herein; and (b) a second container with a composition contained therein, wherein the composition comprises a further cytotoxic or otherwise therapeutic agent. The article of manufacture in this embodiment described herein may further comprise a package insert indicating that the compositions can be used to treat a particular condition. Alternatively, or additionally, the article of manufacture may further comprise a second (or third) container comprising a pharmaceutically-acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.

Polypeptides and Polynucleotides

[0280] The antigen-binding constructs described herein comprise at least one polypeptide. Also described are polynucleotides encoding the polypeptides described herein. The antigen-binding constructs are typically isolated.

[0281] As used herein, "isolated" means an agent (e.g., a polypeptide or polynucleotide) that has been identified and separated and/or recovered from a component of its natural cell culture environment. Contaminant components of its natural environment are materials that would interfere with diagnostic or therapeutic uses for the antigen-binding construct, and may include enzymes, hormones, and other proteinaceous or non-proteinaceous solutes. Isolated also refers to an agent that has been synthetically produced, e.g., via human intervention.

[0282] The terms "polypeptide," "peptide" and "protein" are used interchangeably herein to refer to a polymer of amino acid residues. That is, a description directed to a polypeptide applies equally to a description of a peptide and a description of a protein, and vice versa. The terms apply to naturally occurring amino acid polymers as well as amino acid polymers in which one or more amino acid residues is a non-naturally encoded amino acid. As used herein, the terms encompass amino acid chains of any length, including full length proteins, wherein the amino acid residues are linked by covalent peptide bonds.

[0283] The term "amino acid" refers to naturally occurring and non-naturally occurring amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to the naturally occurring amino acids. Naturally encoded amino acids are the 20 common amino acids (alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, praline, serine, threonine, tryptophan, tyrosine, and valine) and pyrrolysine and selenocysteine. Amino acid analogs refers to compounds that have the same basic chemical structure as a naturally occurring amino acid, i.e., an a carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, such as, homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs have modified R groups (such as, norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. Reference to an amino acid includes, for example, naturally occurring proteogenic L-amino acids; D-amino acids, chemically modified amino acids such as amino acid variants and derivatives; naturally occurring non-proteogenic amino acids such as .beta.-alanine, ornithine, etc.; and chemically synthesized compounds having properties known in the art to be characteristic of amino acids. Examples of non-naturally occurring amino acids include, but are not limited to, a-methyl amino acids (e.g. a-methyl alanine), D-amino acids, histidine-like amino acids (e.g., 2-amino-histidine, .beta.-hydroxy-histidine, homohistidine), amino acids having an extra methylene in the side chain ("homo" amino acids), and amino acids in which a carboxylic acid functional group in the side chain is replaced with a sulfonic acid group (e.g., cysteic acid). The incorporation of non-natural amino acids, including synthetic non-native amino acids, substituted amino acids, or one or more D-amino acids into the proteins of the present invention may be advantageous in a number of different ways. D-amino acid-containing peptides, etc., exhibit increased stability in vitro or in vivo compared to L-amino acid-containing counterparts. Thus, the construction of peptides, etc., incorporating D-amino acids can be particularly useful when greater intracellular stability is desired or required. More specifically, D-peptides, etc., are resistant to endogenous peptidases and proteases, thereby providing improved bioavailability of the molecule, and prolonged lifetimes in vivo when such properties are desirable. Additionally, D-peptides, etc., cannot be processed efficiently for major histocompatibility complex class II-restricted presentation to T helper cells, and are therefore, less likely to induce humoral immune responses in the whole organism.

[0284] Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise, may be referred to by their commonly accepted single-letter codes.

[0285] Also included in the invention are polynucleotides encoding polypeptides of the antigen-binding constructs. The term "polynucleotide" or "nucleotide sequence" is intended to indicate a consecutive stretch of two or more nucleotide molecules. The nucleotide sequence may be of genomic, cDNA, RNA, semisynthetic or synthetic origin, or any combination thereof.

[0286] The term "nucleic acid" refers to deoxyribonucleotides, deoxyribonucleosides, ribonucleosides, or ribonucleotides and polymers thereof in either single- or double-stranded form. Unless specifically limited, the term encompasses nucleic acids containing known analogues of natural nucleotides which have similar binding properties as the reference nucleic acid and are metabolized in a manner similar to naturally occurring nucleotides. Unless specifically limited otherwise, the term also refers to oligonucleotide analogs including PNA (peptidonucleic acid), analogs of DNA used in antisense technology (phosphorothioates, phosphoroamidates, and the like). Unless otherwise indicated, a particular nucleic acid sequence also implicitly encompasses conservatively modified variants thereof (including but not limited to, degenerate codon substitutions) and complementary sequences as well as the sequence explicitly indicated. Specifically, degenerate codon substitutions may be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and/or deoxyinosine residues (Batzer et al., Nucleic Acid Res. 19:5081 (1991); Ohtsuka et al., J. Biol. Chem. 260:2605-2608 (1985); Rossolini et al., Mol. Cell. Probes 8:91-98 (1994)).

[0287] "Conservatively modified variants" applies to both amino acid and nucleic acid sequences. With respect to particular nucleic acid sequences, "conservatively modified variants" refers to those nucleic acids which encode identical or essentially identical amino acid sequences, or where the nucleic acid does not encode an amino acid sequence, to essentially identical sequences. Because of the degeneracy of the genetic code, a large number of functionally identical nucleic acids encode any given protein. For instance, the codons GCA, GCC, GCG and GCU all encode the amino acid alanine. Thus, at every position where an alanine is specified by a codon, the codon can be altered to any of the corresponding codons described without altering the encoded polypeptide. Such nucleic acid variations are "silent variations," which are one species of conservatively modified variations. Every nucleic acid sequence herein which encodes a polypeptide also describes every possible silent variation of the nucleic acid. One of ordinary skill in the art will recognize that each codon in a nucleic acid (except AUG, which is ordinarily the only codon for methionine, and TGG, which is ordinarily the only codon for tryptophan) can be modified to yield a functionally identical molecule. Accordingly, each silent variation of a nucleic acid which encodes a polypeptide is implicit in each described sequence.

[0288] As to amino acid sequences, one of ordinary skill in the art will recognize that individual substitutions, deletions or additions to a nucleic acid, peptide, polypeptide, or protein sequence which alters, adds or deletes a single amino acid or a small percentage of amino acids in the encoded sequence is a "conservatively modified variant" where the alteration results in the deletion of an amino acid, addition of an amino acid, or substitution of an amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are known to those of ordinary skill in the art. Such conservatively modified variants are in addition to and do not exclude polymorphic variants, interspecies homologs, and alleles described herein.

[0289] Conservative substitution tables providing functionally similar amino acids are known to those of ordinary skill in the art. The following eight groups each contain amino acids that are conservative substitutions for one another: 1) Alanine (A), Glycine (G); 2) Aspartic acid (D), Glutamic acid (E); 3) Asparagine (N), Glutamine (Q); 4) Arginine (R), Lysine (K); 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W); 7) Serine (S), Threonine (T); and

[0139] 8) Cysteine (C), Methionine (M) (see, e.g., Creighton, Proteins: Structures and Molecular Properties (W H Freeman & Co.; 2nd edition (December 1993)

[0290] The terms "identical" or percent "identity," in the context of two or more nucleic acids or polypeptide sequences, refer to two or more sequences or subsequences that are the same. Sequences are "substantially identical" if they have a percentage of amino acid residues or nucleotides that are the same (i.e., about 60% identity, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, or about 95% identity over a specified region), when compared and aligned for maximum correspondence over a comparison window, or designated region as measured using one of the following sequence comparison algorithms (or other algorithms available to persons of ordinary skill in the art) or by manual alignment and visual inspection. This definition also refers to the complement of a test sequence. The identity can exist over a region that is at least about 50 amino acids or nucleotides in length, or over a region that is 75-100 amino acids or nucleotides in length, or, where not specified, across the entire sequence of a polynucleotide or polypeptide. A polynucleotide encoding a polypeptide of the present invention, including homologs from species other than human, may be obtained by a process comprising the steps of screening a library under stringent hybridization conditions with a labeled probe having a polynucleotide sequence described herein or a fragment thereof, and isolating full-length cDNA and genomic clones containing said polynucleotide sequence. Such hybridization techniques are well known to the skilled artisan.

[0291] For sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Default program parameters can be used, or alternative parameters can be designated. The sequence comparison algorithm then calculates the percent sequence identities for the test sequences relative to the reference sequence, based on the program parameters.

[0292] A "comparison window", as used herein, includes reference to a segment of any one of the number of contiguous positions selected from the group consisting of from 20 to 600, usually about 50 to about 200, more usually about 100 to about 150 in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned. Methods of alignment of sequences for comparison are known to those of ordinary skill in the art. Optimal alignment of sequences for comparison can be conducted, including but not limited to, by the local homology algorithm of Smith and Waterman (1970) Adv. Appl. Math. 2:482c, by the homology alignment algorithm of Needleman and Wunsch (1970) J. Mol. Biol. 48:443, by the search for similarity method of Pearson and Lipman (1988) Proc. Nat'l. Acad. Sci. USA 85:2444, by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, Wis.), or by manual alignment and visual inspection (see, e.g., Ausubel et al., Current Protocols in Molecular Biology (1995 supplement)).

[0293] One example of an algorithm that is suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al. (1997) Nuc. Acids Res. 25:3389-3402, and Altschul et al. (1990) J. Mol. Biol. 215:403-410, respectively. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information available at the World Wide Web at ncbi.nlm.nih.gov. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a wordlength (W) of 11, an expectation (E) or 10, M=5, N=-4 and a comparison of both strands. For amino acid sequences, the BLASTP program uses as defaults a wordlength of 3, and expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff and Henikoff (1992) Proc. Natl. Acad. Sci. USA 89:10915) alignments (B) of 50, expectation (E) of 10, M=5, N=-4, and a comparison of both strands. The BLAST algorithm is typically performed with the "low complexity" filter turned off

[0294] The BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90:5873-5787). One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a nucleic acid is considered similar to a reference sequence if the smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than about 0.2, or less than about 0.01, or less than about 0.001.

[0295] The phrase "selectively (or specifically) hybridizes to" refers to the binding, duplexing, or hybridizing of a molecule only to a particular nucleotide sequence under stringent hybridization conditions when that sequence is present in a complex mixture (including but not limited to, total cellular or library DNA or RNA).

[0296] The phrase "stringent hybridization conditions" refers to hybridization of sequences of DNA, RNA, or other nucleic acids, or combinations thereof under conditions of low ionic strength and high temperature as is known in the art. Typically, under stringent conditions a probe will hybridize to its target subsequence in a complex mixture of nucleic acid (including but not limited to, total cellular or library DNA or RNA) but does not hybridize to other sequences in the complex mixture. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures. An extensive guide to the hybridization of nucleic acids is found in Tijssen, Laboratory Techniques in Biochemistry and Molecular Biology--Hybridization with Nucleic Probes, "Overview of principles of hybridization and the strategy of nucleic acid assays" (1993).

[0297] As used herein, the terms "engineer, engineered, engineering", are considered to include any manipulation of the peptide backbone or the post-translational modifications of a naturally occurring or recombinant polypeptide or fragment thereof. Engineering includes modifications of the amino acid sequence, of the glycosylation pattern, or of the side chain group of individual amino acids, as well as combinations of these approaches. The engineered proteins are expressed and produced by standard molecular biology techniques.

[0298] By "isolated nucleic acid molecule or polynucleotide" is intended a nucleic acid molecule, DNA or RNA, which has been removed from its native environment. For example, a recombinant polynucleotide encoding a polypeptide contained in a vector is considered isolated. Further examples of an isolated polynucleotide include recombinant polynucleotides maintained in heterologous host cells or purified (partially or substantially) polynucleotides in solution. An isolated polynucleotide includes a polynucleotide molecule contained in cells that ordinarily contain the polynucleotide molecule, but the polynucleotide molecule is present extrachromosomally or at a chromosomal location that is different from its natural chromosomal location. Isolated RNA molecules include in vivo or in vitro RNA transcripts, as well as positive and negative strand forms, and double-stranded forms. Isolated polynucleotides or nucleic acids described herein, further include such molecules produced synthetically, e.g., via PCR or chemical synthesis. In addition, a polynucleotide or a nucleic acid, in certain embodiments, include a regulatory element such as a promoter, ribosome binding site, or a transcription terminator.

[0299] The term "polymerase chain reaction" or "PCR" generally refers to a method for amplification of a desired nucleotide sequence in vitro, as described, for example, in U.S. Pat. No. 4,683,195. In general, the PCR method involves repeated cycles of primer extension synthesis, using oligonucleotide primers capable of hybridising preferentially to a template nucleic acid.

[0300] By a nucleic acid or polynucleotide having a nucleotide sequence at least, for example, 95% "identical" to a reference nucleotide sequence of the present invention, it is intended that the nucleotide sequence of the polynucleotide is identical to the reference sequence except that the polynucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence. In other words, to obtain a polynucleotide having a nucleotide sequence at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. These alterations of the reference sequence may occur at the 5' or 3' terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence. As a practical matter, whether any particular polynucleotide sequence is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to a nucleotide sequence of the present invention can be determined conventionally using known computer programs, such as the ones discussed above for polypeptides (e.g. ALIGN-2).

[0301] A derivative, or a variant of a polypeptide is said to share "homology" or be "homologous" with the peptide if the amino acid sequences of the derivative or variant has at least 50% identity with a 100 amino acid sequence from the original peptide. In certain embodiments, the derivative or variant is at least 75% the same as that of either the peptide or a fragment of the peptide having the same number of amino acid residues as the derivative. In certain embodiments, the derivative or variant is at least 85% the same as that of either the peptide or a fragment of the peptide having the same number of amino acid residues as the derivative. In certain embodiments, the amino acid sequence of the derivative is at least 90% the same as the peptide or a fragment of the peptide having the same number of amino acid residues as the derivative. In some embodiments, the amino acid sequence of the derivative is at least 95% the same as the peptide or a fragment of the peptide having the same number of amino acid residues as the derivative. In certain embodiments, the derivative or variant is at least 99% the same as that of either the peptide or a fragment of the peptide having the same number of amino acid residues as the derivative.

[0302] The term "modified," as used herein refers to any changes made to a given polypeptide, such as changes to the length of the polypeptide, the amino acid sequence, chemical structure, co-translational modification, or post-translational modification of a polypeptide. The form "(modified)" term means that the polypeptides being discussed are optionally modified, that is, the polypeptides under discussion can be modified or unmodified.

[0303] In some aspects, an antigen-binding construct comprises an amino acid sequence that is at least 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identical to a relevant amino acid sequence or fragment thereof set forth in the Table(s) or accession number(s) disclosed herein. In some aspects, an isolated antigen-binding construct comprises an amino acid sequence encoded by a polynucleotide that is at least 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identical to a relevant nucleotide sequence or fragment thereof set forth in Table(s) or accession number(s) disclosed herein.

[0304] It is to be understood that this invention is not limited to the particular protocols; cell lines, constructs, and reagents described herein and as such may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention

[0305] All publications and patents mentioned herein are incorporated herein by reference for the purpose of describing and disclosing, for example, the constructs and methodologies that are described in the publications, which might be used in connection with the presently described invention. The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the inventors are not entitled to antedate such disclosure by virtue of prior invention or for any other reason.

EXAMPLES

[0306] Below are examples of specific embodiments for carrying out the present invention. The examples are offered for illustrative purposes only, and are not intended to limit the scope of the present invention in any way. Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperatures, etc.), but some experimental error and deviation should, of course, be allowed for.

[0307] The practice of the present invention will employ, unless otherwise indicated, conventional methods of protein chemistry, biochemistry, recombinant DNA techniques and pharmacology, within the skill of the art. Such techniques are explained fully in the literature. See, e.g., T. E. Creighton, Proteins: Structures and Molecular Properties (W.H. Freeman and Company, 1993); A. L. Lehninger, Biochemistry (Worth Publishers, Inc., current addition); Sambrook, et al., Molecular Cloning: A Laboratory Manual (2nd Edition, 1989); Methods In Enzymology (S. Colowick and N. Kaplan eds., Academic Press, Inc.); Remington's Pharmaceutical Sciences, 18th Edition (Easton, Pa.: Mack Publishing Company, 1990); Carey and Sundberg Advanced Organic Chemistry 3.sup.rd Ed. (Plenum Press) Vols A and B (1992).

Example 1: Preparation of Exemplary Anti-HER2 Bispecific Antibodies and Controls

[0308] A number of exemplary anti-HER2 biparatopic antibodies (or antigen-binding constructs) and controls were prepared as described below. The antibodies and controls have been prepared in different formats, and representations of exemplary biparatopic formats are shown in FIG. 1. In all of the formats shown in FIG. 1, the heterodimeric Fc is depicted with one chain (Chain A) shown in black and the other (Chain B) shown in grey, while one antigen-binding domain (1) is shown in hatched fill, while the other antigen-binding domain (2) is shown in white.

[0309] FIG. 1A depicts the structure of a biparatopic antibody in a Fab-Fab format. FIGS. 1B to 1E depict the structure of possible versions of a biparatopic antibody in an scFv-Fab format. In FIG. 1B, antigen-binding domain 1 is an scFv, fused to Chain A, while antigen-binding domain 2 is a Fab, fused to Chain B. In FIG. 1C, antigen-binding domain 1 is a Fab, fused to Chain A, while antigen-binding domain 2 is an scFv, fused to Chain B. In FIG. 1D, antigen-binding domain 2 is a Fab, fused to Chain A, while antigen-binding domain 1 is an scFv, fused to Chain B. In FIG. 1E, antigen-binding domain 2 is an scFv, fused to Chain A, while antigen-binding domain 1 is a Fab, fused to Chain B. In FIG. 1F, both antigen-binding domains are scFvs.

[0310] The sequences of the following variants are provided in the Sequence Table found after the Examples. CDR regions were identified using a combination of the Kabat and Chothia methods. Regions may vary slightly based on method used for identification.

[0311] Exemplary Anti-HER2 Biparatopic Antibodies

[0312] Exemplary anti-HER2 biparatopic antibodies were prepared as shown in Table 1.

TABLE-US-00008 TABLE 1 Exemplary anti-HER2 biparatbopic antibodies Variant Chain A Chain B 5019 domain ECD2 ECD4 containing the epitope Format Fab scFv Antibody Pertuzumab Trastuzumab name CH3 T350V_L351Y_F405A_Y407V T366I_N390R_K392M_T394W sequence substitutions 5020 domain ECD4 ECD2 containing the epitope format scFv Fab Antibody Trastuzumab Pertuzumab name CH3 L351Y_S400E_F405A_Y407V T350V_T366L_K392L_T394W sequence substitutions 7091 domain ECD2 ECD4 containing the epitope format Fab scFv Antibody Pertuzumab Trastuzumab name CH3 T350V_L351Y_F405A_Y407V T350V_T366L_K392L_T394W sequence substitutions 10000 domain ECD2 ECD4 containing the epitope format Fab scFv Antibody Pertuzumab - with Y96A in VL Trastuzumab name region and T30A/A49G/L69F in VH region CH3 T350V_L351Y_F405A_Y407V T350V_T366L_K392L_T394W sequence substitutions 6902 domain ECD2 ECD4 containing the epitope format Fab Fab Antibody Trastuzumab Pertuzumab name Fab HC: L143E_K145T HC: D146G_Q179K substitutions LC: Q124R LC: Q124E_Q160E_T180E CH3 T350V_L351Y_F405A_Y407V T350V_T366L_K392L_T394W sequence substitutions 6903 domain ECD2 ECD4 containing the epitope format Fab Fab Fab HC: L143E_K145T HC: D146G_Q179K substitutions LC: Q124R_Q1160K_T178R LC: Q124E_Q160E_T180E Antibody Trastuzumab Pertuzumab name CH3 T350V_L351Y_F405A_Y407V T350V_T366L_K392L_T394W sequence substitutions 6717 domain ECD4 ECD2 containing the epitope format scFv scFv Antibody Pertuzumab Trastuzumab name CH3 T350V_L351Y_F405A_Y407V T366I_N390R_K392M_T394W sequence substitutions Notes: CH3 numbering according to EU index as in Kabat referring to the numbering of the EU antibody (Edelman et al., 1969, Proc Natl Acad Sci USA 63: 78-85); Fab or variable domain numbering according to Kabat (Kabat and Wu, 1991; Kabat et al, Sequences of proteins of immunological interest. 5th Edition - US Department of Health and Human Services, NIH publication no 91-3242, p 647 (1991)) "domain containing the epitope" = domain of HER2 to which antigen-binding moiety binds; "Antibody name" = antibody from which antigen-binding moiety is derived, includes substitutions compared to wild-type when present; "Fab substitutions" = substitutions in Fab that promote correct light chain pairing; "CH3 sequence substitutions" = substitutions in CH3 domain that promote formation of heterodimeric Fc

[0313] Exemplary Anti-HER2 Monovalent Control Antibodies

[0314] v1040: a monovalent anti-HER2 antibody, where the HER2 binding domain is a Fab derived from trastuzumab on chain A, and the Fc region is a heterodimer having the mutations T350V_L351Y_F405A_Y407V in Chain A, T350V_T366L_K392L_T394W in Chain B, and the hinge region of Chain B having the mutation C226S; the antigen-binding domain binds to domain 4 of HER2.

[0315] v630--a monovalent anti-HER2 antibody, where the HER2 binding domain is an scFv derived from trastuzumab on Chain A, and the Fc region is a heterodimer having the mutations L351Y_S400E_F405A_Y407V in Chain A, T366I_N390R_K392M_T394W in Chain B; and the hinge region having the mutation C226S (EU numbering) in both chains; the antigen-binding domain binds to domain 4 of HER2.

[0316] v4182: a monovalent anti-HER2 antibody, where the HER2 binding domain is a Fab derived from pertuzumab on chain A, and the Fc region is a heterodimer having the mutations T350V_L351Y_F405A_Y407V in Chain A, T350V_T366L_K392L_T394W in Chain B, and the hinge region of Chain B having the mutation C226S; the antigen-binding domain binds to domain 2 of HER2.

[0317] Exemplary Anti-HER2 Monospecific Bivalent Antibody Controls (Full-Sized Antibodies, FSAs)

[0318] v506 is a wild-type anti HER2 produced in-house in Chinese Hamster Ovary (CHO) cells, as a control. Both HER2 binding domains are derived from trastuzumab in the Fab format and the Fc is a wild type homodimer; the antigen-binding domain binds to domain 4 of HER2. This antibody is also referred to as a trastuzumab analog.

[0319] v792, is wild-type trastuzumab with a IgG1 hinge, where both HER2 binding domains are derived from trastuzumab in the Fab format, and the and the Fc region is a heterodimer having the mutations T350V_L351Y_F405A_Y407V in Chain A, and T350V_T366L_K392L_T394W Chain B; the antigen-binding domain binds to domain 4 of HER2. This antibody is also referred to as a trastuzumab analog.

[0320] v4184, a bivalent anti-HER2 antibody, where both HER2 binding domains are derived from pertuzumab in the Fab format, and the Fc region is a heterodimer having the mutations T350V_L351Y_F405A_Y407V in Chain A, and T350V_T366L_K392L_T394W Chain B. The antigen-binding domain binds to domain 2 of HER2. This antibody is also referred to as a pertuzumab analog.

[0321] hIgG, is a commercial non-specific polyclonal antibody control (Jackson ImmunoResearch, #009-000-003).

[0322] These antibodies and controls (other than human IgG) were cloned and expressed as follows. The genes encoding the antibody heavy and light chains were constructed via gene synthesis using codons optimized for human/mammalian expression. The Trastuzumab Fab sequence was generated from a known HER2/neu domain 4 binding antibody (Carter P. et al. (1992) Humanization of an anti p185 HER2 antibody for human cancer therapy. Proc Natl Acad Sci 89, 4285.) And the Fc was an IgG1 isotype. The scFv sequence was generated from the VH and VL domains of Trastuzumab using a glycine-serine linker (Carter P. et al. (1992) Humanization of an anti p185 her2 antibody for human cancer therapy. Proc Natl Acad Sci 89, 4285.). The Pertuzumab Fab sequence was generated from a known HER2/neu domain 2 binding Ab (Adams C W et al. (2006) Humanization of a recombinant monoclonal antibody to produce a therapeutic her dimerization inhibitor, Pertuzumab. Cancer Immunol Immunother. 2006; 55(6):717-27).

[0323] The final gene products were sub-cloned into the mammalian expression vector PTT5 (NRC-BRI, Canada) and expressed in CHO cells (Durocher, Y., Perret, S. & Kamen, A. High-level and high-throughput recombinant protein production by transient transfection of suspension-growing CHO cells. Nucleic acids research 30, e9 (2002)).

[0324] The CHO cells were transfected in exponential growth phase (1.5 to 2 million cells/ml) with aqueous 1 mg/ml 25 kDa polyethylenimine (PEI, polysciences) at a PEI:DNA ratio of 2.5:1. (Raymond C. et al. A simplified polyethylenimine-mediated transfection process for large-scale and high-throughput applications. Methods. 55(1):44-51 (2011)). To determine the optimal concentration range for forming heterodimers, the DNA was transfected in optimal DNA ratios of the heavy chain a (HC-A), light chain (LC), and heavy chain B (HC-B) that allow for heterodimer formation (e.g. HC-A/HC-B/LC ratios=30:30:40 (v5019). Transfected cells were harvested after 5-6 days with the culture medium collected after centrifugation at 4000 rpm and clarified using a 0.45 .mu.m filter.

[0325] The clarified culture medium was loaded onto a MabSelect SuRe (GE Healthcare) protein-A column and washed with 10 column volumes of PBS buffer at pH 7.2. The antibody was eluted with 10 column volumes of citrate buffer at pH 3.6 with the pooled fractions containing the antibody neutralized with TRIS at pH 11.

[0326] The protein-A antibody eluate was further purified by gel filtration (SEC). For gel filtration, 3.5 mg of the antibody mixture was concentrated to 1.5 mL and loaded onto a Sephadex 200 HiLoad 16/600 200 pg column (GE Healthcare) via an AKTA Express FPLC at a flow-rate of 1 mL/min. PBS buffer at pH 7.4 was used at a flow-rate of 1 mL/min. Fractions corresponding to the purified antibody were collected, concentrated to .about.1 mg/mL.

[0327] Exemplary anti-HER2 ECD2.times.ECD4 biparatopic antibodies with different molecular formats (e.g. v6717, scFv-scFv IgG1; v6903 and v6902 Fab-Fab IgG1; v5019, v7091 and v10000 Fab-scFv IgG1) were cloned, expressed and purified as described above.

[0328] To quantify antibody purity and to determine the amount of target heterodimer protein and possible homodimer and/or half antibody and/or mispaired light chain contaminant, LC-MS intact mass analysis was performed. The LC-MS intact mass analysis was performed as described in Example 2, excluding DAR analysis calculations used for ADC molecules.

[0329] The data is shown in Table 2. Table 2 shows that expression and purification of these biparatopic antibodies resulted in 100% of the desired product for v6717, 91% of the desired heterodimeric product for v6903, and 62% of the desired product for v6902. The numbers in brackets indicate the quantities of the main peak plus a side peak of +81 Da. This side peak is typically detected with variants that contain C-terminal HA tags (such of v6903 and v6902). Adding the main and side peaks yields heterodimer purities of approximately 98% and 67% for v6903 and v6903. Based on the high heterodimer purity, v6903 was identified as the representative Fab-Fab anti-HER2 biparatopic variant for direct comparison to the scFv-scFv and Fab-scFv formats. v6903 was included in all format comparison assays.

TABLE-US-00009 TABLE 2 Expression and purification of antibodies Variant Desired heterodimer species (+side peak) 6717 100.0 6903 90.9 (97.7) 6902 62.4 (67.4)

Example 2: Preparation of Exemplary Anti-HER2 Biparatopic Antibody Drug Conjugates (ADCs)

[0330] The following anti-HER2 biparatopic antibody drug conjugates (anti-HER2 biparatopic-ADCs) were prepared. ADCs of variants 5019, 7091, 10000 and 506 were prepared. These ADCs are identified as follows:

[0331] v6363 (v5019 conjugated to DM1)

[0332] v7148 (v7091 conjugated to DM1)

[0333] v10553 (v10000 conjugated to DM1)

[0334] v6246 (v506 conjugated to DM1, analogous to T-DM1, trastuzumab-emtansine)

[0335] v6249 (human IgG conjugated to DM1)

[0336] The ADCs were prepared via direct coupling to maytansine. Antibodies purified by Protein A and SEC, as described in Example 1 (>95% purity), were used in the preparation of the ADC molecules. ADCs were conjugated following the method described in Kovtun Y V, Audette C A, Ye Y, et al. Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res 2006; 66:3214-21. The ADCs had an average molar ratio of 3.0 maytansinoid molecules per antibody as determined by LC/MS and described below.

[0337] Details of the reagents used in the ADC conjugation reaction are as follows: Conjugation Buffer 1: 50 mM Potassium Phosphate/50 mM Sodium Chloride, pH 6.5, 2 mM EDTA. Conjugation Buffer 2: 50 mM Sodium Succinate, pH 5.0. ADC formulation buffer: 20 mM Sodium Succinate, 6% (w/v) Trehalose, 0.02% polysorbate 20, pH 5.0. Dimethylacetamide (DMA); 10 mM SMCC in DMA (prepared before conjugation), 10 mM DM1-SH in DMA (prepared before conjugation), 1 mM DTNB in PBS, 1 mM Cysteine in buffer, 20 mM Sodium Succinate, pH 5.0. UV-VIS spectrophotometer (Nano drop 100 from Fisher Scientific), PD-10 columns (GE Healthcare).

[0338] The ADCs were prepared as follows. The starting antibody solution was loaded onto the PD-10 column, previously equilibrated with 25 mL of Conjugation Buffer 1, followed by 0.5 ml Conjugation Buffer 1. The antibody eluate was collect and the concentration measured at A.sub.280 and the concentration was adjusted to 20 mg/mL. The 10 mM SMCC-DM1 solution in DMA was prepared. A 7.5 molar equivalent of SMCC-DM1 to antibody was added to the antibody solution and DMA was added to a final DMA volume of 10% v/v. The reaction was briefly mixed and incubated at RT for 2 h. A second PD-10 column was equilibrated with 25 ml of Conjugation Buffer 1 and the antibody-MCC-DM1 solution was added to the column follow by 0.5 ml of Buffer 1. The antibody-MCC-DM1 eluate was collected and the A.sub.252 and A.sub.280 of antibody solution was measured. The Antibody-MCC-DM1 concentration was calculated (.quadrature.=1.45 mg.sup.-1cm.sup.-1, or 217500 M.sup.-1cm.sup.-1). The ADCs were analyzed on a SEC-HPLC column for high MW analysis (SEC-HPLC column TOSOH, G3000-SWXL, 7.8 mm.times.30 cm, Buffer, 100 mM Sodium phosphate, 300 mM Sodium Chloride, pH 7.0, flow rate: 1 ml/min).

[0339] ADC drug to antibody ratio (DAR) was analysed by HIC-HPLC_using the Tosoh TSK gel Butyl-NPR column (4.6 mm.times.3.5 mm.times.2.5 mm). Elution was performed at 1 ml/min using a gradient of 10-90% buffer B over 25 min followed by 100% buffer B for 4 min. Buffer A comprises 20 mM sodium phosphate, 1.5 M ammonium sulphate, pH 7.0. Buffer B comprises 20 mM sodium phosphate, 25% v/v isopropanol, pH 7.0.

[0340] ADC drug to antibody ratio (DAR) was determined by LC-MS by the following method. The antibodies were deglycosylated with PNGase F prior to loading on the LC-MS. Liquid chromatography was carried out on an Agilent 1100 Series HPLC under the following conditions:

[0341] Flow rate: 1 mL/min split post column to 100 uL/min to MS. Solvents: A=0.1% formic acid in ddH2O, B=65% acetonitrile, 25% THF, 9.9% ddH2O, 0.1% formic acid. Column: 2.1.times.30 mm PorosR2. Column Temperature: 80.degree. C.; solvent also pre-heated. Gradient: 20% B (0-3 min), 20-90% B (3-6 min), 90-20% B (6-7 min), 20% B (7-9 min).

[0342] Mass Spectrometry (MS) was subsequently carried out on an LTQ-Orbitrap XL mass spectrometer under the following conditions: Ionization method using Ion Max Electrospray. Calibration and Tuning Method: 2 mg/mL solution of CsI is infused at a flowrate of 104/min. The Orbitrap was tuned on m/z 2211 using the Automatic Tune feature (overall CsI ion range observed: 1690 to 2800). Cone Voltage: 40V; Tube Lens: 115V; FT Resolution: 7,500; Scan range m/z 400-4000; Scan Delay: 1.5 min. A molecular weight profile of the data was generated using Thermo's Promass deconvolution software. Average DAR of the sample was determined as a function of DAR observed at each fractional peak (using the calculation: (DAR.times.fractional peak intensity)).

[0343] Table 3 summarizes the average DAR for the ADC molecules. The average DAR for the exemplary anti-HER2 biparatopic antibody and control was approximately 3.

TABLE-US-00010 TABLE 3 Average DAR for ADCs DAR (LC-MS) DAR (HIC) n v6246 2.9 3.0 5 v6363 2.6 3.3 5 v7148 3.4 3.9 1 v10553 4.0 4.0 1

Example 3: Expression and Bench-Scale Purification of Anti-HER2 Biparatopic Antibody

[0344] The anti-HER2 biparatopic antibodies (v5019, v7091 and v10000) described in Example 1 were expressed in 10 and/or 25 L volumes and purified by protein A and size exclusion chromatography (SEC) as follows.

[0345] The clarified culture medium was loaded onto a MabSelect SuRe (GE Healthcare) protein-A column and washed with 10 column volumes of PBS buffer at pH 7.2. The antibody was eluted with 10 column volumes of citrate buffer at pH 3.6 with the pooled fractions containing the antibody neutralized with Tris at pH 11.

[0346] The protein-A antibody eluate was further purified by gel filtration (SEC). For gel filtration, 3.5 mg of the antibody mixture was concentrated to 1.5 mL and loaded onto a Sephadex 200 HiLoad 16/600 200 pg column (GE Healthcare) via an AKTA Express FPLC at a flow-rate of 1 mL/min. PBS buffer at pH 7.4 was used at a flow-rate of 1 mL/min. Fractions corresponding to the purified antibody were collected, concentrated to .about.1 mg/mL. The purified proteins were analyzed by LC-MS as described in Example 2.

[0347] The results of the 10 L expression and bench-scale protein A and SEC purification are shown in FIGS. 2A and 2B. FIG. 2A shows the SEC chromatograph of the protein A purified v5019 and FIG. 2B shows the non-reducing SDS-PAGE gel that compares the relative purity of a protein A pooled fraction as well as SEC fractions 15 and 19 and pooled SEC fractions 16-18. These results show that the anti-HER2 biparatopic antibody was expressed and that purification by protein A and SEC yielded a pure protein sample. Further quantification was performed by UPLC-SEC and LC-MS analysis and is described in Example 4.

[0348] The results of the 25 L expression and bench-scale protein A purification is shown in FIG. 2C. FIG. 2C shows SDS-PAGE gel that compares the relative purity of a protein A purified v10000. Lane M contains: protein marker; lane 1 contains: v10000 under reducing conditions; lane 2 contains v10000 under non-reducing conditions. The SDS-PAGE gel shows that v10000 is pure and runs at the correct predicted MW of approximately 125 kDa under non-reducing conditions. Under reducing conditions two heavy chains bands are visible corresponding to the CH-A heavy chain (approximately 49 kDa) and the CH-B heavy chain (approximately 52.5 kDa); the CH-A light chain is visible and runs at the correct predicted mass of approximately 23.5 kDa. These results show that the anti-HER2 biparatopic antibody was expressed and that one-step purification by protein A yielded a pure protein sample. Further quantification was performed by UPLC-SEC and LC-MS analysis and is described in Example 4.

Example 4: Analysis of Biparatopic Anti-HER2 Antibody Purity by UPLC-SEC and LC-MS

[0349] The purity and percent aggregation of exemplary protein A and SEC purified biparatopic anti-HER2 heteromultimers was determined by UPLC-SEC by the method described.

[0350] UPLC-SEC analysis was performed using a Waters BEH200 SEC column set to 30.degree. C. (2.5 mL, 4.6.times.150 mm, stainless steel, 1.7 .mu.m particles) at 0.4 ml/min. Run times consisted of 7 min and a total volume per injection of 2.8 mL with running buffers of 25 mM sodium phosphate, 150 mM sodium acetate, pH 7.1; and, 150 mM sodium phosphate, pH 6.4-7.1. Detection by absorbance was facilitated at 190-400 nm and by fluorescence with excitation at 280 nm and emission collected from 300-360 nm. Peak integration was analyzed by Empower 3 software.

[0351] UPLC-SEC results of the pooled v5019 SEC fractions are shown in FIG. 3A. These results indicate that the exemplary anti-HER2 biparatopic antibody was purified to >99% purity with less than 1% HMW species by protein A and SEC chromatography.

[0352] UPLC-SEC results of the v10000 pooled Protein A fractions are shown in FIG. 3B. These results indicate that the exemplary anti-HER2 biparatopic antibody was purified to >96% purity with less than 1% HMW species by protein A chromatography.

[0353] The purity of exemplary biparatopic anti-HER2 antibodies was determined using LC-MS under standard conditions by the method described in Example 2. Results from LC-MS analysis of the pooled SEC fractions of v5019 are shown in FIG. 4A. This data shows that the exemplary biparatopic anti-HER2 heterodimer has a heterodimer purity of 100%. Results from LC-MS analysis of the pooled protein A fractions of v10000 are shown in FIG. 4B. This data shows that the exemplary biparatopic anti-HER2 heterodimer has a heterodimer purity of 98% following a one-step protein A purification.

[0354] Antibodies purified by protein A chromatography and/or protein A and SEC were used for the assays described in the following Examples.

Example 5. Large-Scale Expression and Manufacturability Assessment of Biparatopic Anti-HER2 Antibody Purified by Protein A and CEX Chromatography

[0355] The exemplary anti-HER2 biparatopic antibody v5019 described in Example 1 was expressed in a 25 L scale and purified as follows.

[0356] Antibody was obtained from supernatant followed by a two-step purification method that consisted of Protein A purification (MabSelect.TM. resin; GE Healthcare) followed by cation exchange chromatography (HiTrap.TM. SP FF resin; GE Healthcare) by the protocol described.

[0357] CHO-3E7 cells were maintained in serum-free Freestyle CHO expression medium (Invitrogen, Carlsbad, Calif., USA) in Erlenmeyer Flasks at 37.degree. C. with 5% CO2 (Corning Inc., Acton, Mass.) on an orbital shaker (VWR Scientific, Chester, Pa.). Two days before transfection, the cells were seeded at an appropriate density in a 50 L CellBag with a volume of 25 L using the Wave Bioreactor System 20/50 (GE Healthcare Bio-Science Corp). On the day of transfection, DNA and PEI (Polysciences, Eppelheim, Germany) were mixed at an optimal ratio and added to the cells using the method described in Example 1. Cell supernatants collected on day 6 was used for further purification.

[0358] Cell culture broth was centrifuged and filtered before loading onto 30 mL Mabselect.TM. resin packed in XK26/20 (GE Healthcare, Uppsala, Sweden) at 10.0 mL/min. After washing and elution with appropriate buffer, the fractions were collected and neutralized with 1 M Tris-HCl, pH 9.0. The target protein was further purified via 20 mL SP FF resin packed in XK16/20 (GE Healthcare, Uppsala, Sweden). MabSelect.TM. purified sample was diluted with 20 mM NaAC, pH5.5 to adjust the conductivity to <5 ms/cm and 50 mM citrate acid (pH3.0) was added adjust the sample pH value to 5.5. Sample was loaded at a 1 mL/min onto the HiTrap.TM. SP FF resin (GE Healthcare) and washed with 20 mM NaAC. Protein was eluted using a gradient elution 0-100% of 20 mM NaAC, 1 M NaCl, pH5.5, 10 CV at 1 mL/min.

[0359] The purified protein was analyzed by SDS-PAGE as described in Example 1, and LC-MS for heterodimer purity by the method described in example 4. The results are shown in FIGS. 5A and 5B. FIG. 5A shows the SDS-PAGE results of v5019 following MabSelect.TM. and HiTrap.TM. SP FF purification; lane M contains: protein marker; lane 1: v5019 under reducing conditions (3 .mu.g); Lane 2: v5019 under non-reducing conditions (2.5 .mu.g). The SDS-PAGE gel shows that v5019 is relatively pure following MabSelect.TM. and HiTrap.TM. SP FF purification and, under non-reducing conditions, runs at the correct predicted MW of approximately 125 kDa. Under reducing conditions two heavy chains bands are visible corresponding to the CH-A heavy chain (approximately 49 kDa) and the CH-B heavy chain (approximately 52.5 kDa); the CH-A light chain is visible and runs at the correct predicted mass of approximately 23.5 kDa.

[0360] LC-MS analysis of the MabSelect.TM. and HiTrap.TM. SP FF purified v5019 was performed to determine heterodimer purity using the method described in Example 4. Results from the LC-MS analysis are shown in FIG. 5B. These results show that v5019 purification using MabSelect.TM. and HiTrap.TM. SP FF yields protein with >99% heterodimer purity and with little (<1%) or undetectable homodimer or half antibody contamination.

Example 6: Comparison of Bmax of a Biparatopic Anti-HER2 Antibody Against Bmax of Controls in Cell Lines Expressing Low to High Levels of HER2

[0361] The following experiment was performed to measure the ability of an exemplary biparatopic anti-HER2 antibody to bind to cells expressing varying levels of HER2 in comparison to controls. The cell lines used were SKOV3 (HER2 2+/3+), JIMT-1 (HER2 2+), MDA-MB-231 (HER2 0/1+), and MCF7 (HER2 1+). The biparatopic anti-HER2 antibodies tested include v5019, v7091 and v10000. The ability of the biparatopic anti-HER2 antibodies to bind to the HER2 expressing (HER2+) cells was determined as described below, with specific measurement of B.sub.max and apparent K.sub.D (equilibrium dissociation constant).

[0362] Binding of the test antibodies to the surface of HER2+ cells was determined by flow cytometry. Cells were washed with PBS and resuspended in DMEM at 1.times.10.sup.5 cells/100 .mu.l. 100 .mu.l cell suspension was added into each microcentrifuge tube, followed by 10 .mu.l/tube of the antibody variants. The tubes were incubated for 2 hr 4.degree. C. on a rotator. The microcentrifuge tubes were centrifuged for 2 min 2000 RPM at room temperature and the cell pellets washed with 500 .mu.l media. Each cell pellet was resuspended 100 .mu.l of fluorochrome-labelled secondary antibody diluted in media to 2 .mu.g/sample. The samples were then incubated for 1 hr at 4.degree. C. on a rotator. After incubation, the cells were centrifuged for 2 min at 2000 rpm and washed in media. The cells were resuspended in 500 .mu.l media, filtered in tube containing 5 .mu.l propidium iodide (PI) and analyzed on a BD LSR II flow cytometer according to the manufacturer's instructions. The K.sub.D of exemplary biparatopic anti-HER2 heterodimer antibody and control antibodies were assessed by FACS with data analysis and curve fitting performed in GraphPad Prism.

[0363] The results are shown in FIGS. 6A-6G. These results demonstrate that exemplary biparatopic anti-HER2 antibodies (v5019, v7091 and v10000) can bind to HER2+ cells with approximately a 1.5-fold higher Bmax compared to an anti-HER2 FSA (v506). The results in FIG. 6A-6G also show that biparatopic anti-HER2 antibodies (v5019, v7091 and v10000) can bind to HER2+ cells with a similar Bmax compared to a combination of two anti-HER2 FSAs (v506+v4184).

[0364] The binding results for HER2+ SKOV3 cells (HER2 2/3+) are shown in FIGS. 6A, 6E and Table 4 and Table 5. The results in FIG. 6A and Table 4 show that exemplary biparatopic anti-HER2 antibody (v5019) displays approximately a 1.5-fold higher Bmax in binding to SKOV3 cells compared to two different anti-HER2 FSAs (v506 or v4184). The results also show that exemplary biparatopic anti-HER2 antibody (v5019) displays equivalent Bmax compared to the combination of two anti-HER2 FSAs (v506+v4184). The apparent K.sub.D of v5019 for binding to SKOV3 was approximately 2 to 4-fold higher compared to either anti-HER2 FSA alone (v506 or v4184), or the combination of two anti-HER2 FSAs (v506+v4184).

TABLE-US-00011 TABLE 4 Binding to SKOV3 cells Antibody variant K.sub.D (nM) Bmax v506 2.713 29190 v4184 4.108 29204 v5019 8.084 47401 v506 + v4184 4.414 49062

[0365] The results in FIG. 6E and Table 5 show that exemplary biparatopic anti-HER2 antibodies (v5019, 7091 and v10000) display approximately a 1.5 to 1.6-fold higher Bmax in binding to SKOV3 cells compared to two different anti-HER2 FSAs (v506 or v4184). The results also show that exemplary biparatopic anti-HER2 antibodies (v5019, 7091 and v10000) display equivalent Bmax compared to the combination of two anti-HER2 FSAs (v506+v4184). The apparent K.sub.D of v5019, v7091, v10000 and the combination of two anti-HER2 FSAs (v506+v4184) for binding to SKOV3 was approximately 2 to 3-fold higher compared to either anti-HER2 FSA alone (v506 or v4184).

TABLE-US-00012 TABLE 5 Binding to SKOV3 Antibody Variant K.sub.D (nM) Bmax v506 4.8 30007 v4184 5.6 27628 v506 + v4184 10.0 49014 v5019 13.6 47693 v7091 14.5 44737 v10000 10.3 48054

[0366] Binding curves in the JIMT-1 cell line (HER2 2+) are shown in FIG. 6B and Table 6. These results show that exemplary biparatopic anti-HER2 antibody (v5019) displays approximately a 1.5-fold higher Bmax in binding to JIMT-1 cells compared to an anti-HER2 FSAs (v506). The results also show that exemplary biparatopic anti-HER2 antibody (v5019) displays equivalent Bmax compared to the combination of two anti-HER2 FSAs (v506+v4184). The apparent K.sub.D of v5019 for binding to JIMT-1 was approximately 2-fold higher compared to the anti-HER2 FSA (v506), and was similar (approximately 1.2 fold greater) compared to the combination of two anti-HER2 FSAs (v506+v4184).

TABLE-US-00013 TABLE 6 Binding to JIMT-1 cells Antibody variant K.sub.D (nM) Bmax v506 1.875 4905 v5019 4.317 7203 v506 + v4184 5.057 7200

[0367] Binding curves in the MCF7 cell line (HER2 1+) are shown in FIG. 6C, 6F and Tables 7 and 8. These results show that exemplary biparatopic anti-HER2 antibodies (v5019, 7091 and v10000) display approximately a 1.5-fold higher Bmax in binding to MCF7 cells compared to an anti-HER2 FSAs (v506). The results in FIG. 6C also show that exemplary biparatopic anti-HER2 antibody (v5019) displays equivalent Bmax compared to the combination of two anti-HER2 FSAs (v506+v4184). The apparent K.sub.D of v5019 for binding to MCF7 was similar to the anti-HER2 FSA (v506) and the combination of two anti-HER2 FSAs (v506+v4184).

TABLE-US-00014 TABLE 7 Binding to MCF7 cells Antibody variant K.sub.D (nM) Bmax v506 1.301 542 v5019 1.506 872 v506 + v4184 2.095 903

The results in FIG. 6F and Table 8 show that exemplary biparatopic anti-HER2 antibodies (v5019, v7091 and v10000) display approximately 1.6 to 1.7-fold greater Bmax compared to the FSA monospecific v506. The apparent K.sub.D of v5019, v7091 and v10000 was similar to the anti-HER2 FSA (v506).

TABLE-US-00015 TABLE 8 Binding to MCF7 cells Antibody Variant K.sub.D (nM) Bmax v506 3.5 571 v5019 5.6 968 v7091 6.5 918 v10000 3.7 915

[0368] Binding curves in the MDA-MB-231 cell line (HER2 0/1+) are shown in FIG. 6D and Table 9. These results show that exemplary biparatopic anti-HER2 antibody (v5019) displays approximately a 1.5-fold higher Bmax in binding to MDA-MB-231 cells compared to an anti-HER2 FSA (v506). The results also show that exemplary biparatopic anti-HER2 antibody (v5019) displays equivalent Bmax compared to the combination of two anti-HER2 FSAs (v506+v4184). The apparent K.sub.D of v5019 for binding to MDA-MB-231 was approximately 2.4-fold lower compared to the anti-HER2 FSA (v506) and was approximately 1.7-fold higher compared to the combination of two anti-HER2 FSAs (v506+v4184).

TABLE-US-00016 TABLE 9 Binding to MDA-MB-231 cells Antibody variant K.sub.D (nM) Bmax v506 8.364 0.9521 v5019 3.543 1.411 v506 + v4184 2.040 1.542

[0369] Binding curves in the WI-38 lung fibroblast cell line are shown in FIG. 6G and Table 10. The WI-38 cell line is a normal lung epithelium that expresses basal levels (HER2 0+, .about.10,000 receptors/cell) of HER2 (Carter et al. 1992, PNAS, 89:4285-4289; Yarden 2000, HER2: Basic Research, Prognosis and Therapy). These results show that exemplary biparatopic anti-HER2 antibodies (v5019, v7091, v10000) displays equivalent cell surface decoration (Bmax) in binding to WI-38 cells compared to an anti-HER2 FSAs (v506); however, note that binding for v506 did not appear to reach saturation, and thus KD could not be determined. The apparent K.sub.D among the exemplary biparatopic anti-HER2 antibodies was equivalent.

TABLE-US-00017 TABLE 10 Binding to WI-38 cells Antibody Variant K.sub.D (nM) Bmax v506 Not determined ~366 v5019 7.0 380 v7091 8.3 371 v10000 8.4 418

[0370] These results show that an exemplary biparatopic anti-HER2 antibody can bind to HER2 1+, 2+ and 3+ tumor cells to levels that are approximately 1.5 to 1.6-fold greater than an anti-HER2 monospecific FSA, and that exemplary biparatopic anti-HER2 antibodies can bind to HER2 1+, 2+ and 3+ tumor cells to equivalent levels compared to the combination of two unique monospecific anti-HER2 FSAs with different epitope specificities. These results also show that the biparatopic anti-HER2 antibodies do not show increased binding (i.e. compared to monospecific anti-HER2 antibody, v506) to basal HER2 expressing cells that express approximately 10,000 HER2 receptors/cell or less, and that a threshold for increased cell surface binding to the biparatopic anti-HER2 antibodies occurs when the HER2 receptor level is approximately >10,000 receptors/cell. Based on this data it would be expected that the exemplary biparatopic anti-HER2 antibodies would have increased cell surface binding to HER2 3+, 2+ and 1+ tumor cells but would not have increased cell surface binding to non-tumor cells that express basal levels of the HER2 receptor at approximately 10,000 receptors or less.

Example 7: Ability of Biparatopic Anti-HER2 Antibody to Inhibit Growth of HER2+ Cells

[0371] The ability of an exemplary biparatopic anti-HER2 antibody to inhibit growth of cells expressing HER2 at the 3+ and 2+ level was measured. The experiment was carried out in the HER2 3+ cell lines BT-474, SKBr3, SKOV3, and HER2 2+ JIMT-1. The biparatopic anti-HER2 antibodies v5019, v7091 and v10000 were tested. The ability of the biparatopic anti-HER2 antibodies to inhibit the growth of BT-474 cells (200 nM antibody); SKOV3, SKBr3 and JIMT-1 cells (300 nM antibody) was measured as described below.

[0372] Test antibodies were diluted in media and added to the cells at 10 .mu.l/well in triplicate. The plates were incubated for 3 days 37.degree. C. Cell viability was measured using either AlamarBlue.TM. (Biosource # dal1100), or CelltiterGlo.RTM. and absorbance read as per the manufacturer's instructions. Data was normalized to untreated control and analysis was performed in GraphPad prism.

[0373] The growth inhibition results are shown in FIG. 7A-E. A summary of the results is provided in Tables 11A and 11B. The results FIGS. 7A-B and Table 11A indicate that exemplary anti-HER2 biparatopic (v5019) is capable of growth inhibition of HER2+ SKOV3 and BT-474 cell lines. FIG. 10A shows that anti-HER2 biparatopic antibody mediated the greatest growth inhibition of SKOV3 when compared to anti-HER2 FSA (v506) and when compared to the combination of two anti-HER2 FSA antibodies (v506+v4184).

TABLE-US-00018 TABLE 11A Growth Inhibition of HER2 3+ Cancer Cells % Survival Treatment SKOV3 HER2 2+/3+ BT-474 HER2 3+ v506 88 37 v506 + v4184 96 32 v5019 77 43

[0374] The results in FIGS. 7C-E and Table 11B indicate that exemplary anti-HER2 biparatopic antibodies (v5019, v7091 and v10000) can inhibit growth of HER2 3+ SKBR3, HER2 2+/3+ SKOV3, and HER2 2+ JIMT-1 tumor cell lines. FIG. 7C shows that anti-HER2 biparatopic antibodies v7091 and v10000 mediated the greatest growth inhibition of HER2 3+ SKBr3 breast tumor cells. FIG. 7D shows that anti-HER2 biparatopic antibodies (v7091 and v10000) mediated the greatest growth inhibition of HER2 3+ SKOV3 ovarian tumor cells. FIG. 7E shows that anti-HER2 biparatopic antibodies (v7091 and v10000) mediated the greatest growth inhibition of HER2 2+ Herceptin-resistant JIMT-1 tumor cells. In all cell lines tested, exemplary anti-HER2 biparatopic antibodies (v7091 and v10000) mediated greater growth inhibition compared to the anti-HER2 FSA monospecific antibody (v506).

TABLE-US-00019 TABLE 11B Growth inhibition of HER2 3+ Cancer Cells % Survival Treatment SKBr3 HER2 3+ SKOV3 HER2 2+/3+ JIMT-1 HER2 2+ v506 52 107 107 v5019 59 83 106 v7091 35 79 85 v10000 34 73 84

[0375] These results show that exemplary saturating concentrations of biparatopic anti-HER2 antibodies can growth inhibit HER2 3+ and 2+ breast and ovarian and HER2 2+ Trastuzumab resistant tumor cells approximately 20% greater than a FSA anti-HER2 monospecific antibody.

Example 8: Preferential Binding of Paratopes of Biparatopic Anti-HER2 Antibodies to Dimeric HER2 Compared to HER2 ECD

[0376] This experiment was performed to determine the ability of the individual paratopes of exemplary biparatopic anti-HER2 antibodies to bind to dimeric HER2 and the HER2 ECD as a surrogate for differential binding between membrane bound HER2 (HER2-Fc) and the shed HER2 ECD. The experiment was carried out as follows.

[0377] Surface plasmon resonance (SPR) analysis: affinity of monovalent anti-HER2 antibodies (v1040 or v4182) for binding to the HER2 extracellular domain (sHER-2, Ebioscience BMS362, encoding amino acid 23-652 of the full length protein) and HER2-Fc (dimeric HER2-Fc fusion encoding the amino acid 1-652 of the extracellular domain; Sino Biological Inc., 10004-H02H) was measured by SPR using the T200 system from Biacore (GE Healthcare). Binding to the HER2 ECD was determined by the following method. HER2 ECD in 10 mm Hepes pH 6.8, was immobilized on CMS chip through amine coupling to a level of 44 RU (response units). Monovalent anti-HER2 antibodies were passed over the surface of the HER2 immobilized chip at concentrations ranging from 0.76-60 nM. Binding to the HER2-Fc was determined by the following method. HER2-Fc in 10 mm Hepes pH 6.8, was immobilized on CMS chip through amine coupling to a level of 43 RU. Monovalent anti-HER2 antibodies were passed over the surface of the HER2 immobilized chip at concentrations ranging from 0.76-60 nM. Antibody concentrations were analyzed for binding in triplicate. Equilibrium dissociation binding constants (K.sub.D) and kinetics (ka and kd) were determined using the single cycle kinetics method. Sensograms were fit globally to a 1:1 Langmuir binding model. All experiments were conducted at room temperature.

[0378] Results are shown in FIG. 8A, FIG. 8B, Table 11C and Table 11D. The results in FIG. 8A and Table 11C show SPR binding data of the monovalent anti-HER2 antibody (v1040; representing the antigen-binding domain on CH-B of exemplary anti-HER2 biparatopic antibody). FIG. 8A illustrates the K.sub.D values (nM) of v1040 binding to immobilized HER2 ECD or HER2-Fc and shows that monovalent anti-HER2 antibody has a lower K.sub.D for binding to the HER2-Fc compared to the HER2 ECD. Table 11C shows the ka (1/M s) and kd (1/s) values of the monovalent anti-HER2 antibody (OA) compared to the full-sized anti-HER2 antibody (FSA) in binding to the HER2 ECD and HER2-FC (`HER2 mem`). This data shows comparable on (ka) and off (kd) rates of the OA and FSA for binding to the HER2 ECD and HER2-Fc.

TABLE-US-00020 TABLE 11C ka (1/M s) and kd (1/s) values of the monovalent anti-HER2 antibody (OA) compared to the full-sized anti-HER2 antibody (FSA) in binding to the HER2 ECD and HER2-FC (`HER2 mem` ka (1/Ms) kd (1/s) OA vs. HER2 ECD 2.00E+05 6.15E-05 FSA vs. HER2 ECD 4.14E+05 2.01E-05 OA vs. HER2 mem 1.88E+05 4.38E-05 FSA vs. HER2 mem 3.41E+05 4.94E-06*

[0379] Results in FIG. 8B and Table 11D show the SPR binding data of the monovalent anti-HER2 antibody (v4182; representing the antigen-binding domain on CH-A of exemplary anti-HER2 biparatopic antibody). FIG. 8B illustrates the K.sub.D values (nM) of v4182 binding to immobilized HER2 ECD or HER2-Fc and shows that monovalent anti-HER2 antibody has a lower K.sub.D for binding to the HER2-Fc compared to the HER2 ECD. Table 11D shows the ka (1/M s) and kd (1/s) values of the monovalent anti-HER2 antibody (OA) compared to the full-sized anti-HER2 antibody (FSA) in binding to the HER2 ECD and HER2-FC (`HER2 mem`). This data shows comparable on rates (ka) and off rates (kd) of the OA and FSA for binding to the HER2 ECD and HER2-Fc.

TABLE-US-00021 TABLE 11D ka (1/Ms) kd (1/s) OA vs. HER2 ECD 9.08E+04 6.17E-04 FSA vs. HER2 ECD 9.55E+04 3.93E-04 OA vs. HER2 mem 1.39E+05 2.04E-04 FSA vs. HER2 mem 1.77E+05 6.84E-05

[0380] These data show that each of the paratopes of the exemplary anti-HER2 biparatopic antibody have lower K.sub.D values for binding to the dimeric HER2 antigen, a representative of membrane bound HER2, as compared to the HER2 ECD. Based on this data it would be expected that the exemplary anti-HER2 antibody would have a higher binding affinity for the membrane bound HER2 antigen as compared to the shed HER2 ECD that is present in the serum of diseased patients and can act as a sink for the therapeutic antibody (Brodowicz T, et al. Soluble HER-2/neu neutralizes biologic effects of anti-HER-2/neu antibody on breast cancer cells in vitro. Int J Cancer. 1997; 73:875-879). For example, baseline HER2 ECD levels.ltoreq.15 ng/mL; whereas patients with progressive disease have HER2 ECD.gtoreq.38 ng/mL.

Example 9: Whole Cell Loading and Internalization of Biparatopic Anti-HER2 Antibody in HER2+ Cells

[0381] This experiment was performed to assess the ability of an exemplary biparatopic anti-HER2 antibody to be internalized in HER2 2+ cells. The direct internalization method was followed according to the protocol detailed in Schmidt, M. et al., Kinetics of anti-carcinoembryonic antigen antibody internalization: effects of affinity, bivalency, and stability. Cancer Immunol Immunother (2008) 57:1879-1890. Specifically, the antibodies were directly labeled using the AlexaFluor.RTM. 488 Protein Labeling Kit (Invitrogen, cat. no. A10235), according to the manufacturer's instructions.

[0382] For the internalization assay, 12 well plates were seeded with 1.times.10.sup.5 cells/well and incubated overnight at 37.degree. C.+5% CO2. The following day, the labeled antibodies were added at 200 nM in DMEM+10% FBS and incubated 24 hours at 37.degree. C.+5% CO2. Under dark conditions, media was aspirated and wells were washed 2.times.500 .mu.L PBS. To harvest cells, cell dissociation buffer was added (250 .mu.L) at 37.degree. C. Cells were pelleted and resuspended in 100 .mu.L DMEM+10% FBS without or with anti-Alexa Fluor 488, rabbit IgG fraction (Molecular Probes, A11094) at 50 .mu.g/mL, and incubated on ice for 30 min. Prior to analysis 300 .mu.L DMEM+10% FBS the samples filtered 4 .mu.l propidium iodide was added. Samples were analyzed using the LSRII flow cytometer.

[0383] The ability of exemplary anti-HER2 biparatopic antibody to internalize in HER2+ cells is shown in FIG. 9A and FIG. 9B. FIG. 9A shows the results of detectable surface and internal antibody in BT-474 cells following 24 h incubation with the exemplary anti-HER2 biparatopic antibody and anti-HER2 FSA control. These results show that incubation with exemplary anti-HER2 biparatopic antibody (v5019) results in approximately 2-fold more internalized antibody in BT-474 cells compared to the anti-HER2 FSA control. FIG. 9B shows the results of detectable surface and internal antibody in JIMT-1 cells following 24 h incubation with the exemplary anti-HER2 biparatopic antibody and anti-HER2 FSA control. These results show that incubation with exemplary anti-HER2 biparatopic antibody (v5019) results in approximately 2-fold more internalized antibody in JIMT-1 cells compared to the anti-HER2 FSA control. The amount of surface staining post 24 h was comparable among the biparatopic anti-HER2 and anti-HER2 FSA in both BT-474 and JIMT-1 cells.

[0384] The results in FIG. 10A-F show a comparison of detectable antibody bound to the surface of whole cells after 2 h at 4.degree. C., compared to antibody bound to the surface following incubation for 24 h at 37.degree. C.; in addition to the amount of internalized antibody following 24 h at 37.degree. C. FIG. 10A shows the results in BT-474 cells following incubation with the exemplary anti-HER2 biparatopic antibody and anti-HER2 FSA control. These results show that incubation of exemplary anti-HER2 biparatopic antibody with BT-474 cells for 24 h results in approximately a 15% reduction of antibody detected on the surface of whole cells. FIG. 10A also shows that incubation with exemplary anti-HER2 biparatopic antibody (v5019) results in approximately 2-fold more internalized antibody in BT-474 cells compared to the anti-HER2 FSA control.

[0385] FIG. 10B shows the results in JIMT-1 cells following incubation with the exemplary anti-HER2 biparatopic antibody and anti-HER2 FSA control. FIG. 10B is a repeat of the experiment shown in FIG. 9B with the addition of surface staining following 2 h at 4.degree. C. These results show that incubation of exemplary anti-HER2 biparatopic antibody with JIMT-1 cells for 24 h results in approximately a 57% reduction of antibody detected on the surface of whole cells. FIG. 10B also shows that incubation with exemplary anti-HER2 biparatopic antibody (v5019) results more internalized antibody in BT-474 cells following 24 incubation at 37.degree. C., compared to the anti-HER2 FSA control.

[0386] FIG. 10C shows the results in SKOV3 cells following incubation with the exemplary anti-HER2 biparatopic antibody. These results show that incubation of exemplary anti-HER2 biparatopic antibody with SKOV3 cells for 24 h results in approximately a 32% reduction of antibody detected on the surface of whole cells.

[0387] FIG. 10D shows the results in MCF7 cells following incubation with the exemplary anti-HER2 biparatopic antibody. These results show that incubation of exemplary anti-HER2 biparatopic antibody with MCF7 cells for 24 h results in approximately a 45% reduction of antibody detected on the surface of whole cells.

[0388] FIG. 10E shows the results in SKOV3 cells following incubation with the exemplary anti-HER2 biparatopic antibodies, v5019, v7091 and v10000. These results show that incubation of exemplary anti-HER2 biparatopic antibodies results in 1.5 to 1.8-fold more internalized antibody with SKOV3 cells compared to the anti-HER2 FSA control. Incubation with the anti-HER2 FSA control for 24 h resulted in the greatest reduction (.about.77%) of antibody detected on the surface of whole cells.

[0389] FIG. 10F shows the results in JIMT-1 cells following incubation with the exemplary anti-HER2 biparatopic antibodies, v5019, v7091 and v10000. These results show that incubation of exemplary anti-HER2 biparatopic antibodies results in 1.4 to 1.8-fold more internalized antibody with JIMT-1 cells compared to the anti-HER2 FSA control. Incubation with the anti-HER2 biparatopic antibodies (v5019 and v10000) for 24 h resulted in the greatest reduction (.about.64%) of antibody detected on the surface of whole cells.

[0390] These results show that exemplary anti-HER2 biparatopic antibodies have superior internalization properties in HER2+ cells compared to a monospecific anti-HER2 FSA. The reduction of surface antibody detected following 24 h incubation at 37.degree. C. shows that an exemplary anti-HER2 biparatopic antibody is capable of reducing the amount of cell surface HER2 receptor following incubation in HER2+ cells and that surface HER2 reduction post incubation is greatest in HER2 2+ tumor cells.

Example 10: Cellular Staining and Location of an Anti-HER2 Biparatopic Antibody Following Incubation with HER2+ Cells at 1, 3 and 16 Hours

[0391] This experiment was performed to analyze internalization of the exemplary anti-HER2 biparatopic antibody in HER2+ JIMT-1 cells at different time points and as an orthogonal method to that presented in Example 9 to analyze whole cell loading and internalization.

[0392] JIMT-1 cells were incubated with the antibody (v506, v4184, v5019, or a combination of v506 and v4184) at 200 nM in serum-free DMEM, 37.degree. C.+5% CO.sub.2 for 1h, 3h and 16h. Cells were gently washed two times with warmed sterile PBS (500 ml/well). Cells were fixed with 250 ml of 10% formalin/PBS solution for 10 min at RT. The fixed cells were washed three times with PBS (500 .mu.l/well), permeabilized with 250 .mu.l/well of PBS containing 0.2% Triton X-100 for 5 min, and washed three times with 500 .mu.l/well PBS. Cells were blocked with 500 .mu.l/well of PBS+5% goat serum for 1 h at RT. Blocking buffer was removed, and 300 .mu.l/well secondary antibody (Alexa Fluor 488-conjugated AffiniPure Fab Fragment Goat anti-Human IgG (H+L); Jackson ImmunoResearch Laboritories, Inc.; 109-547-003) was incubated for 1 h at RT. Cells were washed three times with 500 .mu.l/well of PBS and the coverslips containing fixed cells were then mounted on a slide using Prolong gold anti-fade with DAPI (Life Technologies; #P36931). 60.times. single images were acquired using Olympus FV1000 Confocal microscope.

[0393] The results indicated that the exemplary anti-HER2 biparatopic antibody (v5019) was internalized into JIMT-1 cells at 3 h and was primarily located close to the nuclei. Comparing images at the 3h incubation showed a greater amount of internal staining associated with the anti-HER2 biparatopic antibody compared to the combination of two anti-HER2 FSAs (v506+v4184) and compared to the individual anti-HER2 FSA (v506 or v4184). Differences in the cellular location of antibody staining were seen when the anti-HER2 biparatopic antibody (v5019) results were compared with the anti-HER2 FSA (v4184); where the anti-HER2 FSA (v4184) showed pronounced plasma membrane staining at the 1, 3 and 16 h time points. The amount of detectable antibody was reduced at the 16 h for the anti-HER2 FSA (v506), the combination of two anti-HER2 FSAs (v506+v4184) and anti-HER2 biparatopic antibody treatments (data not shown).

[0394] These results show that the exemplary anti-HER2 biparatopic antibody v5019 was internalized in HER2+ cells and the internalized antibody was detectable after 3 h incubation. These results are consistent with the results presented in Example 9 that show exemplary anti-HER2 biparatopic antibody can internalize to greater amounts in HER2+ cells compared to an anti-HER2 FSA.

Example 11: ADCC of HER2+ Cells Mediated by Biparatopic Anti-HER2 Antibody Compared to Controls

[0395] This experiment was performed in order to measure the ability of an exemplary biparatopic anti-HER2 antibody to mediate ADCC in SKOV3 cells (ovarian cancer, HER2 2+/3+).

[0396] Target cells were pre-incubated with test antibodies (10-fold descending concentrations from 45 .mu.g/ml) for 30 min followed by adding effector cells with effector/target cell ratio of 5:1 and the incubation continued for 6 hours at 37.degree. C.+5% CO.sub.2. Samples were tested with 8 concentrations, 10 fold descending from 45 .mu.g/ml. LDH release was measured using LDH assay kit.

[0397] Dose-response studies were performed with various concentrations of the samples with a effector/target (E/T) ratios of 5:1. 3:1 and 1:1. Half maximal effective concentration (EC.sub.50) values were analyzed with the sigmoidal dose-response non-linear regression fit using GraphPad prism.

[0398] Cells were maintained in McCoy's 5a complete medium at 37.degree. C./5% CO.sub.2 and regularly sub-cultured with suitable medium supplemented with 10% FBS according to protocol from ATCC. Cells with passage number fewer than p10 were used in the assays. The samples were diluted to concentrations between 0.3-300 nM with phenol red free DMEM medium supplemented with 1% FBS and 1% pen/strep prior to use in the assay.

[0399] The ADCC results in HER2+ SKOV3 cells at an effector to target cell ratio of 5:1 are shown in FIG. 11A and Table 12. These results show that the exemplary biparatopic anti-HER2 antibody (v5019) mediated the greatest percentage of maximum target cell lysis by ADCC when compared to the anti-HER2 FSA (v792) and combination of two different anti-HER2 FSAs (v792+v4184). The difference in maximum cell lysis mediated by the exemplary biparatopic anti-HER2 antibody was approximately 1.6-fold greater compared to the anti-HER2 FSA, and approximately 1.2-fold greater compared to a combination of two different anti-HER2 FSAs (v792+v4184).

TABLE-US-00022 TABLE 12 Antibody variant EC.sub.50 (nM) % Max Cell Lysis v792 ~0.032 17.82 v5019 ~0.164 28.57 v792 + v4184 ~0.042 23.85

[0400] The ADCC results in HER2+ SKOV3 cells at an effector to target cell ratio of 3:1 are shown in FIG. 11B and Table 13. These results show that the exemplary biparatopic anti-HER2 antibody (v5019) mediated the greatest percentage of maximum target cell lysis by ADCC when compared to the anti-HER2 FSA (v792) and combination of two different anti-HER2 FSAs (v792+v4184). The difference in maximum cell lysis mediated by the exemplary biparatopic anti-HER2 antibody was approximately 1.3-fold greater compared to the anti-HER2 FSA, and approximately 1.8-fold greater compared to a combination of two different anti-HER2 FSAs (v792+v4184).

TABLE-US-00023 TABLE 13 Antibody variant EC.sub.50 (nM) % Max Cell Lysis v792 1.064 16.9 v5019 ~0.4608 22.3 v792 + v4184 ~1.078 12.3

[0401] The ADCC results in HER2+ SKOV3 cells at an effector to target cell ratio of 1:1 are shown in FIG. 11C and Table 14. These results show that the exemplary biparatopic anti-HER2 antibody (v5019) mediated the greatest percentage of maximum target cell lysis by ADCC when to compared to the anti-HER2 FSA (v792) and combination of two different anti-HER2 FSAs (v792+v4184). The difference in maximum cell lysis mediated by the exemplary biparatopic anti-HER2 antibody was approximately 1.8-fold greater compared to the anti-HER2 FSA, and approximately 1.13-fold greater compared to a combination of two different anti-HER2 FSAs (v792+v4184).

TABLE-US-00024 TABLE 14 Antibody variant EC.sub.50 (nM) % Max Cell Lysis v792 1.429 7.529 v5019 ~1.075 13.29 v792 + v4184 ~0.1121 11.73

[0402] The results in FIG. 11 and Tables 12-14 show that the exemplary biparatopic HER2 antibody mediates the greatest ADCC of SKOV3 cells at different E:T ratios when compared to an anti-HER2 FSA and combination of two anti-HER2 FSAs. The observation of increased ADCC mediated by the anti-HER2 biparatopic antibody would be expected in HER2+ diseased patients who express variable and/or reduced circulating effector cells following chemotherapy (Suzuki E. et al. Clin Cancer Res 2007; 13:1875-1882). The observations in FIG. 11 are consistent with the whole cell binding Bmax data presented in Example 6, that shows an approximate 1.5-fold increase in cell binding to the exemplary anti-HER2 biparatopic antibody compared to the anti-HER2 FSA.

Example 12: Ability of Exemplary Anti-HER2 Antibody to Bind to HER2 ECD

[0403] An SPR assay was used to evaluate the mechanism by which an exemplary anti-HER2 biparatopic antibody binds to HER2 ECD; specifically, to understand whether both paratopes of one biparatopic antibody molecule can bind to one HER2 ECD (Cis binding; 1:1 antibody to HER2 molecules) or if each paratope of one biparatopic antibody can bind two different HER2 ECDs (Trans binding; 1:2 antibody to HER2 molecules). A representation of cis vs. trans binding is illustrated in FIG. 14. The correlation between a reduced (slower) off-rate with increasing antibody capture levels (surface density) is an indication of Trans binding (i.e. one antibody molecule binding to two HER2 molecules.

[0404] Affinity and binding kinetics of the exemplary biparatopic anti-HER2 antibody (v5019) to recombinant human HER2 were measured and compared to that of monovalent anti-HER2 antibodies (v630 or v4182; comprising the individual paratopes of v5019) was measured by SPR using the T200 system from Biacore (GE Healthcare). Between 2000 and 4000 RU of anti-human Fc injected at concentration between 5 and 10 .mu.g/ml was immobilized on a CMS chip using standard amine coupling. Monovalent anti-HER2 antibody (v630 or v4182) and exemplary biparatopic anti-HER2 antibody (v5019) were captured on the anti-human Fc (injected at concentration ranging 0.08 to 8 .mu.g/ml in PBST, 1 min at 10 ul/min) at response levels ranging from 350-15 RU. Recombinant human HER2 was diluted in PBST and injected at starting concentration of either 120 nM, 200 nM or 300 nM with 3-fold dilutions and injected at a flow rate of 50 .mu.l/min for 3 minutes, followed by dissociation for another 30 minutes at the end of the last injection. HER2 dilutions were analyzed in duplicate. Sensograms were fit globally to a 1:1 Langmuir binding model. All experiments were conducted at 25.degree. C.

[0405] The results are shown in FIG. 12 and FIG. 13.

[0406] The results in FIG. 12A show the ka (1/Ms) of monovalent anti-HER2 (v630 and v4182) and exemplary biparatopic anti-HER2 antibody (v5019) for binding to recombinant human HER2 over a range of injected and captured antibody concentrations on the surface of the chip. These results show that ka does not change when for v630, v4182 and v5019 at different antibody capture levels.

[0407] The results in FIG. 12B show the kd (1/s) of monovalent anti-HER2 (v630 and v4182) and exemplary biparatopic anti-HER2 antibody (v5019) for binding to recombinant human HER2 over a range of injected and captured antibody concentrations on the surface of the chip. These results show that kd decreased only for the exemplary anti-HER2 biparatopic antibody (v5019) at increasing antibody capture levels.

[0408] The results in FIG. 12C show the K.sub.D (M) of monovalent anti-HER2 (v630 and v4182) and exemplary biparatopic anti-HER2 antibody (v5019) for binding to recombinant human HER2 over a range of injected and captured antibody concentrations on the surface of the chip. These results show that K.sub.D decreased only for the exemplary anti-HER2 biparatopic antibody (v5019) at increasing antibody capture levels. This result correlated to the decreasing kd values shown in FIG. 15B.

[0409] The results in FIG. 13A show the kd (1/s) of exemplary biparatopic anti-HER2 antibody (v5019) for binding to recombinant human HER2 over a range of antibody capture levels. These results show kd values are inversely proportional to higher RUs of antibody captured on the surface of the chip (i.e slower off-rates at higher antibody capture levels). The results indicate that exemplary biparatopic anti-HER2 antibody (v5019) is capable of binding HER2 ECD2 and HER2 ECD4 on two separate HER2 molecules (i.e. trans binding) as is evidenced by the reduction in off-rate at higher antibody capture levels. This data is supported by a similar experiment presented in FIG. 47 and discussed in Example 43, where bivalent monospecific anti-HER2 FSA (v506) demonstrated Cis binding (1:1 antibody to HER2) where the kd (1/s) and K.sub.D (M) values remained constant at increasing antibody capture levels as is expected for this molecule.

[0410] The results in FIG. 13B show the kd (1/s) of monovalent anti-HER2 antibody (v4182) for binding to recombinant human HER2 over a range of antibody capture levels. These results show no change in kd values over the range of different antibody RUs captured on the surface of the chip. These results show that monovalent anti-HER2 antibody (v4182) is binding monovalently 1:1 (cis binding).

[0411] The results in FIG. 13C show the kd (1/s) of monovalent anti-HER2 antibody (v630) for binding to recombinant human HER2 over a range of antibody capture levels. These results show no change in kd values over the range of different antibody RUs captured on the surface of the chip. These results show that monovalent anti-HER2 antibody (v630) is binding monovalently 1:1 (cis binding). This data is supported by the experiment presented in FIG. 47 and discussed in Example 43X, where the bivalent monospecific anti-HER2 FSA (v506) showed no change in kd (1/s).

[0412] The results in FIG. 12, and FIG. 13 indicate that exemplary biparatopic anti-HER2 antibody (v5019) is capable of simultaneously binding to two HER2 molecules in trans (antibody to HER2 ratio 1:2). The trans mechanism of binding detected by SPR is consistent with the higher cell surface saturation binding data (Bmax), presented in Example 6, in combination with the internalization data presented in Examples 9 and 10.

Example 13: Effect of Exemplary Biparatopic Anti-HER2 Antibody Incubation on AKT Phosphorylation in BT-474 Cells

[0413] The ability of an exemplary anti-HER2 biparatopic antibody to reduce pAKT signaling in BT-474 cells was tested using the AKT Colorimetric In-Cell ELISA Kit (Thermo Scientific; cat no. 62215) according to the manufacturer's instructions with the following modifications. Cells were seeded at 5.times.10.sup.3/well and incubated 24 h at 37.degree. C.+5% CO.sub.2. Cells were incubated with 100 nM antibody for with 30 min followed by a 15 min incubation with rhHRG-f31. Cells were washed, fixed, and permeabilized according to the instructions. Secondary antibodies (1:5000; Jackson ImmunoReasearch, HRP-donkey anti-mouse IgG, JIR, Cat#715-036-150, HRP-donkey anti-rabbit IgG, JIR, Cat#711-036-452) were added and the assay processed according to the manufacturer's instructions.

[0414] The results in FIG. 15 show that incubation with exemplary anti-HER2 biparatopic antibody mediated an approximate 1.2-fold reduction in p-Akt levels in the presence of HRG.beta.1 relative to the human IgG control (CTL). The combination of two anti-HER2 FSAs (v506+v4184) mediated the greatest reduction in p-Akt levels in the presence HRG.beta.1 that was approximately 1.5-fold less compared to the human IgG control. A modest reduction in p-Akt was detected with the exemplary anti-HER2 biparatopic antibody in the absence of ligand (HRG.beta.1) compared to the human IgG control antibody.

[0415] These data show that exemplary anti-HER2 biparatopic antibody can block ligand-activated signaling in HER2+ cells.

Example 14: Effect of Biparatopic Anti-HER2 Antibody on Cardiomyocyte Viability

[0416] The effect of exemplary biparatopic anti-HER2 antibodies and ADCs on cardiomyocyte viability was measured in order to obtain a preliminary indication of potentially cardiotoxic effects.

[0417] iCell cardiomyocytes (Cellular Dynamics International, CMC-100-010), that express basal levels of the HER2 receptor, were grown according the manufacturer's instructions and used as target cells to assess cardiomyocyte health following antibody treatment. The assay was performed as follows. Cells were seeded in 96-well plates (15,000 cells/well) and maintained for 48 h. The cell medium was replaced with maintenance media and cells were maintained for 72h. To access the effects of antibody-induced cardiotoxicity, cells were treated for 72 h with 10 and 100 nM of, variants alone or in combinations. To access the effects of anthracycline-induced cardiotoxicity (alone or in combination with the exemplary biparatopic anti-HER2 antibodies), cells were treated with 3 uM (.about.IC.sub.20) of doxorubicin for 1 hr followed by 72 h with 10 and 100 nM of, antibody variants alone or in combinations. Cell viability was assessed by quantitating cellular ATP levels with the CellTiter-Glo.RTM. Luminescent Cell Viability Assay (Promega, G7570) and/or Sulphorhodamine (Sigma 230162-5G) as per the manufacturer's instructions.

[0418] The results are shown in FIG. 16A-C. The results in FIG. 16A show that incubation of the cardiomyocytes with therapeutically relevant concentrations of exemplary anti-HER2 biparatopic antibody (v5019) and exemplary anti-HER2 biparatopic-ADC (v6363), did not affect cardiomyocyte viability relative to the untreated control (`mock`).

[0419] The results in FIG. 16B show that incubation of the cardiomyocytes with therapeutically relevant concentrations of exemplary anti-HER2 biparatopic antibodies (v5019, v7091 and v10000), and exemplary anti-HER2 biparatopic-ADCs (v6363, v7148 and v10553), had no effect on cardiomyocyte viability relative to the untreated control (`mock`). Based on the results in FIGS. 16A and 16B it is expected that exemplary anti-HER2 biparatopic antibodies and exemplary anti-HER2 biparatopic-ADCs should not induce cardiomyopathy, for example through mitochondrial dysfunction, as is reported with other anti-HER2 targeting antibodies (Grazette L. P. et al. Inhibition of ErbB2 Causes Mitochondrial Dysfunction in Cardiomyocytes; Journal of the American College of Cardiology: 2004; 44:11).

[0420] The results in FIG. 16C show that pretreatment of the cardiomyocytes with doxorubicin followed by incubation with therapeutically relevant concentrations of exemplary anti-HER2 biparatopic antibodies (v5019, v7091 and v10000) and exemplary anti-HER2 biparatopic-ADCs (v6363, v7148 and v10553), had no effect on cardiomyocyte viability relative to the untreated control+doxorubicin (`Mock+Dox`). Based on the results in FIG. 16C it is expected that exemplary anti-HER2 biparatopic antibodies and exemplary anti-HER2 biparatopic-ADCs should not result in an increased risk of cardiac dysfunction in patients receiving concurrent anthracycline treatment (Seidman A, Hudis C, Pierri M K, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol (2002) 20:1215-1221).

[0421] FIGS. 16A-C show that incubation of cardiomyocytes with the anti-HER2 biparatopic antibodies and ADCs had equivalent effects compared to monospecific anti-HER2 FSA antibody (v506), anti-HER2 FSA combination (v506+v4184) and ADC (v6246) when treated either alone, or in combination with doxorubicin. Based on these results, it is expected that exemplary anti-HER2 biparatopic antibodies and ADCs would not have greater cardiotoxic effects compared to anti-monospecific anti-HER2 FSA, trastuzumab or ADC, T-DM1.

Example 15: Cytotoxicity of Exemplary Biparatopic Anti-HER2-ADCs in HER2+ Cells

[0422] The ability of exemplary biparatopic anti-HER2-ADC antibodies (v6363, v7148 and v10553) to mediate cellular cytotoxicity in HER2+ cells was measured. Human IgG conjugated to DM1 (v6249) was used as a control in some cases. The experiment was carried out in HER2+ breast tumor cell lines JIMT-1, MCF7, MDA-MB-231, the HER2+ ovarian tumor cell line SKOV3, and HER2+ gastric cell line NCI-N87. The cytotoxicity of exemplary biparatopic anti-HER2-ADC antibodies in HER2+ cells was evaluated and compared to the monospecific anti-HER2 FSA-ADC (v6246) and anti-HER2-FSA-ADC+ anti-HER2-FSA controls (v6246+v4184). The method was conducted as described in Example 7 with the following modifications. The anti-HER2 ADCs were incubated with the target SKOV3 and JIMT-1 (FIGS. 17A and B) cells for 24 h, cells washed, media replaced and cell survival was evaluated after 5 day incubation at 37.degree. C. The anti-HER2 ADCs were incubated with target MCF7 and MDA-MB-231 target cells for 6 h (FIGS. 17C and D), cells washed media replaced and cell survival was evaluated at 5 days incubation at 37.degree. C. In FIG. 17E-G, anti-HER2 ADCs were incubated continuously with target SKOV3, JIMT-1, NCI-N87 cells for 5 days. Cell viability was measured as described in Example 7 using either AlamarBlue.TM. (FIGS. 17A-D) or Celltiter-Glo.RTM. (FIGS. 17E-G).

[0423] The results are shown in FIG. 17A-G and the data is summarized in Tables 15 and 16.

[0424] The results in FIG. 17A and Table 15 and 16 show that exemplary anti-HER2 biparatopic-ADC (v6363) is more cytotoxic in JIMT-1 compared to the anti-HER2-FSA-ADC (v6246) and the combination of anti-HER2-FSA-ADC+ anti-HER2 FSA (v6246+v4184). The exemplary anti-HER2 biparatopic-ADC had a superior EC.sub.50 that was approximately 13-fold lower compared to the anti-HER2 FSA-ADC control.

[0425] The results in FIG. 17B and Table 15 show that exemplary anti-HER2 biparatopic-ADC (v6363) is more cytotoxic in SKOV3 compared to the anti-HER2-FSA-ADC (v6246) and the combination of anti-HER2-FSA-ADC+ anti-HER2 FSA (v6246+v4184). The exemplary anti-HER2 biparatopic-ADC had a superior EC.sub.50 that was approximately 5-fold lower compared to the anti-HER2 FSA-ADC control.

[0426] The results in FIG. 17C and Table 15 show that exemplary anti-HER2 biparatopic-ADC (v6363) is more cytotoxic in MCF7 compared to the anti-HER2-FSA-ADC (v6246) and the combination of anti-HER2-FSA-ADC+ anti-HER2 FSA (v6246+v4184). The exemplary anti-HER2 biparatopic-ADC had a superior EC.sub.50 that was approximately 2-fold lower compared to the anti-HER2 FSA-ADC control.

[0427] The results in FIG. 17D and Table 15 show that exemplary anti-HER2 biparatopic-ADC (v6363) is more cytotoxic in MDA-MB-231 compared to the anti-HER2-FSA-ADC (v6246) and the combination of anti-HER2-FSA-ADC+ anti-HER2 FSA (v6246+v4184). The exemplary anti-HER2 biparatopic-ADC had a superior EC.sub.50 that was approximately 2-fold lower compared to the anti-HER2 FSA-ADC control.

TABLE-US-00025 TABLE 15 v6246 0.9225 5.942 122.0 ~1075 v6246 + 4184 3.146 12.68 ~24432 136.4 v6363 0.1776 0.4443 58.55 141.0 indicates data missing or illegible when filed

[0428] The results in FIG. 17E and Table 16 show that exemplary anti-HER2 biparatopic-ADCs (v6363, v7148 and v10553) are more cytotoxic in SKOV3 ovarian tumor cells compared to the anti-HER2-FSA-ADC (v6246). The exemplary anti-HER2 biparatopic-ADCs had a superior EC.sub.50 values that were approximately 2 to 7-fold lower compared to the anti-HER2 FSA-ADC control.

[0429] The results in FIG. 17F and Table 16 show that exemplary anti-HER2 biparatopic-ADCs (v6363, v7148 and v10553) are more cytotoxic in JIMT-1 breast tumor cells compared to the anti-HER2-FSA-ADC (v6246). The exemplary anti-HER2 biparatopic-ADCs had a superior EC.sub.50 values were approximately 6 to 9-fold lower compared to the anti-HER2 FSA-ADC control.

[0430] The results in FIG. 17G and Table 16 show that exemplary anti-HER2 biparatopic-ADCs (v6363, v7148 and v10553) are cytotoxic in NCI-N87 gastric tumor cells. The exemplary anti-HER2 biparatopic-ADCs had has approximately equivalent EC.sub.50 values compared to the anti-HER2 FSA-ADC control.

TABLE-US-00026 TABLE 16 Antibody EC.sub.50 (nM) variant SKOV3 JIMT-1 NCI-N87 v6246 0.22 3.52 1.04 v6363 0.03 0.56 1.33 v7148 0.06 0.56 2.74 v10553 0.09 0.39 1.69

These results show that exemplary anti-HER2 biparatopic-ADCs (v6363, v7148 and v10553) are more cytotoxic compared to anti-HER-FSA-ADC control in HER2 3+, 2+, and 1+ breast tumor cells. These results also show that exemplary anti-HER2 biparatopic-ADCs (v6363, v7148 and v10553) are cytotoxic in HER2 2/3+ gastric tumor cells. These results are consistent with the internalization results presented in Example 9.

Example 16: Effect of a Biparatopic Anti-HER2 Antibody in a Human Ovarian Cancer Cell Xenograft Model

[0431] The established human ovarian cancer cell derived xenograft model SKOV3 was used to assess the anti-tumor efficacy of an exemplary biparatopic anti-HER2 antibody.

[0432] Female athymic nude mice were inoculated with the tumor via the insertion of a 1 mm.sup.3 tumor fragment subcutaneously. Tumors were monitored until they reached an average volume of 220 mm.sup.3; animals were then randomized into 3 treatment groups: IgG control, anti-HER2 FSA (v506), and biparatopic anti-HER2 antibody (v5019).

[0433] Fifteen animals were included in each group. Dosing for each group is as follows:

[0434] A) IgG control was dosed intravenously with a loading dose of 30 mg/kg on study day 1 then with maintenance doses of 20 mg/kg twice per week to study day 39.

[0435] B) Anti-HER2 FSA (v506) was dosed intravenously with a loading dose of 15 mg/kg on study day 1 then with maintenance doses of 10 mg/kg twice per week to study day 18. On days 22 through 39, 5 mg/kg anti-HER2 FSA was dosed intravenously twice per week. Anti-HER2 FSA (v4184) was dosed simultaneously at 5 mg/kg intraperitoneally twice per week.

[0436] C) Biparatopic anti-HER2 antibody was dosed intravenously with a loading dose of 15 mg/kg on study day 1 then with maintenance doses of 10 mg/kg twice per week to study day 39.

[0437] Tumor volume was measured twice weekly over the course of the study, number of responders and median survival was assessed at day 22. The results are shown in FIG. 18 and Table 17.

[0438] The biparatopic anti-HER2 and anti-HER2 FSA demonstrated superior tumor growth inhibition compared to IgG control. The biparatopic anti-HER2 antibody induced superior tumor growth inhibition compared to anti-HER2 FSA combination (FIG. 18A). The biparatopic anti-HER2 antibody was associated with an increase in the number of responding tumors compared to anti-HER2 FSA v506 at day 22 (11 and 5, respectively)(Table 17). The exemplary biparatopic anti-HER2 antibody and anti-HER2 FSA demonstrated superior survival compared to IgG control. The biparatopic anti-HER2 antibody had a superior median survival (61 days) compared to anti-HER2 FSA (36 days)(FIG. 18B and Table 17). On study day 22 a second anti-HER2 FSA (v4184) was added in combination to the anti-HER2 FSA (v506). The combination of two anti-HER2 FSAs induced a further tumour growth inhibition compared to anti-HER2 FSA (v506) alone.

TABLE-US-00027 TABLE 17 n = 15, Day 22 IgG v506 v5019 Mean TV 1908 (+766%) 1291 (+486%) 697 (+217%) (mm3) (% change from Baseline) % TGI 0 32 63 Responders 0/15 5/15 11/15 (TV <50% of control) Median Survival (days) 22 36 61

Example 17: Effect of a Biparatopic Anti-HER2 Antibody Drug Conjugate (ADC) in a Human Ovarian Cancer Cell Line Xenograft Model

[0439] The established human ovarian cancer cell derived xenograft model SKOV3 was used to assess the anti-tumor efficacy of an exemplary biparatopic anti-HER2 antibody conjugated to DM1 (v6363).

[0440] Female athymic nude mice were inoculated with the tumor via the insertion of a 1 mm.sup.3 tumor fragment subcutaneously. Tumors were monitored until they reached an average volume of 220 mm.sup.3; animals were then randomized into 3 treatment groups: IgG control, anti-HER2 FSA-ADC, and a biparatopic anti-HER2-ADC.

[0441] Fifteen animals were included in each group. Dosing for each group is as follows:

[0442] A) IgG control was dosed intravenously with a loading dose of 30 mg/kg on study day 1 then with maintenance doses of 20 mg/kg twice per week to study day 39.

[0443] B) Anti-HER2 FSA-ADC (v6246) was dosed intravenously with a loading dose of 10 mg/kg on study day 1 then with a maintenance dose of 5 mg/kg on day 15 and 29.

[0444] C) Biparatopic anti-HER2 antibody-ADC (v6363) was dosed intravenously with a loading dose of 10 mg/kg on study day 1 then with a maintenance dose of 5 mg/kg on day 15 and 29.

[0445] Tumor volume was measured throughout the study, and the number of responders and median survival was assessed at day 22. The results are shown in FIG. 19. A summary of the results is shown in Table 18.

[0446] The biparatopic anti-HER2-ADC and anti-HER2 FSA-ADC inhibited tumor growth better than IgG control (FIG. 19A and Table 18). The biparatopic anti-HER2-ADC inhibited tumor growth to a greater degree than did the anti-HER2 FSA-ADC. The biparatopic anti-HER2-ADC group was associated with an increase in the number of responding tumors compared to anti-HER2 FSA-ADC (11 and 9, respectively). The biparatopic anti-HER2-ADC and anti-HER2 FSA-ADC groups demonstrated superior survival compared to IgG control (FIG. 19B and Table 18). The biparatopic anti-HER2 antibody group demonstrated median survival of 61 days compared to the anti-HER2 FSA-ADC which had a median survival of 36 days (FIG. 19B and Table 18).

TABLE-US-00028 TABLE 18 n = 15, Day 22 IgG v6246 v6363 Mean TV 1908 (+766%) 873 (+297%) 632 (+187%) (mm3) (% change from Baseline) % TGI 0 54% 67% Responders 0/15 9/15 11/15 (TV <50% of control) Median survival (days) 22 36 61

Example 18: Effect of a Biparatopic Anti-HER2 Antibody Drug Conjugate (ADC) in a Human Primary Cell Xenograft Model (HBCx-13b)

[0447] The trastuzumab resistant patient derived xenograft model from human breast cancer, HBCx-13B, was used to assess the anti-tumor efficacy of an exemplary biparatopic anti-HER2 antibody conjugated to DM1.

[0448] Female athymic nude mice were inoculated with the tumor via the insertion of a 20 mm.sup.3 tumor fragment subcutaneously. Tumors were monitored until they reached an average volume of 100 mm.sup.3; animals were then randomized into 3 treatment groups: anti-HER2 FSA (v506), anti-HER2 FSA-ADC (v6246), and the biparatopic anti-HER2-ADC (v6363). Seven animals were included in each group. Dosing for each group was as follows:

[0449] A) Anti-HER2 FSA was dosed intravenously with a loading dose of 15 mg/kg on study day 1 and maintenance doses of 10 mg/kg administered on study days 4, 8, 11, 15, 18, 22, and 25.

[0450] B) Anti-HER2 FSA-ADC was dosed intravenously with a loading dose of 10 mg/kg on study day 1 then with a maintenance dose of 5 mg/kg on day 22.

[0451] C) Biparatopic anti-HER2 antibody-ADC was dosed intravenously with a loading dose of 10 mg/kg on study day 1 then with a maintenance dose of 5 mg/kg on day 22.

[0452] Tumor volume was measured throughout the study, and mean tumor volume, complete response, and zero residual disease parameters were assessed at Day 50. The results are shown in FIG. 20. A summary of the results is shown in Table 19.

[0453] The biparatopic anti-HER2-ADC and anti-HER2 FSA-ADC demonstrated greater tumor growth inhibition compared to an anti-HER2 FSA (v506). The biparatopic anti-HER2-ADC inhibited tumor growth better than the anti-HER2 FSA-ADC. The biparatopic anti-HER2-ADC group as compared to the anti-HER2 FSA-ADC group was associated with an increase in the number of tumors showing complete responses (more than a 10% decrease below baseline), 7 and 4 respectively, and showing zero residual disease, 5 and 2 respectively.

TABLE-US-00029 TABLE 19 n = 7, Day 50 v506 v6246 v6363 Mean TV 1149 (+1018%) 262 (+153%) 26 (-75%) (mm3) (% change from Baseline) % TGI 0% 77% 98% Complete response 0 4/7 7/7 (>10% baseline regression) Zero residual disease 0 2/7 5/7 (TV <20 mm3)

Example 19: Effect of a Biparatopic Anti-HER2 Antibody Drug Conjugate (ADC) in a Human Primary Cell Xenograft Model (T226)

[0454] The patient derived trastuzumab resistant xenograft model from human breast cancer, T226, was used to assess the anti-tumor efficacy of an exemplary biparatopic anti-HER2-ADC.

[0455] Female athymic nude mice were inoculated with the tumor via the insertion of a 20 mm.sup.3 tumor fragment subcutaneously. Tumors were monitored until they reached an average volume of 100 mm.sup.3; animals were then randomized into 4 treatment groups: IgG control (n=15), anti-HER2 FSA (v506; n=15), anti-HER2 FSA-ADC (v6246; n=16), and the biparatopic anti-HER2-ADC conjugate (v6363; n=16). Dosing for each group was as follows:

[0456] A) IgG control was dosed intravenously with a loading dose of 15 mg/kg on study day 1 and maintenance doses of 10 mg/kg administered on study days 4, 8, 11, 15, 18, 22, and 25

[0457] B) Anti-HER2 FSA was dosed intravenously with a loading dose of 15 mg/kg on study day 1 and maintenance doses of 10 mg/kg administered on study days 4, 8, 11, 15, 18, 22, and 25

[0458] C) Anti-HER2 FSA-ADC was dosed intravenously with 5 mg/kg on study days 1 and 15

[0459] D) Biparatopic anti-HER2-ADC conjugate was dosed intravenously with 5 mg/kg on study days 1 and 15.

[0460] Tumor volume was measured throughout the course of the study, and mean tumor volume and complete response parameters were assessed at day 31. The results are shown in FIG. 21. A summary of the results is shown in Table 20.

[0461] The biparatopic anti-HER2-ADC and anti-HER2 FSA-ADC demonstrated better tumor growth inhibition compared to the anti-HER2 FSA (v506) and IgG control. The exemplary biparatopic anti-HER2-ADC induced equivalent tumor growth inhibition and complete baseline regression compared to anti-HER2 FSA-ADC (FIG. 21 and Table 20) in this model.

TABLE-US-00030 TABLE 20 v506 v6363 Day 31 IgG (n = 13) (n = 13) v6246 (n = 16) (n = 16) Mean TV 1797 1611 422 572 (mm3) (% change (+1728%) (+1573) (+332%) (+483%) from Baseline) % TGI (vs. hIgG) 0% 11% 77% 68% Complete response 0/13 0/14 1/16 1/16 (>10% baseline regression)

Example 20: Effect of a Biparatopic Anti-HER2 Antibody Drug Conjugate (ADC) in a Human Primary Cell Xenograft Model (HBCx-5)

[0462] The patient derived trastuzumab resistant xenograft model from human breast cancer, HBCx-5 (invasive ductal carcinoma, luminal B), was used to assess the anti-tumor efficacy of an exemplary biparatopic anti-HER2-ADC.

[0463] Female athymic nude mice were inoculated with the tumor via the insertion of a 20 mm.sup.3 tumor fragment subcutaneously. Tumors were monitored until they reached an average volume of 100 mm.sup.3; animals were then randomized into 4 treatment groups: IgG control (n=15), anti-HER2 FSA (v506; n=15), anti-HER2 FSA-ADC (v6246; n=16), and the biparatopic anti-HER2-ADC (v6363; n=16). Dosing for each group was as follows:

[0464] A) IgG control was dosed intravenously with a loading dose of 15 mg/kg on study day 1 and maintenance doses of 10 mg/kg administered on study days 4, 8, 11, 15, 18, 22, and 25

[0465] B) Anti-HER2 FSA was dosed intravenously with a loading dose of 15 mg/kg on study day 1 and maintenance doses of 10 mg/kg administered on study days 4, 8, 11, 15, 18, 22, and 25

[0466] C) Anti-HER2 FSA-ADC was dosed intravenously with 10 mg/kg on study days 1 and 15, 22, 29, 36

[0467] D) Biparatopic anti-HER2-ADC was dosed intravenously with 10 mg/kg on study days 1 and 15, 22, 29, 36.

[0468] Tumor volume was measured throughout the course of the study, and the mean tumor volume, T/C ratio, number of responders, complete response, and zero residual disease parameters were assessed at day 43. The results are shown in FIG. 22. A summary of the results is shown in Table 21.

[0469] The biparatopic anti-HER2-ADC and anti-HER2 FSA-ADC demonstrated better tumor growth inhibition compared to an anti-HER2 FSA (v506) and IgG control. The exemplary biparatopic anti-HER2-ADC induced equivalent tumor growth inhibition and had an increased number of responders compared to anti-HER2 FSA-ADC (FIG. 22 and Table 21) in the trastuzumab resistant HBCx-5 human breast cancer xenograft model.

TABLE-US-00031 TABLE 21 IgG Herceptin T-DM1 6363 Day 43 (n = 4) (n = 5) (n = 7) (n = 7) Mean TV 922 815 193 241 (mm3) (% change (+693%) (+598%) (+65%) (+106%) from Baseline) T/C (IgG) ratio 1 0.88 0.21 0.26 Responders 0/4 1/5 6/7 7/7 (TV<50% of control) Complete response 0/4 0/5 1/7 0/7 (>10% baseline regression) Zero residual disease 0/4 0/5 0/7 0/7 (TV <20 mm3)

Example 21: Effect of a Biparatopic Anti-HER2 Antibody Drug Conjugate (ADC) to Anti-HER2 Treatment Resistant Tumors in a Human Cell Line Xenograft Model (SKOV3)

[0470] The established human ovarian cancer cell derived xenograft model SKOV3, described in Example 17, was used to assess the anti-tumor efficacy of an exemplary biparatopic anti-HER2-ADC in anti-HER2 treatment resistant tumors.

[0471] The methods were followed as described in Example 17 with the following modifications. A cohort of animals was dosed with an anti-HER2 antibody intravenously with 15 mg/kg on study day 1 and with 10 mg/kg on day 4, 8, 15; however, this treatment failed to demonstrate an efficacious response by day 15 in this model. This treatment group was then converted to treatment with the exemplary biparatopic anti-HER2 antibody drug conjugate (v6363) and was dosed with 5 mg/kg and on study day 19 and 27 and 15 mg/kg on study day 34, 41 and 48.

[0472] Tumor volume was measured twice weekly throughout the course of the experiment.

[0473] The results are shown in FIG. 23 and indicate that the group treated with exemplary biparatopic anti-HER2-ADC (v6363) showed tumor regression to a mean tumor volume less than the initial mean starting volume of 220 mm.sup.3.

Example 22: Effect of a Biparatopic Anti-HER2 Antibody Drug Conjugate (ADC) on Anti-HER2 Treatment Resistant Tumors in Human Primary Cell Xenograft Model (HBCx-13b)

[0474] The trastuzumab resistant patient derived xenograft model from human breast cancer, HBCx-13B, was used to assess the anti-tumor efficacy of an exemplary biparatopic anti-HER2 antibody conjugated to DM1.

[0475] The methods were followed as described in Example 18 with the following modifications. A cohort of animals was dosed with a bi-specific anti-ErbB family targeting antibody intravenously with 15 mg/kg on study day 1 and with 10 mg/kg on day 4, 8, 15, 18, 22, and 25; however, this treatment failed to demonstrate an efficacious response. This treatment group was then converted to treatment with the exemplary biparatopic anti-HER2 antibody drug conjugate (v6363) and was dosed with 10 mg/kg on days 31, 52 and with 5 mg/kg on day 45. Tumor volume was measured throughout the duration of the study.

[0476] The results are shown in FIG. 24. These results show that the exemplary biparatopic anti-HER2-ADC (v6363) prevented tumour progression. From the first dose to day 57 the tumour volume of the v6363 treated group increased by less than 2% while in the same interval the v506 treated group grew by more than 110%.

Example 23: Analysis of Fucose Content of an Exemplary Biparatopic Anti-HER2 Antibody

[0477] Glycopeptide analysis was performed to quantify the fucose content of the N-linked glycan of the exemplary biparatopic anti-HER2 antibodies (v5019, v7091 and v10000).

[0478] The glycopeptide analysis was performed as follows. Antibody samples were reduced with 10 mM DTT at 56.degree. C. 1 h and alkylated with 55 mM iodoacetamide at RT 1 h and digested in-solution with trypsin in 50 mM ammonium bicarbonate overnight at 37.degree. C. Tryptic digests were analyzed by nanoLC-MS/MS on a QTof-Ultima. The NCBI database was searched with Mascot to identify protein sequences. MaxEnt3 (MassLynx) was used to deconvolute the glycopeptide ions and to quantify the different glycoforms.

[0479] A summary of the glycopeptide analysis results is in Table 22. The N-linked glycans of exemplary biparatopic anti-HER2 antibodies (v5019, v7091 and v10000) are, approximately 90% fucosylated (10% N-linked glycans without fucose). The N-linked glycans of monospecific anti-HER2 FSA (v506) are, approximately 96% fucosylated (4% N-linked glycans without fucose) and Herceptin.RTM. is approximately 87% fucosylated (4% N-linked glycans without fucose).

TABLE-US-00032 TABLE 22 Fc N-linked Glycopeptide Analysis Average Antibody % of Glycopeptides Average % of Glycopeptides Variant Observed With Fucose Observed Without Fucose n v506 96.4 3.6 5 Herceptin .RTM. 86.5 13.4 4 v5019 90.5 9.4 6 v7091 89.9 26.9 3 v10000 89.2 10.7 5

[0480] These results show that biparatopic anti-HER2 antibodies (with a heterodimeric Fc), expressed transiently in CHO cells, have approximately 3% higher fucose content in the N-glycan compared to commercial Herceptin.RTM.. The homodimeric anti-HER2 FSA (v506), expressed transiently in CHO cells, has the highest fucose content of approximately 96%.

Example 24: Thermal Stability of an Exemplary Biparatopic Anti-HER2 Antibody

[0481] Thermal stability of exemplary biparatopic anti-HER2 antibodies (v5019, v7091 and v10000) and ADCs (v6363, v7148 and v10533) was measured by DSC as described below.

[0482] DSC was performed in the MicroCal.TM. VP-Capillary DSC (GE Healthcare) using a purified protein sample (anti-HER2 biparatopic antibodies and anti-HER2 biparatopic-ADCs) adjusted to about 0.3 mg/ml in PBS. The sample was scanned from 20 to 100.degree. C. at a 60.degree. C./hr rate, with low feedback, 8 sec filter, 5 min preTstat, and 70 psi nitrogen pressure. The resulting thermogram was analyzed using Origin 7 software.

[0483] The thermal stability results of exemplary biparatopic anti-HER2 antibodies (v5019, v7091 and v10000) are shown in FIG. 25A-C. FIG. 25A shows the thermogram for v5019; the Fc and chain A Fab of each have a T.sub.m of 75.degree. Celsius and the chain B scFv of 5019 has a T.sub.m of 69.degree. Celsius. FIG. 25B shows the thermogram for v10000; the Fc CH3 domain has a T.sub.m 82.degree. Celsius, Fab chain A has T.sub.m of 76.5.degree. Celsius and the chain B scFv has a T.sub.m of 69.5.degree. Celsius. FIG. 25C shows the thermogram for v7091; the Fc CH3 domain has a T.sub.m 82.degree. Celsius, Fab chain A has T.sub.m of 76.7.degree. Celsius and the chain B scFv has a T.sub.m of 69.5.degree. Celsius.

[0484] The thermal stability results of exemplary biparatopic anti-HER2 ADCs (v6363, v7148 and v10533) are shown in FIG. 26A-C. FIG. 26A shows the thermogram for v6363; the Fc has a T.sub.m of 75.degree. Celsius and the chain A Fab and Fc CH3 domain have a T.sub.m of 75.degree. Celsius. The chain B scFv of 6363 has a T.sub.m of 69.degree. Celsius. FIG. 26B shows the thermogram for v10553; the Fc CH3 domain has a T.sub.m of 83.degree. Celsius, the chain A Fab has a T.sub.m of 75.7.degree. Celsius and the chain B scFv has a T.sub.m of 66.2.degree. Celsius. FIG. 26C shows the thermogram for v7148; the Fc CH3 domain has a T.sub.m of 82.6.degree. Celsius, the chain A Fab has a T.sub.m of 74.8.degree. Celsius and the chain B scFv has a T.sub.m of 66.6.degree. Celsius.

[0485] The exemplary biparatopic antibodies and ADCs have thermal stability comparable to wildtype IgG.

Example 25: Ability of an Exemplary Biparatopic Anti-HER2 Antibody to Elicit ADCC of Breast Tumor Cells Expressing Varying Levels of HER2

[0486] The ability of exemplary biparatopic antibody (v5019) to elicit dose-dependent ADCC of HER2 positive 3+, 2+, and 0/1+ HER2 expressing (triple-negative) breast cancer cell lines was examined. The ADCC experiments were performed as described in Example 11 with the exception that NK effector cell to target cell ratio remained constant at 5:1.

[0487] The ADCC results are shown in FIG. 27 and Table 23. The results in FIG. 27A-C show that exemplary biparatopic antibody (v5019) elicits approximately 1.2 to 1.3-fold greater maximum cell lysis of HER2 positive 3+, 2+ and 0/1+ HER2 expressing breast cancer cells compared to Herceptin.RTM.. The results also show that v5019 (90% N-glycans with fucose) more effectively mediates ADCC of HER2 positive 3+, 2+ and 0/1+ HER2 expressing breast cancer despite having approximately a 4% higher fucose content in the N-glycan (resulting in lower binding affinity to CD16 on NK cells) compared to Herceptin.RTM. (86% N-glycans with fucose; Example 23). The higher target cell killing elicited by v5019 is presumably due to increased tumor cell decoration as described in Example 6.

TABLE-US-00033 TABLE 23 ADCC of HER2 3+, 2+ and 0/1+ HER2 expressing breast cancer cells SKBr3 HER2 3+ JIMT-1 HER2 2+ Max % Max % MDA-MB-231 HER2 0/1+ Target Cell EC.sub.50 Target EC.sub.50 Max % Target EC.sub.50 Treatment Lysis (nM) Cell Lysis (nM) Cell Lysis (nM) v5019 30 ~0.9 60 0.001 53 0.9 Herceptin .RTM. 23 ~0.9 51 0.002 44 0.9

[0488] The ADCC results in FIG. 27D show that exemplary biparatopic antibodies (v7091 and v10000) elicit similar maximal cell lysis compared to Herceptin.RTM. in the basal HER2 expressing WI-38 cell line. The ADCC results support the cell binding data (Example 6), showing that a threshold for increased binding and ADCC occurs when the HER2 receptor levels are greater than 10,000 HER2/cell. Based on this data it would be expected that the exemplary biparatopic anti-HER2 antibodies would have increased cell surface binding and ADCC of HER2 3+, 2+ and 1+ tumor cells but would not have increase cell surface binding and ADCC of non-tumor cells that express basal levels of the HER2 receptor at approximately 10,000 receptors or less.

Example 26: Effect of Antibody Afucosylation on ADCC

[0489] The ability of afucosylated exemplary biparatopic antibodies (v5019-afuco, 10000-afuco) to elicit dose-dependent ADCC of HER2 positive 2/3+, 2+ and 0/1+ HER2 expressing (triple-negative) breast cancer cell lines, was examined. ADCC experiments were performed as described in Example 11, in SKOV3 cells, MDA-MB-231 cells and ZR75-1 cells with the exception that a constant NK effector cell or PBMC effector to target (E:T) cell ratio of 5:1 was used. Afucosylated exemplary biparatopic antibodies were produced transiently in CHO cells as described in Example 1, using the transiently expressed RMD enzyme as described in von Horsten et al. 2010 Glycobiology 20:1607-1618. The fucose content of v5019-afuco and v10000-afuco were measured as described in Example 23 and determined to be less <2% fucosylated (data not shown). Data using NK effector cells is shown in FIG. 28A-B, while data using PBMCs is shown in FIG. 28C.

[0490] FIG. 28A, FIG. 28B and Table 24 show that afucosylated v5019 (v5019-afuco) elicits ADCC of HER 2/3+ and 0/1+ HER2 expressing breast cancer cells with approximately 1.5 to 1.7-fold higher maximum cell lysis than Herceptin.RTM..

TABLE-US-00034 TABLE 24 ADCC of HER2 2/3+ and basal HER2 expressing (triple-negative) breast cancer cells MDA- SKOV3 HER2 2+/3+ MD-231 HER2 0/1+ Max % Target Max % Target Treatment Cell Lysis EC.sub.50 (nM) Cell Lysis EC.sub.50 (nM) v5019- 24 ~0.6 58 ~0.6 afucosylated Herceptin .RTM. 14 ~0.6 40 ~0.3

[0491] The results in FIG. 28C and Table 25 show that v10000 elicits ADCC of HER2 2+ ZR-75-1 breast cancer cells with approximately 1.3-fold greater maximal cell lysis than Herceptin.RTM., and v10000-afuco elicits approximately 1.5-fold greater maximal cell lysis than Herceptin.RTM..

TABLE-US-00035 TABLE 25 ADCC of HER2 2/3+ breast cancer cells ZR-751 HER2 2+ Max % Target Treatment Cell Lysis EC.sub.50 (nM) v10000 28 ~0.06 v10000-afucosylated 32 ~0.7 Herceptin .RTM. 21 ~0.5

[0492] The ADCC results show that the exemplary afucosylated biparatopic antibodies (v5019-afuco, v10000-afuco) elicit approximately 15-25% greater maximum cell lysis compared to the fucosylated antibodies (v5019 Example 25, v10000) when Herceptin.RTM. is used as a benchmark. These results show that reducing the fucose content of the Fc N-glycan results in increased maximal cell lysis by ADCC.

Example 27: Ability of Exemplary Biparatopic Anti-HER2 Antibody to Inhibit Growth of HER2 3+ Breast Cancer Cells in the Presence of Exogenous Growth-Stimulatory Ligands (EGF and HRG)

[0493] The ability of 5019 to inhibit growth of HER2 3+ breast cancer cells in the presence of exogenous growth-stimulatory ligands (EGF and HRG) was examined.

[0494] Test antibodies and exogenous ligand (10 ng/mL HRG or 50 ng/mL EGF) were added to the target BT-474 HER2 3+ cells in triplicate and incubated for 5 days at 37.degree. C. Cell viability was measured using AlamarBlue.TM. (37.degree. C. for 2 hr), absorbance read at 530/580 nm. Data was normalised to untreated control and analysis was performed using GraphPad Prism.

[0495] The results are shown in FIG. 29 and Table 26. The results show that exemplary biparatopic antibody v5019 inhibits the growth of HER2 3+ breast cancer cells in the absence of growth stimulatory ligand (70% inhibition), as well as in the presence of EGF (40% inhibition) or HRG (.about.10% inhibition). The anti-HER2 monospecific FSA (v506) does not block EGF or HRG induced tumor cell growth via other erbB receptors EGFR and HER3. v5019 is superior to v506 in inhibiting HER2 and ligand-dependent dimerization and growth via other companion erbB receptors.

TABLE-US-00036 TABLE 26 Growth Inhibition of HER2 3+ Cancer Cells % Survival Treatment Antibody only +EGF +HRG Mock 100 122 110 v506 41 114 129 v5019 31 56 92

[0496] These results show that exemplary biparatopic antibody is capable of reducing ligand-dependent growth of HER2+ cells, presumably due binding of the anti-ECD2 chain A Fab arm and subsequent blocking of ligand stimulated receptor homo- and heterodimerization, and erbB signaling.

Example 28: Effect of a Biparatopic Anti HER2 Antibody in a Trastuzumab-Resistant and Chemotherapy Resistant HER2 3+ Patient-Derived (PDX) Metastatic Breast Cancer Xenograft Model of Invasive Ductal Breast Carcinoma

[0497] The HER2 3+ (ER-PR negative) patient derived xenograft model from invasive ductal human breast cancer, HBCx-13B, was used to assess the anti-tumor efficacy of an exemplary biparatopic anti-HER2 antibody, v7187. v7187 is an afucosylated version of v5019. The model is resistant to single agent trastuzumab, the combination of trastuzumab and pertuzumab (see example 31), capecitabine, docetaxel, and adriamycin/cyclophosphamide.

[0498] Female athymic nude mice were inoculated subcutaneously with a 20 mm.sup.3 tumor fragment. Tumors were then monitored until reaching an average volume of 140 mm3. Animals were then randomized into 2 treatment groups: vehicle control and v7187 with eight animals in each group. IV Dosing was as follows. Vehicle control was dosed intravenously with 5 ml/kg of formulation buffer twice per week to study day 43. v7187 was dosed intravenously with 10 mg/kg twice per week to study day 43. Tumor volume was measured throughout the study, and other parameters assessed at day 43 as shown in Table 27.

[0499] The results are shown in FIG. 30 and Table 27. The results show that tumors treated with vehicle control showed continual progression and exceeded 1600 mm.sup.3 by study day 43. Mice treated with v7187 showed significantly greater tumor growth inhibition (T/C-0.44) with a mean tumor volume of 740 mm.sup.3 on day 43. v7187 induced responses in 5/8 tumors with a single tumor showing complete regression with zero residual disease on study day 43. Animals treated with v7187 had a superior response rate with 5/8 tumors responding to therapy compared to 0/8 mice treated with vehicle control. In addition, treatment with v7187 significantly delayed tumor progression compared to vehicle control with doubling times of 19 and 11 days respectively.

TABLE-US-00037 TABLE 27 Tumour Response Vehicle V7087 Day 43 Mean TV (mm3) 1683 740 (% Change from (+1079%) (+422%) Baseline) T/C ratio 1 0.44 Responders 0/8 5/8 (TV < 50% of control) PR (>10% 0/8 1/8 baseline regression) ZRD (TV < 20 mm3) 0/8 1/8 Time to Doubling 11 19 progression time (days)

[0500] These data show that the exemplary anti-HER2 biparatopic (v7187) is efficacious in a Trastuzumab+Pertuzumab resistant HER2 3+ metastatic breast cancer tumor xenograft model. V7187 treatment has a high response rate and can significantly impair tumor progression of standard of care treatment resistant HER2 3+ breast cancers.

Example 29: Assessment of Biparatopic Anti-HER2 ADC Binding to HER2+ Tumor Cell Lines

[0501] The ability of exemplary biparatopic anti-HER2 ADCs to bind and saturate HER2 positive 3+, 2+, breast and ovarian tumor cell lines was analyzed by FACS as described in Example 6.

[0502] The data is shown in FIG. 31. FIG. 31A shows v6363 binding to SKOV3 tumor cell lines with approximately a 2.0-fold greater Bmax (MFI) than T-DM1 (v6246) at saturating concentrations. FIG. 31B shows v6363 binds to JIMT-1 tumor cell lines with approximately a 1.6-fold greater Bmax (MFI) than T-DM1 (v6246) at saturating concentrations. These data show that v6363 (ADC) has similar tumor cell binding properties of increased cell surface binding compared to the parent unconjugated v5019 antibody (Example 6). Conjugation of v5019 with SMCC-DM1 (v6363) does not alter the antigen-binding properties of the antibody.

[0503] The FACS binding assay was repeated to include direct comparison to the exemplary biparatopic antibodies (v5019, v7091 and v10000) and ADCs (v6363, v7148 and v10553). The data is shown in FIG. 31C and FIG. 31D. The exemplary biparatopic anti-HER2 ADCs (v6363, v7148 and v10553) have equivalent cell surface saturation (Bmax) compared to the unlabeled biparatopic antibodies (v5019, v7091 and v10000).

[0504] These data show that conjugation of exemplary biparatopic antibodies (v5019, v7091 and v10000) with SMCC-DM1 does not alter the binding properties. The exemplary anti-HER2 biparatopic anti-HER2 ADCs (v6363, v7148 and v10553) have approximately 1.5-fold (or greater) increased cell surface binding compared to a monospecific anti-HER2 ADC (v6246, T-DM1).

Example 30: Dose-Dependent Tumour Growth Inhibition of an Exemplary Anti-HER2 Biparatopic-ADC in a HER2 3+ (ER-PR Negative) Patient Derived Xenograft Model

[0505] The HER2 3+ (ER-PR negative) patient derived xenograft model from invasive ductal human breast cancer, HBCx-13B, was used to assess the anti-tumor efficacy of an exemplary biparatopic anti-HER2 ADC, v6363. The model is resistant to single agent trastuzumab, the combination of trastuzumab and pertuzumab (see example 31), capecitabine, docetaxel, and adriamycin/cyclophosphamide.

[0506] Female athymic nude mice were inoculated with the tumor via the subcutaneous insertion of a 20 mm.sup.3 tumor fragment. Tumors were monitored until they reached an average volume of 160 mm.sup.3; animals were then randomized into 5 treatment groups: non-specific human IgG control, and 4 escalating doses of v6363. 8-10 animals were included in each group. Dosing for each group was as follows. IgG control was dosed intravenously with 10 mg/kg twice per week to study day 29. v6363 was dosed intravenously with 0.3, 1, 3, or 10 mg/kg on study days 1, 15, and 29. Tumor volume was assessed throughout the study and parameters assessed as indicated in Table 29.

[0507] The results are shown in FIG. 32 and Table 28. These results show that the exemplary anti-HER2 biparatopic ADC (v6363) mediated dose-dependent tumor growth inhibition in the Trastuzumab-resistant HBCx-13b PDX model (FIG. 32A). In addition, v6363 improved overall survival in a dose-dependent manner, with median survival time of more than 63 days for 3 mg/kg and 10 mg/kg doses compared to 43 days for IgG control (FIG. 32B and Table 28). The 3 mg/kg dose was associated with an increased response rate (5/10) compared to control (0/8). All mice treated with v6363 at 10 mg/kg dose not only responded to therapy (9/9) but also showed prevention of tumor progression. Moreover, the majority of tumors had objective partial responses (7/9) and, at the end of the study, many had zero residual disease (6/9). v6363 was well tolerated at all doses, no adverse events were observed and no body weight loss was observed.

TABLE-US-00038 TABLE 28 6363 6363 6363 6363 0.3 1 3 10 Tumour Response IgG mg/kg mg/kg mg/kg mg/kg Day 43 Mean TV 1963 1916 1613 1268 84 (mm3) (% (+1119%) (+1073%) (+895%) (+682%) (-49%) change from Baseline) T/C (IgG) 1 0.97 0.82 0.64 0.04 ratio Re- 0/8 0/10 2/10 5/10 9/9 sponders (TV < 50% of control) PR 0/8 0/10 0/10 0/10 7/9 (>10% baseline re- gression) ZRD 0/8 0/10 0/10 0/10 6/9 (TV < 20 mm3) Time to Tumor 9 9 14 17 52 pro- doubling gression time (days) Survival Median 43 41 50 >63 >63 Re- Survival sponse (Days) Body % Change +10% +10% +9% +5% +0% Weight from Baseline

[0508] These data show that the exemplary anti-HER2 biparatopic ADC (v6363) is efficacious in a Trastuzumab+Pertuzumab resistant HER2 3+ metastatic breast cancer tumor xenograft model. v6363 treatment is associated with a high response rate, significantly impairs tumor progression, and prolongs survival in a standard of care resistant HER2 3+ breast cancers.

Example 31: Biparatopic Anti-HER2-ADC Compared to Standard of Care Combinations in the Trastuzumab Resistant PDX HBCx-13b

[0509] The efficacy of v6363 in a HER2 3+, ER-PR negative Trastuzumab resistant patient-derived breast cancer xenograft model (HBCx-13b), was evaluated and compared to to the combination of: Herceptin.TM.+Perjeta.TM.; and Herceptin.TM.+Docetaxel.

[0510] Female athymic nude mice were inoculated with the tumor via the subcutaneous insertion of a 20 mm3 tumor fragment. Tumors were monitored until they reached an average volume of 100 mm3; animals were then randomized into 4 treatment groups (8-10 animals/group): non-specific human IgG control, Herceptin.TM.+Docetaxel, Herceptin.TM.+Perjeta.TM., and v6363. Dosing for each group was as follow. IgG control was dosed intravenously with 10 mg/kg twice per week to study day 29. Herceptin.TM.+Docetaxel combination Herceptin.TM. was dosed intravenously with 10 mg/kg IV twice weekly to study day 29 and Docetaxel was dosed intraperitoneally with 20 mg/kg on study day 1 and 22. Herceptin.TM.+Perjeta.TM. combination Herceptin was dosed intravenously with 5 mg/kg twice per week to study day 29 and Perjeta.TM. was dosed intravenously with 5 mg/kg twice per week to study day 29. The dosing of Herceptin.TM. and Perjeta.TM. was concurrent. v6363 was dosed intravenously with 10 mg/kg on study day 1, 15, and 29.

[0511] The results are shown in FIG. 33 and Table 29. FIG. 33A shows tumor volume over time, and FIG. 33B shows a survival plot. These results show that the combination of Herceptin.TM.+Perjeta.TM. did not produce any tumor growth inhibition compared to control IgG and exceeded 1800 mm.sup.3 on day 39. The combination of Herceptin.TM.+Docetaxel did not significantly reduce tumor growth but did prolong median survival to 53 days compared to 43 days for IgG control. v6363 produced significant tumor growth inhibition (T/C-0.04), where, all tumors responded to therapy and 7/10 tumors experienced complete regressions (zero residual disease). v6363 significantly prolonged survival compared to both combination therapies. Body weights across cohorts were not significantly affected by treatments.

TABLE-US-00039 TABLE 29 HerceptinTM + HerceptinTM + v6363 Tumour Response IgG PerjetaTM Docetaxel 10 mg/kg Day 39 Mean TV (mm3) 1809 1975 1328 76 (% change from (+1023%) (+1085%) (+714%) (-54%) Baseline) T/C (IgG) ratio 1.0 1.10 0.73 0.04 Responders 0/8 0/8 1/10 9/9 (TV < 50% of control) PR 0/8 0/8 0/10 8/9 (>10% baseline regression) ZRD 0/8 0/8 0/10 6/9 (TV < 20 mm3) Survival Median Survival 43 39 53 >63 Response (days) Body % Change from +10% +7% +3% -2% Weight Baseline

[0512] These results show that exemplary anti-HER2 biparatopic ADC (v6363) is superior to standard of care combinations with respect to all parameters tested in this xenograft model.

Example 32: Efficacy of a Biparatopic Anti-HER2-ADC in HER2+ Trastuzumab-Resistant Breast Cancer Cell Derived Tumour Xenograft Model

[0513] The efficacy of v6363 in a HER2 3+ Trastuzumab resistant breast cancer cell-derived (JIMT-1, HER2 2+) xenograft model was evaluated (Tanner et al. 2004. Molecular Cancer Therapeutics 3: 1585-1592).

[0514] Female RAG2 mice were inoculated with the tumor subcutaneously. Tumors were monitored until they reached an average volume of 115 mm.sup.3; animals were then randomized into 2 treatment groups: Trastuzumab (n=10) and v6363. Dosing for each group was as follows. Trastuzumab was dosed intravenously with 15 mg/kg on study day 1 and 10 mg/kg twice per week to study day 26. v6363 was dosed intravenously with 5 mg/kg on study days 1 and 15 and with 10 mg/kg on day 23 and 30 and 9 mg/kg on day 37 and 44.

[0515] The results are shown in FIG. 34 and Table 30. These results show that v6363 significantly inhibited tumor growth (T/C-0.74) compared to Trastuzumab on study day 36. v6363 and Trastuzumab treatment did not significantly change body weight. v6363 serum exposure was 17.9 .mu.g/ml 7 days after the first 10 mg/kg dose.

TABLE-US-00040 TABLE 30 Tumour Response Trastuzumab 6363 Day 36 Mean TV (mm3) 718 532 (% change from (+541) (+335%) Baseline) T/C (Tras) ratio 1 0.74 Responders 1/10 2/13 (TV < 50% of control) PR 0/10 0/13 (>10% baseline regression) ZRD 0/10 0/13 (TV < 20 mm3) Body % Change from +5.8% +3.1% Weight Baseline Drug Mean Serum 187.2 17.9 Exposure Concentration (day 7) (ug/ml)

[0516] These results show that exemplary anti-HER2 biparatopic ADC (v6363) is efficacious in a Trastuzumab-resistant breast cancer and has a potential utility in treating breast cancers that are resistant to current standards of care.

Example 33: Fc.gamma.R Binding to Heterodimeric Fc of Anti-HER2 Biparatopic Antibodies and Anti-HER2 Biparatopic-ADCs

[0517] The binding of anti-HER2 biparatopic antibody (v5019, v7019 v10000) and ADC (v6363, v7148 and v10553) having a heterodimeric Fc, to human Fc.gamma.Rs was assessed and compared to anti-HER2 FSA (v506) and ADC (v6246) having a homodimeric Fc.

[0518] Affinity of Fc.gamma.R to antibody Fc region was measured by SPR using a ProteOn XPR36 (BIO-RAD). HER2 was immobilized (3000 RU) on CMS chip by standard amine coupling. Antibodies were antigen captured on the HER2 surface. Purified Fc.gamma.R was injected various concentration (20-30 .mu.l/min) for 2 minutes, followed by 4 minute dissociation. Sensograms were fit globally to a 1:1 Langmuir binding model. Experiments were conducted at 25.degree. C.

[0519] The results are shown in Table 31. The exemplary heterodimeric anti-HER2 biparatopic antibodies and ADCs bound to CD16aF, CD16aV158, CD32aH, CD32aR131, CD32bY163 and CD64A with comparable affinities. Conjugation of the antibodies with SMCC-DM1 does not negatively affect Fc.gamma.R binding. The heterodimeric anti-HER2 biparatopic antibodies have approximately 1.3 to 2-fold higher affinity to CD16aF, CD32aR131, CD32aH compared to homodimeric anti-HER2 FSA (v506) and ADC (v6246). These results show that the heterodimeric anti-HER2 biparatopic antibodies and ADCs bind different polymorphic forms of Fc.gamma.Rs on immune effector cells with similar or greater affinity than a WT homodimeric IgG1.

TABLE-US-00041 TABLE 31 Human Fc7R Binding by SPR 10 uM 10 uM 10 uM 10 uM 10 uM CD16a v158 CD16aF CD32aR131 CD32aH CD32b Y163 100 nM CD64A Variant KD Ave SD KD Ave SD KD Ave SD KD Ave SD KD Ave SD KD Ave SD v506 1.5E-07 2E-08 7.1E-07 1.E-08 7.6E-07 1.E-07 6.3E-07 2E-08 2.4E-06 1.E-07 8.64E-10 4.33E-10 v6246 1.6E-07 2E-08 7.0E-07 9.E-09 7.4E-07 7.E-08 6.3E-07 2E-08 2.1E-06 7.E-08 1.08E-09 5.13E-10 v10000 1.2E-07 1E-08 4.8E-07 2.E-08 5.1E-07 9.E-08 4.6E-07 2E-08 1.5E-06 7.E-08 8.41E-10 4.74E-10 v10553 1.2E-07 2E-08 4.9E-07 2.E-07 3.5E-07 1.E-07 3.6E-07 4E-09 1.2E-06 7E-08 4.95E-10 1.41E-10 v7091 1.2E-07 1E-08 5.1E-07 2.E-08 5.6E-07 9.E-08 5.0E-07 3E-08 1.7E-06 8E-08 9.68E-10 5.05E-10 v7148 1.2E-07 2E-08 5.4E-07 2.E-07 3.7E-07 1.E-07 4.2E-07 1E-08 1.5E-06 1.E-07 5.77E-10 2.02E-10 v5019 1.3E-07 1E-08 5.2E-07 1.E-08 5.6E-07 6.E-08 4.7E-07 2E-08 1.6E-06 2.E-07 8.44E-10 4.88E-10 v6363 1.2E-07 2E-08 4.5E-07 1.E-07 3.5E-07 1.E-07 3.4E-07 1E-08 1.2E-06 5.E-08 4.58E-10 1.13E-10

Example 34: Efficacy of Exemplary Anti-HER2 Biparatopic Antibodies In Vivo in a Trastuzumab Sensitive Ovarian Cancer Cell Derived Tumour Xenograft Model

[0520] The established human ovarian cancer cell derived xenograft model SKOV3, described in Example 17, was used to assess the anti-tumor efficacy of the exemplary biparatopic anti-HER2 antibodies, v5019, v7091 and v10000.

[0521] Female athymic nude mice were inoculated with a tumor suspension of 325,000 cells in HBSS subcutaneously on the left flank. Tumors were monitored until they reached an average volume of 190 mm.sup.3 and enrolled in a randomized and staggered fashion into 4 treatment groups: non-specific human IgG control, v5019, v7091, and v10000. Dosing for each group was as follows. Non-specific human IgG was dosed intravenously with 10 mg/kg starting on study day 1 twice per week to study day 26. V5019, v7091, and v10000 were dosed intravenously with 3 mg/kg starting on study day 1 twice per week to study day 26. Tumor volume was measured throughout the study, and the parameters listed in Table 32 were measured at day 29.

[0522] The data are presented in FIG. 35A (tumor growth), FIG. 35B (survival plot) and Table 32 and show that treatment with v5019, v7091 and v10000 resulted in comparable tumor growth inhibition (T/C: 0.53-0.71), number of responding tumors, time to progression, and survival on study day 29 compared to IgG control. The serum exposure of v5019, v7091, and v10000 was similar (31-41 microg/ml) on study day 7.

TABLE-US-00042 TABLE 32 IgG v5019 V7091 V10000 Tumour Response (n = 8) (n = 11) (n = 11) (n = 11) Day 29 Mean TV 1903 1001 1354 1114 (mm3) (% (+899%) (+416%) (+618%) (+503%) change from Baseline) T/C (Tras) ratio 1 0.53 0.71 0.58 Responders 1/8 5/11 4/11 6/11 (TV < 50% of control) PR 0/8 1/11 0/11 0/11 (>10% baseline regression) ZRD 0/8 0/11 0/11 0/11 (TV < 20 mm3) Time to Tumor doubling 12 15 16 15 progression time (days) Survival Median survival 29 Na 37 41 (days) Drug Mean Serum na 31.2 41.0 31.2 Exposure Concentration (day 7) (ug/ml)

[0523] These results show that the exemplary anti-HER2 biparatopic antibodies, v5019, v7091, and v10000) have potential utility in treating moderately Trastuzumab sensitive HER2 overexpressing ovarian cancers.

Example 35: Exemplary Biparatopic Anti-Her2 Antibodies Dose-Dependently Inhibit Tumour Growth in the Trastuzumab-Sensitive Ovarian Cancer Cell Derived Tumour Xenograft

[0524] The established human ovarian cancer cell derived xenograft model SKOV3, described in Example 17, was used to assess the dose-dependent efficacy of an exemplary biparatopic anti-HER2 antibody, v10000.

[0525] Female athymic nude mice were inoculated with a tumor suspension of 325,000 cells in HBSS subcutaneously on the left flank. Tumors were monitored until they reached an average volume of 190 mm.sup.3 and enrolled in a randomized and staggered fashion into 6 treatment groups: non-specific human IgG control and 5 escalating doses of v10000. 9-13 animals were included in each group. Dosing for each group was as follows. IgG control was dosed intravenously with 10 mg/kg twice per week to study day 26. V10000 was dosed intravenously with 0.1, 0.3, 1, 3, or 10 mg/kg twice per week.

[0526] The data are presented in FIG. 36 and Table 33 and show that treatment with v10000 dose dependently induces tumor growth inhibition (T/C: 0.28-0.73) compared to control IgG. In addition, v10000 was dose-dependently associated with responding tumors (7/9 at 10 mg/kg and 3/11 at 0.1 mg/kg) increased time to progression (24 days at 10 mg/kg and 12 days at 0.1 mg/kg) on study day 29. The serum exposure of v10000 on day 7 was dose dependent and increased from 0.46 microg/ml with a 0.1 mg/kg dose to 79.3 microg/ml with a 10 mg/kg dose.

TABLE-US-00043 TABLE 33 V10000, V10000, V10000, V10000, V10000, 10 3 mg/kg 1 mg/kg 0.3 mg/kg 0.1 mg/kg Tumor Response IgG (n = 8) mg/kg (n = 9) (n = 11) (n = 11) (n = 13) (n = 11) Day 29 Mean TV (mm3) 1903 (+899%) 543 1114 1534 1535 1385 (% change from (+281%) (+503%) (+688%) (+694%) (+643%) Baseline) T/C ratio 1 0.28 0.58 0.81 0.81 0.73 Responders 1/8 7/9 6/11 2/11 3/13 3/11 (TV < 50% of control) PR 0/8 1/9 0/11 0/11 0/13 0/11 (>10% baseline regression) ZRD 0/8 0/9 0/11 0/11 0/13 0/11 (TV < 20 mm3) Time to Tumor doubling 12 24 15 14 12 12 Progression time (days) Drug Exposure Mean Serum na 79.3 31.2 4.7 1.5 0.46 (Day 7) Concentration (ug/ml)

[0527] These results show that the exemplary anti-HER2 biparatopic antibody, v10000, inhibits tumor progression in a dose-dependent manner.

Example 36: Ability of Anti-HER2 Biparatopic Antibody and Anti-HER2 Biparatopic-ADC to Inhibit Growth of Cell Lines Expressing HER2, and EGFR and/or HER3 at the 3+, 2+ or 1+ Levels

[0528] The following experiment was performed to measure the ability of an exemplary biparatopic anti-HER2 antibody (v10000) and corresponding biparatopic anti-HER2 ADC (v10553) to inhibit growth of a selection of breast, colorectal, gastric, lung, skin, ovarian, renal, pancreatic, head and neck, uterine and bladder tumor cell lines that express HER2, and EGFR and/or HER3 at the 3+, 2+, 1+ or 0+ level as defined by IHC.

[0529] The experiment was conducted as follows. The optimal seeding density for each cell line was uniquely determined to identify a seeding density that yielded approximately 60-90% confluency after the 72 hr duration of the assay. Each cell line was seeded at the optimal seeding density, in the appropriate growth medium per cell line, in a 96-well plate and incubated for 24.degree. C. at 36.degree. C. and 5% CO.sub.2. Antibodies were added at three concentrations (v10000 at 300, 30 and 0.3 nM; v10553 at 300, 1, 0.1 nM), along with the positive and vehicle controls. The positive control chemococktail drug combination of 5-FU (5-fluorouracil), paclitaxel, cisplatin, etoposide (25 microM), the vehicle control consisted of PBS. The antibody treatments and controls were incubated with the cells for 72 h in a cell culture incubator at 36.degree. C. and 5% CO.sub.2. The plates were centrifuged at 1200 RPM for 10 min and culture medium completely removed by aspiration. RPMI SFM medium (200 microL) and MTS (20 microL) was added to each well and incubated at 36.degree. C. and 5% CO.sub.2 for 3 h. Optical density was read at 490 nM and percent growth inhibition was determined relative to the vehicle control.

[0530] The results are shown in FIG. 37 and a summary of all test results are shown in FIG. 38. FIG. 37A shows the growth inhibition results of v10000. These results show that v10000 can inhibit growth of breast, colorectal, gastric, lung, skin, ovarian, renal, pancreatic, head and neck, uterine, and endometrial tumor cell lines that express HER2 and coexpress EGFR and/or HER3 at the 3+, 2+, 1+ or 0+ level. The activity of v10000 and v10553 at 300 nM is summarized in FIG. 38, where `+` indicates cell lines that showed a reduction in cell viability at 300 nM that was >5% of the vehicle control, and `-` indicates .ltoreq.5% viability of the vehicle control.

[0531] FIG. 37B shows the growth inhibition results of v10553. These results show that v10553 can inhibit growth of breast, colorectal, gastric, lung, skin, ovarian, renal, pancreatic, head and neck, uterine and bladder tumor cell lines that express HER2 and coexpress EGFR and/or HER3 at the 3+, 2+, 1+ or 0+ level (see also FIG. 38). The results plotted in FIG. 37B are defined by cell lines that showed a minimum of dose-dependent growth inhibition at 300 and 1 nM, and where the growth inhibition at 1 nM is equal or greater than 5% (FIG. 37B).

[0532] These results show that exemplary biparatopic antibody v10000 and ADC v10553 can inhibit growth of tumor cells originating from breast, colorectal, gastric, lung, skin, ovarian, renal, pancreatic, head and neck, uterine and bladder histologies that express HER2 at the 3+, 2/3+, 2+, 1+ and 0/1+ levels and that coexpress EGFR and/or HER3 at the 2+, 1+ levels.

Example 37: Ability of Anti-HER2 Biparatopic Antibodies to Mediate ADCC of HER2 2+, 1+ and 0/1+ Cancer Cells

[0533] The following experiment was conducted to determine the ability of anti-HER2 biparatopic antibodies to mediate ADCC of tumor cells that express HER2 at the 2+, 1+ and/or 0/1+ levels and that coexpress EGFR and/or HER3 at the 2+ or 1+ level. The anti-HER2 biparatopic antibodies tested were 5019, 10000, and 10154 (an afucosylated version of v10000), with Herceptin.TM. and v506 as controls.

[0534] The ADCC experiment was conducted as described in Example 11 and Example 25 with E/T: 5:1 with NK-92 effector cells (FIG. 39), and as described in Example 26 with E/T 30:1 with PBMC effector cells.

[0535] The results are shown in FIG. 39 (NK-92 effector cells) and FIG. 40 (PBMC effector cells). FIG. 39A shows the ADCC results of the HER2 2+ head and neck tumor cell line (hypopharyngeal carcinoma), FaDu, where the anti-HER2 biparatopic elicits approximately 15% maximal cell lysis. FIG. 39C shows the ADCC results of the HER2 1+BxPC3 pancreatic tumor cell line, and FIG. 39D the results of the HER2 2+ MiaPaca2 pancreatic tumor cell line. FIG. 39B shows the ADCC results of the HER2 0/1+A549 NSCLC (non-small cell lung cancer) tumor cell line. In the BxPC3, MiaPaca2 and A549 tumor cell lines, v10000 mediated approximately 5% maximal tumor cell lysis.

[0536] FIG. 40 shows the ADCC results in A549, NCI-N87, and HCT-116 cells, where PBMCs were used as the effector cells. FIG. 40A shows the ADCC results of the HER2 0/1+A549 NSCLC tumor cell line, where v10000 elicited .about.28% maximum cell lysis and this was comparable to Herceptin.TM. that has equivalent level of fucose content in the N-linked glycan. The exemplary 100% afucosylated (0% fucose) biparatopic v10154 shows an increase in maximal cell lysis (40% maximum cell lysis) and increased potency compared to v10000 and Herceptin that have approximately 88% fucose in the N-linked glycan.

[0537] FIG. 40B shows the ADCC results of the HER2 3+ gastric tumor cell line, NCI-N87. FIG. 40B shows that exemplary biparatopic v5019 (approximately 88% fucosylated) mediates approximately 23% maximal cell lysis and has a lower EC50 compared to Trastuzumab v506 (approximately 98% fucosylated).

[0538] FIG. 40C shows the ADCC results of the HER2 1+ HCT-116 colorectal tumor cell line. FIG. 40C shows that exemplary biparatopic v5019 (approximately 88% fucosylated) mediates approximately 25% maximal cell lysis and is more potent compared to Trastuzumab v506 (approximately 98% fucosylated).

[0539] These results show that exemplary anti-HER2 biparatopic antibodies can elicit ADCC of HER2 01/+, 2+ and 3+ tumor cells that originate from head and neck, gastric, NSCLC, and pancreatic tumor histologies. ADCC in the presence of NK-92 cells as the effector cells had an apparent HER2 2+ receptor level requirement (i.e. 2+ or greater) to show higher (>5%) percentage of maximum cell lysis. However, when PBMC cells were used as effector cells higher levels of maximum cell lysis were achieved (>5% and up to 28% or 40%; v10000 and v10154, respectively) and were independent of HER2 receptor density as ADCC >5% was seen at the 0/1+, 1+ and 3+ HER2 receptor density levels.

Example 38: HER2 Binding Affinity and Kinetics as Measured by SPR

[0540] As indicated in Example 1, anti-HER2 biparatopic antibodies having different antigen-binding moiety formats were constructed, as described in Table 1. The formats included scFv-scFv format (v6717), Fab-Fab format (v6902 and v6903), along with Fab-scFv format (v5019, v7091, and v10000). The following experiment was conducted to compare HER2 binding affinity and kinetics of these exemplary anti-HER2 biparatopic antibody formats.

[0541] Affinity and binding kinetics to murine HER2 ECD (Sino Biological 50714-M08H) was measured by single cycle kinetics with the T200 SPR system from Biacore (GE Healthcare). Between 2000-4000 RU of anti-human Fc was immobilized on a CMS chip using standard amine coupling. 5019 was captured on the anti-human Fc surface at 50 RU. Recombinant HER2 ECD (1.8-120 nM) was injected at 50 .mu.1/min for 3 minutes, followed by a 30 minute dissociation after the last injection. HER2 dilutions were analyzed in duplicate. Sensorgrams were fit globally to a 1:1 Langmuir binding model. All experiments were conducted at room temperature, 25.degree. C.

[0542] The results in Table 34 show that Fab-scFv biparatopic antibodies (v5019 and v7091), Fab-Fab variants (v6902 and v6903) and the scFv-scFv variant (v6717) have comparable binding affinity (1-4 nM). The Fab-scFv variant v10000 had higher binding affinity (lower KD) of approximately 0.6 nM. The monspecific anti-HER2 ECD4 antibody (v506) and anti-HER2 ECD2 antibody (v4184) were included in the assay as controls. These results indicate that the molecular formats including v6717, v6902, v6903, v5019 and/or v7091 have equivalent binding affinities, and thus differences in function between these antibodies may be considered to result from differences in format.

TABLE-US-00044 TABLE 34 Anti- STD DEV body AVERAGE Ka Variant Ka (1/Ms) Kd (1/s) KD (M) (1/Ms) Kd (1/s) KD (M) v506 7.34E+04 4.08E-05 5.56E-10 1.13.E+ 3.04E- 3.28E- 03 06 11 v4184 3.61E+04 5.46E-04 1.56E-08 7.78.E + 2.80E- 4.12E- 03 05 09 v5019 6.01E+04 7.77E-05 1.29E-09 1.30.E+ 8.56E- 4.24E- 03 07 11 v7091 5.17E+04 1.19E-04 2.31E-09 2.70.E + 1.49E- 4.09E- 03 05 10 v10000 6.44E+04 3.69E-05 5.79E-10 6.18.E+ 6.72.E- 1.42.E- 03 06 10 v6902 6.83E+04 1.72E-04 2.72E-09 1.93E+ 4.49E- 1.43E- 04 05 09 v6903 7.10E+04 1.71E-04 2.75E-09 3.60E+ 3.96E- 1.34E- 04 06 09 v6717 1.50E4-05 5.33E-04 4.45E-09 1.28E+ 2.54E- 2.11E- 05 04 09

Example 39: Effect of Anti-HER2 Biparatopic Antibody Format on Binding to HER2+ Tumor Cells

[0543] The following experiment was conducted to compare the whole cell binding properties (Bmax and apparent K.sub.D) of exemplary anti-HER2 ECD2.times.ECD4 biparatopic antibodies that have different molecular formats (e.g. v6717, scFv-scFv IgG1; v6903 and v6902 Fab-Fab IgG1; v5019, v7091 and v10000 Fab-scFv IgG1).

[0544] The experiment was conducted as described in Example 6. The results are shown in FIG. 41 and Tables 35-38. FIG. 41A and Table 35 shows the FACS binding results of the exemplary biparatopic antibodies to the BT474 HER2 3+ breast tumor cell line. The results show that all anti-HER2 antibodies have a higher Bmax (1.5 to 1.7-fold greater) when compared to the monospecific bivalent anti-HER2 antibody v506. The Fab-scFv (v5019, v7091 and v10000) and the Fab-Fab (v6903) formats had approximately a 1.7-fold increased Bmax and the scFv-scFv format (v6717) had a 1.5-fold increased Bmax compared to v506. An equimolar combination of FSAs v506 and v4184 resulted in a 1.7-fold increase in Bmax. The apparent K.sub.D of the exemplary anti-HER2 biparatopic antibodies was approximately 2 to 3-fold higher compared to the monospecific v506.

TABLE-US-00045 TABLE 35 FACS binding BT-474 Antibody Variant K.sub.D (nM) Bmax v506 9.0 23536 v10000 16 39665 v506 + v4184 16 40320 v5019 21 39727 v7091 22 36718 v6717 30 36392 v6903 31 40321

[0545] FIG. 41B and Table 36 shows the FACS binding results to the JIMT-1 HER2 2+ breast tumor cell line. The results show that all anti-HER2 antibodies have a higher Bmax (1.5 to 1.8-fold greater) when compared to the monospecific bivalent anti-HER2 antibody v506. The Fab-scFv (v7091 and v10000) and the Fab-Fab (v6903) formats had approximately a 1.7-fold increased Bmax, the scFv-scFv format (v6717) had a 1.5-fold increased Bmax and the Fab-scFv (v5019) and FSA combination (v506+v4184) had a 1.8-fold increased Bmax compared to v506. The apparent K.sub.D of the exemplary anti-HER2 biparatopic Fab-scFv antibodies was approximately 2 to 4-fold higher compared to the monospecific v506; whereas the K.sub.D of the Fab-Fab (v6903) and scFv-scFv (v6717) were approximately 8-fold higher compared to v506.

TABLE-US-00046 TABLE 36 FACS Binding JIMT-1 Antibody Variant K.sub.D (nM) Bmax v506 3.5 2574 v10000 7.6 4435 v506 + v4184 8.0 4617 v5019 12 4690 v7091 14 4456 v6717 26 3769 v6903 28 4452

[0546] FIG. 41C and Table 37 shows the FACS binding results of the exemplary biparatopic antibodies to the HER2 1+ MCF7 breast tumor cell line. The results show that anti-HER2 antibody v10000 and FSA combination (v506+v4184) have a 1.6-fold higher Bmax compared to the monospecific bivalent anti-HER2 antibody v506. The Fab-scFv (v5019, v7091) had approximately a 1.4-fold; the scFv-scFv format (v6717) a 1.3-fold, and the Fab-Fab format (v6903) had a 1.2-fold increased Bmax compared to v506. The apparent K.sub.D of the exemplary anti-HER2 biparatopic Fab-scFv, Fab-Fab (v6903) and FSA combination (v506+v4184) was approximately 2 to 3-fold lower compared to v506; whereas the K.sub.D of the scFv-scFv (v6717) was approximately 3-fold higher compared to v506.

TABLE-US-00047 TABLE 37 FACS Binding MCF7 Antibody Variant K.sub.D (nM) Bmax v506 + v4184 4.5 1410 v7091 6.1 1216 v5019 6.3 1201 v10000 6.8 1381 v6903 7.1 1105 v506 12 889 v6717 32 1167

[0547] FIG. 41D and Table 38 shows the FACS binding results of the exemplary biparatopic antibodies to the HER2 0/1+ MDA-MD-231 breast tumor cell line. The results show that exemplary biparatopic anti-HER2 antibodies had approximately 1.3 to 1.4-fold increased Bmax compared to the monospecific bivalent anti-HER2 antibody v506. The FSA combination (v506+v4184) had a 1.7-fold increased Bmax The apparent K.sub.D of the exemplary anti-HER2 biparatopic Fab-scFv antibodies (v5019, v7091, v10000) and FSA combination (v506+v4184) had an approximate equivalent KD compared to v506; whereas Fab-Fab (v6903) and scFv-scFv (v6717) was approximately 4 and 16-fold higher K.sub.D respectively, compared to v506.

TABLE-US-00048 TABLE 38 FACS Binding MDA-MB-231 Antibody Variant K.sub.D (nM) Bmax v506 4.8 395 v10000 5.6 558 v506 + v4184 7.3 662 v7091 7.9 525 v5019 8.7 548 v6903 17 534 v6717 77 524

[0548] The tumor cell binding results show that anti-HER2 biparatopic antibodies with different molecular formats have an increased Bmax on HER2 3+, 2+, 1+ and 0/1+ tumor cells compared to a bivalent monospecific anti-HER2 antibody. Of the different anti-HER2 biparatopic antibodies, the scFv-scFv format had the lowest Bmax gain relative to v506 on HER2 3+, 2+, 1+ and 0/1+ tumor cells These results also show that scFv-scFv and Fab-Fab formats have the greatest increase in K.sub.D on HER2 3+, 2+, 1+ and 0/1+ tumor cells compared monospecific v506 (3 to 16-fold increase) and the biparatopic Fab-scFv formats (approximately 2-fold or greater). The increase in K.sub.D is an indication of a reduction in avid binding and suggests that different biparatopic formats have unique mechanisms of binding to HER2 on the cell surface.

Example 40: Effect of Anti-HER2 Biparatopic Antibody Format on Internalization in HER2+ Cells

[0549] The following experiment was conducted to compare the ability of exemplary anti-HER2 ECD2.times.ECD4 biparatopic antibodies that have different molecular formats (e.g. v6717, scFv-scFv IgG1; v6903 and v6902 Fab-Fab IgG1; v5019, v7091 and v10000 Fab-scFv IgG1) to internalize in HER2+ cells expressing HER2 at varying levels.

[0550] The experiment was conducted as detailed in Example 9. The results are shown in FIG. 42 and Tables 39-41. FIG. 42A and Table 39 show the internalization results in HER2 3+BT-474. These results show that the Fab-scFv format (v10000) and the FSA combination (v506+v4184) have 2.2-fold greater quantities of intracellular antibody, compared to the monospecific anti-HER2 v506. The scFv-scFv format (v6717) had 1.9-fold greater; the Fab-scFv formats (v5019 and v7091) had 1.5 to 1.7-fold greater; and the Fab-Fab formats (v6902 and v6903) had 1.2 to 1.3-fold greater quantities of intracellular antibody accumulation compared to v506.

TABLE-US-00049 TABLE 39 Internalization BT-474 Antibody Variant Surface 4.degree. C. Surface37.degree. C. Internal 37.degree. C. v506 2156 1590 3453 v6902 2407 2077 4035 v6903 2717 986 4573 v7091 2759 2227 5111 v5019 2867 2675 5710 v6717 2006 1212 6498 v10000 3355 2851 7528 v506 + v4184 3998 2326 7569

[0551] FIG. 42B and Table 40 show the internalization results in HER2 2+ JIMT-1. These results show that the Fab-scFv format (v10000) and the FSA combination (v506+v4184) have respectively 1.8 and 1.9-fold greater quantities of intracellular antibody, compared to the monospecific anti-HER2 v506. The scFv-scFv (v6717) and the Fab-scFv formats (v5019) have 1.4-fold greater; and the Fab-scFv (v7091) and Fab-Fab formats (v6902 and v6903) had 1.2-fold greater quantities of intracellular antibody accumulation compared to v506.

TABLE-US-00050 TABLE 40 Internalization JIMT-1 Antibody Variant Surface 4.degree. C. Surface 37.degree. C. Internal 37.degree. C. v506 337 -7.1 759 v6902 389 152 926 v7091 426 102 935 v6903 392 130 945 v5019 437 5.2 1035 v6717 247 31 1082 v10000 474 103 1375 v506 + v4184 583 89 1449

[0552] FIG. 42C and Table 41 show the internalization results in HER2 1+ MCF7. These results show that the scFv-scFv format and Fab-scFv formats have 3.0 and 2.8-fold greater quantities of intracellular antibody, compared to the monospecific anti-HER2 v506. The Fab-scFv format (v10000) and the FSA combination (v506+v4184) have approximately 2.0-fold; the Fab-scFv (v7091) and Fab-Fab (v6903) formats have 1.8-fold greater quantities of intracellular antibody accumulation compared to v506.

TABLE-US-00051 TABLE 41 Internalization MCF7 Antibody Variant Surface 4.degree. C. Surface 37.degree. C. Internal 37.degree. C. v506 48 10 48 v7091 77 27 87 v6903 81 35 89 v10000 78 20 96 v506 + v4184 87 19 103 v5019 81 17 134 v6717 48 31 145

[0553] These results show that anti-HER2 biparatopic antibodies with different molecular formats have unique degrees of internalization in HER2 3+, 2+ and 1+ tumor cells that varies with respect to the structure and format of the antigen-binding domains. In general, the monospecific FSA combination of v506 and v4184, the Fab-scFv (v10000, v7091 and v5019) and the scFv-scFv (v6717) biparatopic formats had the higher internalization values in the HER2 3+, 2+ and 1+ tumor cells. Whereas, the Fab-Fab biparatopic formats (v6902 and v6903) had the lowest internalization values in the HER2 3+, 2+ and 1+ tumor cells. These data suggest that the molecular format and geometric spacing of the antigen-binding domains has an influence on the ability of the biparatopic antibodies to cross-link HER2 receptors, and subsequently to internalize in HER2+ tumor cells. The Fab-Fab biparatopic format, having the greatest distance between the two antigen-binding domains, resulted in the lowest degree of internalization, whereas the Fab-scFv and scFv-scFv formats, having shorter distances between the antigen-binding domains, had greater internalization in HER2+ cells. This is consistent with the correlation of potency and shorter linker length as described in Jost et al 2013, Structure 21, 1979-1991).

Example 41: Effect of Anti-HER2 Biparatopic Antibody Format on ADCC in HER2+ Cells

[0554] The following experiment was conducted to compare the ability of exemplary anti-HER2 ECD2.times.ECD4 biparatopic antibodies that have different molecular formats (e.g. v6717, scFv-scFv IgG1; v6903 and v6902 Fab-Fab IgG1; v5019, v7091 and v10000 Fab-scFv IgG1) to mediate ADCC in HER2+ cells expressing HER2 at varying levels.

[0555] Prior to performing the ADCC assay, glycopeptide analysis was performed on the antibody samples to quantify the fucose content in the N-linked glycopeptide. The method was followed as described in Example 23. The results are shown in Table 42; the data shows that exemplary biparatopic variants v5019, v6717, v6903 have equivalent fucose content in the N-linked glycan (91-93%). Antibody samples with equivalent levels of fucose in the N-glycan were selected for the ADCC assay to normalize for fucose content in the interpretation of the ADCC assay results.

TABLE-US-00052 TABLE 42 LC-MS Tryptic peptide analysis Percentage of Percentage of Glycopeptides Observed Glycopeptides Observed Variant WITH Fucose WITHOUT Fucose v6903 90.7 9.3 v6717 92.8 7.2 v5019 91.3 8.7

[0556] The ADCC experiment was conducted as described in Example 11 with E/T: 5:1 with NK-92 effector cells. The ADCC results are shown in FIG. 43 and Tables 43-45. FIG. 43A and Table 43 show the ADCC results in HER2 2+ JIMT-1 breast tumor cells. These data show that v5019, v6717 and v6903 elicit similar levels of maximum cell lysis and that the scFv-scFv format (v6717) is less potent compared to v5019 and v6903 when HER2 2+ tumor cells are targets.

TABLE-US-00053 TABLE 43 JIMT-1 ADCC Antibody variant EC50 (nM) % Max Cell Lysis v6903 ~0.03 48 v5019 ~0.16 47 v6717 ~0.72 51

[0557] FIG. 43B and Table 44 show the ADCC results in HER2 1+ MCF7 breast tumor cells. These data show that v5019 and v6717 have slightly higher maximum cell lysis (27-30%) compared to v6903 (24%). These data also show that v6717 is the least potent, followed by v6903 and v5019, which have lower EC50 values.

TABLE-US-00054 TABLE 44 MCF7 ADCC Antibody variant EC.sub.50 (nM) % Max Cell Lysis v5019 ~0.69 27 v6717 109 30 v6903 0.94 24

[0558] FIG. 43C and Table 45 show the ADCC results in HER2 0/1+ MDA-MB-231 breast tumor cells. These data show that v5019 shows slightly higher maximum cell lysis (77%) compared to v6903 (62%) and v6717 (63%). These data also show that v6717 is the least potent, followed by v6903 and v5019, which have lower EC.sub.50 values.

TABLE-US-00055 TABLE 45 MDA-MB-231 ADCC % Max Cell Lysis Antibody variant EC.sub.50 (nM) (top only) v5019 0.20 71 v6717 10 63 v6903 0.79 62

[0559] These data show that exemplary anti-HER2 ECD2.times.ECD4 biparatopic antibodies elicit similar levels of maximum cell lysis by ADCC in HER2 2+ and 1+ tumor cells. Despite similarities in maximal cell lysis, these data also show that the different molecular formats have unique ADCC potencies. The scFv-scFv was the least potent (greatest EC.sub.50 values) in the HER2 2+ and HER2 1+. Differential potencies among the three formats was seen in the ADCC data targeting HER2 1+ cells, where the EC50 values for v6717>v6903>v5019. These data are consistent with the observations presented in Example 40 (FACS binding), where an increase in K.sub.D (reduced affinity) was seen with the Fab-Fab and scFv-scFv formats.

Example 42: Effect of Anti-HER2 Biparatopic Antibody Format on Growth of HER2+ Tumor Cells

[0560] The following experiment was conducted to compare the effect of anti-HER2 biparatopic antibody format on growth of HER2 3+, 2+ and 1+ tumor cells, either basal growth or ligand-stimulated. Basal growth was measured as described in Example 15, while ligand-stimulated growth was measured as described in Example 27. In both types of experiments, growth was measured as % survival with respect to control treatment.

[0561] FIG. 44 and Table 46 show the effect of exemplary anti-HER2 ECD2.times.ECD4 biparatopic antibodies on growth of HER2 3+ breast cancer cells (BT-474) in the presence of exogenous growth-stimulatory ligands (EGF and HRG). In the absence of EGF or HRG, the anti-HER2 biparatopic antibodies were able to inhibit growth of BT-474 cells, where % survival of each treatment group ranked as follows: v6903<v506+v4184<506<v7091<v5019<v10000<v6717. In the presence of HRG, growth inhibition relative to the mock control was achieved only with the FSA combination of v506+v4184. In the presence of EGF, growth inhibition relative to the mock control was achieved, where % survival of each treatment group ranked as follows: v6903<v506+v4184<7091<v10000<5019.

TABLE-US-00056 TABLE 46 % Survival Antibody Treatment only +HRG +EGF Mock 100 143 131 v6717 113 126 129 v10000 70 118 78 v5019 67 133 81 v7091 61 119 61 v506 53 141 118 v506 + v4184 43 89 45 v6903 32 120 39

[0562] FIG. 45 shows the dose-dependent effect of the anti-HER2 biparatopic antibody formats on growth inhibition of the SKBr3 HER2 3+ cell line. The data is consistent with the results presented in FIG. 44, where the rank order potency/efficacy of the biparatopic formats is as follows Fab-Fab>Fab-scFv>scFv-scFv in HER2 3+ tumor cells.

[0563] The effect of anti-HER2 biparatopic antibody formats on survival of HER2+ cells is shown in FIG. 46, where FIG. 46A shows the result in the Trastuzumab sensitive SKOV3 HER2 2+/3+ cell line at 300 nM; FIG. 46B shows the result in JIMT-1 HER2 2+(Trastuzumab resistant) cells at 300 nM, and FIG. 46C shows the result in MCF7 HER2 1+ cell line at 300 nM. In the SKOV3 cell line, little difference was observed among the biparatopic formats in the extent of growth inhibition, and no growth inhibition was observed by any of the test antibodies in JIMT-1 and MCF7 cells.

[0564] The data in FIG. 44 and FIG. 45 show that anti-HER2 ECD2.times.ECD4 biparatopic antibodies with the Fab-scFv and Fab-Fab formats (v5019, v7091, v10000, v6903) are capable of growth inhibition HER2 3+ tumor cells in the absence, and presence of EGF or HRG. In the HER2 3+ cell lines BT-474 and SKBR3, growth inhibition relative to the mock control rank ordered as follows, where v506+v4184>v6903>v7091>v10000>v5019>v506>v6717. The distance between antigen-binding domains (Fab-Fab>Fab-scFv>scFv-scFv) correlates with the rank order of growth inhibition in the HER2 3+ tumor cells. Based on the data in trastuzumab-sensitive tumor cells, BT-474, and SKBr3, it may be expected that the growth inhibition difference among formats is significant at the HER2 3+ level but less so at the HER2 2+ or HER2 1+ levels.

Example 43: Evaluation of HER2 Binding Affinity and Kinetic at Varying Antibody Capture Levels

[0565] The following experiment was conducted to compare HER2 binding kinetics (kd, off-rate) of exemplary anti-HER2 ECD2.times.ECD4 biparatopic antibodies when captured at varying surface densities by SPR. The correlation between a reduced (slower) off-rate with increasing antibody capture levels (surface density) is an indication of Trans binding (i.e. one antibody molecule binding to two HER2 molecules, described in Example 12). In this experiment the Fab-Fab format (v6903) was compared to the Fab-scFv format (v7091) to determine potential difference in Trans binding among the variants. Due to the larger spatial distance between antigen-binding domains, it is hypothesized that the Fab-Fab format may be capable of Cis binding (engaging ECD 2 and 4 on one HER2 molecule); whereas, the Fab-scFv would not capable of Cis binding due to the shorter distance between the it's antigen-binding domains. The anti-HER2 monospecific v506 was included as a control.

[0566] The experiment was conducted by SPR as described in Example 12. The data are shown in FIG. 47. FIG. 47A shows the plot and linear regression analysis for the kd (1/s) at different antibody capture levels with v6903 and v7091. Both v7091 and v6093 show a trend for decreasing off-rate with increasing surface capture levels; however, the correlation is significant with the Fab-scFv variant (v7091; P value=0.023) but not the Fab-Fab format (v6093; P value=0.053). The off-rate remained unchanged with varying antibody capture levels for the anti-HER2 monospecific control, v506.

[0567] FIG. 47B shows the plot and linear regression analysis for the K.sub.D (M) at different antibody capture levels with v6903 and v7091. Similar to the off-rate comparison, both v7091 and v6093 show a trend for increasing affinity (lower K.sub.D value) with increasing surface capture levels. However, the correlation is significant with the Fab-scFv variant (v7091; P value=0.04) but not the Fab-Fab format (v6093; P value=0.51). The K.sub.D remained unchanged with varying antibody capture levels for the anti-HER2 monospecific control, v506. The data in FIG. 47 shows that the Fab-Fab and Fab-scFv anti-HER2 biparatopic antibody formats show trends of decreasing off-rates with increasing antibody surface capture levels; these trends are unique compared to a monospecific anti-Her2 antibody.

Example 44: Affinity and Stability Engineering of the Pertuzumab Fab

[0568] As indicated in Table 1, one variant (v10000) contains mutations in the Pertuzumab Fab. This Fab was derived from affinity and stability engineering in silico efforts, which were measured experimentally as monovalent or One-Armed Antibodies (OAAs).

[0569] Variant 9996: a monovalent anti-HER2 antibody, where the HER2 binding domain is a Fab derived from pertuzumab on chain A, with Y96A in VL region and T30A/A49G/L69F in VH region (Kabat numbering) and the Fc region is a heterodimer having the mutations T350V_L351Y_F405A_Y407V (EU numbering) in Chain A, T350V_T366L_K392L_T394W (EU numbering) in Chain B, and the hinge region of Chain B having the mutation C226S; the antigen-binding domain binds to domain 4 of HER2.

[0570] Variant 10014: a monovalent anti-HER2 antibody, where the HER2 binding domain is a Fab derived from pertuzumab on chain A, with Y96A in VL region and T30A in VH region (Kabat numbering) and the Fc region is a heterodimer having the mutations T350V_L351Y_F405A_Y407V (EU numbering) in Chain A, T350V_T366L_K392L_T394W (EU numbering) in Chain B, and the hinge region of Chain B having the mutation C226S; the antigen-binding domain binds to domain 4 of HER2.

[0571] Variant 10013: a monovalent anti-HER2 antibody, where the HER2 binding domain is a Fab derived from wild type pertuzumab on chain A, and the Fc region is a heterodimer having the mutations T350V_L35 1Y_F405A_Y407V (EU numbering) in Chain A, T350V_T366L_K392L_T394W (EU numbering) in Chain B, and the hinge region of Chain B having the mutation C226S; the antigen-binding domain binds to domain 4 of HER2.

[0572] The following experiments were conducted to compare HER2 binding affinity and stability of the engineered Pertuzumab variants.

[0573] OAA variants were cloned and expressed as described in Example 1.

[0574] OAA were purified by protein A chromatography and Size Exclusion Chromatography, as described in Example 1.

[0575] Heterodimer purity (i.e. amount of OAA with a heterodimeric Fc) was assessed by non-reducing High Throughput Protein Express assay using Caliper LabChip GXII (Perkin Elmer #760499). Procedures were carried out according to HT Protein Express LabChip User Guide version2 LabChip GXII User Manual, with the following modifications. Heterodimer samples, at either 2 .mu.l or 5 .mu.l (concentration range 5-2000 ng/.mu.1), were added to separate wells in 96 well plates (BioRad # HSP9601) along with 7 .mu.l of HT Protein Express Sample Buffer (Perkin Elmer #760328). The heterodimer samples were then denatured at 70.degree. C. for 15 mins. The LabChip instrument is operated using the HT Protein Express Chip (Perkin Elmer #760499) and the Ab-200 assay setting. After use, the chip was cleaned with MilliQ water and stored at 4.degree. C.

[0576] The stability of the samples was assessed by measuring melting temperature or Tm, as determined by DSC with the protocol shown in example 24. The DSC was measured before and after SEC purification.

[0577] The affinity towards HER2 ECD of the samples was measured by SPR following the protocol from example 12. The SPR was measured before and after SEC purification. As summarized in Table 47A and 47B, the mutations in the variable domain have increased the HER2 affinity of the Fab compared to wild type pertuzumab, while maintaining WT stability. (.sup.1 Purity determined by Caliper LabChip; .sup.2 KD(WT)/KD(mut)

TABLE-US-00057 TABLE 47A SPR pre-SEC Het SPR post-SEC Pr-A KD Fold purity KD Fold OAA Fab HC Yield KD AVE STDEV wrt post- KD AVE STDEV wrt variant mutations LC mut (mg/L) (nM) (nM) n WT.sup.2 SEC.sup.1 (nM) (nM) n WT v9996 T30A/A49G/ Y96A 22 1.7E-09 1.7E-10 5 9.6 93% 1.8E-09 1.6E-11 2 8.4 L69F v10014 T30A Y96A 20 2.0E-09 3.1E-10 4 8.1 81% 2.1E-09 5.2E-10 3 7.0 v10013 WT WT 18 1.6E-08 5.1E-09 16 1.0 91% 1.5E-08 3.5E-09 4 1.0

TABLE-US-00058 TABLE 47B DSC DSC pre-SEC post-SEC .DELTA.Tm .DELTA.Tm wrt wrt OAA Tm WT Tm WT variant (C.) (C.) (C.) (C.) v9996 77.2 -0.2 77.2 -0.7 v10014 75.5 -1.9 75.5 -2.4 v10013 77.4 0.0 77.9 0.0

Example 45: Effect of v10000 on Survival and Tumor Growth in a Xenograft Model of HER2-Low, Non-Small Cell Lung Cancer (NSCLC)

[0578] This experiment was performed to assess efficacy of v10000 compared to control IgG (v6908) in an A549 xenograft model of lung cancer. A549 cells are derived from non-squamous non-small cell lung cancer that is HER2-low, non-HER2 gene amplified, HER3+, EGFR-low and moderately sensitive to Cisplatin at the MTD (maximum tolerated dose). The study was carried out as described below.

[0579] Tumor cell suspensions were implanted subcutaneously into athymic nude mice. When tumors reached 158 mm.sup.3 the animals were randomly assigned to groups as shown in Table A1, and treatment began in a blinded and controlled study. Animals were treated according to Regimen 1 on Day 1, followed by treatment according to Regimen 2 on subsequent days as indicated in Table A1.

TABLE-US-00059 TABLE A1 Study Design Regimen 1 Regimen 2 Group Dosage Dosage (n) Agent (mg/kg) Route Schedule Agent (mg/kg) Route Schedule 1 (20) v6908 15 iv Day 1 v6908 10 iv Days 4, 8, 11, 15, 18, 22 and 25 2 (20) v10000 15 iv Day 1 v10000 10 iv Days 4, 8, 11, 15, 18, 22 and 25

[0580] Tumor volume was measured by calipers twice weekly. The study duration was 66 days with survival as the primary endpoint. Additional tumor response criteria were measured and are shown in Table A2. Mice were euthanized when tumor volume exceeded 800 mm.sup.3, the surviving percentage versus study day was plotted on a Kaplan-Meier and was statistically assessed using a log-rank test. Serum concentration of v10000 was determined by HER2 ELISA on study day 7.

[0581] The results are shown in FIG. 48A (tumor volume) and FIG. 48B (Kaplan-Meier survival). Variant 10000 reduced tumor growth compared to v6908 treated controls and significantly prolonged survival by log-rank test (FIG. 48B and Table A3). Animals treated with v10000 had a median survival of greater than 66 days while those treated with v6908 had a median survival of 25.78 days (FIG. 48B and Table A2). Tumor volume on study day 30 was 461 mm3 and 810 mm3 for v10000 and v6908 treated groups respectively (FIG. 48A and Table A2). Serum exposure was 140.9 microg/mL on study day 7, indicating that the anticipated serum concentration was achieved.

[0582] These results show that treatment with v10000 was able to reduce tumor growth and prolong survival compared to treatment with a control hIgG in this HER2-low non-gene amplified NSCLC model.

TABLE-US-00060 TABLE A2 A549 Tumor Response Profile 6908 10000 Tumor Response on Day 30 Mean TV (mm.sup.3) (% .DELTA. from base line) 810 (413%) 461 (191%) Treatment/Control Ratio 1.00 0.57 RECIST Scores CR (TV <20 mm.sup.3) 0/20 0/20 PR (>30% baseline regression) 0/20 1/20 PD (>20% baseline growth) 20/20 19/20 SD (neither PD or PR) 0/20 0/20 Median Time to Progression (days) 3.30 2.31 Survival Response Median Survival (days) 25.78 >66 CR--Complete Response PR--Partial Response PD--Progressive Disease SD--Stable Disease

TABLE-US-00061 TABLE A3 Log Rank Summary Group 6908 6908 -- 10000 .star-solid..star-solid..star-solid. Legend: ns = not significant, .star-solid. = P < 0.05. .star-solid..star-solid. = P < 0.01, .star-solid..star-solid..star-solid. = P < 0.001

Example 46: Effect of v10000 on Survival and Tumor Growth in a Xenograft Model of HER2-Low, Head and Neck Squamous Cell Carcinoma

[0583] This experiment was performed to assess efficacy of v10000 compared to Herceptin.TM. (v6336) and control human IgG (v6908) in the FaDu xenograft model of head and neck cancer. FaDu cells are derived from squamous cell cancer of the head and neck that is HER2 low, non-HER2 gene amplified, HER3+, EGFR+ and highly sensitive to Cisplatin at the MTD. The study was carried out as described below.

[0584] Tumor cell suspensions were implanted subcutaneously into athymic nude mice. When tumors reached 121 mm.sup.3 the animals were randomly assigned to groups as shown in Table A4, and treatment began in a blinded and controlled study. Cisplatin was purchased and provided for the study by Charles River Laboratories (Morrisville, N.C.). Animals were treated according to Regimen 1 at Day 1, followed by Regimen 2 on subsequent days as noted in Table A4.

TABLE-US-00062 TABLE A4 Study Design Regimen 1 Regimen 2 Group Dosage Dosage (n) Agent (mg/kg) Route Schedule Agent (mg/kg) Route Schedule 1 (15) v6908 15 iv Day 1 v6908 10 iv Days 4, 8, 11, 15, 18, 22 and 25 2 (15) v6336 15 iv Day 1 v6336 10 iv Days 4, 8, 11, 15, 18, 22 and 25 3 (15) v10000 15 iv Day 1 v10000 10 iv Days 4, 8, 11, 15, 18, 22 and 25 4 (15) Cisplatin 2 ip Day 1, 3, 5, 7, 9, 11 5 (15) v10000 15 iv Day 1 v10000 10 iv Days 4, 8, 11, 15, 18, 22 and 25 Cisplatin 2 ip Day 1, 3, 5, 7, 9, 11

[0585] Tumor volume was measured by calipers twice weekly. The study duration was 59 days with survival as the primary endpoint. Additional tumor response criteria were measured and are shown in Table A5. Mice were euthanized when tumor volume exceeded 2000 mm.sup.3, the surviving percentage versus study day was plotted on a Kaplan-Meier and was statistically assessed using a log-rank test. Serum concentration of v10000 and v6336 was determined by HER2 ELISA on study day 7.

[0586] The results are shown in FIG. 49A (tumor volume) and FIG. 49B (Kaplan-Meier survival). Variant 10000 reduced tumor growth compared to v6908 treated controls and v6336, as well as significantly prolonged survival by log-rank test compared to v6908 (FIG. 48B and Table A3). Animals treated with v10000 had a median survival of greater than 46 days while those treated with v6908 and v6336 had median survivals of 25 and 40 days, respectively (FIG. 49B and Table A5). Tumor volume on study day 25 was 1025, 1979, 1257 mm.sup.3 for v10000, v6908 and v6336 treated groups respectively (FIG. 49A and Table A5). Serum exposure was 116.6 microg/mL for v10000, 119.9 microg/mL for v6336, and 107.2 microg/mL for v10000+Cisplatin on study day 7, indicating that the anticipated serum concentration was achieved for each test article.

[0587] These results show that treatment with v10000 as a monotherapy was able to decrease tumor volume and prolong survival, compared to treatment with control IgG in this model of HER2-low non-gene amplified head and neck cancer. Overall, v10000 showed a trend towards decreasing tumor volume compared to v6336 (Herceptin.TM.).

[0588] Variant 10000 was also tested in combination with cisplatin. The combination of v10000 and cisplatin significantly prolonged survival compared to v6908, v6336, and single agent cisplatin (Table A5). The median survival of the v10000 and cisplatin combination was 53 days while the median survival of v6908, v6336, and single agent cisplatin was 25, 40, and 40 days, respectively.

[0589] These results demonstrate that treatment with v10000 in combination with cisplatin was able to decrease tumor growth and prolong survival compared to v6908 and v6336, in this model of head and neck cancer.

TABLE-US-00063 TABLE A5 FaDu Tumor Response Profile 6908 6336 10000 cisplatin 10000 + cisplatin Tumor Response on Day 25 Mean TV (mm.sup.3) (% .DELTA. from base 1979 1257 1025 1070 816 line) (1532%) (929%) (782%) (782%) (573%) Treatment/Control Ratio 1.00 0.63 0.52 0.54 0.41 RECIST Scores CR (TV <20 mm.sup.3) 0/15 0/14 0/15 0/15 0/15 PR (>30% baseline regression) 0/15 0/14 0/15 0/15 0/15 PD (>20% baseline growth) 15/15 14/14 15/15 15/15 15/15 SD (neither PD or PR) 0/15 0/15 0/15 0/15 0/15 Median Time to Progression 5.9 7.6 7.8 8.4 10.8 (days) Survival Response Median Survival (days) 25 40 46 40 53 CR--Complete Response PR--Partial Response PD--Progressive Disease SD--Stable Disease

TABLE-US-00064 TABLE A6 Log Rank Summary Group 6908 6336 10000 Cisplatin 6908 -- -- -- -- 6336 .star-solid..star-solid. -- -- -- 10000 .star-solid..star-solid..star-solid. n/s -- -- Cisplatin .star-solid..star-solid..star-solid. n/s .star-solid. -- 10000 + Cisplatin .star-solid..star-solid..star-solid. .star-solid. n/s .star-solid..star-solid..star-solid. Legend: ns = not significant, .star-solid. = P < 0.05. .star-solid..star-solid. = P < 0.01, .star-solid..star-solid..star-solid. = P < 0.001

Example 47: Effect of v10000 on Survival and Tumor Growth Inhibition in a Xenograft Model of HER2 1+, ER+ Breast Cancer

[0590] This experiment was performed to assess efficacy of v10000 compared to a control IgG (v6908) or Herceptin.TM. (v6336) in the ST1337B xenograft model of breast cancer. ST1337B is a patient derived xenograft (PDX) established in nude mice from an ER+/PR- breast cancer with a luminal B molecular classification. ST1337 is HER2 1+ as measured by IHC. The study was carried out as described below.

[0591] Tumor fragments were implanted subcutaneously into athymic nude mice. When tumors reached 180 mm.sup.3 the animals were randomly assigned to groups as shown in Table A7 and treatment began in a blinded and controlled study. Animals were treated according to Regimen 1 as shown in Table A7

TABLE-US-00065 TABLE A7 Study Design Regimen 1 Group Dosage (n) Agent (mg/kg) Route Schedule 1 (15) v6908 30 iv Days 1,4, 8, 11, 15, 18, 22, 25, 28, and 32 2 (15) V6336 10 iv Days 1, 4, 8, 11, 15, 18, 22, 25, 28, and 32 3 (15) v10000 3 iv Days 1, 4, 8, 11, 15, 18, 22, 25, 28, and 32 4 (15) v10000 10 iv Days 1, 4, 8, 11, 15, 18, 22, 25, 28, and 32 5 (15) v10000 30 iv Days 1, 4, 8, 11, 15, 18, 22, 25, 28, and 32

[0592] Tumor volume was measured by calipers twice weekly. The study duration was 63 days with survival as the primary endpoint. Additional tumor response criteria were measured and are shown in Table A8. Mice were euthanized when tumor volume exceeded 2000 mm.sup.3, the surviving percentage versus study day was plotted on a Kaplan-Meier and was statistically assessed using a log-rank test. Serum concentration of v10000 and v6336 was determined by HER2 ELISA on study day 7 and on day 36, 4 days following the last dose on day 32.

[0593] The results are shown in FIG. 50A (tumor volume) and FIG. 50B (Kaplan-Meier survival). Treatment with variant 10000 at all doses tested reduced tumor growth compared to treatment with v6908 and significantly prolonged survival by log-rank test compared to v6908 (FIG. 50B and Table A9). In addition, treatment with v10000 at 30 mg/kg significantly prolonged survival compared to treatment with v6336 at 10 mg/kg (FIG. 50B and Table A8). Animals treated with v10000 had median survivals of 49, 59, and 59 days for the 3, 10 and 30 mg/kg doses respectively (FIG. 50B and Table A8). Tumor volume on study day 29 for treatment with v10000 at 3, 10 and 30 mg/kg was 1010, 1016, and 931 mm3, respectively. Tumor volumes for v6908 and v6336 on study day 29 was 1898 and 1264 mm3 respectively (FIG. 50A and Table A8). The serum exposure of v6336 and v10000 is shown in Table A10. These results confirm that increasing the dosage of v10000 results in an increase in serum concentration of v10000, and that similar doses of v10000 and v6336 result in similar serum concentrations of antibody.

[0594] These results indicate that treatment with v10000 is able to decrease tumor volume and prolong survival in this model of HER2-low ER+ breast cancer, when compared to the IgG control and to Herceptin.TM..

TABLE-US-00066 TABLE A8 ST1337b Tumor Response Profile 6908, 6336, 10000, 10000, 30 mg/kg 10 mg/kg 3 mg/kg 10 mg/kg 10000, 30 mg/kg Tumor Response on Day 29 Mean TV (mm.sup.3) (% .DELTA. from base 1898 1264 1010 1016 931 line) (953%) (601%) (460%) (457%) (411%) Treatment/Control Ratio 1.00 0.66 0.53 0.53 0.49 RECIST Scores CR (TV <20 mm.sup.3) 0/15 0/15 0/15 0/15 0/15 PR (>30% baseline regression) 0/15 0/15 0/15 0/15 0/15 PD (>20% baseline growth) 15/15 15/15 15/15 15/15 15/15 SD (neither PD or PR) 0/15 0/15 0/15 0/15 0/15 Median Time to Progression 11 10 14 26 13 (days) Survival Response Median Survival (days) 29 43 49 59 59 CR--Complete Response PR--Partial Response PD--Progressive Disease SD--Stable Disease

TABLE-US-00067 TABLE A9 Log Rank Summary 6908, 6336, 10000, 10000, 10000, Group 30 mg/kg 10 mg/kg 3 mg/kg 10 mg/kg 30 mg/kg 6908, -- -- -- -- 30 mg/kg 6336, .star-solid..star-solid. -- -- -- -- 10 mg/kg 10000, .star-solid..star-solid. n/s -- -- -- 3 mg/kg 10000, .star-solid..star-solid..star-solid. n/s n/s -- -- 10 mg/kg 10000, .star-solid..star-solid..star-solid. .star-solid. n/s n/s -- 30 mg/kg Legend: ns = not significant, .star-solid. = P < 0.05. .star-solid..star-solid. = P < 0.01, .star-solid..star-solid..star-solid. = P < 0.001

TABLE-US-00068 TABLE A10 Serum Exposure Summary 10000, 10000, Sample Day 6336, 10 mg/kg 10000, 3 mg/kg 10 mg/kg 30 mg/kg 7 133.0 30.7 101.7 286.6 36 135.2 46.0 186.3 279.7

Example 48: Effect of v10000 on Survival and Tumor Growth Inhibition in a Xenograft Model of HER2 Negative Pancreatic Cancer

[0595] This experiment was performed to assess efficacy of v10000 compared to a control IgG (v12470), Herceptin.TM. (v6336), and nab-paclitaxel as single agents and v10000 in combination with nab-paclitaxel (Abraxane.TM. Celgene) in the ST803 xenograft model of pancreatic cancer. ST803 is a patient-derived xenograft (PDX) of pancreatic cancer (South Texas Accelerated Research Therapeutics, San Antonio, Tex. 78229) that is HER2 negative as measured by IHC. The study was carried out as described below.

[0596] Tumor fragments were implanted subcutaneously into athymic nude mice. When tumors reached 170 mm.sup.3 the animals were randomly assigned to groups as shown in Table All and treatment began in a blinded and controlled study. Animals were treated according to Regimen 1 and 2 as shown in Table A11. All treatments were administered intravenously.

TABLE-US-00069 TABLE A11 Study Design Regimen 1 Regimen 2 Group Dosage Dosage Sched- (n) Agent (mg/kg) Schedule Agent (mg/kg) ule 1 (20) v12470 30 Twice weekly for four weeks 2 (20) V6336 30 Twice weekly for four weeks 3 (20) v10000 30 Twice weekly for four weeks 4 (20) v12470 30 Twice weekly nab- 30 Days 2, for four weeks paclitaxel 9, 16 5 (20) v10000 30 Twice weekly nab- 30 Days 2, for four weeks paclitaxel 9, 16

[0597] Tumor volume was measured by calipers twice weekly. The study duration was 71 days with survival as the primary endpoint. Additional tumor response criteria were measured and are shown in Table A12. Mice were euthanized when tumor volume exceeded 2000 mm.sup.3; the surviving percentage versus study day was plotted on a Kaplan-Meier and was statistically assessed using a log-rank test. Serum concentration in groups dosed with v10000 and v6336 was determined by HER2 ELISA on study day 7.

[0598] The results are shown in FIG. 51A (tumor volume) and FIG. 51B (Kaplan-Meier survival). Only treatment with variant 10000 in combination with nab-paclitaxel reduced tumor growth and significantly prolonged survival by log-rank test compared to treatment with control IgG (v12470) (FIG. 51B and Table A13). In addition, treatment with v10000 in combination with nab-paclitaxel significantly prolonged survival compared to treatment with nab-paclitaxel plus control IgG (FIG. 51B and Table A13). The median survival of v10000 in combination with nab-paclitaxel was greater than 71 days while the median survival of v12470, v6336, v10000, and nab-paclitaxel as single agents was 58.8, 65.9, 69.3, and 60.6 days respectively. Mean tumor volume on study day 54 for treatment with v10000 in combination with nab-paclitaxel was 1073 mm3. Tumor volumes for v12470, v6336, v10000, and nab-paclitaxel as single agents on study day 54 was 1663, 1494, 1305, and 1365 mm3 respectively (FIG. 51A and Table A12). The serum exposure of v6336 and v10000 from day 14 serum samples is shown in Table A14.

[0599] These results indicate that treatment with v10000 in combination with nab-paclitaxel is able to decrease tumor volume and prolong survival in this model of HER2 negative pancreatic cancer, when compared to the IgG control, Herceptin.TM., and single agent v10000.

TABLE-US-00070 TABLE A12 ST803 Tumor Response Profile 12470 + nab- 12470 + nab- 12470 6336 10000 pac* pac* Tumor Response on Day 54 Mean TV (mm.sup.3) (% .DELTA. from base 1663 1494 1305 1365 1073 line) (+888%) (+806%) (+659%) (+693%) (+522%) Treatment/Control Ratio 1.00 0.90 0.78 0.82 0.64 RECIST Scores CR (TV <20 mm.sup.3) 0/18 0/17 0/20 0/16 0/19 PR (>30% baseline regression) 0/18 0/17 0/20 0/16 0/19 PD (>20% baseline growth) 18/18 17/17 20/20 16/16 19/19 SD (neither PD or PR) 0/18 0/17 0/20 0/16 0/19 Median Time to Progression 4.4 3.6 3.6 4.4 5.6 (days) Survival Response Median Survival (days) 58.8 65.9 69.3 60.6 >71 CR--Complete Response PR--Partial Response PD--Progressive Disease SD--Stable Disease *nab-paclitaxel

TABLE-US-00071 TABLE A13 Log Rank Summary 12470 + nab- 10000 + nab- Group 12470 6336 10000 pac* pac* 12470 -- -- -- -- 6336 ns -- -- -- -- 10000 ns ns -- -- -- 12470 + nab- ns -- Ns -- -- pac 10000, + nab- .star-solid..star-solid. -- Ns .star-solid..star-solid. -- pac Legend: ns = not significant, .star-solid. = P < 0.05. .star-solid..star-solid. = P < 0.01, .star-solid..star-solid..star-solid. = P < 0.001 *nab-paclitaxel

TABLE-US-00072 TABLE A14 Serum Exposure Summary 10000 (microg/mL) + 6336 10000 nab- Sample Day (microg/mL) (microg/mL) paclitaxel 14 426.7 279 391

Example 49: Effect of v10000 on Tumor Growth Inhibition in a Xenograft Model of HER2 3+ Gastric Cancer

[0600] This experiment was performed to assess efficacy of v10000 compared to a control IgG (v12470) and Herceptin.TM. (v6336) as single agents in the GXA3054 xenograft model of gastric cancer. GXA3054 is a patient derived xenograft (PDX) of gastric cancer that is HER2 3+ (Oncotest GmbH, Am Flughafen 12-14, 79108 Freiburg, Germany). The study was carried out as described below.

[0601] Tumor fragments were implanted subcutaneously into athymic nude mice. When tumors reached 144 mm.sup.3 the animals were randomly assigned to groups as shown in Table A15 and treatment began in a blinded and controlled study. Animals were treated according to Regimen 1 as shown in Table A15.

TABLE-US-00073 TABLE A15 Study Design Regimen 1 Dosage Group (n) Agent (mg/kg) Route Schedule 1 (10) v12470 30 IV Twice weekly for five weeks 2 (10) V6336 30 IV Twice weekly for five weeks 3 (10) v10000 30 IV Twice weekly for five weeks

[0602] Tumor volume was measured by calipers twice weekly. The study duration was 59 days with tumor growth inhibition as the primary endpoint. Additional tumor response criteria were measured and are shown in Table A16. Mice were euthanized when tumor volume exceeded 2000 mm.sup.3.

[0603] The results are shown in FIG. 52 (tumor volume). Treatment with variant 10000 and v6336 reduced tumor growth compared to treatment with control IgG (v12470) (FIG. 52 and Table A16). In addition, treatment with v10000 reduced tumor growth compared to treatment with v6336 (FIG. 52 and Table A16). Mean tumor volume on study day 35 for treatment with control IgG, v10000 and v6336 was 1340, 236, and 7.8 mm3, respectively. Tumor growth inhibition on day 35 for v10000 and v6336 was 111 and 92%, respectively (Table A16). On day 35 tumors treated with v10000 showed greater responses (7/10 complete and 3/10 partial responses) compared to tumors treated with v6336 (0/10 complete and 1/10 partial response) (Table A16). At the completion of the study, on day 59, 9/10 tumors treated with v10000 had complete responses with no evidence of recurrent tumor, while for v6336 treated tumors only 1/10 tumors had a complete response.

[0604] These results indicate that treatment with v10000 can regress tumors in this model of HER2 3+ gastric cancer. The tumor growth inhibition of v10000 was superior to IgG control and Herceptin.TM..

TABLE-US-00074 TABLE A16 GXA3054 Tumor Response Profile 12470 6336 10000 Tumor Response on Day 35 Na 92 111 Tumor Growth Inhibition (%) RECIST Scores CR (.ltoreq.-95%) 0/10 0/10 7/10 PR (>-95% and <-66%) 0/10 1/10 3/10 SD (.gtoreq.-66% and .ltoreq.+73%) 0/10 5/10 0/10 PD (>+73%) 10/10 4/10 0/10 CR--Complete Response PR--Partial Response PD--Progressive Disease SD--Stable Disease

[0605] The reagents employed in the examples are generally commercially available or can be prepared using commercially available instrumentation, methods, or reagents known in the art. The foregoing examples illustrate various aspects described herein and practice of the methods described herein. The examples are not intended to provide an exhaustive description of the many different embodiments of the invention. Thus, although the forgoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, those of ordinary skill in the art will realize readily that many changes and modifications can be made thereto without departing from the spirit or scope of the appended claims.

[0606] All publications, patents and patent applications mentioned in this specification are herein incorporated by reference into the specification to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated herein by reference.

TABLE-US-00075 SEQUENCE TABLE Variant Ht clone name H2 clone name L1 clone name L2 clone name 792 1011 1015 -2 -2 5019 3057 720 1811 NA 5020 719 3041 NA 1811 7091 3057 5244 1811 NA 10000 6586 5244 3382 NA 6903 5065 3468 5037 3904 6902 5065 3468 5034 3904 6717 3317 720 NA NA 1040 4560 4553 NA 4561 630 719 716 NA NA 4182 4560 3057 NA 1811 506 642 642 -2 -2 4184 3057 3041 1811 1811 9996 4372 6586 NA 3382 SEQ ID NO. Clone Desc. Sequence (amino acid or 1 642 Full EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADS- VKGRFTISADT SKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAAL- GCL VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVE- PKS CDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK- PRE EQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVS- LTC LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQ- KSL SLSPGK 2 642 Full GAGGTGCAGCTGGTGGAAAGCGGAGGAGGACTGGTGCAGCCAGGAGGATCTCTGCGACTGAGT- TGCGCCGCTTC AGGATTCAACATCAAGGACACCTACATTCACTGGGTGCGACAGGCTCCAGGAAAAGGACTGGAGTGGGTGG- CTC GAATCTATCCCACTAATGGATACACCCGGTATGCCGACTCCGTGAAGGGGAGGTTTACTATTAGCGCCGAT- ACA TCCAAAAACACTGCTTACCTGCAGATGAACAGCCTGCGAGCCGAAGATACCGCTGTGTACTATTGCAGTCG- ATG GGGAGGAGACGGATTCTACGCTATGGATTATTGGGGACAGGGGACCCTGGTGACAGTGAGCTCCGCCTCTA- CCA AGGGCCCCAGTGTGTTTCCCCTGGCTCCTTCTAGTAAATCCACCTCTGGAGGGACAGCCGCTCTGGGATGT- CTG GTGAAGGACTATTTCCCCGAGCCTGTGACCGTGAGTTGGAACTCAGGCGCCCTGACAAGCGGAGTGCACAC- TTT TCCTGCTGTGCTGCAGTCAAGCGGGCTGTACTCCCTGTCCTCTGTGGTGACAGTGCCAAGTTCAAGCCTGG- GCA CACAGACTTATATCTGCAACGTGAATCATAAGCCCTCAAATACAAAAGTGGACAAGAAAGTGGAGCCCAAG- AGC TGTGATAAGACCCACACCTGCCCTCCCTGTCCAGCTCCAGAACTGCTGGGAGGACCTAGCGTGTTCCTGTT- TCC CCCTAAGCCAAAAGACACTCTGATGATTTCCAGGACTCCCGAGGTGACCTGCGTGGTGGTGGACGTGTCTC- ACG AGGACCCCGAAGTGAAGTTCAACTGGTACGTGGATGGCGTGGAAGTGCATAATGCTAAGACAAAACCAAGA- GAG GAACAGTACAACTCCACTTATCGCGTCGTGAGCGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGGAA- GGA GTATAAGTGCAAAGTCAGTAATAAGGCCCTGCCTGCTCCAATCGAAAAAACCATCTCTAAGGCCAAAGGCC- AGC CAAGGGAGCCCCAGGTGTACACACTGCCACCCAGCAGAGACGAACTGACCAAGAACCAGGTGTCCCTGACA- TGT CTGGTGAAAGGCTTCTATCCTAGTGATATTGCTGTGGAGTGGGAATCAAATGGACAGCCAGAGAACAATTA- CAA GACCACACCTCCAGTGCTGGACAGCGATGGCAGCTTCTTCCTGTATTCCAAGCTGACAGTGGATAAATCTC- GAT GGCAGCAGGGGAACGTGTTTAGTTGTTCAGTGATGCATGAAGCCCTGCACAATCATTACACTCAGAAGAGC- CTG TCCCTGTCTCCCGGCAAA 3 642 VH EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVK- GRFTISADT SKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS 4 642 VH GAGGTGCAGCTGGTGGAAAGCGGAGGAGGACTGGTGCAGCCAGGAGGATCTCTGCGACTGAGTTG- CGCCGCTTC AGGATTCAACATCAAGGACACCTACATTCACTGGGTGCGACAGGCTCCAGGAAAAGGACTGGAGTGGGTGG- CTC GAATCTATCCCACTAATGGATACACCCGGTATGCCGACTCCGTGAAGGGGAGGTTTACTATTAGCGCCGAT- ACA TCCAAAAACACTGCTTACCTGCAGATGAACAGCCTGCGAGCCGAAGATACCGCTGTGTACTATTGCAGTCG- ATG GGGAGGAGACGGATTCTACGCTATGGATTATTGGGGACAGGGGACCCTGGTGACAGTGAGCTCC 5 642 H1 GFNIKDTY 6 642 H1 GGATTCAACATCAAGGACACCTAC 7 642 H3 SRWGGDGFYAMDY 8 642 H3 AGTCGATGGGGAGGAGACGGATTCTACGCTATGGATTAT 9 642 H2 IYPTNGYT 10 642 H2 ATCTATCCCACTAATGGATACACC 11 642 CH1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLY- SLSSVVTVPSS SLGTQTYICNVNHKPSNTKVDKKV 12 642 CH1 GCCTCTACCAAGGGCCCCAGTGTGTTTCCCCTGGCTCCTTCTAGTAAATCCACCTCTGGAGGG- ACAGCCGCTCT GGGATGTCTGGTGAAGGACTATTTCCCCGAGCCTGTGACCGTGAGTTGGAACTCAGGCGCCCTGACAAGCG- GAG TGCACACTTTTCCTGCTGTGCTGCAGTCAAGCGGGCTGTACTCCCTGTCCTCTGTGGTGACAGTGCCAAGT- TCA AGCCTGGGCACACAGACTTATATCTGCAACGTGAATCATAAGCCCTCAAATACAAAAGTGGACAAGAAAGT- G 13 642 CH2 APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE- EQYNSTYRVVS VLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 14 642 CH2 GCTCCAGAACTGCTGGGAGGACCTAGCGTGTTCCTGTTTCCCCCTAAGCCAAAAGACACTCTG- ATGATTTCCAG GACTCCCGAGGTGACCTGCGTGGTGGTGGACGTGTCTCACGAGGACCCCGAAGTGAAGTTCAACTGGTACG- TGG ATGGCGTGGAAGTGCATAATGCTAAGACAAAACCAAGAGAGGAACAGTACAACTCCACTTATCGCGTCGTG- AGC GTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGGAAGGAGTATAAGTGCAAAGTCAGTAATAAGGCCCT- GCC TGCTCCAATCGAAAAAACCATCTCTAAGGCCAAA 15 642 CH3 GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGS- FFLYSKLTVDK SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG 16 642 CH3 GGCCAGCCAAGGGAGCCCCAGGTGTACACACTGCCACCCAGCAGAGACGAACTGACCAAGAAC- CAGGTGTCCCT GACATGTCTGGTGAAAGGCTTCTATCCTAGTGATATTGCTGTGGAGTGGGAATCAAATGGACAGCCAGAGA- ACA ATTACAAGACCACACCTCCAGTGCTGGACAGCGATGGCAGCTTCTTCCTGTATTCCAAGCTGACAGTGGAT- AAA TCTCGATGGCAGCAGGGGAACGTGTTTAGTTGTTCAGTGATGCATGAAGCCCTGCACAATCATTACACTCA- GAA GAGCCTGTCCCTGTCTCCCGGC 17 3468 Full EVQLVESGGGLVQPGGSLRLSCAASGFTFTDYTMDWVRQAPGKGLEWVADVNPNSGCSIYNQRFKGRFTLSVD- R SKNTLYLQMNSLRAEDTAVYYCARNLGPSFYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALG- CLV KGYFPEPVTVSWNSGALTSGVHTFPAVLKSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEP- KSC DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKP- REE QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYVLPPSRDELTKNQVSL- LCL VKGFYPSDIAVEWESNGQPENNYLTWPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQK- SLS LSPG 18 3468 Full GAAGTGCAGCTGGTCGAATCTGGAGGAGGACTGGTGCAGCCAGGAGGGTCCCTGCGCCTGTCTTGCGCCGCTA- G TGGCTTCACTTTTACCGACTACACCATGGATTGGGTGCGACAGGCACCTGGAAAGGGCCTGGAGTGGGTCG- CCG ATGTGAACCCAAATAGCGGAGGCTCCATCTACAACCAGCGGTTCAAGGGCCGGTTCACCCTGTCAGTGGAC- CGG AGCAAAAACACCCTGTATCTGCAGATGAATAGCCTGCGAGCCGAAGATACTGCTGTGTACTATTGCGCCCG- GAA TCTGGGGCCCTCCTTCTACTTTGACTATTGGGGGCAGGGAACTCTGGTCACCGTGAGCTCCGCCTCCACCA- AGG GACCTTCTGTGTTCCCACTGGCTCCCTCTAGTAAATCCACATCTGGGGGAACTGCAGCCCTGGGCTGTCTG- GTG AAGGGCTACTTCCCAGAGCCCGTCACAGTGTCTTGGAACAGTGGCGCTCTGACTTCTGGGGTCCACACCTT- TCC TGCAGTGCTGAAGTCAAGCGGGCTGTACAGCCTGTCCTCTGTGGTCACCGTGCCAAGTTCAAGCCTGGGAA- CAC AGACTTATATCTGCAACGTGAATCACAAGCCATCCAATACAAAAGTCGACAAGAAAGTGGAACCCAAGTCT- TGT GATAAAACCCATACATGCCCCCCTTGTCCTGCACCAGAGCTGCTGGGAGGACCAAGCGTGTTCCTGTTTCC- ACC CAAGCCTAAAGATACACTGATGATTAGTAGGACCCCAGAAGTCACATGCGTGGTCGTGGACGTGAGCCACG- AGG ACCCCGAAGTCAAGTTTAACTGGTACGTGGACGGCGTCGAGGTGCATAATGCCAAGACTAAACCCAGGGAG- GAA CAGTACAACAGTACCTATCGCGTCGTGTCAGTCCTGACAGTGCTGCATCAGGATTGGCTGAACGGGAAAGA- GTA TAAGTGCAAAGTGAGCAATAAGGCTCTGCCCGCACCTATCGAGAAAACAATTTCCAAGGCAAAAGGACAGC- CTA GAGAACCACAGGTGTACGTGCTGCCTCCATCAAGGGATGAGCTGACAAAGAACCAGGTCAGCCTGCTGTGT- CTG GTGAAAGGATTCTATCCCTCTGACATTGCTGTGGAGTGGGAAAGTAATGGCCAGCCTGAGAACAATTACCT- GAC CTGGCCCCCTGTGCTGGACTCAGATGGCAGCTTCTTTCTGTATAGCAAGCTGACCGTCGACAAATCCCGGT- GGC AGCAGGGGAATGTGTTTAGTTGTTCAGTCATGCACGAGGCACTGCACAACCATTACACCCAGAAGTCACTG- TCA CTGTCACCAGGG 19 3468 VH EVQLVESGGGLVQPGGSLRLSCAASGFTFTDYTMDWVRQAPGKGLEWVADVNPNSGCSIYNQR- FKGRFTLSVDR SKNTLYLQMNSLRAEDTAVYYCARNLGPSFYFDYWGQGTLVTVSS 20 3468 VH GAAGTGCAGCTGGTCGAATCTGGAGGAGGACTGGTGCAGCCAGGAGGGTCCCTGCGCCTGTCT- TGCGCCGCTAG TGGCTTCACTTTTACCGACTACACCATGGATTGGGTGCGACAGGCACCTGGAAAGGGCCTGGAGTGGGTCG- CCG ATGTGAACCCAAATAGCGGAGGCTCCATCTACAACCAGCGGTTCAAGGGCCGGTTCACCCTGTCAGTGGAC- CGG AGCAAAAACACCCTGTATCTGCAGATGAATAGCCTGCGAGCCGAAGATACTGCTGTGTACTATTGCGCCCG- GAA TCTGGGGCCCTCCTTCTACTTTGACTATTGGGGGCAGGGAACTCTGGTCACCGTGAGCTCC 21 3468 H1 GFTFTDYT 22 3468 H1 GGCTTCACTTTTACCGACTACACC 23 3468 H3 ARNLGPSFYFDY 24 3468 H3 GCCCGGAATCTGGGGCCCTCCTTCTACTTTGACTAT 25 3468 H2 VNPNSGGS 26 3468 H2 GTGAACCCAAATAGCGGAGGCTCC 27 3468 CH1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKGYFPEPVTVSWNSGALTSGVHTFPAVLKSSGLYSLSSVVTVPS- S SLGTQTYICNVNHKPSNTKVDKKV 28 3468 CH1 GCCTCCACCAAGGGACCTTCTGTGTTCCCACTGGCTCCCTCTAGTAAATCCACATCTGGGGGAACTGCAGCCC- T GGGCTGTCTGGTGAAGGGCTACTTCCCAGAGCCCGTCACAGTGTCTTGGAACAGTGGCGCTCTGACTTCTG- GGG TCCACACCTTTCCTGCAGTGCTGAAGTCAAGCGGGCTGTACAGCCTGTCCTCTGTGGTCACCGTGCCAAGT- TCA AGCCTGGGAACACAGACTTATATCTGCAACGTGAATCACAAGCCATCCAATACAAAAGTCGACAAGAAAGT- G

29 3468 CH2 APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVV- S VLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 30 3468 CH2 GCACCAGAGCTGCTGGGAGGACCAAGCGTGTTCCTGTTTCCACCCAAGCCTAAAGATACACTGATGATTAGTA- G GACCCCAGAAGTCACATGCGTGGTCGTGGACGTGAGCCACGAGGACCCCGAAGTCAAGTTTAACTGGTACG- TGG ACGGCGTCGAGGTGCATAATGCCAAGACTAAACCCAGGGAGGAACAGTACAACAGTACCTATCGCGTCGTG- TCA GTCCTGACAGTGCTGCATCAGGATTGGCTGAACGGGAAAGAGTATAAGTGCAAAGTGAGCAATAAGGCTCT- GCC CGCACCTATCGAGAAAACAATTTCCAAGGCAAAA 31 3468 CH3 GQPREPQVYVLPPSRDELTKNQVSLLCLVKGFYPSDIAVEWESNGQPENNYLTWPPVLDSDGSFFLYSKLTVD- K SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG 32 3468 CH3 GGACAGCCTAGAGAACCACAGGTGTACGTGCTGCCTCCATCAAGGGATGAGCTGACAAAGAACCAGGTCAGCC- T GCTGTGTCTGGTGAAAGGATTCTATCCCTCTGACATTGCTGTGGAGTGGGAAAGTAATGGCCAGCCTGAGA- ACA ATTACCTGACCTGGCCCCCTGTGCTGGACTCAGATGGCAGCTTCTTTCTGTATAGCAAGCTGACCGTCGAC- AAA TCCCGGTGGCAGCAGGGGAATGTGTTTAGTTGTTCAGTCATGCACGAGGCACTGCACAACCATTACACCCA- GAA GTCACTGTCACTGTCACCAGGG 33 1811 Full DIQMTQSPSSLSASVGDRVTITCKASQDVSIGVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTL- T ISSLQPEDFATYYCQQYYIYPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAK- VQW KVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 34 1811 Full GATATTCAGATGACCCAGTCCCCAAGCTCCCTGAGTGCCTCAGTGGGCGACCGAGTCACCATCACATGCAAGG- C TTCCCAGGATGTGTCTATTGGAGTCGCATGGTACCAGCAGAAGCCAGGCAAAGCACCCAAGCTGCTGATCT- ATA GCGCCTCCTACCGGTATACCGGCGTGCCCTCTAGATTCTCTGGCAGTGGGTCAGGAACAGACTTTACTCTG- ACC ATCTCTAGTCTGCAGCCTGAGGATTTCGCTACCTACTATTGCCAGCAGTACTATATCTACCCATATACCTT- TGG CCAGGGGACAAAAGTGGAGATCAAGAGGACTGTGGCCGCTCCCTCCGTCTTCATTTTTCCCCCTTCTGACG- AAC AGCTGAAAAGTGGCACAGCCAGCGTGGTCTGTCTGCTGAACAATTTCTACCCTCGCGAAGCCAAAGTGCAG- TGG AAGGTCGATAACGCTCTGCAGAGCGGCAACAGCCAGGAGTCTGTGACTGAACAGGACAGTAAAGATTCAAC- CTA TAGCCTGTCAAGCACACTGACTCTGAGCAAGGCAGACTACGAGAAGCACAAAGTGTATGCCTGCGAAGTCA- CAC ATCAGGGGCTGTCCTCTCCTGTGACTAAGAGCTTTAACAGAGGAGAGTGT 35 1811 VL DIQMTQSPSSLSASVGDRVTITCKASQDVSIGVAWYQQKPGKAPKLLIYSASYRYTGVPSRFS- GSGSGTDFTLT ISSLQPEDFATYYCQQYYIYPYTFGQGTKVEIK 36 1811 VL GATATTCAGATGACCCAGTCCCCAAGCTCCCTGAGTGCCTCAGTGGGCGACCGAGTCACCATC- ACATGCAAGGC TTCCCAGGATGTGTCTATTGGAGTCGCATGGTACCAGCAGAAGCCAGGCAAAGCACCCAAGCTGCTGATCT- ATA GCGCCTCCTACCGGTATACCGGCGTGCCCTCTAGATTCTCTGGCAGTGGGTCAGGAACAGACTTTACTCTG- ACC ATCTCTAGTCTGCAGCCTGAGGATTTCGCTACCTACTATTGCCAGCAGTACTATATCTACCCATATACCTT- TGG CCAGGGGACAAAAGTGGAGATCAAG 37 1811 L1 QDVSIG 38 1811 L1 CAGGATGTGTCTATTGGA 39 1811 L3 QQYYIYPYT 40 1811 L3 CAGCAGTACTATATCTACCCATATACC 41 1811 L2 SAS 42 1811 L2 AGCGCCTCC 43 1811 CL RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKD- STYSLSSTLTL SKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 44 1811 CL AGGACTGTGGCCGCTCCCTCCGTCTTCATTTTTCCCCCTTCTGACGAACAGCTGAAAAGTGGC- ACAGCCAGCGT GGTCTGTCTGCTGAACAATTTCTACCCTCGCGAAGCCAAAGTGCAGTGGAAGGTCGATAACGCTCTGCAGA- GCG GCAACAGCCAGGAGTCTGTGACTGAACAGGACAGTAAAGATTCAACCTATAGCCTGTCAAGCACACTGACT- CTG AGCAAGGCAGACTACGAGAAGCACAAAGTGTATGCCTGCGAAGTCACACATCAGGGGCTGTCCTCTCCTGT- GAC TAAGAGCTTTAACAGAGGAGAGTGT 45 5034 Full DYKDDDDKDIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGS- R SGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKRTVAAPSVFIFPPSDERLKSGTASVVCLLN- NFY PREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR- GEC 46 5034 Full GACTACAAAGACGACGATGACAAAGATATCCAGATGACCCAGTCCCCTAGCTCCCTGTCCGCTTCTGTGGGCG- A TAGGGTCACTATTACCTGCCGCGCATCTCAGGACGTGAACACCGCAGTCGCCTGGTACCAGCAGAAGCCTG- GGA AAGCTCCAAAGCTGCTGATCTACAGTGCATCATTCCTGTATTCAGGAGTGCCCAGCCGGTTTAGCGGCAGC- AGA TCTGGCACCGATTTCACACTGACTATTTCTAGTCTGCAGCCTGAGGACTTTGCCACATACTATTGCCAGCA- GCA CTATACCACACCCCCTACTTTCGGCCAGGGGACCAAAGTGGAGATCAAGCGAACTGTGGCCGCTCCAAGTG- TCT TCATTTTTCCACCCAGCGATGAAAGACTGAAGTCCGGCACAGCTTCTGTGGTCTGTCTGCTGAACAATTTT- TAC CCCAGAGAGGCCAAAGTGCAGTGGAAGGTCGACAACGCTCTGCAGAGTGGCAACAGCCAGGAGAGCGTGAC- AGA ACAGGATTCCAAAGACTCTACTTATAGTCTGTCAAGCACCCTGACACTGAGCAAGGCAGACTACGAAAAGC- ATA AAGTGTATGCCTGTGAGGTCACACATCAGGGGCTGTCATCACCAGTCACCAAATCATTCAATCGGGGGGAG- TGC 47 5034 VL DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFS- GSRSGTDFTLT ISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK 48 5034 VL GATATCCAGATGACCCAGTCCCCTAGCTCCCTGTCCGCTTCTGTGGGCGATAGGGTCACTATT- ACCTGCCGCGC ATCTCAGGACGTGAACACCGCAGTCGCCTGGTACCAGCAGAAGCCTGGGAAAGCTCCAAAGCTGCTGATCT- ACA GTGCATCATTCCTGTATTCAGGAGTGCCCAGCCGGTTTAGCGGCAGCAGATCTGGCACCGATTTCACACTG- ACT ATTTCTAGTCTGCAGCCTGAGGACTTTGCCACATACTATTGCCAGCAGCACTATACCACACCCCCTACTTT- CGG CCAGGGGACCAAAGTGGAGATCAAG 49 5034 L1 QDVNTA 50 5034 L1 CAGGACGTGAACACCGCA 51 5034 L3 QQHYTTPPT 52 5034 L3 CAGCAGCACTATACCACACCCCCTACT 53 5034 L2 SAS 54 5034 L2 AGTGCATCA 55 5034 CL RTVAAPSVFIFPPSDERLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKD- STYSLSSTLTL SKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 56 5034 CL CGAACTGTGGCCGCTCCAAGTGTCTTCATTTTTCCACCCAGCGATGAAAGACTGAAGTCCGGC- ACAGCTTCTGT GGTCTGTCTGCTGAACAATTTTTACCCCAGAGAGGCCAAAGTGCAGTGGAAGGTCGACAACGCTCTGCAGA- GTG GCAACAGCCAGGAGAGCGTGACAGAACAGGATTCCAAAGACTCTACTTATAGTCTGTCAAGCACCCTGACA- CTG AGCAAGGCAGACTACGAAAAGCATAAAGTGTATGCCTGTGAGGTCACACATCAGGGGCTGTCATCACCAGT- CAC CAAATCATTCAATCGGGGGGAGTGC 57 5037 Full DYKDDDDKDIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGS- R SGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKRTVAAPSVFIFPPSDERLKSGTASVVCLLN- NFY PREAKVQWKVDNALQSGNSKESVTEQDSKDSTYSLSSRLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR- GEC 58 5037 Full GACTACAAAGACGACGATGACAAAGATATCCAGATGACCCAGTCCCCTAGCTCCCTGTCCGCTTCTGTGGGCG- A TAGGGTCACTATTACCTGCCGCGCATCTCAGGACGTGAACACCGCAGTCGCCTGGTACCAGCAGAAGCCTG- GGA AAGCTCCAAAGCTGCTGATCTACAGTGCATCATTCCTGTATTCAGGAGTGCCCAGCCGGTTTAGCGGCAGC- AGA TCTGGCACCGATTTCACACTGACTATTTCTAGTCTGCAGCCTGAGGACTTTGCCACATACTATTGCCAGCA- GCA CTATACCACACCCCCTACTTTCGGCCAGGGGACCAAAGTGGAGATCAAGCGAACTGTGGCCGCTCCAAGTG- TCT TCATTTTTCCACCCAGCGATGAAAGACTGAAGTCCGGCACAGCTTCTGTGGTCTGTCTGCTGAACAATTTT- TAC CCCAGAGAGGCCAAAGTGCAGTGGAAGGTCGACAACGCTCTGCAGAGTGGCAACAGCAAGGAGAGCGTGAC- AGA ACAGGATTCCAAAGACTCTACTTATAGTCTGTCAAGCAGACTGACACTGAGCAAGGCAGACTACGAAAAGC- ATA AAGTGTATGCCTGTGAGGTCACACATCAGGGGCTGTCATCACCAGTCACCAAATCATTCAATCGGGGGGAG- TGC 59 5037 VL DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFS- GSRSGTDFTLT ISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK 60 5037 VL GATATCCAGATGACCCAGTCCCCTAGCTCCCTGTCCGCTTCTGTGGGCGATAGGGTCACTATT- ACCTGCCGCGC ATCTCAGGACGTGAACACCGCAGTCGCCTGGTACCAGCAGAAGCCTGGGAAAGCTCCAAAGCTGCTGATCT- ACA GTGCATCATTCCTGTATTCAGGAGTGCCCAGCCGGTTTAGCGGCAGCAGATCTGGCACCGATTTCACACTG- ACT ATTTCTAGTCTGCAGCCTGAGGACTTTGCCACATACTATTGCCAGCAGCACTATACCACACCCCCTACTTT- CGG CCAGGGGACCAAAGTGGAGATCAAG 61 5037 L1 QDVNTA 62 5037 L1 CAGGACGTGAACACCGCA 63 5037 L3 QQHYTTPPT 64 5037 L3 CAGCAGCACTATACCACACCCCCTACT 65 5037 L2 SAS 66 5037 L2 AGTGCATCA 67 5037 CL RTVAAPSVFIFPPSDERLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSKESVTEQDSKD- STYSLSSRLTL SKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 68 5037 CL CGAACTGTGGCCGCTCCAAGTGTCTTCATTTTTCCACCCAGCGATGAAAGACTGAAGTCCGGC- ACAGCTTCTGT GGTCTGTCTGCTGAACAATTTTTACCCCAGAGAGGCCAAAGTGCAGTGGAAGGTCGACAACGCTCTGCAGA- GTG GCAACAGCAAGGAGAGCGTGACAGAACAGGATTCCAAAGACTCTACTTATAGTCTGTCAAGCAGACTGACA- CTG AGCAAGGCAGACTACGAAAAGCATAAAGTGTATGCCTGTGAGGTCACACATCAGGGGCTGTCATCACCAGT- CAC CAAATCATTCAATCGGGGGGAGTGC 69 3382 Full DIQMTQSPSSLSASVGDRVTITCKASQDVSIGVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTL- T ISSLQPEDFATYYCQQYYIYPATFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAK- VQW KVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 70 3382 Full GATATTCAGATGACCCAGTCCCCAAGCTCCCTGAGTGCCTCAGTGGGCGACCGAGTCACCATCACATGCAAGG- C TTCCCAGGATGTGTCTATTGGAGTCGCATGGTACCAGCAGAAGCCAGGCAAAGCACCCAAGCTGCTGATCT- ATA GCGCCTCCTACCGGTATACCGGCGTGCCCTCTAGATTCTCTGGCAGTGGGTCAGGAACAGACTTTACTCTG- ACC ATCTCTAGTCTGCAGCCTGAGGATTTCGCTACCTACTATTGCCAGCAGTACTATATCTACCCAGCCACCTT- TGG CCAGGGGACAAAAGTGGAGATCAAGAGGACTGTGGCCGCTCCCTCCGTCTTCATTTTTCCCCCTTCTGACG-

AAC AGCTGAAAAGTGGCACAGCCAGCGTGGTCTGTCTGCTGAACAATTTCTACCCTCGCGAAGCCAAAGTGCAG- TGG AAGGTCGATAACGCTCTGCAGAGCGGCAACAGCCAGGAGTCTGTGACTGAACAGGACAGTAAAGATTCAAC- CTA TAGCCTGTCAAGCACACTGACTCTGAGCAAGGCAGACTACGAGAAGCACAAAGTGTATGCCTGCGAAGTCA- CAC ATCAGGGGCTGTCCTCTCCTGTGACTAAGAGCTTTAACAGAGGAGAGTGT 71 3382 VL DIQMTQSPSSLSASVGDRVTITCKASQDVSIGVAWYQQKPGKAPKLLIYSASYRYTGVPSRFS- GSGSGTDFTLT ISSLQPEDFATYYCQQYYIYPATFGQGTKVEIK 72 3382 VL GATATTCAGATGACCCAGTCCCCAAGCTCCCTGAGTGCCTCAGTGGGCGACCGAGTCACCATC- ACATGCAAGGC TTCCCAGGATGTGTCTATTGGAGTCGCATGGTACCAGCAGAAGCCAGGCAAAGCACCCAAGCTGCTGATCT- ATA GCGCCTCCTACCGGTATACCGGCGTGCCCTCTAGATTCTCTGGCAGTGGGTCAGGAACAGACTTTACTCTG- ACC ATCTCTAGTCTGCAGCCTGAGGATTTCGCTACCTACTATTGCCAGCAGTACTATATCTACCCAGCCACCTT- TGG CCAGGGGACAAAAGTGGAGATCAAG 73 3382 L1 QDVSIG 74 3382 L1 CAGGATGTGTCTATTGGA 75 3382 L3 QQYYIYPAT 76 3382 L3 CAGCAGTACTATATCTACCCAGCCACC 77 3382 L2 SAS 78 3382 L2 AGCGCCTCC 79 3382 CL RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKD- STYSLSSTLTL SKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 80 3382 CL AGGACTGTGGCCGCTCCCTCCGTCTTCATTTTTCCCCCTTCTGACGAACAGCTGAAAAGTGGC- ACAGCCAGCGT GGTCTGTCTGCTGAACAATTTCTACCCTCGCGAAGCCAAAGTGCAGTGGAAGGTCGATAACGCTCTGCAGA- GCG GCAACAGCCAGGAGTCTGTGACTGAACAGGACAGTAAAGATTCAACCTATAGCCTGTCAAGCACACTGACT- CTG AGCAAGGCAGACTACGAGAAGCACAAAGTGTATGCCTGCGAAGTCACACATCAGGGGCTGTCCTCTCCTGT- GAC TAAGAGCTTTAACAGAGGAGAGTGT 81 5065 Full EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISAD- T SKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAAL- GCE VTDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVE- PKS CDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK- PRE EQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYVYPPSRDELTKNQVS- LTC LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFALVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQ- KSL SLSPG 82 5065 Full GAGGTGCAGCTGGTCGAAAGCGGAGGAGGACTGGTGCAGCCAGGAGGGTCACTGCGACTGAGCTGCGCAGCTT- C CGGCTTCAACATCAAGGACACCTACATTCACTGGGTCCGCCAGGCTCCTGGAAAAGGCCTGGAGTGGGTGG- CAC GAATCTATCCAACTAATGGATACACCCGGTATGCCGACTCCGTGAAGGGCCGGTTCACCATTTCTGCAGAT- ACA AGTAAAAACACTGCCTACCTGCAGATGAACAGCCTGCGAGCCGAAGATACAGCCGTGTACTATTGCAGCCG- ATG GGGAGGCGACGGCTTCTACGCTATGGATTATTGGGGGCAGGGAACCCTGGTCACAGTGAGCTCCGCATCAA- CAA AGGGGCCTAGCGTGTTTCCACTGGCCCCCTCTAGTAAATCCACCTCTGGGGGAACAGCAGCCCTGGGATGT- GAG GTGACCGACTACTTCCCAGAGCCCGTCACTGTGAGCTGGAACTCCGGCGCCCTGACATCTGGGGTCCATAC- TTT TCCTGCTGTGCTGCAGTCAAGCGGCCTGTACAGCCTGTCCTCTGTGGTCACTGTGCCAAGTTCAAGCCTGG- GGA CTCAGACCTATATCTGCAACGTGAATCACAAGCCATCCAATACCAAAGTCGACAAGAAAGTGGAACCCAAG- TCT TGTGATAAAACACATACTTGCCCCCCTTGTCCTGCACCAGAGCTGCTGGGAGGACCAAGCGTGTTCCTGTT- TCC ACCCAAGCCTAAAGACACCCTGATGATTAGTAGGACTCCAGAAGTCACCTGCGTGGTCGTGGACGTGAGCC- ACG AGGACCCCGAAGTCAAGTTCAACTGGTACGTGGATGGCGTCGAGGTGCATAATGCCAAGACAAAACCCAGG- GAG GAACAGTACAACTCCACTTATCGCGTCGTGTCTGTCCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAA- GGA GTATAAGTGCAAAGTGAGCAATAAGGCTCTGCCCGCACCTATCGAGAAAACAATTTCCAAGGCTAAAGGGC- AGC CTAGAGAACCACAGGTGTACGTGTACCCTCCATCTAGGGACGAGCTGACCAAGAACCAGGTCAGTCTGACA- TGT CTGGTGAAAGGGTTCTATCCCAGCGATATCGCAGTGGAGTGGGAATCCAATGGACAGCCTGAGAACAATTA- CAA GACCACACCCCCTGTGCTGGACTCTGATGGAAGTTTCGCCCTGGTGAGTAAGCTGACCGTCGATAAATCAC- GGT GGCAGCAGGGCAACGTGTTCAGCTGTTCAGTGATGCACGAAGCACTGCACAACCACTACACCCAGAAAAGC- CTG TCCCTGTCCCCCGGC 83 5065 VH EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADS- VKGRFTISADT SKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS 84 5065 VH GAGGTGCAGCTGGTCGAAAGCGGAGGAGGACTGGTGCAGCCAGGAGGGTCACTGCGACTGAGC- TGCGCAGCTTC CGGCTTCAACATCAAGGACACCTACATTCACTGGGTCCGCCAGGCTCCTGGAAAAGGCCTGGAGTGGGTGG- CAC GAATCTATCCAACTAATGGATACACCCGGTATGCCGACTCCGTGAAGGGCCGGTTCACCATTTCTGCAGAT- ACA AGTAAAAACACTGCCTACCTGCAGATGAACAGCCTGCGAGCCGAAGATACAGCCGTGTACTATTGCAGCCG- ATG GGGAGGCGACGGCTTCTACGCTATGGATTATTGGGGGCAGGGAACCCTGGTCACAGTGAGCTCC 85 5065 H1 GFNIKDTY 86 5065 H1 GGCTTCAACATCAAGGACACCTAC 87 5065 H3 SRWGGDGFYAMDY 88 5065 H3 AGCCGATGGGGAGGCGACGGCTTCTACGCTATGGATTAT 89 5065 H2 IYPTNGYT 90 5065 H2 ATCTATCCAACTAATGGATACACC 91 5065 CH1 ASTKGPSVFPLAPSSKSTSGGTAALGCEVTDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPS- S SLGTQTYICNVNHKPSNTKVDKKV 92 5065 CH1 GCATCAACAAAGGGGCCTAGCGTGTTTCCACTGGCCCCCTCTAGTAAATCCACCTCTGGGGGAACAGCAGCCC- T GGGATGTGAGGTGACCGACTACTTCCCAGAGCCCGTCACTGTGAGCTGGAACTCCGGCGCCCTGACATCTG- GGG TCCATACTTTTCCTGCTGTGCTGCAGTCAAGCGGCCTGTACAGCCTGTCCTCTGTGGTCACTGTGCCAAGT- TCA AGCCTGGGGACTCAGACCTATATCTGCAACGTGAATCACAAGCCATCCAATACCAAAGTCGACAAGAAAGT- G 93 5065 CH2 APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVV- S VLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 94 5065 CH2 GCACCAGAGCTGCTGGGAGGACCAAGCGTGTTCCTGTTTCCACCCAAGCCTAAAGACACCCTGATGATTAGTA- G GACTCCAGAAGTCACCTGCGTGGTCGTGGACGTGAGCCACGAGGACCCCGAAGTCAAGTTCAACTGGTACG- TGG ATGGCGTCGAGGTGCATAATGCCAAGACAAAACCCAGGGAGGAACAGTACAACTCCACTTATCGCGTCGTG- TCT GTCCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAGGAGTATAAGTGCAAAGTGAGCAATAAGGCTCT- GCC CGCACCTATCGAGAAAACAATTTCCAAGGCTAAA 95 5065 CH3 GQPREPQVYVYPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFALVSKLTVD- K SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG 96 5065 CH3 GGGCAGCCTAGAGAACCACAGGTGTACGTGTACCCTCCATCTAGGGACGAGCTGACCAAGAACCAGGTCAGTC- T GACATGTCTGGTGAAAGGGTTCTATCCCAGCGATATCGCAGTGGAGTGGGAATCCAATGGACAGCCTGAGA- ACA ATTACAAGACCACACCCCCTGTGCTGGACTCTGATGGAAGTTTCGCCCTGGTGAGTAAGCTGACCGTCGAT- AAA TCACGGTGGCAGCAGGGCAACGTGTTCAGCTGTTCAGTGATGCACGAAGCACTGCACAACCACTACACCCA- GAA AAGCCTGTCCCTGTCCCCCGGC 97 6586 Full EVQLVESGGGLVQPGGSLRLSCAASGFTFADYTMDWVRQAPGKGLEWVGDVNPNSGCSIYNQRFKGRFTFSVD- R SKNTLYLQMNSLRAEDTAVYYCARNLGPSFYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALG- CLV KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEP- KSC DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKP- REE QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYVYPPSRDELTKNQVSL- TCL VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFALVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQK- SLS LSPG 98 6586 Full GAGGTGCAGCTGGTGGAATCAGGAGGGGGCCTGGTGCAGCCCGGAGGGTCTCTGCGACTGTCATGTGCCGCTT- C TGGGTTCACTTTCGCAGACTACACAATGGATTGGGTGCGACAGGCCCCCGGAAAGGGACTGGAGTGGGTGG- GCG ATGTCAACCCTAATTCTGGCGGGAGTATCTACAACCAGCGGTTCAAGGGGAGATTCACTTTTTCAGTGGAC- AGA AGCAAAAACACCCTGTATCTGCAGATGAACAGCCTGAGGGCCGAAGATACCGCTGTCTACTATTGCGCTCG- CAA TCTGGGCCCCAGTTTCTACTTTGACTATTGGGGGCAGGGAACCCTGGTGACAGTCAGCTCCGCTAGCACTA- AGG GGCCTTCCGTGTTTCCACTGGCTCCCTCTAGTAAATCCACCTCTGGAGGCACAGCTGCACTGGGATGTCTG- GTG AAGGATTACTTCCCTGAACCAGTCACAGTGAGTTGGAACTCAGGGGCTCTGACAAGTGGAGTCCATACTTT- TCC CGCAGTGCTGCAGTCAAGCGGACTGTACTCCCTGTCCTCTGTGGTCACCGTGCCTAGTTCAAGCCTGGGCA- CCC AGACATATATCTGCAACGTGAATCACAAGCCATCAAATACAAAAGTCGACAAGAAAGTGGAGCCCAAGAGC- TGT GATAAAACTCATACCTGCCCACCTTGTCCGGCGCCAGAACTGCTGGGAGGACCAAGCGTGTTCCTGTTTCC- ACC CAAGCCTAAAGACACCCTGATGATTTCCCGGACTCCTGAGGTCACCTGCGTGGTCGTGGACGTGTCTCACG- AGG ACCCCGAAGTCAAGTTCAACTGGTACGTGGATGGCGTCGAAGTGCATAATGCCAAGACCAAACCCCGGGAG- GAA CAGTACAACTCTACCTATAGAGTCGTGAGTGTCCTGACAGTGCTGCACCAGGACTGGCTGAATGGGAAGGA- GTA TAAGTGTAAAGTGAGCAACAAAGCCCTGCCCGCCCCAATCGAAAAAACAATCTCTAAAGCAAAAGGACAGC- CTC GCGAACCACAGGTCTACGTCTACCCCCCATCAAGAGATGAACTGACAAAAAATCAGGTCTCTCTGACATGC- CTG GTCAAAGGATTCTACCCTTCCGACATCGCCGTGGAGTGGGAAAGTAACGGCCAGCCCGAGAACAATTACAA- GAC CACACCCCCTGTCCTGGACTCTGATGGGAGTTTCGCTCTGGTGTCAAAGCTGACCGTCGATAAAAGCCGGT- GGC AGCAGGGCAATGTGTTTAGCTGCTCCGTCATGCACGAAGCCCTGCACAATCACTACACACAGAAGTCCCTG- AGC CTGAGCCCTGGC 99 6586 VH EVQLVESGGGLVQPGGSLRLSCAASGFTFADYTMDWVRQAPGKGLEWVGDVNPNSGCSIYNQR- FKGRFTFSVDR SKNTLYLQMNSLRAEDTAVYYCARNLGPSFYFDYWGQGTLVTVSS 100 6586 VH GAGGTGCAGCTGGTGGAATCAGGAGGGGGCCTGGTGCAGCCCGGAGGGTCTCTGCGACTGTCATGTGCCGCTT- C TGGGTTCACTTTCGCAGACTACACAATGGATTGGGTGCGACAGGCCCCCGGAAAGGGACTGGAGTGGGTGG- GCG ATGTCAACCCTAATTCTGGCGGGAGTATCTACAACCAGCGGTTCAAGGGGAGATTCACTTTTTCAGTGGAC- AGA AGCAAAAACACCCTGTATCTGCAGATGAACAGCCTGAGGGCCGAAGATACCGCTGTCTACTATTGCGCTCG- CAA TCTGGGCCCCAGTTTCTACTTTGACTATTGGGGGCAGGGAACCCTGGTGACAGTCAGCTCC 101 6586 H1 GFTFADYT 102 6586 H1 GGGTTCACTTTCGCAGACTACACA 103 6586 H3 ARNLGPSFYFDY

104 6586 H3 GCTCGCAATCTGGGCCCCAGTTTCTACTTTGACTAT 105 6586 H2 VNPNSGGS 106 6586 H2 GTCAACCCTAATTCTGGCGGGAGT 107 6586 CH1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPS- S SLGTQTYICNVNHKPSNTKVDKKV 108 6586 CH1 GCTAGCACTAAGGGGCCTTCCGTGTTTCCACTGGCTCCCTCTAGTAAATCCACCTCTGGAGGCACAGCTGCAC- T GGGATGTCTGGTGAAGGATTACTTCCCTGAACCAGTCACAGTGAGTTGGAACTCAGGGGCTCTGACAAGTG- GAG TCCATACTTTTCCCGCAGTGCTGCAGTCAAGCGGACTGTACTCCCTGTCCTCTGTGGTCACCGTGCCTAGT- TCA AGCCTGGGCACCCAGACATATATCTGCAACGTGAATCACAAGCCATCAAATACAAAAGTCGACAAGAAAGT- G 109 6586 CH2 APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVV- S VLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 110 6586 CH2 GCGCCAGAACTGCTGGGAGGACCAAGCGTGTTCCTGTTTCCACCCAAGCCTAAAGACACCCTGATGATTTCCC- G GACTCCTGAGGTCACCTGCGTGGTCGTGGACGTGTCTCACGAGGACCCCGAAGTCAAGTTCAACTGGTACG- TGG ATGGCGTCGAAGTGCATAATGCCAAGACCAAACCCCGGGAGGAACAGTACAACTCTACCTATAGAGTCGTG- AGT GTCCTGACAGTGCTGCACCAGGACTGGCTGAATGGGAAGGAGTATAAGTGTAAAGTGAGCAACAAAGCCCT- GCC CGCCCCAATCGAAAAAACAATCTCTAAAGCAAAA 111 6586 CH3 GQPREPQVYVYPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFALVSKLTVD- K SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG 112 6586 CH3 GGACAGCCTCGCGAACCACAGGTCTACGTCTACCCCCCATCAAGAGATGAACTGACAAAAAATCAGGTCTCTC- T GACATGCCTGGTCAAAGGATTCTACCCTTCCGACATCGCCGTGGAGTGGGAAAGTAACGGCCAGCCCGAGA- ACA ATTACAAGACCACACCCCCTGTCCTGGACTCTGATGGGAGTTTCGCTCTGGTGTCAAAGCTGACCGTCGAT- AAA AGCCGGTGGCAGCAGGGCAATGTGTTTAGCTGCTCCGTCATGCACGAAGCCCTGCACAATCACTACACACA- GAA GTCCCTGAGCCTGAGCCCTGGC 113 3904 Full YPYDVPDYATGSDIQMTQSPSSLSASVGDRVTITCKASQDVSIGVAWYQQKPGKAPKLLIYSASYRYTGVPSR- F SGSGSGTDFTLTISSLQPEDFATYYCQQYYIYPYTFGQGTKVEIKRTVAAPSVFIFPPSDEELKSGTASVV- CLL NNFYPREAKVQWKVDNALQSGNSEESVTEQDSKDSTYSLSSTLELSKADYEKHKVYACEVTHQGLSSPVTK- SFN RGEC 114 3904 Full TATCCCTACGATGTGCCTGACTACGCTACTGGCTCCGATATCCAGATGACCCAGTCTCCAAGCTCCCTGAGTG- C ATCAGTGGGGGACCGAGTCACCATCACATGCAAGGCTTCCCAGGATGTGTCTATTGGAGTCGCATGGTACC- AGC AGAAGCCAGGCAAAGCACCCAAGCTGCTGATCTACAGCGCCTCCTACCGGTATACTGGGGTGCCTTCCAGA- TTC TCTGGCAGTGGGTCAGGAACCGACTTTACTCTGACCATCTCTAGTCTGCAGCCCGAGGATTTCGCCACCTA- CTA TTGCCAGCAGTACTATATCTACCCTTATACCTTTGGCCAGGGGACAAAAGTGGAGATCAAGAGGACAGTGG- CCG CTCCAAGTGTCTTCATTTTTCCCCCTTCCGACGAAGAGCTGAAAAGTGGAACTGCTTCAGTGGTCTGTCTG- CTG AACAATTTCTACCCCCGCGAAGCCAAAGTGCAGTGGAAGGTCGATAACGCTCTGCAGAGCGGCAATTCCGA- GGA GTCTGTGACAGAACAGGACAGTAAAGATTCAACTTATAGCCTGTCAAGCACACTGGAGCTGTCTAAGGCAG- ACT ACGAGAAGCACAAAGTGTATGCCTGCGAAGTCACCCATCAGGGGCTGTCCTCTCCCGTGACAAAGAGCTTT- AAC AGAGGAGAGTGT 115 3904 VL DIQMTQSPSSLSASVGDRVTITCKASQDVSIGVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTL- T ISSLQPEDFATYYCQQYYIYPYTFGQGTKVEIK 116 3904 VL GATATCCAGATGACCCAGTCTCCAAGCTCCCTGAGTGCATCAGTGGGGGACCGAGTCACCATCACATGCAAGG- C TTCCCAGGATGTGTCTATTGGAGTCGCATGGTACCAGCAGAAGCCAGGCAAAGCACCCAAGCTGCTGATCT- ACA GCGCCTCCTACCGGTATACTGGGGTGCCTTCCAGATTCTCTGGCAGTGGGTCAGGAACCGACTTTACTCTG- ACC ATCTCTAGTCTGCAGCCCGAGGATTTCGCCACCTACTATTGCCAGCAGTACTATATCTACCCTTATACCTT- TGG CCAGGGGACAAAAGTGGAGATCAAG 117 3904 L1 QDVSIG 118 3904 L1 CAGGATGTGTCTATTGGA 119 3904 L3 QQYYIYPYT 120 3904 L3 CAGCAGTACTATATCTACCCTTATACC 121 3904 L2 SAS 122 3904 L2 AGCGCCTCC 123 3904 CL RTVAAPSVFIFPPSDEELKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSEESVTEQDSKDSTYSLSSTLE- L SKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 124 3904 CL AGGACAGTGGCCGCTCCAAGTGTCTTCATTTTTCCCCCTTCCGACGAAGAGCTGAAAAGTGGAACTGCTTCAG- T GGTCTGTCTGCTGAACAATTTCTACCCCCGCGAAGCCAAAGTGCAGTGGAAGGTCGATAACGCTCTGCAGA- GCG GCAATTCCGAGGAGTCTGTGACAGAACAGGACAGTAAAGATTCAACTTATAGCCTGTCAAGCACACTGGAG- CTG TCTAAGGCAGACTACGAGAAGCACAAAGTGTATGCCTGCGAAGTCACCCATCAGGGGCTGTCCTCTCCCGT- GAC AAAGAGCTTTAACAGAGGAGAGTGT 125 4553 Full EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISAD- T SKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAAL- GCL VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVE- PKS CDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK- PRE EQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYVYPPSRDELTKNQVS- LTC LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFALVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQ- KSL SLSPGK 126 4553 Full GAAGTCCAGCTGGTCGAAAGCGGAGGAGGACTGGTGCAGCCAGGAGGGTCTCTGCGACTGAGTTGCGCCGCTT- C AGGCTTCAACATCAAGGACACCTACATTCACTGGGTGCGCCAGGCTCCTGGAAAAGGCCTGGAGTGGGTGG- CAC GAATCTATCCAACTAATGGATACACCCGGTATGCAGACAGCGTGAAGGGCCGGTTCACCATTAGCGCAGAT- ACA TCCAAAAACACTGCCTACCTGCAGATGAACAGCCTGCGAGCCGAAGATACTGCTGTGTACTATTGCAGTCG- GTG GGGAGGCGACGGCTTCTACGCTATGGATTATTGGGGGCAGGGAACCCTGGTCACAGTGAGCTCCGCATCTA- CAA AGGGGCCTAGTGTGTTTCCACTGGCCCCCTCTAGTAAATCCACCTCTGGGGGAACAGCAGCCCTGGGATGT- CTG GTGAAGGACTATTTCCCAGAGCCCGTCACTGTGAGTTGGAACTCAGGCGCCCTGACATCCGGGGTCCATAC- TTT TCCTGCTGTGCTGCAGTCAAGCGGCCTGTACTCTCTGTCCTCTGTGGTCACCGTGCCAAGTTCAAGCCTGG- GGA CTCAGACCTATATCTGCAACGTGAATCACAAGCCAAGCAATACAAAAGTCGACAAGAAAGTGGAACCCAAG- AGC TGTGATAAAACACATACTTGCCCCCCTTGTCCTGCACCAGAGCTGCTGGGAGGACCATCCGTGTTCCTGTT- TCC ACCCAAGCCTAAAGACACCCTGATGATTTCCAGGACTCCAGAAGTCACCTGCGTGGTCGTGGACGTGTCTC- ACG AGGACCCCGAAGTCAAGTTCAACTGGTACGTGGATGGCGTCGAGGTGCATAATGCCAAGACAAAACCCAGG- GAG GAACAGTACAACTCAACTTATCGCGTCGTGAGCGTCCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAA- GGA GTATAAGTGCAAAGTGAGCAATAAGGCTCTGCCCGCACCTATCGAGAAAACCATTAGCAAGGCCAAAGGGC- AGC CTAGAGAACCACAGGTCTACGTGTATCCTCCAAGCAGGGACGAGCTGACCAAGAACCAGGTCTCCCTGACA- TGT CTGGTGAAAGGGTTTTACCCCAGTGATATCGCTGTGGAGTGGGAATCAAATGGACAGCCTGAAAACAATTA- TAA GACCACACCCCCTGTGCTGGACAGCGATGGCAGCTTCGCTCTGGTCTCCAAGCTGACTGTGGATAAATCTC- GGT GGCAGCAGGGCAACGTCTTTAGTTGTTCAGTGATGCATGAGGCACTGCACAATCATTACACCCAGAAGAGC- CTG TCCCTGTCTCCCGGCAAA 127 4553 VH EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISAD- T SKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS 128 4553 VH GAAGTCCAGCTGGTCGAAAGCGGAGGAGGACTGGTGCAGCCAGGAGGGTCTCTGCGACTGAGTTGCGCCGCTT- C AGGCTTCAACATCAAGGACACCTACATTCACTGGGTGCGCCAGGCTCCTGGAAAAGGCCTGGAGTGGGTGG- CAC GAATCTATCCAACTAATGGATACACCCGGTATGCAGACAGCGTGAAGGGCCGGTTCACCATTAGCGCAGAT- ACA TCCAAAAACACTGCCTACCTGCAGATGAACAGCCTGCGAGCCGAAGATACTGCTGTGTACTATTGCAGTCG- GTG GGGAGGCGACGGCTTCTACGCTATGGATTATTGGGGGCAGGGAACCCTGGTCACAGTGAGCTCC 129 4553 H1 GFNIKDTY 130 4553 H1 GGCTTCAACATCAAGGACACCTAC 131 4553 H3 SRWGGDGFYAMDY 132 4553 H3 AGTCGGTGGGGAGGCGACGGCTTCTACGCTATGGATTAT 133 4553 H2 IYPTNGYT 134 4553 H2 ATCTATCCAACTAATGGATACACC 135 4553 CH1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPS- S SLGTQTYICNVNHKPSNTKVDKKV 136 4553 CH1 GCATCTACAAAGGGGCCTAGTGTGTTTCCACTGGCCCCCTCTAGTAAATCCACCTCTGGGGGAACAGCAGCCC- T GGGATGTCTGGTGAAGGACTATTTCCCAGAGCCCGTCACTGTGAGTTGGAACTCAGGCGCCCTGACATCCG- GGG TCCATACTTTTCCTGCTGTGCTGCAGTCAAGCGGCCTGTACTCTCTGTCCTCTGTGGTCACCGTGCCAAGT- TCA AGCCTGGGGACTCAGACCTATATCTGCAACGTGAATCACAAGCCAAGCAATACAAAAGTCGACAAGAAAGT- G 137 4553 CH2 APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVV- S VLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 138 4553 CH2 GCACCAGAGCTGCTGGGAGGACCATCCGTGTTCCTGTTTCCACCCAAGCCTAAAGACACCCTGATGATTTCCA- G GACTCCAGAAGTCACCTGCGTGGTCGTGGACGTGTCTCACGAGGACCCCGAAGTCAAGTTCAACTGGTACG- TGG ATGGCGTCGAGGTGCATAATGCCAAGACAAAACCCAGGGAGGAACAGTACAACTCAACTTATCGCGTCGTG- AGC GTCCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAGGAGTATAAGTGCAAAGTGAGCAATAAGGCTCT- GCC CGCACCTATCGAGAAAACCATTAGCAAGGCCAAA 139 4553 CH3 GQPREPQVYVYPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFALVSKLTVD- K SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG 140 4553 CH3 GGGCAGCCTAGAGAACCACAGGTCTACGTGTATCCTCCAAGCAGGGACGAGCTGACCAAGAACCAGGTCTCCC- T GACATGTCTGGTGAAAGGGTTTTACCCCAGTGATATCGCTGTGGAGTGGGAATCAAATGGACAGCCTGAAA- ACA ATTATAAGACCACACCCCCTGTGCTGGACAGCGATGGCAGCTTCGCTCTGGTCTCCAAGCTGACTGTGGAT-

AAA TCTCGGTGGCAGCAGGGCAACGTCTTTAGTTGTTCAGTGATGCATGAGGCACTGCACAATCATTACACCCA- GAA GAGCCTGTCCCTGTCTCCCGGC 141 716 Full EPKSSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK- T KPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTK- NQV SLICLVKGFYPSDIAVEWESNGQPENRYMTWPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN- HYT QKSLSLSPGK 142 716 Full GAGCCCAAGAGCAGCGATAAGACCCACACCTGCCCTCCCTGTCCAGCTCCAGAACTGCTGGGAGGACCTAGCG- T GTTCCTGTTTCCCCCTAAGCCAAAAGACACTCTGATGATTTCCAGGACTCCCGAGGTGACCTGCGTGGTGG- TGG ACGTGTCTCACGAGGACCCCGAAGTGAAGTTCAACTGGTACGTGGATGGCGTGGAAGTGCATAATGCTAAG- ACA AAACCAAGAGAGGAACAGTACAACTCCACTTATCGCGTCGTGAGCGTGCTGACCGTGCTGCACCAGGACTG- GCT GAACGGGAAGGAGTATAAGTGCAAAGTCAGTAATAAGGCCCTGCCTGCTCCAATCGAAAAAACCATCTCTA- AGG CCAAAGGCCAGCCAAGGGAGCCCCAGGTGTACACACTGCCACCCAGCAGAGACGAACTGACCAAGAACCAG- GTG TCCCTGATCTGTCTGGTGAAAGGCTTCTATCCTAGTGATATTGCTGTGGAGTGGGAATCAAATGGACAGCC- AGA GAACAGATACATGACCTGGCCTCCAGTGCTGGACAGCGATGGCAGCTTCTTCCTGTATTCCAAGCTGACAG- TGG ATAAATCTCGATGGCAGCAGGGGAACGTGTTTAGTTGTTCAGTGATGCATGAAGCCCTGCACAATCATTAC- ACT CAGAAGAGCCTGTCCCTGTCTCCCGGCAAA 143 716 CH2 APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVV- S VLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 144 716 CH2 GCTCCAGAACTGCTGGGAGGACCTAGCGTGTTCCTGTTTCCCCCTAAGCCAAAAGACACTCTGATGATTTCCA- G GACTCCCGAGGTGACCTGCGTGGTGGTGGACGTGTCTCACGAGGACCCCGAAGTGAAGTTCAACTGGTACG- TGG ATGGCGTGGAAGTGCATAATGCTAAGACAAAACCAAGAGAGGAACAGTACAACTCCACTTATCGCGTCGTG- AGC GTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGGAAGGAGTATAAGTGCAAAGTCAGTAATAAGGCCCT- GCC TGCTCCAATCGAAAAAACCATCTCTAAGGCCAAA 145 716 CH3 GQPREPQVYTLPPSRDELTKNQVSLICLVKGFYPSDIAVEWESNGQPENRYMTWPPVLDSDGSFFLYSKLTVD- K SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG 146 716 CH3 GGCCAGCCAAGGGAGCCCCAGGTGTACACACTGCCACCCAGCAGAGACGAACTGACCAAGAACCAGGTGTCCC- T GATCTGTCTGGTGAAAGGCTTCTATCCTAGTGATATTGCTGTGGAGTGGGAATCAAATGGACAGCCAGAGA- ACA GATACATGACCTGGCCTCCAGTGCTGGACAGCGATGGCAGCTTCTTCCTGTATTCCAAGCTGACAGTGGAT- AAA TCTCGATGGCAGCAGGGGAACGTGTTTAGTTGTTCAGTGATGCATGAAGCCCTGCACAATCATTACACTCA- GAA GAGCCTGTCCCTGTCTCCCGGC 147 719 Full DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTL- T ISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKGGSGGGSGGGSGGGSGGGSGEVQLVESGGGLVQPGGSL- RLS CAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTA- VYY CSRWGGDGFYAMDYWGQGTLVTVSSAAEPKSSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEV- TCV VVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIE- KTI SKAKGQPREPQVYTYPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDEDGSFALV- SKL TVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPCK 148 719 Full GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGG- C AAGTCAGGACGTTAACACCGCTGTAGCTTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCT- ATT CTGCATCCTTTTTGTACAGTGGGGTCCCATCAAGGTTCAGTGGCAGTCGATCTGGGACAGATTTCACTCTC- ACC ATCAGCAGTCTGCAACCTGAAGATTTTGCAACTTACTACTGTCAACAGCATTACACTACCCCACCCACTTT- CGG CCAAGGGACCAAAGTGGAGATCAAAGGTGGTTCTGGTGGTGGTTCTGGTGGTGGTTCTGGTGGTGGTTCTG- GTG GTGGTTCTGGTGAAGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGCGGGTCCCTGAGACTC- TCC TGTGCAGCCTCTGGATTCAACATTAAAGATACTTATATCCACTGGGTCCGGCAAGCTCCAGGGAAGGGCCT- GGA GTGGGTCGCACGTATTTATCCCACAAATGGTTACACACGGTATGCGGACTCTGTGAAGGGCCGATTCACCA- TCT CCGCAGACACTTCCAAGAACACCGCGTATCTGCAAATGAACAGTCTGAGAGCTGAGGACACGGCCGTTTAT- TAC TGTTCAAGATGGGGCGGAGACGGTTTCTACGCTATGGACTACTGGGGCCAAGGGACCCTGGTCACCGTCTC- CTC AGCCGCCGAGCCCAAGAGCAGCGATAAGACCCACACCTGCCCTCCCTGTCCAGCTCCAGAACTGCTGGGAG- GAC CTAGCGTGTTCCTGTTTCCCCCTAAGCCAAAAGACACTCTGATGATTTCCAGGACTCCCGAGGTGACCTGC- GTG GTGGTGGACGTGTCTCACGAGGACCCCGAAGTGAAGTTCAACTGGTACGTGGATGGCGTGGAAGTGCATAA- TGC TAAGACAAAACCAAGAGAGGAACAGTACAACTCCACTTATCGCGTCGTGAGCGTGCTGACCGTGCTGCACC- AGG ACTGGCTGAACGGGAAGGAGTATAAGTGCAAAGTCAGTAATAAGGCCCTGCCTGCTCCAATCGAAAAAACC- ATC TCTAAGGCCAAAGGCCAGCCAAGGGAGCCCCAGGTGTACACATACCCACCCAGCAGAGACGAACTGACCAA- GAA CCAGGTGTCCCTGACATGTCTGGTGAAAGGCTTCTATCCTAGTGATATTGCTGTGGAGTGGGAATCAAATG- GAC AGCCAGAGAACAATTACAAGACCACACCTCCAGTGCTGGACGAGGATGGCAGCTTCGCCCTGGTGTCCAAG- CTG ACAGTGGATAAATCTCGATGGCAGCAGGGGAACGTGTTTAGTTGTTCAGTGATGCATGAAGCCCTGCACAA- TCA TTACACTCAGAAGAGCCTGTCCCTGTCTCCCGGCAAA 149 719 VL DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFS- GSRSGTDFTLT ISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK 150 719 VL GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATC- ACTTGCCGGGC AAGTCAGGACGTTAACACCGCTGTAGCTTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCT- ATT CTGCATCCTTTTTGTACAGTGGGGTCCCATCAAGGTTCAGTGGCAGTCGATCTGGGACAGATTTCACTCTC- ACC ATCAGCAGTCTGCAACCTGAAGATTTTGCAACTTACTACTGTCAACAGCATTACACTACCCCACCCACTTT- CGG CCAAGGGACCAAAGTGGAGATCAAA 151 719 L1 QDVNTA 152 719 L1 CAGGACGTTAACACCGCT 153 719 L3 QQHYTTPPT 154 719 L3 CAACAGCATTACACTACCCCACCCACT 155 719 L2 SAS 156 719 L2 TCTGCATCC 157 719 VH EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADS- VKGRFTISADT SKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS 158 719 VH GAAGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGCGGGTCCCTGAGACTCTCC- TGTGCAGCCTC TGGATTCAACATTAAAGATACTTATATCCACTGGGTCCGGCAAGCTCCAGGGAAGGGCCTGGAGTGGGTCG- CAC GTATTTATCCCACAAATGGTTACACACGGTATGCGGACTCTGTGAAGGGCCGATTCACCATCTCCGCAGAC- ACT TCCAAGAACACCGCGTATCTGCAAATGAACAGTCTGAGAGCTGAGGACACGGCCGTTTATTACTGTTCAAG- ATG GGGCGGAGACGGTTTCTACGCTATGGACTACTGGGGCCAAGGGACCCTGGTCACCGTCTCCTCA 159 719 H1 GFNIKDTY 160 719 H1 GGATTCAACATTAAAGATACTTAT 161 719 H3 SRWGGDGFYAMDY 162 719 H3 TCAAGATGGGGCGGAGACGGTTTCTACGCTATGGACTAC 163 719 H2 IYPTNGYT 164 719 H2 ATTTATCCCACAAATGGTTACACA 165 719 CH2 APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVV- S VLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 166 719 CH2 GCTCCAGAACTGCTGGGAGGACCTAGCGTGTTCCTGTTTCCCCCTAAGCCAAAAGACACTCTGATGATTTCCA- G GACTCCCGAGGTGACCTGCGTGGTGGTGGACGTGTCTCACGAGGACCCCGAAGTGAAGTTCAACTGGTACG- TGG ATGGCGTGGAAGTGCATAATGCTAAGACAAAACCAAGAGAGGAACAGTACAACTCCACTTATCGCGTCGTG- AGC GTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGGAAGGAGTATAAGTGCAAAGTCAGTAATAAGGCCCT- GCC TGCTCCAATCGAAAAAACCATCTCTAAGGCCAAA 167 719 CH3 GQPREPQVYTYPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDEDGSFALVSKLTVD- K SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG 168 719 CH3 GGCCAGCCAAGGGAGCCCCAGGTGTACACATACCCACCCAGCAGAGACGAACTGACCAAGAACCAGGTGTCCC- T GACATGTCTGGTGAAAGGCTTCTATCCTAGTGATATTGCTGTGGAGTGGGAATCAAATGGACAGCCAGAGA- ACA ATTACAAGACCACACCTCCAGTGCTGGACGAGGATGGCAGCTTCGCCCTGGTGTCCAAGCTGACAGTGGAT- AAA TCTCGATGGCAGCAGGGGAACGTGTTTAGTTGTTCAGTGATGCATGAAGCCCTGCACAATCATTACACTCA- GAA GAGCCTGTCCCTGTCTCCCGGC 169 720 Full DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTL- T ISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKGGSGGGSGGGSGGGSGGGSGEVQLVESGGGLVQPGGSL- RLS CAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTA- VYY CSRWGGDGFYAMDYWGQGTLVTVSSAAEPKSSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEV- TCV VVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIE- KTI SKAKGQPREPQVYTLPPSRDELTKNQVSLICLVKGFYPSDIAVEWESNGQPENRYMTWPPVLDSDGSFFLY- SKL TVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPCK 170 720 Full GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGG- C AAGTCAGGACGTTAACACCGCTGTAGCTTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCT- ATT CTGCATCCTTTTTGTACAGTGGGGTCCCATCAAGGTTCAGTGGCAGTCGATCTGGGACAGATTTCACTCTC- ACC ATCAGCAGTCTGCAACCTGAAGATTTTGCAACTTACTACTGTCAACAGCATTACACTACCCCACCCACTTT- CGG CCAAGGGACCAAAGTGGAGATCAAAGGTGGTTCTGGTGGTGGTTCTGGTGGTGGTTCTGGTGGTGGTTCTG- GTG GTGGTTCTGGTGAAGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGCGGGTCCCTGAGACTC- TCC TGTGCAGCCTCTGGATTCAACATTAAAGATACTTATATCCACTGGGTCCGGCAAGCTCCAGGGAAGGGCCT- GGA GTGGGTCGCACGTATTTATCCCACAAATGGTTACACACGGTATGCGGACTCTGTGAAGGGCCGATTCACCA- TCT CCGCAGACACTTCCAAGAACACCGCGTATCTGCAAATGAACAGTCTGAGAGCTGAGGACACGGCCGTTTAT- TAC TGTTCAAGATGGGGCGGAGACGGTTTCTACGCTATGGACTACTGGGGCCAAGGGACCCTGGTCACCGTCTC- CTC AGCCGCCGAGCCCAAGAGCAGCGATAAGACCCACACCTGCCCTCCCTGTCCAGCTCCAGAACTGCTGGGAG- GAC CTAGCGTGTTCCTGTTTCCCCCTAAGCCAAAAGACACTCTGATGATTTCCAGGACTCCCGAGGTGACCTGC- GTG GTGGTGGACGTGTCTCACGAGGACCCCGAAGTGAAGTTCAACTGGTACGTGGATGGCGTGGAAGTGCATAA- TGC TAAGACAAAACCAAGAGAGGAACAGTACAACTCCACTTATCGCGTCGTGAGCGTGCTGACCGTGCTGCACC- AGG

ACTGGCTGAACGGGAAGGAGTATAAGTGCAAAGTCAGTAATAAGGCCCTGCCTGCTCCAATCGAAAAAACC- ATC TCTAAGGCCAAAGGCCAGCCAAGGGAGCCCCAGGTGTACACACTGCCACCCAGCAGAGACGAACTGACCAA- GAA CCAGGTGTCCCTGATCTGTCTGGTGAAAGGCTTCTATCCTAGTGATATTGCTGTGGAGTGGGAATCAAATG- GAC AGCCAGAGAACAGATACATGACCTGGCCTCCAGTGCTGGACAGCGATGGCAGCTTCTTCCTGTATTCCAAG- CTG ACAGTGGATAAATCTCGATGGCAGCAGGGGAACGTGTTTAGTTGTTCAGTGATGCATGAAGCCCTGCACAA- TCA TTACACTCAGAAGAGCCTGTCCCTGTCTCCCGGCAAA 171 720 VL DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFS- GSRSGTDFTLT ISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK 172 720 VL GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATC- ACTTGCCGGGC AAGTCAGGACGTTAACACCGCTGTAGCTTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCT- ATT CTGCATCCTTTTTGTACAGTGGGGTCCCATCAAGGTTCAGTGGCAGTCGATCTGGGACAGATTTCACTCTC- ACC ATCAGCAGTCTGCAACCTGAAGATTTTGCAACTTACTACTGTCAACAGCATTACACTACCCCACCCACTTT- CGG CCAAGGGACCAAAGTGGAGATCAAA 173 720 L1 QDVNTA 174 720 L1 CAGGACGTTAACACCGCT 175 720 L3 QQHYTTPPT 176 720 L3 CAACAGCATTACACTACCCCACCCACT 177 720 L2 SAS 178 720 L2 TCTGCATCC 179 720 VH EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADS- VKGRFTISADT S SKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVS 180 720 VH GAAGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGCGGGTCCCTGAGACTCTCC- TGTGCAGCCTC TGGATTCAACATTAAAGATACTTATATCCACTGGGTCCGGCAAGCTCCAGGGAAGGGCCTGGAGTGGGTCG- CAC GTATTTATCCCACAAATGGTTACACACGGTATGCGGACTCTGTGAAGGGCCGATTCACCATCTCCGCAGAC- ACT TCCAAGAACACCGCGTATCTGCAAATGAACAGTCTGAGAGCTGAGGACACGGCCGTTTATTACTGTTCAAG- ATG GGGCGGAGACGGTTTCTACGCTATGGACTACTGGGGCCAAGGGACCCTGGTCACCGTCTCCTCA 181 720 H1 GFNIKDTY 182 720 H1 GGATTCAACATTAAAGATACTTAT 183 720 H3 SRWGGDGFYAMDY 184 720 H3 TCAAGATGGGGCGGAGACGGTTTCTACGCTATGGACTAC 185 720 H2 IYPTNGYT 186 720 H2 ATTTATCCCACAAATGGTTACACA 187 720 CH2 APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVV- S VLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 188 720 CH2 GCTCCAGAACTGCTGGGAGGACCTAGCGTGTTCCTGTTTCCCCCTAAGCCAAAAGACACTCTGATGATTTCCA- G GACTCCCGAGGTGACCTGCGTGGTGGTGGACGTGTCTCACGAGGACCCCGAAGTGAAGTTCAACTGGTACG- TGG ATGGCGTGGAAGTGCATAATGCTAAGACAAAACCAAGAGAGGAACAGTACAACTCCACTTATCGCGTCGTG- AGC GTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGGAAGGAGTATAAGTGCAAAGTCAGTAATAAGGCCCT- GCC TGCTCCAATCGAAAAAACCATCTCTAAGGCCAAA 189 720 CH3 GQPREPQVYTLPPSRDELTKNQVSLICLVKGFYPSDIAVEWESNGQPENRYMTWPPVLDSDGSFFLYSKLTVD- K PG SRWQQGNVFSCSVMHEALHNHYTQKSLSLS 190 720 CH3 GGCCAGCCAAGGGAGCCCCAGGTGTACACACTGCCACCCAGCAGAGACGAACTGACCAAGAACCAGGTGTCCC- T GATCTGTCTGGTGAAAGGCTTCTATCCTAGTGATATTGCTGTGGAGTGGGAATCAAATGGACAGCCAGAGA- ACA GATACATGACCTGGCCTCCAGTGCTGGACAGCGATGGCAGCTTCTTCCTGTATTCCAAGCTGACAGTGGAT- AAA TCTCGATGGCAGCAGGGGAACGTGTTTAGTTGTTCAGTGATGCATGAAGCCCTGCACAATCATTACACTCA- GAA GAGCCTGTCCCTGTCTCCCGGC 191 4561 Full DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTL- T ISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAK- VQW KVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 192 4561 Full GATATTCAGATGACCCAGTCCCCTAGCTCCCTGTCCGCTTCTGTGGGCGACAGGGTCACTATCACCTGCCGCG- C ATCTCAGGATGTGAACACCGCAGTCGCCTGGTACCAGCAGAAGCCTGGGAAAGCTCCAAAGCTGCTGATCT- ACA GTGCATCATTCCTGTATTCAGGAGTGCCCAGCCGGTTTAGCGGCAGCAGATCTGGCACCGACTTCACACTG- ACT ATCTCTAGTCTGCAGCCTGAGGATTTTGCCACATACTATTGCCAGCAGCACTATACCACACCCCCTACTTT- CGG CCAGGGGACCAAAGTGGAGATCAAGCGAACTGTGGCCGCTCCAAGTGTCTTCATTTTTCCACCCAGCGACG- AAC AGCTGAAATCCGGCACAGCTTCTGTGGTCTGTCTGCTGAACAACTTCTACCCCAGAGAGGCCAAAGTGCAG- TGG AAGGTCGATAACGCTCTGCAGAGTGGCAACAGCCAGGAGAGCGTGACAGAACAGGACTCCAAAGATTCTAC- TTA TAGTCTGTCAAGCACCCTGACACTGAGCAAGGCAGACTACGAAAAGCATAAAGTGTATGCCTGTGAGGTGA- CCC ATCAGGGGCTGTCTTCTCCCGTGACCAAGTCTTTCAACCGAGGCGAATGT 193 4561 VL DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTL- T ISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK 194 4561 VL GATATTCAGATGACCCAGTCCCCTAGCTCCCTGTCCGCTTCTGTGGGCGACAGGGTCACTATCACCTGCCGCG- C ATCTCAGGATGTGAACACCGCAGTCGCCTGGTACCAGCAGAAGCCTGGGAAAGCTCCAAAGCTGCTGATCT- ACA GTGCATCATTCCTGTATTCAGGAGTGCCCAGCCGGTTTAGCGGCAGCAGATCTGGCACCGACTTCACACTG- ACT ATCTCTAGTCTGCAGCCTGAGGATTTTGCCACATACTATTGCCAGCAGCACTATACCACACCCCCTACTTT- CGG CCAGGGGACCAAAGTGGAGATCAAG 195 4561 L1 QDVNTA 196 4561 L1 CAGGATGTGAACACCGCA 197 4561 L3 QQHYTTPPT 198 4561 L3 CAGCAGCACTATACCACACCCCCTACT 199 4561 L2 SAS 200 4561 L2 AGTGCATCA 201 4561 CL RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT- L SKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 202 4561 CL CGAACTGTGGCCGCTCCAAGTGTCTTCATTTTTCCACCCAGCGACGAACAGCTGAAATCCGGCACAGCTTCTG- T GGTCTGTCTGCTGAACAACTTCTACCCCAGAGAGGCCAAAGTGCAGTGGAAGGTCGATAACGCTCTGCAGA- GTG GCAACAGCCAGGAGAGCGTGACAGAACAGGACTCCAAAGATTCTACTTATAGTCTGTCAAGCACCCTGACA- CTG AGCAAGGCAGACTACGAAAAGCATAAAGTGTATGCCTGTGAGGTGACCCATCAGGGGCTGTCTTCTCCCGT- GAC CAAGTCTTTCAACCGAGGCGAATGT 203 3041 Full EVQLVESGGGLVQPGGSLRLSCAASGFTFTDYTMDWVRQAPGKGLEWVADVNPNSGCSIYNQRFKGRFTLSVD- R SKNTLYLQMNSLRAEDTAVYYCARNLGPSFYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALG- CLV KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEP- KSC DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKP- REE QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYVLPPSRDELTKNQVSL- LCL VKGFYPSDIAVEWESNGQPENNYLTWPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQK- SLS LSPG 204 3041 Full GAAGTGCAGCTGGTCGAATCTGGAGGAGGACTGGTGCAGCCAGGAGGGTCCCTGCGCCTGTCTTGCGCCGCTA- G TGGCTTCACTTTTACCGACTACACCATGGATTGGGTGCGACAGGCACCTGGAAAGGGCCTGGAGTGGGTCG- CCG ATGTGAACCCAAATAGCGGAGGCTCCATCTACAACCAGCGGTTCAAGGGCCGGTTCACCCTGTCAGTGGAC- CGG AGCAAAAACACCCTGTATCTGCAGATGAATAGCCTGCGAGCCGAAGATACTGCTGTGTACTATTGCGCCCG- GAA TCTGGGGCCCTCCTTCTACTTTGACTATTGGGGGCAGGGAACTCTGGTCACCGTGAGCTCCGCCTCCACCA- AGG GACCTTCTGTGTTCCCACTGGCTCCCTCTAGTAAATCCACATCTGGGGGAACTGCAGCCCTGGGCTGTCTG- GTG AAGGACTACTTCCCAGAGCCCGTCACAGTGTCTTGGAACAGTGGCGCTCTGACTTCTGGGGTCCACACCTT- TCC TGCAGTGCTGCAGTCAAGCGGGCTGTACAGCCTGTCCTCTGTGGTCACCGTGCCAAGTTCAAGCCTGGGAA- CAC AGACTTATATCTGCAACGTGAATCACAAGCCATCCAATACAAAAGTCGACAAGAAAGTGGAACCCAAGTCT- TGT GATAAAACCCATACATGCCCCCCTTGTCCTGCACCAGAGCTGCTGGGAGGACCAAGCGTGTTCCTGTTTCC- ACC CAAGCCTAAAGATACACTGATGATTAGTAGGACCCCAGAAGTCACATGCGTGGTCGTGGACGTGAGCCACG- AGG ACCCCGAAGTCAAGTTTAACTGGTACGTGGACGGCGTCGAGGTGCATAATGCCAAGACTAAACCCAGGGAG- GAA CAGTACAACAGTACCTATCGCGTCGTGTCAGTCCTGACAGTGCTGCATCAGGATTGGCTGAACGGGAAAGA- GTA TAAGTGCAAAGTGAGCAATAAGGCTCTGCCCGCACCTATCGAGAAAACAATTTCCAAGGCAAAAGGACAGC- CTA GAGAACCACAGGTGTACGTGCTGCCTCCATCAAGGGATGAGCTGACAAAGAACCAGGTCAGCCTGCTGTGT- CTG GTGAAAGGATTCTATCCCTCTGACATTGCTGTGGAGTGGGAAAGTAATGGCCAGCCTGAGAACAATTACCT- GAC CTGGCCCCCTGTGCTGGACTCAGATGGCAGCTTCTTTCTGTATAGCAAGCTGACCGTCGACAAATCCCGGT- GGC AGCAGGGGAATGTGTTTAGTTGTTCAGTCATGCACGAGGCACTGCACAACCATTACACCCAGAAGTCACTG- TCA CTGTCACCAGGG 205 3041 VH EVQLVESGGGLVQPGGSLRLSCAASGFTFTDYTMDWVRQAPGKGLEWVADVNPNSGCSIYNQRFKGRFTLSVD- R SKNTLYLQMNSLRAEDTAVYYCARNLGPSFYFDYWGQGTLVTVSS 206 3041 VH GAAGTGCAGCTGGTCGAATCTGGAGGAGGACTGGTGCAGCCAGGAGGGTCCCTGCGCCTGTCTTGCGCCGCTA- G TGGCTTCACTTTTACCGACTACACCATGGATTGGGTGCGACAGGCACCTGGAAAGGGCCTGGAGTGGGTCG- CCG ATGTGAACCCAAATAGCGGAGGCTCCATCTACAACCAGCGGTTCAAGGGCCGGTTCACCCTGTCAGTGGAC- CGG AGCAAAAACACCCTGTATCTGCAGATGAATAGCCTGCGAGCCGAAGATACTGCTGTGTACTATTGCGCCCG- GAA TCTGGGGCCCTCCTTCTACTTTGACTATTGGGGGCAGGGAACTCTGGTCACCGTGAGCTCC 207 3041 H1 GFTFTDYT 208 3041 H1 GGCTTCACTTTTACCGACTACACC 209 3041 H3 ARNLGPSFYFDY 210 3041 H3 GCCCGGAATCTGGGGCCCTCCTTCTACTTTGACTAT 211 3041 H2 VNPNSGGS 212 3041 H2 GTGAACCCAAATAGCGGAGGCTCC 213 3041 CH1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPS- S

SLGTQTYICNVNHKPSNTKVDKKV 214 3041 CH1 GCCTCCACCAAGGGACCTTCTGTGTTCCCACTGGCTCCCTCTAGTAAATCCACATCTGGGGGAACTGCAGCCC- T GGGCTGTCTGGTGAAGGACTACTTCCCAGAGCCCGTCACAGTGTCTTGGAACAGTGGCGCTCTGACTTCTG- GGG TCCACACCTTTCCTGCAGTGCTGCAGTCAAGCGGGCTGTACAGCCTGTCCTCTGTGGTCACCGTGCCAAGT- TCA AGCCTGGGAACACAGACTTATATCTGCAACGTGAATCACAAGCCATCCAATACAAAAGTCGACAAGAAAGT- G 215 3041 CH2 APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVV- S VLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 216 3041 CH2 GCACCAGAGCTGCTGGGAGGACCAAGCGTGTTCCTGTTTCCACCCAAGCCTAAAGATACACTGATGATTAGTA- G GACCCCAGAAGTCACATGCGTGGTCGTGGACGTGAGCCACGAGGACCCCGAAGTCAAGTTTAACTGGTACG- TGG ACGGCGTCGAGGTGCATAATGCCAAGACTAAACCCAGGGAGGAACAGTACAACAGTACCTATCGCGTCGTG- TCA GTCCTGACAGTGCTGCATCAGGATTGGCTGAACGGGAAAGAGTATAAGTGCAAAGTGAGCAATAAGGCTCT- GCC CGCACCTATCGAGAAAACAATTTCCAAGGCAAAA 217 3041 CH3 GQPREPQVYVLPPSRDELTKNQVSLLCLVKGFYPSDIAVEWESNGQPENNYLTWPPVLDSDGSFFLYSKLTVD- K SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG 218 3041 CH3 GGACAGCCTAGAGAACCACAGGTGTACGTGCTGCCTCCATCAAGGGATGAGCTGACAAAGAACCAGGTCAGCC- T GCTGTGTCTGGTGAAAGGATTCTATCCCTCTGACATTGCTGTGGAGTGGGAAAGTAATGGCCAGCCTGAGA- ACA ATTACCTGACCTGGCCCCCTGTGCTGGACTCAGATGGCAGCTTCTTTCTGTATAGCAAGCTGACCGTCGAC- AAA TCCCGGTGGCAGCAGGGGAATGTGTTTAGTTGTTCAGTCATGCACGAGGCACTGCACAACCATTACACCCA- GAA GTCACTGTCACTGTCACCAGGG 219 3057 Full EVQLVESGGGLVQPGGSLRLSCAASGFTFTDYTMDWVRQAPGKGLEWVADVNPNSGCSIYNQRFKGRFTLSVD- R SKNTLYLQMNSLRAEDTAVYYCARNLGPSFYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALG- CLV KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEP- KSC DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKP- REE QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYVYPPSRDELTKNQVSL- TCL VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFALVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQK- SLS LSPG 220 3057 Full GAAGTGCAGCTGGTCGAATCTGGAGGAGGACTGGTGCAGCCAGGAGGGTCCCTGCGCCTGTCTTGCGCCGCTA- G TGGCTTCACTTTTACCGACTACACCATGGATTGGGTGCGACAGGCACCTGGAAAGGGCCTGGAGTGGGTCG- CCG ATGTGAACCCAAATAGCGGAGGCTCCATCTACAACCAGCGGTTCAAGGGCCGGTTCACCCTGTCAGTGGAC- CGG AGCAAAAACACCCTGTATCTGCAGATGAATAGCCTGCGAGCCGAAGATACTGCTGTGTACTATTGCGCCCG- GAA TCTGGGGCCCTCCTTCTACTTTGACTATTGGGGGCAGGGAACTCTGGTCACCGTGAGCTCCGCCTCCACCA- AGG GACCTTCTGTGTTCCCACTGGCTCCCTCTAGTAAATCCACATCTGGGGGAACTGCAGCCCTGGGCTGTCTG- GTG AAGGACTACTTCCCAGAGCCCGTCACAGTGTCTTGGAACAGTGGCGCTCTGACTTCTGGGGTCCACACCTT- TCC TGCAGTGCTGCAGTCAAGCGGGCTGTACAGCCTGTCCTCTGTGGTCACCGTGCCAAGTTCAAGCCTGGGAA- CAC AGACTTATATCTGCAACGTGAATCACAAGCCATCCAATACAAAAGTCGACAAGAAAGTGGAACCCAAGTCT- TGT GATAAAACCCATACATGCCCCCCTTGTCCTGCACCAGAGCTGCTGGGAGGACCAAGCGTGTTCCTGTTTCC- ACC CAAGCCTAAAGATACACTGATGATTAGTAGGACCCCAGAAGTCACATGCGTGGTCGTGGACGTGAGCCACG- AGG ACCCCGAAGTCAAGTTTAACTGGTACGTGGACGGCGTCGAGGTGCATAATGCCAAGACTAAACCCAGGGAG- GAA CAGTACAACAGTACCTATCGCGTCGTGTCAGTCCTGACAGTGCTGCATCAGGATTGGCTGAACGGGAAAGA- GTA TAAGTGCAAAGTGAGCAATAAGGCTCTGCCCGCACCTATCGAGAAAACAATTTCCAAGGCAAAAGGACAGC- CTA GAGAACCACAGGTGTACGTGTATCCTCCATCAAGGGATGAGCTGACAAAGAACCAGGTCAGCCTGACTTGT- CTG GTGAAAGGATTCTATCCCTCTGACATTGCTGTGGAGTGGGAAAGTAATGGCCAGCCTGAGAACAATTACAA- GAC CACACCCCCTGTGCTGGACTCAGATGGCAGCTTCGCGCTGGTGAGCAAGCTGACCGTCGACAAATCCCGGT- GGC AGCAGGGGAATGTGTTTAGTTGTTCAGTCATGCACGAGGCACTGCACAACCATTACACCCAGAAGTCACTG- TCA CTGTCACCAGGG 221 3057 VH EVQLVESGGGLVQPGGSLRLSCAASGFTFTDYTMDWVRQAPGKGLEWVADVNPNSGCSIYNQRFKGRFTLSVD- R SKNTLYLQMNSLRAEDTAVYYCARNLGPSFYFDYWGQGTLVTVSS 222 3057 VH GAAGTGCAGCTGGTCGAATCTGGAGGAGGACTGGTGCAGCCAGGAGGGTCCCTGCGCCTGTCTTGCGCCGCTA- G TGGCTTCACTTTTACCGACTACACCATGGATTGGGTGCGACAGGCACCTGGAAAGGGCCTGGAGTGGGTCG- CCG ATGTGAACCCAAATAGCGGAGGCTCCATCTACAACCAGCGGTTCAAGGGCCGGTTCACCCTGTCAGTGGAC- CGG AGCAAAAACACCCTGTATCTGCAGATGAATAGCCTGCGAGCCGAAGATACTGCTGTGTACTATTGCGCCCG- GAA TCTGGGGCCCTCCTTCTACTTTGACTATTGGGGGCAGGGAACTCTGGTCACCGTGAGCTCC 223 3057 H1 GFTFTDYT 224 3057 H1 GGCTTCACTTTTACCGACTACACC 225 3057 H3 ARNLGPSFYFDY 226 3057 H3 GCCCGGAATCTGGGGCCCTCCTTCTACTTTGACTAT 227 3057 H2 VNPNSGGS 228 3057 H2 GTGAACCCAAATAGCGGAGGCTCC 229 3057 CH1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPS- S SLGTQTYICNVNHKPSNTKVDKKV 230 3057 CH1 GCCTCCACCAAGGGACCTTCTGTGTTCCCACTGGCTCCCTCTAGTAAATCCACATCTGGGGGAACTGCAGCCC- T GGGCTGTCTGGTGAAGGACTACTTCCCAGAGCCCGTCACAGTGTCTTGGAACAGTGGCGCTCTGACTTCTG- GGG TCCACACCTTTCCTGCAGTGCTGCAGTCAAGCGGGCTGTACAGCCTGTCCTCTGTGGTCACCGTGCCAAGT- TCA AGCCTGGGAACACAGACTTATATCTGCAACGTGAATCACAAGCCATCCAATACAAAAGTCGACAAGAAAGT- G 231 3057 CH2 APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVV- S VLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 232 3057 CH2 GCACCAGAGCTGCTGGGAGGACCAAGCGTGTTCCTGTTTCCACCCAAGCCTAAAGATACACTGATGATTAGTA- G GACCCCAGAAGTCACATGCGTGGTCGTGGACGTGAGCCACGAGGACCCCGAAGTCAAGTTTAACTGGTACG- TGG ACGGCGTCGAGGTGCATAATGCCAAGACTAAACCCAGGGAGGAACAGTACAACAGTACCTATCGCGTCGTG- TCA GTCCTGACAGTGCTGCATCAGGATTGGCTGAACGGGAAAGAGTATAAGTGCAAAGTGAGCAATAAGGCTCT- GCC CGCACCTATCGAGAAAACAATTTCCAAGGCAAAA 233 3057 CH3 GQPREPQVYVYPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFALVSKLTVD- K SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG 234 3057 CH3 GGACAGCCTAGAGAACCACAGGTGTACGTGTATCCTCCATCAAGGGATGAGCTGACAAAGAACCAGGTCAGCC- T GACTTGTCTGGTGAAAGGATTCTATCCCTCTGACATTGCTGTGGAGTGGGAAAGTAATGGCCAGCCTGAGA- ACA ATTACAAGACCACACCCCCTGTGCTGGACTCAGATGGCAGCTTCGCGCTGGTGAGCAAGCTGACCGTCGAC- AAA TCCCGGTGGCAGCAGGGGAATGTGTTTAGTTGTTCAGTCATGCACGAGGCACTGCACAACCATTACACCCA- GAA GTCACTGTCACTGTCACCAGGG 235 1011 Full EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISAD- T SKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAAL- GCL VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVE- PKS CDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK- PRE EQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYVYPPSRDELTKNQVS- LTC LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFALVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQ- KSL SLSPGK 236 1011 Full GAGGTGCAGCTGGTGGAAAGCGGAGGAGGACTGGTGCAGCCAGGAGGATCTCTGCGACTGAGTTGCGCCGCTT- C AGGATTCAACATCAAGGACACCTACATTCACTGGGTGCGACAGGCTCCAGGAAAAGGACTGGAGTGGGTGG- CTC GAATCTATCCCACTAATGGATACACCCGGTATGCCGACTCCGTGAAGGGGAGGTTTACTATTAGCGCCGAT- ACA TCCAAAAACACTGCTTACCTGCAGATGAACAGCCTGCGAGCCGAAGATACCGCTGTGTACTATTGCAGTCG- ATG GGGAGGAGACGGATTCTACGCTATGGATTATTGGGGACAGGGGACCCTGGTGACAGTGAGCTCCGCCTCTA- CCA AGGGCCCCAGTGTGTTTCCCCTGGCTCCTTCTAGTAAATCCACCTCTGGAGGGACAGCCGCTCTGGGATGT- CTG GTGAAGGACTATTTCCCCGAGCCTGTGACCGTGAGTTGGAACTCAGGCGCCCTGACAAGCGGAGTGCACAC- TTT TCCTGCTGTGCTGCAGTCAAGCGGGCTGTACTCCCTGTCCTCTGTGGTGACAGTGCCAAGTTCAAGCCTGG- GCA CACAGACTTATATCTGCAACGTGAATCATAAGCCCTCAAATACAAAAGTGGACAAGAAAGTGGAGCCCAAG- AGC TGTGATAAGACCCACACCTGCCCTCCCTGTCCAGCTCCAGAACTGCTGGGAGGACCTAGCGTGTTCCTGTT- TCC CCCTAAGCCAAAAGACACTCTGATGATTTCCAGGACTCCCGAGGTGACCTGCGTGGTGGTGGACGTGTCTC- ACG AGGACCCCGAAGTGAAGTTCAACTGGTACGTGGATGGCGTGGAAGTGCATAATGCTAAGACAAAACCAAGA- GAG GAACAGTACAACTCCACTTATCGCGTCGTGAGCGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGGAA- GGA GTATAAGTGCAAAGTCAGTAATAAGGCCCTGCCTGCTCCAATCGAAAAAACCATCTCTAAGGCCAAAGGCC- AGC CAAGGGAGCCCCAGGTGTACGTGTACCCACCCAGCAGAGACGAACTGACCAAGAACCAGGTGTCCCTGACA- TGT CTGGTGAAAGGCTTCTATCCTAGTGATATTGCTGTGGAGTGGGAATCAAATGGACAGCCAGAGAACAATTA- CAA GACCACACCTCCAGTGCTGGACAGCGATGGCAGCTTCGCCCTGGTGTCCAAGCTGACAGTGGATAAATCTC- GAT GGCAGCAGGGGAACGTGTTTAGTTGTTCAGTGATGCATGAAGCCCTGCACAATCATTACACTCAGAAGAGC- CTG TCCCTGTCTCCCGGCAAA 237 1011 VH EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISAD- T SKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS 238 1011 VH GAGGTGCAGCTGGTGGAAAGCGGAGGAGGACTGGTGCAGCCAGGAGGATCTCTGCGACTGAGTTGCGCCGCTT- C AGGATTCAACATCAAGGACACCTACATTCACTGGGTGCGACAGGCTCCAGGAAAAGGACTGGAGTGGGTGG- CTC GAATCTATCCCACTAATGGATACACCCGGTATGCCGACTCCGTGAAGGGGAGGTTTACTATTAGCGCCGAT- ACA TCCAAAAACACTGCTTACCTGCAGATGAACAGCCTGCGAGCCGAAGATACCGCTGTGTACTATTGCAGTCG- ATG GGGAGGAGACGGATTCTACGCTATGGATTATTGGGGACAGGGGACCCTGGTGACAGTGAGCTCC 239 1011 H1 GFNIKDTY 240 1011 H1 GGATTCAACATCAAGGACACCTAC 241 1011 H3 SRWGGDGFYAMDY 242 1011 H3 AGTCGATGGGGAGGAGACGGATTCTACGCTATGGATTAT

243 1011 H2 IYPTNGYT 244 1011 H2 ATCTATCCCACTAATGGATACACC 245 1011 CH1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPS- S SLGTQTYICNVNHKPSNTKVDKKV 246 1011 CH1 GCCTCTACCAAGGGCCCCAGTGTGTTTCCCCTGGCTCCTTCTAGTAAATCCACCTCTGGAGGGACAGCCGCTC- T GGGATGTCTGGTGAAGGACTATTTCCCCGAGCCTGTGACCGTGAGTTGGAACTCAGGCGCCCTGACAAGCG- GAG TGCACACTTTTCCTGCTGTGCTGCAGTCAAGCGGGCTGTACTCCCTGTCCTCTGTGGTGACAGTGCCAAGT- TCA AGCCTGGGCACACAGACTTATATCTGCAACGTGAATCATAAGCCCTCAAATACAAAAGTGGACAAGAAAGT- G 247 1011 CH2 APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVV- S VLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 248 1011 CH2 GCTCCAGAACTGCTGGGAGGACCTAGCGTGTTCCTGTTTCCCCCTAAGCCAAAAGACACTCTGATGATTTCCA- G GACTCCCGAGGTGACCTGCGTGGTGGTGGACGTGTCTCACGAGGACCCCGAAGTGAAGTTCAACTGGTACG- TGG ATGGCGTGGAAGTGCATAATGCTAAGACAAAACCAAGAGAGGAACAGTACAACTCCACTTATCGCGTCGTG- AGC GTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGGAAGGAGTATAAGTGCAAAGTCAGTAATAAGGCCCT- GCC TGCTCCAATCGAAAAAACCATCTCTAAGGCCAAA 249 1011 CH3 GQPREPQVYVYPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFALVSKLTVD- K SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG 250 1011 CH3 GGCCAGCCAAGGGAGCCCCAGGTGTACGTGTACCCACCCAGCAGAGACGAACTGACCAAGAACCAGGTGTCCC- T GACATGTCTGGTGAAAGGCTTCTATCCTAGTGATATTGCTGTGGAGTGGGAATCAAATGGACAGCCAGAGA- ACA ATTACAAGACCACACCTCCAGTGCTGGACAGCGATGGCAGCTTCGCCCTGGTGTCCAAGCTGACAGTGGAT- AAA TCTCGATGGCAGCAGGGGAACGTGTTTAGTTGTTCAGTGATGCATGAAGCCCTGCACAATCATTACACTCA- GAA GAGCCTGTCCCTGTCTCCCGGC 251 4560 Full EPKSSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK- T KPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYVLPPSRDELTK- NQV SLLCLVKGFYPSDIAVEWESNGQPENNYLTWPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN- HYT QKSLSLSPGK 252 4560 Full GAACCTAAAAGCAGCGACAAGACCCACACATGCCCCCCTTGTCCAGCTCCAGAACTGCTGGGAGGACCAAGCG- T GTTCCTGTTTCCACCCAAGCCCAAAGATACACTGATGATCAGCCGAACTCCCGAGGTCACCTGCGTGGTCG- TGG ACGTGTCCCACGAGGACCCCGAAGTCAAGTTCAACTGGTACGTGGACGGCGTCGAAGTGCATAATGCAAAG- ACT AAACCACGGGAGGAACAGTACAACTCTACATATAGAGTCGTGAGTGTCCTGACTGTGCTGCATCAGGATTG- GCT GAACGGCAAAGAGTATAAGTGCAAAGTGTCTAATAAGGCCCTGCCTGCTCCAATCGAGAAAACTATTAGTA- AGG CAAAAGGGCAGCCCAGGGAACCTCAGGTCTACGTGCTGCCTCCAAGTCGCGACGAGCTGACCAAGAACCAG- GTC TCACTGCTGTGTCTGGTGAAAGGATTCTATCCTTCCGATATTGCCGTGGAGTGGGAATCTAATGGCCAGCC- AGA GAACAATTACCTGACCTGGCCCCCTGTGCTGGACAGCGATGGGTCCTTCTTTCTGTATTCAAAGCTGACAG- TGG ACAAAAGCAGATGGCAGCAGGGAAACGTCTTTAGCTGTTCCGTGATGCACGAAGCCCTGCACAATCATTAC- ACC CAGAAGTCTCTGAGTCTGTCACCTGGCAAA 253 4560 CH2 APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVV- S VLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 254 4560 CH2 GCTCCAGAACTGCTGGGAGGACCAAGCGTGTTCCTGTTTCCACCCAAGCCCAAAGATACACTGATGATCAGCC- G AACTCCCGAGGTCACCTGCGTGGTCGTGGACGTGTCCCACGAGGACCCCGAAGTCAAGTTCAACTGGTACG- TGG ACGGCGTCGAAGTGCATAATGCAAAGACTAAACCACGGGAGGAACAGTACAACTCTACATATAGAGTCGTG- AGT GTCCTGACTGTGCTGCATCAGGATTGGCTGAACGGCAAAGAGTATAAGTGCAAAGTGTCTAATAAGGCCCT- GCC TGCTCCAATCGAGAAAACTATTAGTAAGGCAAAA 255 4560 CH3 GQPREPQVYVLPPSRDELTKNQVSLLCLVKGFYPSDIAVEWESNGQPENNYLTWPPVLDSDGSFFLYSKLTVD- K SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG 256 4560 CH3 GGGCAGCCCAGGGAACCTCAGGTCTACGTGCTGCCTCCAAGTCGCGACGAGCTGACCAAGAACCAGGTCTCAC- T GCTGTGTCTGGTGAAAGGATTCTATCCTTCCGATATTGCCGTGGAGTGGGAATCTAATGGCCAGCCAGAGA- ACA ATTACCTGACCTGGCCCCCTGTGCTGGACAGCGATGGGTCCTTCTTTCTGTATTCAAAGCTGACAGTGGAC- AAA AGCAGATGGCAGCAGGGAAACGTCTTTAGCTGTTCCGTGATGCACGAAGCCCTGCACAATCATTACACCCA- GAA GTCTCTGAGTCTGTCACCTGGC 257 3317 Full DIQMTQSPSSLSASVGDRVTITCKASQDVSIGVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTL- T ISSLQPEDFATYYCQQYYIYPYTFGQGTKVEIKGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCA- ASG FTFTDYTMDWVRQAPGKGLEWVADVNPNSGCSIYNQRFKGRFTLSVDRSKNTLYLQMNSLRAEDTAVYYCA- RNL GPSFYFDYWGQGTLVTVSSAAEPKSSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVD- VSH EDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA- KGQ PREPQVYVYPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFALVSKLTVD- KSR WQQGNVFSCSVMHEALHNHYTQKSLSLSPCK 258 3317 Full GACATTCAGATGACCCAGAGCCCTAGCTCCCTGAGTGCCTCAGTCGGGGACAGGGTGACTATCACCTGCAAGG- C TTCACAGGATGTCAGCATTGGCGTGGCATGGTACCAGCAGAAGCCAGGGAAAGCACCCAAGCTGCTGATCT- ATA GCGCCTCCTACAGGTATACAGGCGTGCCATCCCGCTTCTCTGGCAGTGGGTCAGGAACTGACTTTACACTG- ACT ATTTCTAGTCTGCAGCCCGAAGATTTCGCCACATACTATTGCCAGCAGTACTATATCTACCCTTATACTTT- TGG CCAGGGGACCAAAGTGGAGATTAAGGGCGGAGGAGGCTCCGGAGGAGGAGGGTCTGGAGGAGGAGGAAGTG- AGG TCCAGCTGGTGGAATCTGGAGGAGGACTGGTGCAGCCAGGAGGGTCCCTGAGGCTGTCTTGTGCCGCTAGT- GGC TTCACCTTTACAGACTACACAATGGATTGGGTGCGCCAGGCACCAGGAAAGGGACTGGAATGGGTCGCTGA- TGT GAACCCTAATAGCGGAGGCTCCATCTACAACCAGCGGTTCAAAGGACGGTTCACCCTGTCAGTGGACCGGA- GCA AGAACACCCTGTATCTGCAGATGAACAGCCTGAGAGCCGAGGATACTGCTGTGTACTATTGCGCCAGGAAT- CTG GGCCCAAGCTTCTACTTTGACTATTGGGGGCAGGGAACACTGGTCACTGTGTCAAGCGCAGCCGAACCCAA- ATC CTCTGATAAGACTCACACCTGCCCACCTTGTCCAGCTCCAGAGCTGCTGGGAGGACCTAGCGTGTTCCTGT- TTC CACCCAAGCCAAAAGACACTCTGATGATTTCTAGAACCCCTGAAGTGACATGTGTGGTCGTGGACGTCAGT- CAC GAGGACCCCGAAGTCAAATTCAACTGGTACGTGGATGGCGTCGAGGTGCATAATGCCAAGACCAAACCCCG- AGA GGAACAGTACAACTCAACCTATCGGGTCGTGAGCGTCCTGACAGTGCTGCATCAGGACTGGCTGAACGGCA- AGG AGTATAAGTGCAAAGTGAGCAACAAGGCTCTGCCTGCACCAATCGAGAAGACCATTTCCAAGGCTAAAGGG- CAG CCCCGCGAACCTCAGGTCTACGTGTATCCTCCAAGCCGAGATGAGCTGACAAAAAACCAGGTCTCCCTGAC- TTG TCTGGTGAAGGGATTTTACCCAAGTGACATCGCAGTGGAGTGGGAATCAAATGGCCAGCCCGAAAACAATT- ATA AGACCACACCCCCTGTGCTGGACTCTGATGGGAGTTTCGCACTGGTCTCCAAACTGACCGTGGACAAGTCT- CGG TGGCAGCAGGGAAACGTCTTTAGCTGTTCCGTGATGCACGAGGCCCTGCACAATCATTACACACAGAAATC- TCT GAGTCTGTCACCTGGCAAG 259 3317 VL DIQMTQSPSSLSASVGDRVTITCKASQDVSIGVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTL- T ISSLQPEDFATYYCQQYYIYPYTFGQGTKVEIK 260 3317 VL GACATTCAGATGACCCAGAGCCCTAGCTCCCTGAGTGCCTCAGTCGGGGACAGGGTGACTATCACCTGCAAGG- C TTCACAGGATGTCAGCATTGGCGTGGCATGGTACCAGCAGAAGCCAGGGAAAGCACCCAAGCTGCTGATCT- ATA GCGCCTCCTACAGGTATACAGGCGTGCCATCCCGCTTCTCTGGCAGTGGGTCAGGAACTGACTTTACACTG- ACT ATTTCTAGTCTGCAGCCCGAAGATTTCGCCACATACTATTGCCAGCAGTACTATATCTACCCTTATACTTT- TGG CCAGGGGACCAAAGTGGAGATTAAG 261 3317 L1 QDVSIG 262 3317 L1 CAGGATGTCAGCATTGGC 263 3317 L3 QQYYIYPYT 264 3317 L3 CAGCAGTACTATATCTACCCTTATACT 265 3317 L2 SAS 266 3317 L2 AGCGCCTCC 267 3317 VH EVQLVESGGGLVQPGGSLRLSCAASGFTFTDYTMDWVRQAPGKGLEWVADVNPNSGCSIYNQRFKGRFTLSVD- R SKNTLYLQMNSLRAEDTAVYYCARNLGPSFYFDYWGQGTLVTVSS 268 3317 VH GAGGTCCAGCTGGTGGAATCTGGAGGAGGACTGGTGCAGCCAGGAGGGTCCCTGAGGCTGTCTTGTGCCGCTA- G TGGCTTCACCTTTACAGACTACACAATGGATTGGGTGCGCCAGGCACCAGGAAAGGGACTGGAATGGGTCG- CTG ATGTGAACCCTAATAGCGGAGGCTCCATCTACAACCAGCGGTTCAAAGGACGGTTCACCCTGTCAGTGGAC- CGG AGCAAGAACACCCTGTATCTGCAGATGAACAGCCTGAGAGCCGAGGATACTGCTGTGTACTATTGCGCCAG- GAA TCTGGGCCCAAGCTTCTACTTTGACTATTGGGGGCAGGGAACACTGGTCACTGTGTCAAGC 269 3317 H1 GFTFTDYT 270 3317 H1 GGCTTCACCTTTACAGACTACACA 271 3317 H3 ARNLGPSFYFDY 272 3317 H3 GCCAGGAATCTGGGCCCAAGCTTCTACTTTGACTAT 273 3317 H2 VNPNSGGS 274 3317 H2 GTGAACCCTAATAGCGGAGGCTCC 275 3317 CH2 APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVV- S VLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 276 3317 CH2 GCTCCAGAGCTGCTGGGAGGACCTAGCGTGTTCCTGTTTCCACCCAAGCCAAAAGACACTCTGATGATTTCTA- G AACCCCTGAAGTGACATGTGTGGTCGTGGACGTCAGTCACGAGGACCCCGAAGTCAAATTCAACTGGTACG- TGG ATGGCGTCGAGGTGCATAATGCCAAGACCAAACCCCGAGAGGAACAGTACAACTCAACCTATCGGGTCGTG- AGC GTCCTGACAGTGCTGCATCAGGACTGGCTGAACGGCAAGGAGTATAAGTGCAAAGTGAGCAACAAGGCTCT- GCC TGCACCAATCGAGAAGACCATTTCCAAGGCTAAA 277 3317 CH3 GQPREPQVYVYPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFALVSKLTVD- K SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG 278 3317 CH3 GGGCAGCCCCGCGAACCTCAGGTCTACGTGTATCCTCCAAGCCGAGATGAGCTGACAAAAAACCAGGTCTCCC- T GACTTGTCTGGTGAAGGGATTTTACCCAAGTGACATCGCAGTGGAGTGGGAATCAAATGGCCAGCCCGAAA- ACA

ATTATAAGACCACACCCCCTGTGCTGGACTCTGATGGGAGTTTCGCACTGGTCTCCAAACTGACCGTGGAC- AAG TCTCGGTGGCAGCAGGGAAACGTCTTTAGCTGTTCCGTGATGCACGAGGCCCTGCACAATCATTACACACA- GAA ATCTCTGAGTCTGTCACCTGGC 279 1015 Full EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISAD- T SKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAAL- GCL VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVE- PKS CDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK- PRE EQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYVLPPSRDELTKNQVS- LLC LVKGFYPSDIAVEWESNGQPENNYLTWPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQ- KSL SLSPGK 280 1015 Full GAGGTGCAGCTGGTGGAAAGCGGAGGAGGACTGGTGCAGCCAGGAGGATCTCTGCGACTGAGTTGCGCCGCTT- C AGGATTCAACATCAAGGACACCTACATTCACTGGGTGCGACAGGCTCCAGGAAAAGGACTGGAGTGGGTGG- CTC GAATCTATCCCACTAATGGATACACCCGGTATGCCGACTCCGTGAAGGGGAGGTTTACTATTAGCGCCGAT- ACA TCCAAAAACACTGCTTACCTGCAGATGAACAGCCTGCGAGCCGAAGATACCGCTGTGTACTATTGCAGTCG- ATG GGGAGGAGACGGATTCTACGCTATGGATTATTGGGGACAGGGGACCCTGGTGACAGTGAGCTCCGCCTCTA- CCA AGGGCCCCAGTGTGTTTCCCCTGGCTCCTTCTAGTAAATCCACCTCTGGAGGGACAGCCGCTCTGGGATGT- CTG GTGAAGGACTATTTCCCCGAGCCTGTGACCGTGAGTTGGAACTCAGGCGCCCTGACAAGCGGAGTGCACAC- TTT TCCTGCTGTGCTGCAGTCAAGCGGGCTGTACTCCCTGTCCTCTGTGGTGACAGTGCCAAGTTCAAGCCTGG- GCA CACAGACTTATATCTGCAACGTGAATCATAAGCCCTCAAATACAAAAGTGGACAAGAAAGTGGAGCCCAAG- AGC TGTGATAAGACCCACACCTGCCCTCCCTGTCCAGCTCCAGAACTGCTGGGAGGACCTAGCGTGTTCCTGTT- TCC CCCTAAGCCAAAAGACACTCTGATGATTTCCAGGACTCCCGAGGTGACCTGCGTGGTGGTGGACGTGTCTC- ACG AGGACCCCGAAGTGAAGTTCAACTGGTACGTGGATGGCGTGGAAGTGCATAATGCTAAGACAAAACCAAGA- GAG GAACAGTACAACTCCACTTATCGCGTCGTGAGCGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGGAA- GGA GTATAAGTGCAAAGTCAGTAATAAGGCCCTGCCTGCTCCAATCGAAAAAACCATCTCTAAGGCCAAAGGCC- AGC CAAGGGAGCCCCAGGTGTACGTGCTGCCACCCAGCAGAGACGAACTGACCAAGAACCAGGTGTCCCTGCTG- TGT CTGGTGAAAGGCTTCTATCCTAGTGATATTGCTGTGGAGTGGGAATCAAATGGACAGCCAGAGAACAATTA- CCT GACCTGGCCTCCAGTGCTGGACAGCGATGGCAGCTTCTTCCTGTATTCCAAGCTGACAGTGGATAAATCTC- GAT GGCAGCAGGGGAACGTGTTTAGTTGTTCAGTGATGCATGAAGCCCTGCACAATCATTACACTCAGAAGAGC- CTG TCCCTGTCTCCCGGCAAA 281 1015 VH EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISAD- T SKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS 282 1015 VH GAGGTGCAGCTGGTGGAAAGCGGAGGAGGACTGGTGCAGCCAGGAGGATCTCTGCGACTGAGTTGCGCCGCTT- C AGGATTCAACATCAAGGACACCTACATTCACTGGGTGCGACAGGCTCCAGGAAAAGGACTGGAGTGGGTGG- CTC GAATCTATCCCACTAATGGATACACCCGGTATGCCGACTCCGTGAAGGGGAGGTTTACTATTAGCGCCGAT- ACA TCCAAAAACACTGCTTACCTGCAGATGAACAGCCTGCGAGCCGAAGATACCGCTGTGTACTATTGCAGTCG- ATG GGGAGGAGACGGATTCTACGCTATGGATTATTGGGGACAGGGGACCCTGGTGACAGTGAGCTCC 283 1015 H1 GFNIKDTY 284 1015 H1 GGATTCAACATCAAGGACACCTAC 285 1015 H3 SRWGGDGFYAMDY 286 1015 H3 AGTCGATGGGGAGGAGACGGATTCTACGCTATGGATTAT 287 1015 H2 IYPTNGYT 288 1015 H2 ATCTATCCCACTAATGGATACACC 289 1015 CH1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPS- S SLGTQTYICNVNHKPSNTKVDKKV 290 1015 CH1 GCCTCTACCAAGGGCCCCAGTGTGTTTCCCCTGGCTCCTTCTAGTAAATCCACCTCTGGAGGGACAGCCGCTC- T GGGATGTCTGGTGAAGGACTATTTCCCCGAGCCTGTGACCGTGAGTTGGAACTCAGGCGCCCTGACAAGCG- GAG TGCACACTTTTCCTGCTGTGCTGCAGTCAAGCGGGCTGTACTCCCTGTCCTCTGTGGTGACAGTGCCAAGT- TCA AGCCTGGGCACACAGACTTATATCTGCAACGTGAATCATAAGCCCTCAAATACAAAAGTGGACAAGAAAGT- G 291 1015 CH2 APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVV- S VLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 292 1015 CH2 GCTCCAGAACTGCTGGGAGGACCTAGCGTGTTCCTGTTTCCCCCTAAGCCAAAAGACACTCTGATGATTTCCA- G GACTCCCGAGGTGACCTGCGTGGTGGTGGACGTGTCTCACGAGGACCCCGAAGTGAAGTTCAACTGGTACG- TGG ATGGCGTGGAAGTGCATAATGCTAAGACAAAACCAAGAGAGGAACAGTACAACTCCACTTATCGCGTCGTG- AGC GTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGGAAGGAGTATAAGTGCAAAGTCAGTAATAAGGCCCT- GCC TGCTCCAATCGAAAAAACCATCTCTAAGGCCAAA 293 1015 CH3 GQPREPQVYVLPPSRDELTKNQVSLLCLVKGFYPSDIAVEWESNGQPENNYLTWPPVLDSDGSFFLYSKLTVD- K SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG 294 1015 CH3 GGCCAGCCAAGGGAGCCCCAGGTGTACGTGCTGCCACCCAGCAGAGACGAACTGACCAAGAACCAGGTGTCCC- T GCTGTGTCTGGTGAAAGGCTTCTATCCTAGTGATATTGCTGTGGAGTGGGAATCAAATGGACAGCCAGAGA- ACA ATTACCTGACCTGGCCTCCAGTGCTGGACAGCGATGGCAGCTTCTTCCTGTATTCCAAGCTGACAGTGGAT- AAA TCTCGATGGCAGCAGGGGAACGTGTTTAGTTGTTCAGTGATGCATGAAGCCCTGCACAATCATTACACTCA- GAA GAGCCTGTCCCTGTCTCCCGGC 295 5244 Full DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTL- T ISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKGGSGGGSGGGSGGGSGGGSGEVQLVESGGGLVQPGGSL- RLS CAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTA- VYY CSRWGGDGFYAMDYWGQGTLVTVSSAAEPKSSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEV- TCV VVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIE- KTI SKAKGQPREPQVYVLPPSRDELTKNQVSLLCLVKGFYPSDIAVEWESNGQPENNYLTWPPVLDSDGSFFLY- SKL TVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG 296 5244 Full GACATTCAGATGACACAGAGCCCCAGCTCCCTGAGTGCTTCAGTCGGCGACAGGGTGACTATCACCTGCCGCG- C ATCCCAGGATGTCAACACCGCTGTGGCATGGTACCAGCAGAAGCCTGGAAAAGCCCCAAAGCTGCTGATCT- ACA GCGCTTCCTTCCTGTATTCTGGCGTGCCAAGTCGGTTTTCTGGAAGTAGATCAGGCACTGACTTCACACTG- ACT ATCTCTAGTCTGCAGCCCGAAGATTTTGCCACCTACTATTGCCAGCAGCACTATACCACACCCCCTACATT- CGG ACAGGGCACTAAAGTGGAGATTAAGGGCGGGTCAGGCGGAGGGAGCGGAGGAGGGTCCGGAGGAGGGTCTG- GAG GAGGGAGTGGAGAGGTCCAGCTGGTGGAATCTGGAGGAGGACTGGTGCAGCCTGGAGGCTCACTGCGACTG- AGC TGTGCCGCTTCCGGCTTTAACATCAAAGACACATACATTCATTGGGTCAGGCAGGCACCAGGGAAGGGACT- GGA ATGGGTGGCCCGCATCTATCCCACAAATGGGTACACTCGATATGCCGACAGCGTGAAAGGACGGTTTACCA- TTT CTGCTGATACCAGTAAGAACACAGCATACCTGCAGATGAACAGCCTGCGCGCAGAGGATACAGCCGTGTAC- TAT TGCAGTCGATGGGGGGGAGACGGCTTCTACGCCATGGATTATTGGGGCCAGGGGACTCTGGTCACCGTGTC- AAG CGCAGCCGAACCTAAATCCTCTGACAAGACCCACACATGCCCACCCTGTCCTGCTCCAGAGCTGCTGGGAG- GAC CATCCGTGTTCCTGTTTCCTCCAAAGCCTAAAGATACACTGATGATTAGCCGCACTCCCGAAGTCACCTGT- GTG GTCGTGGACGTGTCCCACGAGGACCCCGAAGTCAAGTTCAACTGGTACGTGGACGGCGTCGAGGTGCATAA- TGC CAAGACTAAACCAAGAGAGGAACAGTACAATTCAACCTATAGGGTCGTGAGCGTCCTGACAGTGCTGCATC- AGG ATTGGCTGAACGGCAAGGAGTATAAGTGCAAAGTGTCTAACAAGGCCCTGCCCGCTCCTATCGAGAAGACT- ATT AGCAAGGCAAAAGGGCAGCCACGGGAACCCCAGGTCTACGTGCTGCCCCCTAGCAGAGACGAGCTGACCAA- AAA CCAGGTCTCCCTGCTGTGTCTGGTGAAGGGCTTTTATCCTAGTGATATCGCTGTGGAGTGGGAATCAAATG- GGC AGCCAGAAAACAATTACCTGACATGGCCACCCGTGCTGGACAGCGATGGGTCCTTCTTTCTGTATTCCAAA- CTG ACTGTGGACAAGTCTAGATGGCAGCAGGGAAACGTCTTCAGCTGTTCCGTGATGCACGAGGCCCTGCACAA- TCA TTACACCCAGAAGTCTCTGAGTCTGTCACCCGGC 297 5244 VL DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTL- T ISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK 298 5244 VL GACATTCAGATGACACAGAGCCCCAGCTCCCTGAGTGCTTCAGTCGGCGACAGGGTGACTATCACCTGCCGCG- C ATCCCAGGATGTCAACACCGCTGTGGCATGGTACCAGCAGAAGCCTGGAAAAGCCCCAAAGCTGCTGATCT- ACA GCGCTTCCTTCCTGTATTCTGGCGTGCCAAGTCGGTTTTCTGGAAGTAGATCAGGCACTGACTTCACACTG- ACT ATCTCTAGTCTGCAGCCCGAAGATTTTGCCACCTACTATTGCCAGCAGCACTATACCACACCCCCTACATT- CGG ACAGGGCACTAAAGTGGAGATTAAG 299 5244 L1 QDVNTA 300 5244 L1 CAGGATGTCAACACCGCT 301 5244 L3 QQHYTTPPT 302 5244 L3 CAGCAGCACTATACCACACCCCCTACA 303 5244 L2 SAS 304 5244 L2 AGCGCTTCC 305 5244 VH EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISAD- T SKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS 306 5244 VH GAGGTCCAGCTGGTGGAATCTGGAGGAGGACTGGTGCAGCCTGGAGGCTCACTGCGACTGAGCTGTGCCGCTT- C CGGCTTTAACATCAAAGACACATACATTCATTGGGTCAGGCAGGCACCAGGGAAGGGACTGGAATGGGTGG- CCC GCATCTATCCCACAAATGGGTACACTCGATATGCCGACAGCGTGAAAGGACGGTTTACCATTTCTGCTGAT- ACC AGTAAGAACACAGCATACCTGCAGATGAACAGCCTGCGCGCAGAGGATACAGCCGTGTACTATTGCAGTCG- ATG GGGGGGAGACGGCTTCTACGCCATGGATTATTGGGGCCAGGGGACTCTGGTCACCGTGTCAAGC 307 5244 H1 GFNIKDTY 308 5244 H1 GGCTTTAACATCAAAGACACATAC 309 5244 H3 SRWGGDGFYAMDY 310 5244 H3 AGTCGATGGGGGGGAGACGGCTTCTACGCCATGGATTAT 311 5244 H2 IYPTNGYT 312 5244 H2 ATCTATCCCACAAATGGGTACACT 313 5244 CH2 APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVV- S VLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK

314 5244 CH2 GCTCCAGAGCTGCTGGGAGGACCATCCGTGTTCCTGTTTCCTCCAAAGCCTAAAGATACACTGATGATTAGCC- G CACTCCCGAAGTCACCTGTGTGGTCGTGGACGTGTCCCACGAGGACCCCGAAGTCAAGTTCAACTGGTACG- TGG ACGGCGTCGAGGTGCATAATGCCAAGACTAAACCAAGAGAGGAACAGTACAATTCAACCTATAGGGTCGTG- AGC GTCCTGACAGTGCTGCATCAGGATTGGCTGAACGGCAAGGAGTATAAGTGCAAAGTGTCTAACAAGGCCCT- GCC CGCTCCTATCGAGAAGACTATTAGCAAGGCAAAA 315 5244 CH3 GQPREPQVYVLPPSRDELTKNQVSLLCLVKGFYPSDIAVEWESNGQPENNYLTWPPVLDSDGSFFLYSKLTVD- K SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG 316 5244 CH3 GGGCAGCCACGGGAACCCCAGGTCTACGTGCTGCCCCCTAGCAGAGACGAGCTGACCAAAAACCAGGTCTCCC- T GCTGTGTCTGGTGAAGGGCTTTTATCCTAGTGATATCGCTGTGGAGTGGGAATCAAATGGGCAGCCAGAAA- ACA ATTACCTGACATGGCCACCCGTGCTGGACAGCGATGGGTCCTTCTTTCTGTATTCCAAACTGACTGTGGAC- AAG TCTAGATGGCAGCAGGGAAACGTCTTCAGCTGTTCCGTGATGCACGAGGCCCTGCACAATCATTACACCCA- GAA GTCTCTGAGTCTGTCACCCGGC 317 -2 Full DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTL- T ISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAK- VQW KVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 318 -2 Full GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGG- C AAGTCAGGACGTTAACACCGCTGTAGCTTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCT- ATT CTGCATCCTTTTTGTACAGTGGGGTCCCATCAAGGTTCAGTGGCAGTCGATCTGGGACAGATTTCACTCTC- ACC ATCAGCAGTCTGCAACCTGAAGATTTTGCAACTTACTACTGTCAACAGCATTACACTACCCCACCCACTTT- CGG CCAAGGGACCAAAGTGGAGATCAAACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATG- AGC AGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAG- TGG AAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAAGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCAC- CTA CAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCA- CCC ATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGT 319 -2 VL DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSG- SRSGTDFTLT ISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK 320 -2 VL GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCA- CTTGCCGGGC AAGTCAGGACGTTAACACCGCTGTAGCTTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCT- ATT CTGCATCCTTTTTGTACAGTGGGGTCCCATCAAGGTTCAGTGGCAGTCGATCTGGGACAGATTTCACTCTC- ACC ATCAGCAGTCTGCAACCTGAAGATTTTGCAACTTACTACTGTCAACAGCATTACACTACCCCACCCACTTT- CGG CCAAGGGACCAAAGTGGAGATCAAA 321 -2 L1 QDVNTA 322 -2 L1 CAGGACGTTAACACCGCT 323 -2 L3 QQHYTTPPT 324 -2 L3 CAACAGCATTACACTACCCCACCCACT 325 -2 L2 SAS 326 -2 L2 TCTGCATCC 327 -2 CL RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDS- TYSLSSTLTL SKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 328 -2 CL CGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAA- CTGCCTCTGT TGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAAT- CGG GTAACTCCCAAGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACG- CTG AGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGT- CAC AAAGAGCTTCAACAGGGGAGAGTGT 329 4372 Full EPKSSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK- T KPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYVLPPSRDELTK- NQV SLLCLVKGFYPSDIAVEWESNGQPENNYLTWPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN- HYT QKSLSLSPG 330 4372 Full GAACCTAAATCCAGCGACAAGACCCACACATGCCCCCCTTGTCCAGCTCCAGAACTGCTGGGAGGACCAAGCG- T GTTCCTGTTTCCACCCAAGCCCAAAGATACACTGATGATCAGCCGAACTCCCGAGGTCACCTGCGTGGTCG- TGG ACGTGTCCCACGAGGACCCCGAAGTCAAGTTCAACTGGTACGTGGACGGCGTCGAAGTGCATAATGCAAAG- ACT AAACCACGGGAGGAACAGTACAACTCTACATATAGAGTCGTGAGTGTCCTGACTGTGCTGCATCAGGATTG- GCT GAACGGCAAAGAGTATAAGTGCAAAGTGTCTAATAAGGCCCTGCCTGCTCCAATCGAGAAAACTATTAGTA- AGG CAAAAGGGCAGCCCAGGGAACCTCAGGTCTACGTGCTGCCTCCAAGTCGCGACGAGCTGACCAAGAACCAG- GTC TCACTGCTGTGTCTGGTGAAAGGATTCTATCCTTCCGATATTGCCGTGGAGTGGGAATCTAATGGCCAGCC- AGA GAACAATTACCTGACCTGGCCCCCTGTGCTGGACAGCGATGGGTCCTTCTTTCTGTATTCAAAGCTGACAG- TGG ACAAAAGCAGATGGCAGCAGGGAAACGTCTTTAGCTGTTCCGTGATGCACGAAGCCCTGCACAATCATTAC- ACC CAGAAGTCTCTGAGTCTGTCACCTGGC 331 4372 CH2 APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVV- S VLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 332 4372 CH2 GCTCCAGAACTGCTGGGAGGACCAAGCGTGTTCCTGTTTCCACCCAAGCCCAAAGATACACTGATGATCAGCC- G AACTCCCGAGGTCACCTGCGTGGTCGTGGACGTGTCCCACGAGGACCCCGAAGTCAAGTTCAACTGGTACG- TGG ACGGCGTCGAAGTGCATAATGCAAAGACTAAACCACGGGAGGAACAGTACAACTCTACATATAGAGTCGTG- AGT GTCCTGACTGTGCTGCATCAGGATTGGCTGAACGGCAAAGAGTATAAGTGCAAAGTGTCTAATAAGGCCCT- GCC TGCTCCAATCGAGAAAACTATTAGTAAGGCAAAA 333 4372 CH3 GQPREPQVYVLPPSRDELTKNQVSLLCLVKGFYPSDIAVEWESNGQPENNYLTWPPVLDSDGSFFLYSKLTVD- K SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG 334 4372 CH3 GGGCAGCCCAGGGAACCTCAGGTCTACGTGCTGCCTCCAAGTCGCGACGAGCTGACCAAGAACCAGGTCTCAC- T GCTGTGTCTGGTGAAAGGATTCTATCCTTCCGATATTGCCGTGGAGTGGGAATCTAATGGCCAGCCAGAGA- ACA ATTACCTGACCTGGCCCCCTGTGCTGGACAGCGATGGGTCCTTCTTTCTGTATTCAAAGCTGACAGTGGAC- AAA AGCAGATGGCAGCAGGGAAACGTCTTTAGCTGTTCCGTGATGCACGAAGCCCTGCACAATCATTACACCCA- GAA GTCTCTGAGTCTGTCACCTGGC SEQ ID NO: Pertuzumab WT CDR sequences 335 CDR-H2 VNPNSGGS 336 CDR-H3 ARNLGPSFYFDY 337 CDR-H1 GFTFTDYT 338 CDR-L2 SAS 339 CDR-L3 QQYYIYPYT 340 CDR-L1 QDVSIG SEQ ID NO: Trastuzumab WT CDR sequences 341 CDR-H2 IYPTNGYT 342 CDR-H3 SRWGGDGFYAMDY 343 CDR-H1 GFNIKDTY 344 CDR-L2 SAS 345 CDR-L3 QQHYTTPPT 346 CDR-L1 QDVNTA Pertuzumab variant CDR-L3: QQYYIYPAT Clone 3382, variant 10000 (SEQ ID NO: 347) Pertuzumab variant CDR-H1: GFTFADYT Clone 6586, variant 10000 (SEQ ID NO: 348)

Sequence CWU 1

1

3501450PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 1Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Ile Lys Asp Thr 20 25 30 Tyr Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Arg Ile Tyr Pro Thr Asn Gly Tyr Thr Arg Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ser Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125 Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala 130 135 140 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190 Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys 195 200 205 Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp 210 215 220 Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 225 230 235 240 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 245 250 255 Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 260 265 270 Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 275 280 285 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg 290 295 300 Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys 305 310 315 320 Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 325 330 335 Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 340 345 350 Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu 355 360 365 Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 370 375 380 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 385 390 395 400 Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 405 410 415 Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His 420 425 430 Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 435 440 445 Gly Lys 450 21350DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 2gaggtgcagc tggtggaaag cggaggagga ctggtgcagc caggaggatc tctgcgactg 60agttgcgccg cttcaggatt caacatcaag gacacctaca ttcactgggt gcgacaggct 120ccaggaaaag gactggagtg ggtggctcga atctatccca ctaatggata cacccggtat 180gccgactccg tgaaggggag gtttactatt agcgccgata catccaaaaa cactgcttac 240ctgcagatga acagcctgcg agccgaagat accgctgtgt actattgcag tcgatgggga 300ggagacggat tctacgctat ggattattgg ggacagggga ccctggtgac agtgagctcc 360gcctctacca agggccccag tgtgtttccc ctggctcctt ctagtaaatc cacctctgga 420gggacagccg ctctgggatg tctggtgaag gactatttcc ccgagcctgt gaccgtgagt 480tggaactcag gcgccctgac aagcggagtg cacacttttc ctgctgtgct gcagtcaagc 540gggctgtact ccctgtcctc tgtggtgaca gtgccaagtt caagcctggg cacacagact 600tatatctgca acgtgaatca taagccctca aatacaaaag tggacaagaa agtggagccc 660aagagctgtg ataagaccca cacctgccct ccctgtccag ctccagaact gctgggagga 720cctagcgtgt tcctgtttcc ccctaagcca aaagacactc tgatgatttc caggactccc 780gaggtgacct gcgtggtggt ggacgtgtct cacgaggacc ccgaagtgaa gttcaactgg 840tacgtggatg gcgtggaagt gcataatgct aagacaaaac caagagagga acagtacaac 900tccacttatc gcgtcgtgag cgtgctgacc gtgctgcacc aggactggct gaacgggaag 960gagtataagt gcaaagtcag taataaggcc ctgcctgctc caatcgaaaa aaccatctct 1020aaggccaaag gccagccaag ggagccccag gtgtacacac tgccacccag cagagacgaa 1080ctgaccaaga accaggtgtc cctgacatgt ctggtgaaag gcttctatcc tagtgatatt 1140gctgtggagt gggaatcaaa tggacagcca gagaacaatt acaagaccac acctccagtg 1200ctggacagcg atggcagctt cttcctgtat tccaagctga cagtggataa atctcgatgg 1260cagcagggga acgtgtttag ttgttcagtg atgcatgaag ccctgcacaa tcattacact 1320cagaagagcc tgtccctgtc tcccggcaaa 13503120PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 3Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Ile Lys Asp Thr 20 25 30 Tyr Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Arg Ile Tyr Pro Thr Asn Gly Tyr Thr Arg Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ser Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser 115 120 4360DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 4gaggtgcagc tggtggaaag cggaggagga ctggtgcagc caggaggatc tctgcgactg 60agttgcgccg cttcaggatt caacatcaag gacacctaca ttcactgggt gcgacaggct 120ccaggaaaag gactggagtg ggtggctcga atctatccca ctaatggata cacccggtat 180gccgactccg tgaaggggag gtttactatt agcgccgata catccaaaaa cactgcttac 240ctgcagatga acagcctgcg agccgaagat accgctgtgt actattgcag tcgatgggga 300ggagacggat tctacgctat ggattattgg ggacagggga ccctggtgac agtgagctcc 36058PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 5Gly Phe Asn Ile Lys Asp Thr Tyr 1 5 624DNAArtificial SequenceDescription of Artificial Sequence Synthetic oligonucleotide 6ggattcaaca tcaaggacac ctac 24713PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 7Ser Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr 1 5 10 839DNAArtificial SequenceDescription of Artificial Sequence Synthetic oligonucleotide 8agtcgatggg gaggagacgg attctacgct atggattat 3998PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 9Ile Tyr Pro Thr Asn Gly Tyr Thr 1 5 1024DNAArtificial SequenceDescription of Artificial Sequence Synthetic oligonucleotide 10atctatccca ctaatggata cacc 241198PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 11Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 1 5 10 15 Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 25 30 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40 45 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 50 55 60 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 65 70 75 80 Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 85 90 95 Lys Val 12294DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 12gcctctacca agggccccag tgtgtttccc ctggctcctt ctagtaaatc cacctctgga 60gggacagccg ctctgggatg tctggtgaag gactatttcc ccgagcctgt gaccgtgagt 120tggaactcag gcgccctgac aagcggagtg cacacttttc ctgctgtgct gcagtcaagc 180gggctgtact ccctgtcctc tgtggtgaca gtgccaagtt caagcctggg cacacagact 240tatatctgca acgtgaatca taagccctca aatacaaaag tggacaagaa agtg 29413110PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 13Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 1 5 10 15 Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val 20 25 30 Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr 35 40 45 Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu 50 55 60 Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His 65 70 75 80 Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys 85 90 95 Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys 100 105 110 14330DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 14gctccagaac tgctgggagg acctagcgtg ttcctgtttc cccctaagcc aaaagacact 60ctgatgattt ccaggactcc cgaggtgacc tgcgtggtgg tggacgtgtc tcacgaggac 120cccgaagtga agttcaactg gtacgtggat ggcgtggaag tgcataatgc taagacaaaa 180ccaagagagg aacagtacaa ctccacttat cgcgtcgtga gcgtgctgac cgtgctgcac 240caggactggc tgaacgggaa ggagtataag tgcaaagtca gtaataaggc cctgcctgct 300ccaatcgaaa aaaccatctc taaggccaaa 33015106PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 15Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp 1 5 10 15 Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe 20 25 30 Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu 35 40 45 Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe 50 55 60 Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly 65 70 75 80 Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr 85 90 95 Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 100 105 16318DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 16ggccagccaa gggagcccca ggtgtacaca ctgccaccca gcagagacga actgaccaag 60aaccaggtgt ccctgacatg tctggtgaaa ggcttctatc ctagtgatat tgctgtggag 120tgggaatcaa atggacagcc agagaacaat tacaagacca cacctccagt gctggacagc 180gatggcagct tcttcctgta ttccaagctg acagtggata aatctcgatg gcagcagggg 240aacgtgttta gttgttcagt gatgcatgaa gccctgcaca atcattacac tcagaagagc 300ctgtccctgt ctcccggc 31817448PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 17Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Thr Asp Tyr 20 25 30 Thr Met Asp Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Asp Val Asn Pro Asn Ser Gly Gly Ser Ile Tyr Asn Gln Arg Phe 50 55 60 Lys Gly Arg Phe Thr Leu Ser Val Asp Arg Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asn Leu Gly Pro Ser Phe Tyr Phe Asp Tyr Trp Gly Gln Gly 100 105 110 Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe 115 120 125 Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu 130 135 140 Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Val Ser Trp 145 150 155 160 Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu 165 170 175 Lys Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser 180 185 190 Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro 195 200 205 Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys 210 215 220 Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro 225 230 235 240 Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser 245 250 255 Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp 260 265 270 Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn 275 280 285 Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val 290 295 300 Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu 305 310 315 320 Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys 325 330 335 Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Val 340 345 350 Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Leu 355 360 365 Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu 370 375 380 Ser Asn Gly Gln Pro Glu Asn Asn Tyr Leu Thr Trp Pro Pro Val Leu 385 390 395 400 Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys 405 410 415 Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu 420 425 430 Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 435 440 445 181344DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 18gaagtgcagc tggtcgaatc tggaggagga ctggtgcagc caggagggtc cctgcgcctg 60tcttgcgccg ctagtggctt cacttttacc gactacacca tggattgggt gcgacaggca 120cctggaaagg gcctggagtg ggtcgccgat gtgaacccaa atagcggagg ctccatctac 180aaccagcggt tcaagggccg gttcaccctg tcagtggacc ggagcaaaaa caccctgtat 240ctgcagatga atagcctgcg agccgaagat actgctgtgt actattgcgc ccggaatctg 300gggccctcct tctactttga ctattggggg cagggaactc tggtcaccgt gagctccgcc 360tccaccaagg gaccttctgt gttcccactg gctccctcta gtaaatccac atctggggga 420actgcagccc tgggctgtct ggtgaagggc tacttcccag agcccgtcac agtgtcttgg 480aacagtggcg ctctgacttc tggggtccac acctttcctg cagtgctgaa gtcaagcggg 540ctgtacagcc tgtcctctgt ggtcaccgtg ccaagttcaa gcctgggaac acagacttat 600atctgcaacg tgaatcacaa gccatccaat acaaaagtcg acaagaaagt ggaacccaag 660tcttgtgata aaacccatac atgcccccct tgtcctgcac cagagctgct gggaggacca 720agcgtgttcc tgtttccacc caagcctaaa gatacactga tgattagtag gaccccagaa 780gtcacatgcg tggtcgtgga cgtgagccac gaggaccccg aagtcaagtt taactggtac 840gtggacggcg tcgaggtgca taatgccaag actaaaccca gggaggaaca gtacaacagt 900acctatcgcg tcgtgtcagt cctgacagtg ctgcatcagg attggctgaa cgggaaagag 960tataagtgca aagtgagcaa taaggctctg cccgcaccta tcgagaaaac aatttccaag 1020gcaaaaggac agcctagaga accacaggtg tacgtgctgc ctccatcaag ggatgagctg 1080acaaagaacc aggtcagcct gctgtgtctg gtgaaaggat tctatccctc tgacattgct 1140gtggagtggg aaagtaatgg ccagcctgag aacaattacc tgacctggcc ccctgtgctg 1200gactcagatg gcagcttctt tctgtatagc aagctgaccg tcgacaaatc ccggtggcag 1260caggggaatg tgtttagttg ttcagtcatg cacgaggcac tgcacaacca ttacacccag 1320aagtcactgt cactgtcacc aggg 134419119PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 19Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Thr Asp Tyr 20 25 30 Thr Met Asp Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40

45 Ala Asp Val Asn Pro Asn Ser Gly Gly Ser Ile Tyr Asn Gln Arg Phe 50 55 60 Lys Gly Arg Phe Thr Leu Ser Val Asp Arg Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asn Leu Gly Pro Ser Phe Tyr Phe Asp Tyr Trp Gly Gln Gly 100 105 110 Thr Leu Val Thr Val Ser Ser 115 20357DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 20gaagtgcagc tggtcgaatc tggaggagga ctggtgcagc caggagggtc cctgcgcctg 60tcttgcgccg ctagtggctt cacttttacc gactacacca tggattgggt gcgacaggca 120cctggaaagg gcctggagtg ggtcgccgat gtgaacccaa atagcggagg ctccatctac 180aaccagcggt tcaagggccg gttcaccctg tcagtggacc ggagcaaaaa caccctgtat 240ctgcagatga atagcctgcg agccgaagat actgctgtgt actattgcgc ccggaatctg 300gggccctcct tctactttga ctattggggg cagggaactc tggtcaccgt gagctcc 357218PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 21Gly Phe Thr Phe Thr Asp Tyr Thr 1 5 2224DNAArtificial SequenceDescription of Artificial Sequence Synthetic oligonucleotide 22ggcttcactt ttaccgacta cacc 242312PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 23Ala Arg Asn Leu Gly Pro Ser Phe Tyr Phe Asp Tyr 1 5 10 2436DNAArtificial SequenceDescription of Artificial Sequence Synthetic oligonucleotide 24gcccggaatc tggggccctc cttctacttt gactat 36258PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 25Val Asn Pro Asn Ser Gly Gly Ser 1 5 2624DNAArtificial SequenceDescription of Artificial Sequence Synthetic oligonucleotide 26gtgaacccaa atagcggagg ctcc 242798PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 27Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 1 5 10 15 Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Gly Tyr 20 25 30 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40 45 Gly Val His Thr Phe Pro Ala Val Leu Lys Ser Ser Gly Leu Tyr Ser 50 55 60 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 65 70 75 80 Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 85 90 95 Lys Val 28294DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 28gcctccacca agggaccttc tgtgttccca ctggctccct ctagtaaatc cacatctggg 60ggaactgcag ccctgggctg tctggtgaag ggctacttcc cagagcccgt cacagtgtct 120tggaacagtg gcgctctgac ttctggggtc cacacctttc ctgcagtgct gaagtcaagc 180gggctgtaca gcctgtcctc tgtggtcacc gtgccaagtt caagcctggg aacacagact 240tatatctgca acgtgaatca caagccatcc aatacaaaag tcgacaagaa agtg 29429110PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 29Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 1 5 10 15 Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val 20 25 30 Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr 35 40 45 Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu 50 55 60 Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His 65 70 75 80 Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys 85 90 95 Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys 100 105 110 30330DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 30gcaccagagc tgctgggagg accaagcgtg ttcctgtttc cacccaagcc taaagataca 60ctgatgatta gtaggacccc agaagtcaca tgcgtggtcg tggacgtgag ccacgaggac 120cccgaagtca agtttaactg gtacgtggac ggcgtcgagg tgcataatgc caagactaaa 180cccagggagg aacagtacaa cagtacctat cgcgtcgtgt cagtcctgac agtgctgcat 240caggattggc tgaacgggaa agagtataag tgcaaagtga gcaataaggc tctgcccgca 300cctatcgaga aaacaatttc caaggcaaaa 33031106PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 31Gly Gln Pro Arg Glu Pro Gln Val Tyr Val Leu Pro Pro Ser Arg Asp 1 5 10 15 Glu Leu Thr Lys Asn Gln Val Ser Leu Leu Cys Leu Val Lys Gly Phe 20 25 30 Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu 35 40 45 Asn Asn Tyr Leu Thr Trp Pro Pro Val Leu Asp Ser Asp Gly Ser Phe 50 55 60 Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly 65 70 75 80 Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr 85 90 95 Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 100 105 32318DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 32ggacagccta gagaaccaca ggtgtacgtg ctgcctccat caagggatga gctgacaaag 60aaccaggtca gcctgctgtg tctggtgaaa ggattctatc cctctgacat tgctgtggag 120tgggaaagta atggccagcc tgagaacaat tacctgacct ggccccctgt gctggactca 180gatggcagct tctttctgta tagcaagctg accgtcgaca aatcccggtg gcagcagggg 240aatgtgttta gttgttcagt catgcacgag gcactgcaca accattacac ccagaagtca 300ctgtcactgt caccaggg 31833214PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 33Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Val Ser Ile Gly 20 25 30 Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ser Ala Ser Tyr Arg Tyr Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Tyr Ile Tyr Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 34642DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 34gatattcaga tgacccagtc cccaagctcc ctgagtgcct cagtgggcga ccgagtcacc 60atcacatgca aggcttccca ggatgtgtct attggagtcg catggtacca gcagaagcca 120ggcaaagcac ccaagctgct gatctatagc gcctcctacc ggtataccgg cgtgccctct 180agattctctg gcagtgggtc aggaacagac tttactctga ccatctctag tctgcagcct 240gaggatttcg ctacctacta ttgccagcag tactatatct acccatatac ctttggccag 300gggacaaaag tggagatcaa gaggactgtg gccgctccct ccgtcttcat ttttccccct 360tctgacgaac agctgaaaag tggcacagcc agcgtggtct gtctgctgaa caatttctac 420cctcgcgaag ccaaagtgca gtggaaggtc gataacgctc tgcagagcgg caacagccag 480gagtctgtga ctgaacagga cagtaaagat tcaacctata gcctgtcaag cacactgact 540ctgagcaagg cagactacga gaagcacaaa gtgtatgcct gcgaagtcac acatcagggg 600ctgtcctctc ctgtgactaa gagctttaac agaggagagt gt 64235107PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 35Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Val Ser Ile Gly 20 25 30 Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ser Ala Ser Tyr Arg Tyr Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Tyr Ile Tyr Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 36321DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 36gatattcaga tgacccagtc cccaagctcc ctgagtgcct cagtgggcga ccgagtcacc 60atcacatgca aggcttccca ggatgtgtct attggagtcg catggtacca gcagaagcca 120ggcaaagcac ccaagctgct gatctatagc gcctcctacc ggtataccgg cgtgccctct 180agattctctg gcagtgggtc aggaacagac tttactctga ccatctctag tctgcagcct 240gaggatttcg ctacctacta ttgccagcag tactatatct acccatatac ctttggccag 300gggacaaaag tggagatcaa g 321376PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 37Gln Asp Val Ser Ile Gly 1 5 3818DNAArtificial SequenceDescription of Artificial Sequence Synthetic oligonucleotide 38caggatgtgt ctattgga 18399PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 39Gln Gln Tyr Tyr Ile Tyr Pro Tyr Thr 1 5 4027DNAArtificial SequenceDescription of Artificial Sequence Synthetic oligonucleotide 40cagcagtact atatctaccc atatacc 27413PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 41Ser Ala Ser 1 429DNAArtificial SequenceDescription of Artificial Sequence Synthetic oligonucleotide 42agcgcctcc 943107PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 43Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 1 5 10 15 Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 20 25 30 Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 35 40 45 Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 50 55 60 Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 65 70 75 80 Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 85 90 95 Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 100 105 44321DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 44aggactgtgg ccgctccctc cgtcttcatt tttccccctt ctgacgaaca gctgaaaagt 60ggcacagcca gcgtggtctg tctgctgaac aatttctacc ctcgcgaagc caaagtgcag 120tggaaggtcg ataacgctct gcagagcggc aacagccagg agtctgtgac tgaacaggac 180agtaaagatt caacctatag cctgtcaagc acactgactc tgagcaaggc agactacgag 240aagcacaaag tgtatgcctg cgaagtcaca catcaggggc tgtcctctcc tgtgactaag 300agctttaaca gaggagagtg t 32145222PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 45Asp Tyr Lys Asp Asp Asp Asp Lys Asp Ile Gln Met Thr Gln Ser Pro 1 5 10 15 Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg 20 25 30 Ala Ser Gln Asp Val Asn Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro 35 40 45 Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ser Ala Ser Phe Leu Tyr Ser 50 55 60 Gly Val Pro Ser Arg Phe Ser Gly Ser Arg Ser Gly Thr Asp Phe Thr 65 70 75 80 Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys 85 90 95 Gln Gln His Tyr Thr Thr Pro Pro Thr Phe Gly Gln Gly Thr Lys Val 100 105 110 Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro 115 120 125 Ser Asp Glu Arg Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu 130 135 140 Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn 145 150 155 160 Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser 165 170 175 Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala 180 185 190 Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly 195 200 205 Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 210 215 220 46666DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 46gactacaaag acgacgatga caaagatatc cagatgaccc agtcccctag ctccctgtcc 60gcttctgtgg gcgatagggt cactattacc tgccgcgcat ctcaggacgt gaacaccgca 120gtcgcctggt accagcagaa gcctgggaaa gctccaaagc tgctgatcta cagtgcatca 180ttcctgtatt caggagtgcc cagccggttt agcggcagca gatctggcac cgatttcaca 240ctgactattt ctagtctgca gcctgaggac tttgccacat actattgcca gcagcactat 300accacacccc ctactttcgg ccaggggacc aaagtggaga tcaagcgaac tgtggccgct 360ccaagtgtct tcatttttcc acccagcgat gaaagactga agtccggcac agcttctgtg 420gtctgtctgc tgaacaattt ttaccccaga gaggccaaag tgcagtggaa ggtcgacaac 480gctctgcaga gtggcaacag ccaggagagc gtgacagaac aggattccaa agactctact 540tatagtctgt caagcaccct gacactgagc aaggcagact acgaaaagca taaagtgtat 600gcctgtgagg tcacacatca ggggctgtca tcaccagtca ccaaatcatt caatcggggg 660gagtgc 66647107PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 47Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Val Asn Thr Ala 20 25 30 Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Arg Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 48321DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 48gatatccaga tgacccagtc ccctagctcc ctgtccgctt ctgtgggcga tagggtcact 60attacctgcc gcgcatctca ggacgtgaac accgcagtcg cctggtacca gcagaagcct 120gggaaagctc caaagctgct gatctacagt gcatcattcc tgtattcagg agtgcccagc 180cggtttagcg gcagcagatc tggcaccgat ttcacactga ctatttctag tctgcagcct 240gaggactttg ccacatacta ttgccagcag cactatacca caccccctac tttcggccag 300gggaccaaag tggagatcaa g 321496PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 49Gln Asp Val Asn Thr Ala 1 5 5018DNAArtificial SequenceDescription of Artificial Sequence Synthetic oligonucleotide 50caggacgtga acaccgca 18519PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 51Gln Gln His Tyr Thr Thr Pro Pro Thr 1 5 5227DNAArtificial SequenceDescription of Artificial Sequence Synthetic oligonucleotide 52cagcagcact ataccacacc ccctact 27533PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 53Ser Ala Ser 1 549DNAArtificial SequenceDescription of Artificial Sequence Synthetic oligonucleotide 54agtgcatca

955107PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 55Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 1 5 10 15 Arg Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 20 25 30 Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 35 40 45 Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 50 55 60 Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 65 70 75 80 Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 85 90 95 Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 100 105 56321DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 56cgaactgtgg ccgctccaag tgtcttcatt tttccaccca gcgatgaaag actgaagtcc 60ggcacagctt ctgtggtctg tctgctgaac aatttttacc ccagagaggc caaagtgcag 120tggaaggtcg acaacgctct gcagagtggc aacagccagg agagcgtgac agaacaggat 180tccaaagact ctacttatag tctgtcaagc accctgacac tgagcaaggc agactacgaa 240aagcataaag tgtatgcctg tgaggtcaca catcaggggc tgtcatcacc agtcaccaaa 300tcattcaatc ggggggagtg c 32157222PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 57Asp Tyr Lys Asp Asp Asp Asp Lys Asp Ile Gln Met Thr Gln Ser Pro 1 5 10 15 Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg 20 25 30 Ala Ser Gln Asp Val Asn Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro 35 40 45 Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ser Ala Ser Phe Leu Tyr Ser 50 55 60 Gly Val Pro Ser Arg Phe Ser Gly Ser Arg Ser Gly Thr Asp Phe Thr 65 70 75 80 Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys 85 90 95 Gln Gln His Tyr Thr Thr Pro Pro Thr Phe Gly Gln Gly Thr Lys Val 100 105 110 Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro 115 120 125 Ser Asp Glu Arg Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu 130 135 140 Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn 145 150 155 160 Ala Leu Gln Ser Gly Asn Ser Lys Glu Ser Val Thr Glu Gln Asp Ser 165 170 175 Lys Asp Ser Thr Tyr Ser Leu Ser Ser Arg Leu Thr Leu Ser Lys Ala 180 185 190 Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly 195 200 205 Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 210 215 220 58666DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 58gactacaaag acgacgatga caaagatatc cagatgaccc agtcccctag ctccctgtcc 60gcttctgtgg gcgatagggt cactattacc tgccgcgcat ctcaggacgt gaacaccgca 120gtcgcctggt accagcagaa gcctgggaaa gctccaaagc tgctgatcta cagtgcatca 180ttcctgtatt caggagtgcc cagccggttt agcggcagca gatctggcac cgatttcaca 240ctgactattt ctagtctgca gcctgaggac tttgccacat actattgcca gcagcactat 300accacacccc ctactttcgg ccaggggacc aaagtggaga tcaagcgaac tgtggccgct 360ccaagtgtct tcatttttcc acccagcgat gaaagactga agtccggcac agcttctgtg 420gtctgtctgc tgaacaattt ttaccccaga gaggccaaag tgcagtggaa ggtcgacaac 480gctctgcaga gtggcaacag caaggagagc gtgacagaac aggattccaa agactctact 540tatagtctgt caagcagact gacactgagc aaggcagact acgaaaagca taaagtgtat 600gcctgtgagg tcacacatca ggggctgtca tcaccagtca ccaaatcatt caatcggggg 660gagtgc 66659107PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 59Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Val Asn Thr Ala 20 25 30 Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Arg Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 60321DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 60gatatccaga tgacccagtc ccctagctcc ctgtccgctt ctgtgggcga tagggtcact 60attacctgcc gcgcatctca ggacgtgaac accgcagtcg cctggtacca gcagaagcct 120gggaaagctc caaagctgct gatctacagt gcatcattcc tgtattcagg agtgcccagc 180cggtttagcg gcagcagatc tggcaccgat ttcacactga ctatttctag tctgcagcct 240gaggactttg ccacatacta ttgccagcag cactatacca caccccctac tttcggccag 300gggaccaaag tggagatcaa g 321616PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 61Gln Asp Val Asn Thr Ala 1 5 6218DNAArtificial SequenceDescription of Artificial Sequence Synthetic oligonucleotide 62caggacgtga acaccgca 18639PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 63Gln Gln His Tyr Thr Thr Pro Pro Thr 1 5 6427DNAArtificial SequenceDescription of Artificial Sequence Synthetic oligonucleotide 64cagcagcact ataccacacc ccctact 27653PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 65Ser Ala Ser 1 669DNAArtificial SequenceDescription of Artificial Sequence Synthetic oligonucleotide 66agtgcatca 967107PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 67Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 1 5 10 15 Arg Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 20 25 30 Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 35 40 45 Ser Gly Asn Ser Lys Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 50 55 60 Thr Tyr Ser Leu Ser Ser Arg Leu Thr Leu Ser Lys Ala Asp Tyr Glu 65 70 75 80 Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 85 90 95 Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 100 105 68321DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 68cgaactgtgg ccgctccaag tgtcttcatt tttccaccca gcgatgaaag actgaagtcc 60ggcacagctt ctgtggtctg tctgctgaac aatttttacc ccagagaggc caaagtgcag 120tggaaggtcg acaacgctct gcagagtggc aacagcaagg agagcgtgac agaacaggat 180tccaaagact ctacttatag tctgtcaagc agactgacac tgagcaaggc agactacgaa 240aagcataaag tgtatgcctg tgaggtcaca catcaggggc tgtcatcacc agtcaccaaa 300tcattcaatc ggggggagtg c 32169214PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 69Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Val Ser Ile Gly 20 25 30 Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ser Ala Ser Tyr Arg Tyr Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Tyr Ile Tyr Pro Ala 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 70642DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 70gatattcaga tgacccagtc cccaagctcc ctgagtgcct cagtgggcga ccgagtcacc 60atcacatgca aggcttccca ggatgtgtct attggagtcg catggtacca gcagaagcca 120ggcaaagcac ccaagctgct gatctatagc gcctcctacc ggtataccgg cgtgccctct 180agattctctg gcagtgggtc aggaacagac tttactctga ccatctctag tctgcagcct 240gaggatttcg ctacctacta ttgccagcag tactatatct acccagccac ctttggccag 300gggacaaaag tggagatcaa gaggactgtg gccgctccct ccgtcttcat ttttccccct 360tctgacgaac agctgaaaag tggcacagcc agcgtggtct gtctgctgaa caatttctac 420cctcgcgaag ccaaagtgca gtggaaggtc gataacgctc tgcagagcgg caacagccag 480gagtctgtga ctgaacagga cagtaaagat tcaacctata gcctgtcaag cacactgact 540ctgagcaagg cagactacga gaagcacaaa gtgtatgcct gcgaagtcac acatcagggg 600ctgtcctctc ctgtgactaa gagctttaac agaggagagt gt 64271107PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 71Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Val Ser Ile Gly 20 25 30 Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ser Ala Ser Tyr Arg Tyr Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Tyr Ile Tyr Pro Ala 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 72321DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 72gatattcaga tgacccagtc cccaagctcc ctgagtgcct cagtgggcga ccgagtcacc 60atcacatgca aggcttccca ggatgtgtct attggagtcg catggtacca gcagaagcca 120ggcaaagcac ccaagctgct gatctatagc gcctcctacc ggtataccgg cgtgccctct 180agattctctg gcagtgggtc aggaacagac tttactctga ccatctctag tctgcagcct 240gaggatttcg ctacctacta ttgccagcag tactatatct acccagccac ctttggccag 300gggacaaaag tggagatcaa g 321736PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 73Gln Asp Val Ser Ile Gly 1 5 7418DNAArtificial SequenceDescription of Artificial Sequence Synthetic oligonucleotide 74caggatgtgt ctattgga 18759PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 75Gln Gln Tyr Tyr Ile Tyr Pro Ala Thr 1 5 7627DNAArtificial SequenceDescription of Artificial Sequence Synthetic oligonucleotide 76cagcagtact atatctaccc agccacc 27773PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 77Ser Ala Ser 1 789DNAArtificial SequenceDescription of Artificial Sequence Synthetic oligonucleotide 78agcgcctcc 979107PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 79Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 1 5 10 15 Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 20 25 30 Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 35 40 45 Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 50 55 60 Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 65 70 75 80 Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 85 90 95 Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 100 105 80321DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 80aggactgtgg ccgctccctc cgtcttcatt tttccccctt ctgacgaaca gctgaaaagt 60ggcacagcca gcgtggtctg tctgctgaac aatttctacc ctcgcgaagc caaagtgcag 120tggaaggtcg ataacgctct gcagagcggc aacagccagg agtctgtgac tgaacaggac 180agtaaagatt caacctatag cctgtcaagc acactgactc tgagcaaggc agactacgag 240aagcacaaag tgtatgcctg cgaagtcaca catcaggggc tgtcctctcc tgtgactaag 300agctttaaca gaggagagtg t 32181449PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 81Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Ile Lys Asp Thr 20 25 30 Tyr Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Arg Ile Tyr Pro Thr Asn Gly Tyr Thr Arg Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ser Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125 Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala 130 135 140 Leu Gly Cys Glu Val Thr Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190 Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys 195 200 205 Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp 210 215 220 Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 225 230 235 240 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 245 250 255 Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 260 265 270 Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 275 280 285 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg 290 295 300 Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys 305 310 315 320 Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 325 330 335 Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 340 345 350 Val Tyr Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu 355 360 365 Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 370 375 380 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 385 390 395 400 Leu Asp Ser Asp Gly Ser Phe Ala Leu Val Ser Lys Leu Thr Val Asp 405 410 415 Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met

His 420 425 430 Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 435 440 445 Gly 821347DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 82gaggtgcagc tggtcgaaag cggaggagga ctggtgcagc caggagggtc actgcgactg 60agctgcgcag cttccggctt caacatcaag gacacctaca ttcactgggt ccgccaggct 120cctggaaaag gcctggagtg ggtggcacga atctatccaa ctaatggata cacccggtat 180gccgactccg tgaagggccg gttcaccatt tctgcagata caagtaaaaa cactgcctac 240ctgcagatga acagcctgcg agccgaagat acagccgtgt actattgcag ccgatgggga 300ggcgacggct tctacgctat ggattattgg gggcagggaa ccctggtcac agtgagctcc 360gcatcaacaa aggggcctag cgtgtttcca ctggccccct ctagtaaatc cacctctggg 420ggaacagcag ccctgggatg tgaggtgacc gactacttcc cagagcccgt cactgtgagc 480tggaactccg gcgccctgac atctggggtc catacttttc ctgctgtgct gcagtcaagc 540ggcctgtaca gcctgtcctc tgtggtcact gtgccaagtt caagcctggg gactcagacc 600tatatctgca acgtgaatca caagccatcc aataccaaag tcgacaagaa agtggaaccc 660aagtcttgtg ataaaacaca tacttgcccc ccttgtcctg caccagagct gctgggagga 720ccaagcgtgt tcctgtttcc acccaagcct aaagacaccc tgatgattag taggactcca 780gaagtcacct gcgtggtcgt ggacgtgagc cacgaggacc ccgaagtcaa gttcaactgg 840tacgtggatg gcgtcgaggt gcataatgcc aagacaaaac ccagggagga acagtacaac 900tccacttatc gcgtcgtgtc tgtcctgacc gtgctgcacc aggactggct gaacggcaag 960gagtataagt gcaaagtgag caataaggct ctgcccgcac ctatcgagaa aacaatttcc 1020aaggctaaag ggcagcctag agaaccacag gtgtacgtgt accctccatc tagggacgag 1080ctgaccaaga accaggtcag tctgacatgt ctggtgaaag ggttctatcc cagcgatatc 1140gcagtggagt gggaatccaa tggacagcct gagaacaatt acaagaccac accccctgtg 1200ctggactctg atggaagttt cgccctggtg agtaagctga ccgtcgataa atcacggtgg 1260cagcagggca acgtgttcag ctgttcagtg atgcacgaag cactgcacaa ccactacacc 1320cagaaaagcc tgtccctgtc ccccggc 134783120PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 83Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Ile Lys Asp Thr 20 25 30 Tyr Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Arg Ile Tyr Pro Thr Asn Gly Tyr Thr Arg Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ser Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser 115 120 84360DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 84gaggtgcagc tggtcgaaag cggaggagga ctggtgcagc caggagggtc actgcgactg 60agctgcgcag cttccggctt caacatcaag gacacctaca ttcactgggt ccgccaggct 120cctggaaaag gcctggagtg ggtggcacga atctatccaa ctaatggata cacccggtat 180gccgactccg tgaagggccg gttcaccatt tctgcagata caagtaaaaa cactgcctac 240ctgcagatga acagcctgcg agccgaagat acagccgtgt actattgcag ccgatgggga 300ggcgacggct tctacgctat ggattattgg gggcagggaa ccctggtcac agtgagctcc 360858PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 85Gly Phe Asn Ile Lys Asp Thr Tyr 1 5 8624DNAArtificial SequenceDescription of Artificial Sequence Synthetic oligonucleotide 86ggcttcaaca tcaaggacac ctac 248713PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 87Ser Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr 1 5 10 8839DNAArtificial SequenceDescription of Artificial Sequence Synthetic oligonucleotide 88agccgatggg gaggcgacgg cttctacgct atggattat 39898PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 89Ile Tyr Pro Thr Asn Gly Tyr Thr 1 5 9024DNAArtificial SequenceDescription of Artificial Sequence Synthetic oligonucleotide 90atctatccaa ctaatggata cacc 249198PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 91Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 1 5 10 15 Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Glu Val Thr Asp Tyr 20 25 30 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40 45 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 50 55 60 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 65 70 75 80 Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 85 90 95 Lys Val 92294DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 92gcatcaacaa aggggcctag cgtgtttcca ctggccccct ctagtaaatc cacctctggg 60ggaacagcag ccctgggatg tgaggtgacc gactacttcc cagagcccgt cactgtgagc 120tggaactccg gcgccctgac atctggggtc catacttttc ctgctgtgct gcagtcaagc 180ggcctgtaca gcctgtcctc tgtggtcact gtgccaagtt caagcctggg gactcagacc 240tatatctgca acgtgaatca caagccatcc aataccaaag tcgacaagaa agtg 29493110PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 93Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 1 5 10 15 Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val 20 25 30 Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr 35 40 45 Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu 50 55 60 Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His 65 70 75 80 Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys 85 90 95 Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys 100 105 110 94330DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 94gcaccagagc tgctgggagg accaagcgtg ttcctgtttc cacccaagcc taaagacacc 60ctgatgatta gtaggactcc agaagtcacc tgcgtggtcg tggacgtgag ccacgaggac 120cccgaagtca agttcaactg gtacgtggat ggcgtcgagg tgcataatgc caagacaaaa 180cccagggagg aacagtacaa ctccacttat cgcgtcgtgt ctgtcctgac cgtgctgcac 240caggactggc tgaacggcaa ggagtataag tgcaaagtga gcaataaggc tctgcccgca 300cctatcgaga aaacaatttc caaggctaaa 33095106PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 95Gly Gln Pro Arg Glu Pro Gln Val Tyr Val Tyr Pro Pro Ser Arg Asp 1 5 10 15 Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe 20 25 30 Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu 35 40 45 Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe 50 55 60 Ala Leu Val Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly 65 70 75 80 Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr 85 90 95 Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 100 105 96318DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 96gggcagccta gagaaccaca ggtgtacgtg taccctccat ctagggacga gctgaccaag 60aaccaggtca gtctgacatg tctggtgaaa gggttctatc ccagcgatat cgcagtggag 120tgggaatcca atggacagcc tgagaacaat tacaagacca caccccctgt gctggactct 180gatggaagtt tcgccctggt gagtaagctg accgtcgata aatcacggtg gcagcagggc 240aacgtgttca gctgttcagt gatgcacgaa gcactgcaca accactacac ccagaaaagc 300ctgtccctgt cccccggc 31897448PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 97Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ala Asp Tyr 20 25 30 Thr Met Asp Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Gly Asp Val Asn Pro Asn Ser Gly Gly Ser Ile Tyr Asn Gln Arg Phe 50 55 60 Lys Gly Arg Phe Thr Phe Ser Val Asp Arg Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asn Leu Gly Pro Ser Phe Tyr Phe Asp Tyr Trp Gly Gln Gly 100 105 110 Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe 115 120 125 Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu 130 135 140 Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp 145 150 155 160 Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu 165 170 175 Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser 180 185 190 Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro 195 200 205 Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys 210 215 220 Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro 225 230 235 240 Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser 245 250 255 Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp 260 265 270 Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn 275 280 285 Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val 290 295 300 Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu 305 310 315 320 Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys 325 330 335 Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Val 340 345 350 Tyr Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr 355 360 365 Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu 370 375 380 Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu 385 390 395 400 Asp Ser Asp Gly Ser Phe Ala Leu Val Ser Lys Leu Thr Val Asp Lys 405 410 415 Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu 420 425 430 Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 435 440 445 981344DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 98gaggtgcagc tggtggaatc aggagggggc ctggtgcagc ccggagggtc tctgcgactg 60tcatgtgccg cttctgggtt cactttcgca gactacacaa tggattgggt gcgacaggcc 120cccggaaagg gactggagtg ggtgggcgat gtcaacccta attctggcgg gagtatctac 180aaccagcggt tcaaggggag attcactttt tcagtggaca gaagcaaaaa caccctgtat 240ctgcagatga acagcctgag ggccgaagat accgctgtct actattgcgc tcgcaatctg 300ggccccagtt tctactttga ctattggggg cagggaaccc tggtgacagt cagctccgct 360agcactaagg ggccttccgt gtttccactg gctccctcta gtaaatccac ctctggaggc 420acagctgcac tgggatgtct ggtgaaggat tacttccctg aaccagtcac agtgagttgg 480aactcagggg ctctgacaag tggagtccat acttttcccg cagtgctgca gtcaagcgga 540ctgtactccc tgtcctctgt ggtcaccgtg cctagttcaa gcctgggcac ccagacatat 600atctgcaacg tgaatcacaa gccatcaaat acaaaagtcg acaagaaagt ggagcccaag 660agctgtgata aaactcatac ctgcccacct tgtccggcgc cagaactgct gggaggacca 720agcgtgttcc tgtttccacc caagcctaaa gacaccctga tgatttcccg gactcctgag 780gtcacctgcg tggtcgtgga cgtgtctcac gaggaccccg aagtcaagtt caactggtac 840gtggatggcg tcgaagtgca taatgccaag accaaacccc gggaggaaca gtacaactct 900acctatagag tcgtgagtgt cctgacagtg ctgcaccagg actggctgaa tgggaaggag 960tataagtgta aagtgagcaa caaagccctg cccgccccaa tcgaaaaaac aatctctaaa 1020gcaaaaggac agcctcgcga accacaggtc tacgtctacc ccccatcaag agatgaactg 1080acaaaaaatc aggtctctct gacatgcctg gtcaaaggat tctacccttc cgacatcgcc 1140gtggagtggg aaagtaacgg ccagcccgag aacaattaca agaccacacc ccctgtcctg 1200gactctgatg ggagtttcgc tctggtgtca aagctgaccg tcgataaaag ccggtggcag 1260cagggcaatg tgtttagctg ctccgtcatg cacgaagccc tgcacaatca ctacacacag 1320aagtccctga gcctgagccc tggc 134499119PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 99Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ala Asp Tyr 20 25 30 Thr Met Asp Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Gly Asp Val Asn Pro Asn Ser Gly Gly Ser Ile Tyr Asn Gln Arg Phe 50 55 60 Lys Gly Arg Phe Thr Phe Ser Val Asp Arg Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asn Leu Gly Pro Ser Phe Tyr Phe Asp Tyr Trp Gly Gln Gly 100 105 110 Thr Leu Val Thr Val Ser Ser 115 100357DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 100gaggtgcagc tggtggaatc aggagggggc ctggtgcagc ccggagggtc tctgcgactg 60tcatgtgccg cttctgggtt cactttcgca gactacacaa tggattgggt gcgacaggcc 120cccggaaagg gactggagtg ggtgggcgat gtcaacccta attctggcgg gagtatctac 180aaccagcggt tcaaggggag attcactttt tcagtggaca gaagcaaaaa caccctgtat 240ctgcagatga acagcctgag ggccgaagat accgctgtct actattgcgc tcgcaatctg 300ggccccagtt tctactttga ctattggggg cagggaaccc tggtgacagt cagctcc 3571018PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 101Gly Phe Thr Phe Ala Asp Tyr Thr 1 5 10224DNAArtificial SequenceDescription of Artificial Sequence Synthetic oligonucleotide 102gggttcactt tcgcagacta caca 2410312PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 103Ala Arg Asn Leu Gly Pro Ser Phe Tyr Phe Asp Tyr 1 5 10 10436DNAArtificial SequenceDescription of Artificial Sequence Synthetic oligonucleotide 104gctcgcaatc tgggccccag tttctacttt gactat 361058PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 105Val Asn Pro Asn Ser Gly Gly Ser 1 5 10624DNAArtificial SequenceDescription of Artificial Sequence Synthetic oligonucleotide 106gtcaacccta attctggcgg gagt 2410798PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 107Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 1 5 10 15 Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 25 30 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40 45 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 50 55 60 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 65 70 75 80 Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 85 90 95 Lys Val 108294DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 108gctagcacta aggggccttc cgtgtttcca ctggctccct ctagtaaatc cacctctgga 60ggcacagctg cactgggatg tctggtgaag gattacttcc ctgaaccagt cacagtgagt 120tggaactcag gggctctgac aagtggagtc catacttttc ccgcagtgct gcagtcaagc 180ggactgtact ccctgtcctc tgtggtcacc gtgcctagtt caagcctggg cacccagaca 240tatatctgca acgtgaatca caagccatca aatacaaaag

tcgacaagaa agtg 294109110PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 109Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 1 5 10 15 Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val 20 25 30 Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr 35 40 45 Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu 50 55 60 Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His 65 70 75 80 Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys 85 90 95 Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys 100 105 110 110330DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 110gcgccagaac tgctgggagg accaagcgtg ttcctgtttc cacccaagcc taaagacacc 60ctgatgattt cccggactcc tgaggtcacc tgcgtggtcg tggacgtgtc tcacgaggac 120cccgaagtca agttcaactg gtacgtggat ggcgtcgaag tgcataatgc caagaccaaa 180ccccgggagg aacagtacaa ctctacctat agagtcgtga gtgtcctgac agtgctgcac 240caggactggc tgaatgggaa ggagtataag tgtaaagtga gcaacaaagc cctgcccgcc 300ccaatcgaaa aaacaatctc taaagcaaaa 330111106PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 111Gly Gln Pro Arg Glu Pro Gln Val Tyr Val Tyr Pro Pro Ser Arg Asp 1 5 10 15 Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe 20 25 30 Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu 35 40 45 Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe 50 55 60 Ala Leu Val Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly 65 70 75 80 Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr 85 90 95 Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 100 105 112318DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 112ggacagcctc gcgaaccaca ggtctacgtc taccccccat caagagatga actgacaaaa 60aatcaggtct ctctgacatg cctggtcaaa ggattctacc cttccgacat cgccgtggag 120tgggaaagta acggccagcc cgagaacaat tacaagacca caccccctgt cctggactct 180gatgggagtt tcgctctggt gtcaaagctg accgtcgata aaagccggtg gcagcagggc 240aatgtgttta gctgctccgt catgcacgaa gccctgcaca atcactacac acagaagtcc 300ctgagcctga gccctggc 318113226PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 113Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Thr Gly Ser Asp Ile Gln Met 1 5 10 15 Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr 20 25 30 Ile Thr Cys Lys Ala Ser Gln Asp Val Ser Ile Gly Val Ala Trp Tyr 35 40 45 Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ser Ala Ser 50 55 60 Tyr Arg Tyr Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly 65 70 75 80 Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala 85 90 95 Thr Tyr Tyr Cys Gln Gln Tyr Tyr Ile Tyr Pro Tyr Thr Phe Gly Gln 100 105 110 Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe 115 120 125 Ile Phe Pro Pro Ser Asp Glu Glu Leu Lys Ser Gly Thr Ala Ser Val 130 135 140 Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp 145 150 155 160 Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Glu Glu Ser Val Thr 165 170 175 Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Glu 180 185 190 Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val 195 200 205 Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly 210 215 220 Glu Cys 225 114678DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 114tatccctacg atgtgcctga ctacgctact ggctccgata tccagatgac ccagtctcca 60agctccctga gtgcatcagt gggggaccga gtcaccatca catgcaaggc ttcccaggat 120gtgtctattg gagtcgcatg gtaccagcag aagccaggca aagcacccaa gctgctgatc 180tacagcgcct cctaccggta tactggggtg ccttccagat tctctggcag tgggtcagga 240accgacttta ctctgaccat ctctagtctg cagcccgagg atttcgccac ctactattgc 300cagcagtact atatctaccc ttataccttt ggccagggga caaaagtgga gatcaagagg 360acagtggccg ctccaagtgt cttcattttt cccccttccg acgaagagct gaaaagtgga 420actgcttcag tggtctgtct gctgaacaat ttctaccccc gcgaagccaa agtgcagtgg 480aaggtcgata acgctctgca gagcggcaat tccgaggagt ctgtgacaga acaggacagt 540aaagattcaa cttatagcct gtcaagcaca ctggagctgt ctaaggcaga ctacgagaag 600cacaaagtgt atgcctgcga agtcacccat caggggctgt cctctcccgt gacaaagagc 660tttaacagag gagagtgt 678115107PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 115Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Val Ser Ile Gly 20 25 30 Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ser Ala Ser Tyr Arg Tyr Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Tyr Ile Tyr Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 116321DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 116gatatccaga tgacccagtc tccaagctcc ctgagtgcat cagtggggga ccgagtcacc 60atcacatgca aggcttccca ggatgtgtct attggagtcg catggtacca gcagaagcca 120ggcaaagcac ccaagctgct gatctacagc gcctcctacc ggtatactgg ggtgccttcc 180agattctctg gcagtgggtc aggaaccgac tttactctga ccatctctag tctgcagccc 240gaggatttcg ccacctacta ttgccagcag tactatatct acccttatac ctttggccag 300gggacaaaag tggagatcaa g 3211176PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 117Gln Asp Val Ser Ile Gly 1 5 11818DNAArtificial SequenceDescription of Artificial Sequence Synthetic oligonucleotide 118caggatgtgt ctattgga 181199PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 119Gln Gln Tyr Tyr Ile Tyr Pro Tyr Thr 1 5 12027DNAArtificial SequenceDescription of Artificial Sequence Synthetic oligonucleotide 120cagcagtact atatctaccc ttatacc 271213PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 121Ser Ala Ser 1 1229DNAArtificial SequenceDescription of Artificial Sequence Synthetic oligonucleotide 122agcgcctcc 9123107PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 123Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 1 5 10 15 Glu Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 20 25 30 Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 35 40 45 Ser Gly Asn Ser Glu Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 50 55 60 Thr Tyr Ser Leu Ser Ser Thr Leu Glu Leu Ser Lys Ala Asp Tyr Glu 65 70 75 80 Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 85 90 95 Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 100 105 124321DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 124aggacagtgg ccgctccaag tgtcttcatt tttccccctt ccgacgaaga gctgaaaagt 60ggaactgctt cagtggtctg tctgctgaac aatttctacc cccgcgaagc caaagtgcag 120tggaaggtcg ataacgctct gcagagcggc aattccgagg agtctgtgac agaacaggac 180agtaaagatt caacttatag cctgtcaagc acactggagc tgtctaaggc agactacgag 240aagcacaaag tgtatgcctg cgaagtcacc catcaggggc tgtcctctcc cgtgacaaag 300agctttaaca gaggagagtg t 321125450PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 125Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Ile Lys Asp Thr 20 25 30 Tyr Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Arg Ile Tyr Pro Thr Asn Gly Tyr Thr Arg Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ser Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125 Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala 130 135 140 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190 Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys 195 200 205 Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp 210 215 220 Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 225 230 235 240 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 245 250 255 Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 260 265 270 Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 275 280 285 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg 290 295 300 Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys 305 310 315 320 Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 325 330 335 Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 340 345 350 Val Tyr Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu 355 360 365 Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 370 375 380 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 385 390 395 400 Leu Asp Ser Asp Gly Ser Phe Ala Leu Val Ser Lys Leu Thr Val Asp 405 410 415 Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His 420 425 430 Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 435 440 445 Gly Lys 450 1261350DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 126gaagtccagc tggtcgaaag cggaggagga ctggtgcagc caggagggtc tctgcgactg 60agttgcgccg cttcaggctt caacatcaag gacacctaca ttcactgggt gcgccaggct 120cctggaaaag gcctggagtg ggtggcacga atctatccaa ctaatggata cacccggtat 180gcagacagcg tgaagggccg gttcaccatt agcgcagata catccaaaaa cactgcctac 240ctgcagatga acagcctgcg agccgaagat actgctgtgt actattgcag tcggtgggga 300ggcgacggct tctacgctat ggattattgg gggcagggaa ccctggtcac agtgagctcc 360gcatctacaa aggggcctag tgtgtttcca ctggccccct ctagtaaatc cacctctggg 420ggaacagcag ccctgggatg tctggtgaag gactatttcc cagagcccgt cactgtgagt 480tggaactcag gcgccctgac atccggggtc catacttttc ctgctgtgct gcagtcaagc 540ggcctgtact ctctgtcctc tgtggtcacc gtgccaagtt caagcctggg gactcagacc 600tatatctgca acgtgaatca caagccaagc aatacaaaag tcgacaagaa agtggaaccc 660aagagctgtg ataaaacaca tacttgcccc ccttgtcctg caccagagct gctgggagga 720ccatccgtgt tcctgtttcc acccaagcct aaagacaccc tgatgatttc caggactcca 780gaagtcacct gcgtggtcgt ggacgtgtct cacgaggacc ccgaagtcaa gttcaactgg 840tacgtggatg gcgtcgaggt gcataatgcc aagacaaaac ccagggagga acagtacaac 900tcaacttatc gcgtcgtgag cgtcctgacc gtgctgcacc aggactggct gaacggcaag 960gagtataagt gcaaagtgag caataaggct ctgcccgcac ctatcgagaa aaccattagc 1020aaggccaaag ggcagcctag agaaccacag gtctacgtgt atcctccaag cagggacgag 1080ctgaccaaga accaggtctc cctgacatgt ctggtgaaag ggttttaccc cagtgatatc 1140gctgtggagt gggaatcaaa tggacagcct gaaaacaatt ataagaccac accccctgtg 1200ctggacagcg atggcagctt cgctctggtc tccaagctga ctgtggataa atctcggtgg 1260cagcagggca acgtctttag ttgttcagtg atgcatgagg cactgcacaa tcattacacc 1320cagaagagcc tgtccctgtc tcccggcaaa 1350127120PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 127Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Ile Lys Asp Thr 20 25 30 Tyr Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Arg Ile Tyr Pro Thr Asn Gly Tyr Thr Arg Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ser Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser 115 120 128360DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 128gaagtccagc tggtcgaaag cggaggagga ctggtgcagc caggagggtc tctgcgactg 60agttgcgccg cttcaggctt caacatcaag gacacctaca ttcactgggt gcgccaggct 120cctggaaaag gcctggagtg ggtggcacga atctatccaa ctaatggata cacccggtat 180gcagacagcg tgaagggccg gttcaccatt agcgcagata catccaaaaa cactgcctac 240ctgcagatga acagcctgcg agccgaagat actgctgtgt actattgcag tcggtgggga 300ggcgacggct tctacgctat ggattattgg gggcagggaa ccctggtcac agtgagctcc 3601298PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 129Gly Phe Asn Ile Lys Asp Thr Tyr 1 5 13024DNAArtificial SequenceDescription of Artificial Sequence Synthetic oligonucleotide 130ggcttcaaca tcaaggacac ctac 2413113PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 131Ser Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr 1 5 10 13239DNAArtificial SequenceDescription of Artificial Sequence Synthetic oligonucleotide 132agtcggtggg gaggcgacgg cttctacgct atggattat 391338PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 133Ile Tyr Pro Thr Asn Gly Tyr Thr 1 5 13424DNAArtificial SequenceDescription of Artificial Sequence Synthetic oligonucleotide 134atctatccaa ctaatggata cacc 2413598PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 135Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 1 5 10 15 Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 25 30 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35

40 45 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 50 55 60 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 65 70 75 80 Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 85 90 95 Lys Val 136294DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 136gcatctacaa aggggcctag tgtgtttcca ctggccccct ctagtaaatc cacctctggg 60ggaacagcag ccctgggatg tctggtgaag gactatttcc cagagcccgt cactgtgagt 120tggaactcag gcgccctgac atccggggtc catacttttc ctgctgtgct gcagtcaagc 180ggcctgtact ctctgtcctc tgtggtcacc gtgccaagtt caagcctggg gactcagacc 240tatatctgca acgtgaatca caagccaagc aatacaaaag tcgacaagaa agtg 294137110PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 137Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 1 5 10 15 Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val 20 25 30 Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr 35 40 45 Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu 50 55 60 Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His 65 70 75 80 Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys 85 90 95 Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys 100 105 110 138330DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 138gcaccagagc tgctgggagg accatccgtg ttcctgtttc cacccaagcc taaagacacc 60ctgatgattt ccaggactcc agaagtcacc tgcgtggtcg tggacgtgtc tcacgaggac 120cccgaagtca agttcaactg gtacgtggat ggcgtcgagg tgcataatgc caagacaaaa 180cccagggagg aacagtacaa ctcaacttat cgcgtcgtga gcgtcctgac cgtgctgcac 240caggactggc tgaacggcaa ggagtataag tgcaaagtga gcaataaggc tctgcccgca 300cctatcgaga aaaccattag caaggccaaa 330139106PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 139Gly Gln Pro Arg Glu Pro Gln Val Tyr Val Tyr Pro Pro Ser Arg Asp 1 5 10 15 Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe 20 25 30 Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu 35 40 45 Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe 50 55 60 Ala Leu Val Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly 65 70 75 80 Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr 85 90 95 Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 100 105 140318DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 140gggcagccta gagaaccaca ggtctacgtg tatcctccaa gcagggacga gctgaccaag 60aaccaggtct ccctgacatg tctggtgaaa gggttttacc ccagtgatat cgctgtggag 120tgggaatcaa atggacagcc tgaaaacaat tataagacca caccccctgt gctggacagc 180gatggcagct tcgctctggt ctccaagctg actgtggata aatctcggtg gcagcagggc 240aacgtcttta gttgttcagt gatgcatgag gcactgcaca atcattacac ccagaagagc 300ctgtccctgt ctcccggc 318141232PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 141Glu Pro Lys Ser Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 1 5 10 15 Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 20 25 30 Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val 35 40 45 Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val 50 55 60 Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln 65 70 75 80 Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln 85 90 95 Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala 100 105 110 Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro 115 120 125 Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr 130 135 140 Lys Asn Gln Val Ser Leu Ile Cys Leu Val Lys Gly Phe Tyr Pro Ser 145 150 155 160 Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Arg Tyr 165 170 175 Met Thr Trp Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr 180 185 190 Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe 195 200 205 Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys 210 215 220 Ser Leu Ser Leu Ser Pro Gly Lys 225 230 142696DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 142gagcccaaga gcagcgataa gacccacacc tgccctccct gtccagctcc agaactgctg 60ggaggaccta gcgtgttcct gtttccccct aagccaaaag acactctgat gatttccagg 120actcccgagg tgacctgcgt ggtggtggac gtgtctcacg aggaccccga agtgaagttc 180aactggtacg tggatggcgt ggaagtgcat aatgctaaga caaaaccaag agaggaacag 240tacaactcca cttatcgcgt cgtgagcgtg ctgaccgtgc tgcaccagga ctggctgaac 300gggaaggagt ataagtgcaa agtcagtaat aaggccctgc ctgctccaat cgaaaaaacc 360atctctaagg ccaaaggcca gccaagggag ccccaggtgt acacactgcc acccagcaga 420gacgaactga ccaagaacca ggtgtccctg atctgtctgg tgaaaggctt ctatcctagt 480gatattgctg tggagtggga atcaaatgga cagccagaga acagatacat gacctggcct 540ccagtgctgg acagcgatgg cagcttcttc ctgtattcca agctgacagt ggataaatct 600cgatggcagc aggggaacgt gtttagttgt tcagtgatgc atgaagccct gcacaatcat 660tacactcaga agagcctgtc cctgtctccc ggcaaa 696143110PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 143Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 1 5 10 15 Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val 20 25 30 Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr 35 40 45 Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu 50 55 60 Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His 65 70 75 80 Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys 85 90 95 Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys 100 105 110 144330DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 144gctccagaac tgctgggagg acctagcgtg ttcctgtttc cccctaagcc aaaagacact 60ctgatgattt ccaggactcc cgaggtgacc tgcgtggtgg tggacgtgtc tcacgaggac 120cccgaagtga agttcaactg gtacgtggat ggcgtggaag tgcataatgc taagacaaaa 180ccaagagagg aacagtacaa ctccacttat cgcgtcgtga gcgtgctgac cgtgctgcac 240caggactggc tgaacgggaa ggagtataag tgcaaagtca gtaataaggc cctgcctgct 300ccaatcgaaa aaaccatctc taaggccaaa 330145106PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 145Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp 1 5 10 15 Glu Leu Thr Lys Asn Gln Val Ser Leu Ile Cys Leu Val Lys Gly Phe 20 25 30 Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu 35 40 45 Asn Arg Tyr Met Thr Trp Pro Pro Val Leu Asp Ser Asp Gly Ser Phe 50 55 60 Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly 65 70 75 80 Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr 85 90 95 Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 100 105 146318DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 146ggccagccaa gggagcccca ggtgtacaca ctgccaccca gcagagacga actgaccaag 60aaccaggtgt ccctgatctg tctggtgaaa ggcttctatc ctagtgatat tgctgtggag 120tgggaatcaa atggacagcc agagaacaga tacatgacct ggcctccagt gctggacagc 180gatggcagct tcttcctgta ttccaagctg acagtggata aatctcgatg gcagcagggg 240aacgtgttta gttgttcagt gatgcatgaa gccctgcaca atcattacac tcagaagagc 300ctgtccctgt ctcccggc 318147481PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 147Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Val Asn Thr Ala 20 25 30 Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Arg Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gly Gly Ser Gly Gly 100 105 110 Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Glu 115 120 125 Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser 130 135 140 Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Ile Lys Asp Thr Tyr 145 150 155 160 Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala 165 170 175 Arg Ile Tyr Pro Thr Asn Gly Tyr Thr Arg Tyr Ala Asp Ser Val Lys 180 185 190 Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr Leu 195 200 205 Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ser 210 215 220 Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr Trp Gly Gln Gly 225 230 235 240 Thr Leu Val Thr Val Ser Ser Ala Ala Glu Pro Lys Ser Ser Asp Lys 245 250 255 Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro 260 265 270 Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser 275 280 285 Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp 290 295 300 Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn 305 310 315 320 Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val 325 330 335 Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu 340 345 350 Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys 355 360 365 Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr 370 375 380 Tyr Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr 385 390 395 400 Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu 405 410 415 Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu 420 425 430 Asp Glu Asp Gly Ser Phe Ala Leu Val Ser Lys Leu Thr Val Asp Lys 435 440 445 Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu 450 455 460 Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 465 470 475 480 Lys 1481443DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 148gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60atcacttgcc gggcaagtca ggacgttaac accgctgtag cttggtatca gcagaaacca 120gggaaagccc ctaagctcct gatctattct gcatcctttt tgtacagtgg ggtcccatca 180aggttcagtg gcagtcgatc tgggacagat ttcactctca ccatcagcag tctgcaacct 240gaagattttg caacttacta ctgtcaacag cattacacta ccccacccac tttcggccaa 300gggaccaaag tggagatcaa aggtggttct ggtggtggtt ctggtggtgg ttctggtggt 360ggttctggtg gtggttctgg tgaagtgcag ctggtggagt ctgggggagg cttggtacag 420cctggcgggt ccctgagact ctcctgtgca gcctctggat tcaacattaa agatacttat 480atccactggg tccggcaagc tccagggaag ggcctggagt gggtcgcacg tatttatccc 540acaaatggtt acacacggta tgcggactct gtgaagggcc gattcaccat ctccgcagac 600acttccaaga acaccgcgta tctgcaaatg aacagtctga gagctgagga cacggccgtt 660tattactgtt caagatgggg cggagacggt ttctacgcta tggactactg gggccaaggg 720accctggtca ccgtctcctc agccgccgag cccaagagca gcgataagac ccacacctgc 780cctccctgtc cagctccaga actgctggga ggacctagcg tgttcctgtt tccccctaag 840ccaaaagaca ctctgatgat ttccaggact cccgaggtga cctgcgtggt ggtggacgtg 900tctcacgagg accccgaagt gaagttcaac tggtacgtgg atggcgtgga agtgcataat 960gctaagacaa aaccaagaga ggaacagtac aactccactt atcgcgtcgt gagcgtgctg 1020accgtgctgc accaggactg gctgaacggg aaggagtata agtgcaaagt cagtaataag 1080gccctgcctg ctccaatcga aaaaaccatc tctaaggcca aaggccagcc aagggagccc 1140caggtgtaca catacccacc cagcagagac gaactgacca agaaccaggt gtccctgaca 1200tgtctggtga aaggcttcta tcctagtgat attgctgtgg agtgggaatc aaatggacag 1260ccagagaaca attacaagac cacacctcca gtgctggacg aggatggcag cttcgccctg 1320gtgtccaagc tgacagtgga taaatctcga tggcagcagg ggaacgtgtt tagttgttca 1380gtgatgcatg aagccctgca caatcattac actcagaaga gcctgtccct gtctcccggc 1440aaa 1443149107PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 149Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Val Asn Thr Ala 20 25 30 Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Arg Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 150321DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 150gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60atcacttgcc gggcaagtca ggacgttaac accgctgtag cttggtatca gcagaaacca 120gggaaagccc ctaagctcct gatctattct gcatcctttt tgtacagtgg ggtcccatca 180aggttcagtg gcagtcgatc tgggacagat ttcactctca ccatcagcag tctgcaacct 240gaagattttg caacttacta ctgtcaacag cattacacta ccccacccac tttcggccaa 300gggaccaaag tggagatcaa a 3211516PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 151Gln Asp Val Asn Thr Ala 1 5 15218DNAArtificial SequenceDescription of Artificial Sequence Synthetic oligonucleotide 152caggacgtta acaccgct 181539PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 153Gln Gln His Tyr Thr Thr Pro Pro Thr 1 5 15427DNAArtificial SequenceDescription of Artificial Sequence Synthetic oligonucleotide 154caacagcatt acactacccc acccact 271553PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 155Ser Ala Ser 1 1569DNAArtificial SequenceDescription of Artificial Sequence Synthetic oligonucleotide 156tctgcatcc 9157120PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 157Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Ile Lys Asp Thr 20 25 30 Tyr Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Arg Ile Tyr Pro Thr Asn Gly Tyr Thr Arg Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ser Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser 115 120 158360DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 158gaagtgcagc tggtggagtc tgggggaggc ttggtacagc ctggcgggtc cctgagactc 60tcctgtgcag cctctggatt caacattaaa gatacttata tccactgggt ccggcaagct 120ccagggaagg gcctggagtg ggtcgcacgt atttatccca caaatggtta cacacggtat 180gcggactctg tgaagggccg attcaccatc tccgcagaca cttccaagaa caccgcgtat 240ctgcaaatga acagtctgag agctgaggac acggccgttt attactgttc aagatggggc 300ggagacggtt tctacgctat ggactactgg ggccaaggga ccctggtcac cgtctcctca 3601598PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 159Gly Phe Asn Ile Lys Asp Thr Tyr 1 5 16024DNAArtificial SequenceDescription of Artificial Sequence Synthetic oligonucleotide 160ggattcaaca ttaaagatac ttat 2416113PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 161Ser Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr 1 5 10 16239DNAArtificial SequenceDescription of Artificial Sequence Synthetic oligonucleotide 162tcaagatggg gcggagacgg tttctacgct atggactac 391638PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 163Ile Tyr Pro Thr Asn Gly Tyr Thr 1 5 16424DNAArtificial SequenceDescription of Artificial Sequence Synthetic oligonucleotide 164atttatccca caaatggtta caca 24165110PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 165Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 1 5 10 15 Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val 20 25 30 Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr 35 40 45 Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu 50 55 60 Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His 65 70 75 80 Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys 85 90 95 Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys 100 105 110 166330DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 166gctccagaac tgctgggagg acctagcgtg ttcctgtttc cccctaagcc aaaagacact 60ctgatgattt ccaggactcc cgaggtgacc tgcgtggtgg tggacgtgtc tcacgaggac 120cccgaagtga agttcaactg gtacgtggat ggcgtggaag tgcataatgc taagacaaaa 180ccaagagagg aacagtacaa ctccacttat cgcgtcgtga gcgtgctgac cgtgctgcac 240caggactggc tgaacgggaa ggagtataag tgcaaagtca gtaataaggc cctgcctgct 300ccaatcgaaa aaaccatctc taaggccaaa 330167106PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 167Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Tyr Pro Pro Ser Arg Asp 1 5 10 15 Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe 20 25 30 Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu 35 40 45 Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Glu Asp Gly Ser Phe 50 55 60 Ala Leu Val Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly 65 70 75 80 Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr 85 90 95 Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 100 105 168318DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 168ggccagccaa gggagcccca ggtgtacaca tacccaccca gcagagacga actgaccaag 60aaccaggtgt ccctgacatg tctggtgaaa ggcttctatc ctagtgatat tgctgtggag 120tgggaatcaa atggacagcc agagaacaat tacaagacca cacctccagt gctggacgag 180gatggcagct tcgccctggt gtccaagctg acagtggata aatctcgatg gcagcagggg 240aacgtgttta gttgttcagt gatgcatgaa gccctgcaca atcattacac tcagaagagc 300ctgtccctgt ctcccggc 318169481PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 169Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Val Asn Thr Ala 20 25 30 Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Arg Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gly Gly Ser Gly Gly 100 105 110 Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Glu 115 120 125 Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser 130 135 140 Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Ile Lys Asp Thr Tyr 145 150 155 160 Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala 165 170 175 Arg Ile Tyr Pro Thr Asn Gly Tyr Thr Arg Tyr Ala Asp Ser Val Lys 180 185 190 Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr Leu 195 200 205 Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ser 210 215 220 Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr Trp Gly Gln Gly 225 230 235 240 Thr Leu Val Thr Val Ser Ser Ala Ala Glu Pro Lys Ser Ser Asp Lys 245 250 255 Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro 260 265 270 Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser 275 280 285 Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp 290 295 300 Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn 305 310 315 320 Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val 325 330 335 Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu 340 345 350 Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys 355 360 365 Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr 370 375 380 Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Ile 385 390 395 400 Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu 405 410 415 Ser Asn Gly Gln Pro Glu Asn Arg Tyr Met Thr Trp Pro Pro Val Leu 420 425 430 Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys 435 440 445 Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu 450 455 460 Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 465 470 475 480 Lys 1701443DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 170gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60atcacttgcc gggcaagtca ggacgttaac accgctgtag cttggtatca gcagaaacca 120gggaaagccc ctaagctcct gatctattct gcatcctttt tgtacagtgg ggtcccatca 180aggttcagtg gcagtcgatc tgggacagat ttcactctca ccatcagcag tctgcaacct 240gaagattttg caacttacta ctgtcaacag cattacacta ccccacccac tttcggccaa 300gggaccaaag tggagatcaa aggtggttct ggtggtggtt ctggtggtgg ttctggtggt 360ggttctggtg gtggttctgg tgaagtgcag ctggtggagt ctgggggagg cttggtacag 420cctggcgggt ccctgagact ctcctgtgca gcctctggat tcaacattaa agatacttat 480atccactggg tccggcaagc tccagggaag ggcctggagt gggtcgcacg tatttatccc 540acaaatggtt acacacggta tgcggactct gtgaagggcc gattcaccat ctccgcagac 600acttccaaga acaccgcgta tctgcaaatg aacagtctga gagctgagga cacggccgtt 660tattactgtt caagatgggg cggagacggt ttctacgcta tggactactg gggccaaggg 720accctggtca ccgtctcctc agccgccgag cccaagagca gcgataagac ccacacctgc 780cctccctgtc cagctccaga actgctggga ggacctagcg tgttcctgtt tccccctaag 840ccaaaagaca ctctgatgat ttccaggact cccgaggtga cctgcgtggt ggtggacgtg 900tctcacgagg accccgaagt gaagttcaac tggtacgtgg atggcgtgga agtgcataat 960gctaagacaa aaccaagaga ggaacagtac aactccactt atcgcgtcgt gagcgtgctg 1020accgtgctgc accaggactg gctgaacggg aaggagtata agtgcaaagt cagtaataag 1080gccctgcctg ctccaatcga aaaaaccatc tctaaggcca aaggccagcc aagggagccc 1140caggtgtaca cactgccacc cagcagagac gaactgacca agaaccaggt gtccctgatc 1200tgtctggtga aaggcttcta tcctagtgat attgctgtgg agtgggaatc aaatggacag 1260ccagagaaca gatacatgac ctggcctcca gtgctggaca gcgatggcag cttcttcctg 1320tattccaagc tgacagtgga taaatctcga tggcagcagg ggaacgtgtt tagttgttca 1380gtgatgcatg aagccctgca caatcattac actcagaaga gcctgtccct gtctcccggc 1440aaa 1443171107PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 171Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Val Asn Thr Ala 20 25 30 Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Arg Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 172321DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 172gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60atcacttgcc gggcaagtca ggacgttaac accgctgtag cttggtatca gcagaaacca 120gggaaagccc ctaagctcct gatctattct gcatcctttt tgtacagtgg ggtcccatca 180aggttcagtg gcagtcgatc tgggacagat ttcactctca ccatcagcag tctgcaacct 240gaagattttg caacttacta ctgtcaacag cattacacta ccccacccac tttcggccaa 300gggaccaaag tggagatcaa a 3211736PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 173Gln Asp Val Asn Thr Ala 1 5 17418DNAArtificial SequenceDescription of Artificial Sequence Synthetic oligonucleotide 174caggacgtta acaccgct 181759PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 175Gln Gln His Tyr Thr Thr Pro Pro Thr 1 5 17627DNAArtificial SequenceDescription of Artificial Sequence Synthetic oligonucleotide 176caacagcatt acactacccc acccact 271773PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 177Ser Ala Ser 1 1789DNAArtificial SequenceDescription of Artificial Sequence Synthetic oligonucleotide 178tctgcatcc 9179120PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 179Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Ile Lys Asp Thr 20 25 30 Tyr Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Arg Ile Tyr Pro Thr Asn Gly Tyr Thr Arg Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ser Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser 115 120 180360DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 180gaagtgcagc tggtggagtc tgggggaggc ttggtacagc ctggcgggtc cctgagactc 60tcctgtgcag cctctggatt caacattaaa gatacttata tccactgggt ccggcaagct 120ccagggaagg gcctggagtg ggtcgcacgt atttatccca caaatggtta cacacggtat 180gcggactctg tgaagggccg attcaccatc tccgcagaca cttccaagaa caccgcgtat 240ctgcaaatga acagtctgag agctgaggac acggccgttt attactgttc aagatggggc 300ggagacggtt tctacgctat ggactactgg ggccaaggga ccctggtcac cgtctcctca 3601818PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 181Gly Phe Asn Ile Lys Asp Thr Tyr 1 5 18224DNAArtificial SequenceDescription of Artificial Sequence Synthetic oligonucleotide 182ggattcaaca ttaaagatac ttat 2418313PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 183Ser Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr 1 5 10 18439DNAArtificial SequenceDescription of Artificial Sequence Synthetic oligonucleotide 184tcaagatggg gcggagacgg tttctacgct atggactac 391858PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 185Ile Tyr Pro Thr Asn Gly Tyr Thr 1 5 18624DNAArtificial SequenceDescription of Artificial Sequence Synthetic oligonucleotide 186atttatccca caaatggtta caca 24187110PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 187Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 1 5 10 15 Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val 20 25 30 Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr 35 40 45 Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu 50 55 60 Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His 65 70 75 80 Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys 85 90 95 Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys 100 105 110 188330DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 188gctccagaac tgctgggagg acctagcgtg ttcctgtttc cccctaagcc aaaagacact 60ctgatgattt ccaggactcc cgaggtgacc tgcgtggtgg tggacgtgtc tcacgaggac 120cccgaagtga agttcaactg gtacgtggat ggcgtggaag tgcataatgc taagacaaaa 180ccaagagagg aacagtacaa ctccacttat cgcgtcgtga gcgtgctgac cgtgctgcac 240caggactggc tgaacgggaa ggagtataag tgcaaagtca gtaataaggc cctgcctgct 300ccaatcgaaa aaaccatctc taaggccaaa 330189106PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 189Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp 1 5 10 15 Glu Leu Thr Lys Asn Gln Val Ser Leu Ile Cys Leu Val Lys Gly Phe 20 25 30 Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu 35

40 45 Asn Arg Tyr Met Thr Trp Pro Pro Val Leu Asp Ser Asp Gly Ser Phe 50 55 60 Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly 65 70 75 80 Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr 85 90 95 Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 100 105 190318DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 190ggccagccaa gggagcccca ggtgtacaca ctgccaccca gcagagacga actgaccaag 60aaccaggtgt ccctgatctg tctggtgaaa ggcttctatc ctagtgatat tgctgtggag 120tgggaatcaa atggacagcc agagaacaga tacatgacct ggcctccagt gctggacagc 180gatggcagct tcttcctgta ttccaagctg acagtggata aatctcgatg gcagcagggg 240aacgtgttta gttgttcagt gatgcatgaa gccctgcaca atcattacac tcagaagagc 300ctgtccctgt ctcccggc 318191214PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 191Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Val Asn Thr Ala 20 25 30 Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Arg Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 192642DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 192gatattcaga tgacccagtc ccctagctcc ctgtccgctt ctgtgggcga cagggtcact 60atcacctgcc gcgcatctca ggatgtgaac accgcagtcg cctggtacca gcagaagcct 120gggaaagctc caaagctgct gatctacagt gcatcattcc tgtattcagg agtgcccagc 180cggtttagcg gcagcagatc tggcaccgac ttcacactga ctatctctag tctgcagcct 240gaggattttg ccacatacta ttgccagcag cactatacca caccccctac tttcggccag 300gggaccaaag tggagatcaa gcgaactgtg gccgctccaa gtgtcttcat ttttccaccc 360agcgacgaac agctgaaatc cggcacagct tctgtggtct gtctgctgaa caacttctac 420cccagagagg ccaaagtgca gtggaaggtc gataacgctc tgcagagtgg caacagccag 480gagagcgtga cagaacagga ctccaaagat tctacttata gtctgtcaag caccctgaca 540ctgagcaagg cagactacga aaagcataaa gtgtatgcct gtgaggtgac ccatcagggg 600ctgtcttctc ccgtgaccaa gtctttcaac cgaggcgaat gt 642193107PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 193Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Val Asn Thr Ala 20 25 30 Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Arg Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 194321DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 194gatattcaga tgacccagtc ccctagctcc ctgtccgctt ctgtgggcga cagggtcact 60atcacctgcc gcgcatctca ggatgtgaac accgcagtcg cctggtacca gcagaagcct 120gggaaagctc caaagctgct gatctacagt gcatcattcc tgtattcagg agtgcccagc 180cggtttagcg gcagcagatc tggcaccgac ttcacactga ctatctctag tctgcagcct 240gaggattttg ccacatacta ttgccagcag cactatacca caccccctac tttcggccag 300gggaccaaag tggagatcaa g 3211956PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 195Gln Asp Val Asn Thr Ala 1 5 19618DNAArtificial SequenceDescription of Artificial Sequence Synthetic oligonucleotide 196caggatgtga acaccgca 181979PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 197Gln Gln His Tyr Thr Thr Pro Pro Thr 1 5 19827DNAArtificial SequenceDescription of Artificial Sequence Synthetic oligonucleotide 198cagcagcact ataccacacc ccctact 271993PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 199Ser Ala Ser 1 2009DNAArtificial SequenceDescription of Artificial Sequence Synthetic oligonucleotide 200agtgcatca 9201107PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 201Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 1 5 10 15 Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 20 25 30 Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 35 40 45 Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 50 55 60 Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 65 70 75 80 Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 85 90 95 Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 100 105 202321DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 202cgaactgtgg ccgctccaag tgtcttcatt tttccaccca gcgacgaaca gctgaaatcc 60ggcacagctt ctgtggtctg tctgctgaac aacttctacc ccagagaggc caaagtgcag 120tggaaggtcg ataacgctct gcagagtggc aacagccagg agagcgtgac agaacaggac 180tccaaagatt ctacttatag tctgtcaagc accctgacac tgagcaaggc agactacgaa 240aagcataaag tgtatgcctg tgaggtgacc catcaggggc tgtcttctcc cgtgaccaag 300tctttcaacc gaggcgaatg t 321203448PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 203Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Thr Asp Tyr 20 25 30 Thr Met Asp Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Asp Val Asn Pro Asn Ser Gly Gly Ser Ile Tyr Asn Gln Arg Phe 50 55 60 Lys Gly Arg Phe Thr Leu Ser Val Asp Arg Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asn Leu Gly Pro Ser Phe Tyr Phe Asp Tyr Trp Gly Gln Gly 100 105 110 Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe 115 120 125 Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu 130 135 140 Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp 145 150 155 160 Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu 165 170 175 Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser 180 185 190 Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro 195 200 205 Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys 210 215 220 Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro 225 230 235 240 Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser 245 250 255 Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp 260 265 270 Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn 275 280 285 Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val 290 295 300 Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu 305 310 315 320 Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys 325 330 335 Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Val 340 345 350 Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Leu 355 360 365 Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu 370 375 380 Ser Asn Gly Gln Pro Glu Asn Asn Tyr Leu Thr Trp Pro Pro Val Leu 385 390 395 400 Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys 405 410 415 Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu 420 425 430 Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 435 440 445 2041344DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 204gaagtgcagc tggtcgaatc tggaggagga ctggtgcagc caggagggtc cctgcgcctg 60tcttgcgccg ctagtggctt cacttttacc gactacacca tggattgggt gcgacaggca 120cctggaaagg gcctggagtg ggtcgccgat gtgaacccaa atagcggagg ctccatctac 180aaccagcggt tcaagggccg gttcaccctg tcagtggacc ggagcaaaaa caccctgtat 240ctgcagatga atagcctgcg agccgaagat actgctgtgt actattgcgc ccggaatctg 300gggccctcct tctactttga ctattggggg cagggaactc tggtcaccgt gagctccgcc 360tccaccaagg gaccttctgt gttcccactg gctccctcta gtaaatccac atctggggga 420actgcagccc tgggctgtct ggtgaaggac tacttcccag agcccgtcac agtgtcttgg 480aacagtggcg ctctgacttc tggggtccac acctttcctg cagtgctgca gtcaagcggg 540ctgtacagcc tgtcctctgt ggtcaccgtg ccaagttcaa gcctgggaac acagacttat 600atctgcaacg tgaatcacaa gccatccaat acaaaagtcg acaagaaagt ggaacccaag 660tcttgtgata aaacccatac atgcccccct tgtcctgcac cagagctgct gggaggacca 720agcgtgttcc tgtttccacc caagcctaaa gatacactga tgattagtag gaccccagaa 780gtcacatgcg tggtcgtgga cgtgagccac gaggaccccg aagtcaagtt taactggtac 840gtggacggcg tcgaggtgca taatgccaag actaaaccca gggaggaaca gtacaacagt 900acctatcgcg tcgtgtcagt cctgacagtg ctgcatcagg attggctgaa cgggaaagag 960tataagtgca aagtgagcaa taaggctctg cccgcaccta tcgagaaaac aatttccaag 1020gcaaaaggac agcctagaga accacaggtg tacgtgctgc ctccatcaag ggatgagctg 1080acaaagaacc aggtcagcct gctgtgtctg gtgaaaggat tctatccctc tgacattgct 1140gtggagtggg aaagtaatgg ccagcctgag aacaattacc tgacctggcc ccctgtgctg 1200gactcagatg gcagcttctt tctgtatagc aagctgaccg tcgacaaatc ccggtggcag 1260caggggaatg tgtttagttg ttcagtcatg cacgaggcac tgcacaacca ttacacccag 1320aagtcactgt cactgtcacc aggg 1344205119PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 205Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Thr Asp Tyr 20 25 30 Thr Met Asp Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Asp Val Asn Pro Asn Ser Gly Gly Ser Ile Tyr Asn Gln Arg Phe 50 55 60 Lys Gly Arg Phe Thr Leu Ser Val Asp Arg Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asn Leu Gly Pro Ser Phe Tyr Phe Asp Tyr Trp Gly Gln Gly 100 105 110 Thr Leu Val Thr Val Ser Ser 115 206357DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 206gaagtgcagc tggtcgaatc tggaggagga ctggtgcagc caggagggtc cctgcgcctg 60tcttgcgccg ctagtggctt cacttttacc gactacacca tggattgggt gcgacaggca 120cctggaaagg gcctggagtg ggtcgccgat gtgaacccaa atagcggagg ctccatctac 180aaccagcggt tcaagggccg gttcaccctg tcagtggacc ggagcaaaaa caccctgtat 240ctgcagatga atagcctgcg agccgaagat actgctgtgt actattgcgc ccggaatctg 300gggccctcct tctactttga ctattggggg cagggaactc tggtcaccgt gagctcc 3572078PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 207Gly Phe Thr Phe Thr Asp Tyr Thr 1 5 20824DNAArtificial SequenceDescription of Artificial Sequence Synthetic oligonucleotide 208ggcttcactt ttaccgacta cacc 2420912PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 209Ala Arg Asn Leu Gly Pro Ser Phe Tyr Phe Asp Tyr 1 5 10 21036DNAArtificial SequenceDescription of Artificial Sequence Synthetic oligonucleotide 210gcccggaatc tggggccctc cttctacttt gactat 362118PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 211Val Asn Pro Asn Ser Gly Gly Ser 1 5 21224DNAArtificial SequenceDescription of Artificial Sequence Synthetic oligonucleotide 212gtgaacccaa atagcggagg ctcc 2421398PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 213Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 1 5 10 15 Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 25 30 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40 45 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 50 55 60 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 65 70 75 80 Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 85 90 95 Lys Val 214294DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 214gcctccacca agggaccttc tgtgttccca ctggctccct ctagtaaatc cacatctggg 60ggaactgcag ccctgggctg tctggtgaag gactacttcc cagagcccgt cacagtgtct 120tggaacagtg gcgctctgac ttctggggtc cacacctttc ctgcagtgct gcagtcaagc 180gggctgtaca gcctgtcctc tgtggtcacc gtgccaagtt caagcctggg aacacagact 240tatatctgca acgtgaatca caagccatcc aatacaaaag tcgacaagaa agtg 294215110PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 215Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 1 5 10 15 Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val 20 25 30 Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr 35 40 45 Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu 50 55 60 Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His 65 70 75 80 Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys 85 90 95 Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys 100 105 110 216330DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 216gcaccagagc tgctgggagg accaagcgtg ttcctgtttc cacccaagcc taaagataca 60ctgatgatta gtaggacccc agaagtcaca tgcgtggtcg tggacgtgag ccacgaggac

120cccgaagtca agtttaactg gtacgtggac ggcgtcgagg tgcataatgc caagactaaa 180cccagggagg aacagtacaa cagtacctat cgcgtcgtgt cagtcctgac agtgctgcat 240caggattggc tgaacgggaa agagtataag tgcaaagtga gcaataaggc tctgcccgca 300cctatcgaga aaacaatttc caaggcaaaa 330217106PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 217Gly Gln Pro Arg Glu Pro Gln Val Tyr Val Leu Pro Pro Ser Arg Asp 1 5 10 15 Glu Leu Thr Lys Asn Gln Val Ser Leu Leu Cys Leu Val Lys Gly Phe 20 25 30 Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu 35 40 45 Asn Asn Tyr Leu Thr Trp Pro Pro Val Leu Asp Ser Asp Gly Ser Phe 50 55 60 Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly 65 70 75 80 Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr 85 90 95 Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 100 105 218318DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 218ggacagccta gagaaccaca ggtgtacgtg ctgcctccat caagggatga gctgacaaag 60aaccaggtca gcctgctgtg tctggtgaaa ggattctatc cctctgacat tgctgtggag 120tgggaaagta atggccagcc tgagaacaat tacctgacct ggccccctgt gctggactca 180gatggcagct tctttctgta tagcaagctg accgtcgaca aatcccggtg gcagcagggg 240aatgtgttta gttgttcagt catgcacgag gcactgcaca accattacac ccagaagtca 300ctgtcactgt caccaggg 318219448PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 219Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Thr Asp Tyr 20 25 30 Thr Met Asp Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Asp Val Asn Pro Asn Ser Gly Gly Ser Ile Tyr Asn Gln Arg Phe 50 55 60 Lys Gly Arg Phe Thr Leu Ser Val Asp Arg Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asn Leu Gly Pro Ser Phe Tyr Phe Asp Tyr Trp Gly Gln Gly 100 105 110 Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe 115 120 125 Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu 130 135 140 Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp 145 150 155 160 Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu 165 170 175 Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser 180 185 190 Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro 195 200 205 Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys 210 215 220 Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro 225 230 235 240 Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser 245 250 255 Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp 260 265 270 Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn 275 280 285 Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val 290 295 300 Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu 305 310 315 320 Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys 325 330 335 Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Val 340 345 350 Tyr Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr 355 360 365 Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu 370 375 380 Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu 385 390 395 400 Asp Ser Asp Gly Ser Phe Ala Leu Val Ser Lys Leu Thr Val Asp Lys 405 410 415 Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu 420 425 430 Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 435 440 445 2201344DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 220gaagtgcagc tggtcgaatc tggaggagga ctggtgcagc caggagggtc cctgcgcctg 60tcttgcgccg ctagtggctt cacttttacc gactacacca tggattgggt gcgacaggca 120cctggaaagg gcctggagtg ggtcgccgat gtgaacccaa atagcggagg ctccatctac 180aaccagcggt tcaagggccg gttcaccctg tcagtggacc ggagcaaaaa caccctgtat 240ctgcagatga atagcctgcg agccgaagat actgctgtgt actattgcgc ccggaatctg 300gggccctcct tctactttga ctattggggg cagggaactc tggtcaccgt gagctccgcc 360tccaccaagg gaccttctgt gttcccactg gctccctcta gtaaatccac atctggggga 420actgcagccc tgggctgtct ggtgaaggac tacttcccag agcccgtcac agtgtcttgg 480aacagtggcg ctctgacttc tggggtccac acctttcctg cagtgctgca gtcaagcggg 540ctgtacagcc tgtcctctgt ggtcaccgtg ccaagttcaa gcctgggaac acagacttat 600atctgcaacg tgaatcacaa gccatccaat acaaaagtcg acaagaaagt ggaacccaag 660tcttgtgata aaacccatac atgcccccct tgtcctgcac cagagctgct gggaggacca 720agcgtgttcc tgtttccacc caagcctaaa gatacactga tgattagtag gaccccagaa 780gtcacatgcg tggtcgtgga cgtgagccac gaggaccccg aagtcaagtt taactggtac 840gtggacggcg tcgaggtgca taatgccaag actaaaccca gggaggaaca gtacaacagt 900acctatcgcg tcgtgtcagt cctgacagtg ctgcatcagg attggctgaa cgggaaagag 960tataagtgca aagtgagcaa taaggctctg cccgcaccta tcgagaaaac aatttccaag 1020gcaaaaggac agcctagaga accacaggtg tacgtgtatc ctccatcaag ggatgagctg 1080acaaagaacc aggtcagcct gacttgtctg gtgaaaggat tctatccctc tgacattgct 1140gtggagtggg aaagtaatgg ccagcctgag aacaattaca agaccacacc ccctgtgctg 1200gactcagatg gcagcttcgc gctggtgagc aagctgaccg tcgacaaatc ccggtggcag 1260caggggaatg tgtttagttg ttcagtcatg cacgaggcac tgcacaacca ttacacccag 1320aagtcactgt cactgtcacc aggg 1344221119PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 221Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Thr Asp Tyr 20 25 30 Thr Met Asp Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Asp Val Asn Pro Asn Ser Gly Gly Ser Ile Tyr Asn Gln Arg Phe 50 55 60 Lys Gly Arg Phe Thr Leu Ser Val Asp Arg Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asn Leu Gly Pro Ser Phe Tyr Phe Asp Tyr Trp Gly Gln Gly 100 105 110 Thr Leu Val Thr Val Ser Ser 115 222357DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 222gaagtgcagc tggtcgaatc tggaggagga ctggtgcagc caggagggtc cctgcgcctg 60tcttgcgccg ctagtggctt cacttttacc gactacacca tggattgggt gcgacaggca 120cctggaaagg gcctggagtg ggtcgccgat gtgaacccaa atagcggagg ctccatctac 180aaccagcggt tcaagggccg gttcaccctg tcagtggacc ggagcaaaaa caccctgtat 240ctgcagatga atagcctgcg agccgaagat actgctgtgt actattgcgc ccggaatctg 300gggccctcct tctactttga ctattggggg cagggaactc tggtcaccgt gagctcc 3572238PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 223Gly Phe Thr Phe Thr Asp Tyr Thr 1 5 22424DNAArtificial SequenceDescription of Artificial Sequence Synthetic oligonucleotide 224ggcttcactt ttaccgacta cacc 2422512PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 225Ala Arg Asn Leu Gly Pro Ser Phe Tyr Phe Asp Tyr 1 5 10 22636DNAArtificial SequenceDescription of Artificial Sequence Synthetic oligonucleotide 226gcccggaatc tggggccctc cttctacttt gactat 362278PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 227Val Asn Pro Asn Ser Gly Gly Ser 1 5 22824DNAArtificial SequenceDescription of Artificial Sequence Synthetic oligonucleotide 228gtgaacccaa atagcggagg ctcc 2422998PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 229Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 1 5 10 15 Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 25 30 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40 45 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 50 55 60 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 65 70 75 80 Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 85 90 95 Lys Val 230294DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 230gcctccacca agggaccttc tgtgttccca ctggctccct ctagtaaatc cacatctggg 60ggaactgcag ccctgggctg tctggtgaag gactacttcc cagagcccgt cacagtgtct 120tggaacagtg gcgctctgac ttctggggtc cacacctttc ctgcagtgct gcagtcaagc 180gggctgtaca gcctgtcctc tgtggtcacc gtgccaagtt caagcctggg aacacagact 240tatatctgca acgtgaatca caagccatcc aatacaaaag tcgacaagaa agtg 294231110PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 231Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 1 5 10 15 Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val 20 25 30 Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr 35 40 45 Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu 50 55 60 Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His 65 70 75 80 Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys 85 90 95 Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys 100 105 110 232330DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 232gcaccagagc tgctgggagg accaagcgtg ttcctgtttc cacccaagcc taaagataca 60ctgatgatta gtaggacccc agaagtcaca tgcgtggtcg tggacgtgag ccacgaggac 120cccgaagtca agtttaactg gtacgtggac ggcgtcgagg tgcataatgc caagactaaa 180cccagggagg aacagtacaa cagtacctat cgcgtcgtgt cagtcctgac agtgctgcat 240caggattggc tgaacgggaa agagtataag tgcaaagtga gcaataaggc tctgcccgca 300cctatcgaga aaacaatttc caaggcaaaa 330233106PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 233Gly Gln Pro Arg Glu Pro Gln Val Tyr Val Tyr Pro Pro Ser Arg Asp 1 5 10 15 Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe 20 25 30 Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu 35 40 45 Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe 50 55 60 Ala Leu Val Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly 65 70 75 80 Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr 85 90 95 Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 100 105 234318DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 234ggacagccta gagaaccaca ggtgtacgtg tatcctccat caagggatga gctgacaaag 60aaccaggtca gcctgacttg tctggtgaaa ggattctatc cctctgacat tgctgtggag 120tgggaaagta atggccagcc tgagaacaat tacaagacca caccccctgt gctggactca 180gatggcagct tcgcgctggt gagcaagctg accgtcgaca aatcccggtg gcagcagggg 240aatgtgttta gttgttcagt catgcacgag gcactgcaca accattacac ccagaagtca 300ctgtcactgt caccaggg 318235450PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 235Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Ile Lys Asp Thr 20 25 30 Tyr Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Arg Ile Tyr Pro Thr Asn Gly Tyr Thr Arg Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ser Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125 Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala 130 135 140 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190 Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys 195 200 205 Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp 210 215 220 Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 225 230 235 240 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 245 250 255 Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 260 265 270 Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 275 280 285 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg 290 295 300 Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys 305 310 315 320 Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 325 330 335 Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 340 345 350 Val Tyr Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu 355 360 365 Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 370 375 380 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 385 390 395 400 Leu Asp Ser Asp Gly Ser Phe Ala Leu Val Ser Lys Leu Thr Val Asp 405 410 415 Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His 420 425 430 Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 435 440 445 Gly Lys 450 2361350DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 236gaggtgcagc tggtggaaag cggaggagga ctggtgcagc caggaggatc tctgcgactg 60agttgcgccg cttcaggatt caacatcaag gacacctaca ttcactgggt gcgacaggct 120ccaggaaaag gactggagtg ggtggctcga atctatccca ctaatggata cacccggtat 180gccgactccg tgaaggggag gtttactatt agcgccgata catccaaaaa cactgcttac 240ctgcagatga acagcctgcg agccgaagat accgctgtgt actattgcag tcgatgggga

300ggagacggat tctacgctat ggattattgg ggacagggga ccctggtgac agtgagctcc 360gcctctacca agggccccag tgtgtttccc ctggctcctt ctagtaaatc cacctctgga 420gggacagccg ctctgggatg tctggtgaag gactatttcc ccgagcctgt gaccgtgagt 480tggaactcag gcgccctgac aagcggagtg cacacttttc ctgctgtgct gcagtcaagc 540gggctgtact ccctgtcctc tgtggtgaca gtgccaagtt caagcctggg cacacagact 600tatatctgca acgtgaatca taagccctca aatacaaaag tggacaagaa agtggagccc 660aagagctgtg ataagaccca cacctgccct ccctgtccag ctccagaact gctgggagga 720cctagcgtgt tcctgtttcc ccctaagcca aaagacactc tgatgatttc caggactccc 780gaggtgacct gcgtggtggt ggacgtgtct cacgaggacc ccgaagtgaa gttcaactgg 840tacgtggatg gcgtggaagt gcataatgct aagacaaaac caagagagga acagtacaac 900tccacttatc gcgtcgtgag cgtgctgacc gtgctgcacc aggactggct gaacgggaag 960gagtataagt gcaaagtcag taataaggcc ctgcctgctc caatcgaaaa aaccatctct 1020aaggccaaag gccagccaag ggagccccag gtgtacgtgt acccacccag cagagacgaa 1080ctgaccaaga accaggtgtc cctgacatgt ctggtgaaag gcttctatcc tagtgatatt 1140gctgtggagt gggaatcaaa tggacagcca gagaacaatt acaagaccac acctccagtg 1200ctggacagcg atggcagctt cgccctggtg tccaagctga cagtggataa atctcgatgg 1260cagcagggga acgtgtttag ttgttcagtg atgcatgaag ccctgcacaa tcattacact 1320cagaagagcc tgtccctgtc tcccggcaaa 1350237120PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 237Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Ile Lys Asp Thr 20 25 30 Tyr Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Arg Ile Tyr Pro Thr Asn Gly Tyr Thr Arg Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ser Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser 115 120 238360DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 238gaggtgcagc tggtggaaag cggaggagga ctggtgcagc caggaggatc tctgcgactg 60agttgcgccg cttcaggatt caacatcaag gacacctaca ttcactgggt gcgacaggct 120ccaggaaaag gactggagtg ggtggctcga atctatccca ctaatggata cacccggtat 180gccgactccg tgaaggggag gtttactatt agcgccgata catccaaaaa cactgcttac 240ctgcagatga acagcctgcg agccgaagat accgctgtgt actattgcag tcgatgggga 300ggagacggat tctacgctat ggattattgg ggacagggga ccctggtgac agtgagctcc 3602398PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 239Gly Phe Asn Ile Lys Asp Thr Tyr 1 5 24024DNAArtificial SequenceDescription of Artificial Sequence Synthetic oligonucleotide 240ggattcaaca tcaaggacac ctac 2424113PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 241Ser Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr 1 5 10 24239DNAArtificial SequenceDescription of Artificial Sequence Synthetic oligonucleotide 242agtcgatggg gaggagacgg attctacgct atggattat 392438PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 243Ile Tyr Pro Thr Asn Gly Tyr Thr 1 5 24424DNAArtificial SequenceDescription of Artificial Sequence Synthetic oligonucleotide 244atctatccca ctaatggata cacc 2424598PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 245Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 1 5 10 15 Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 25 30 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40 45 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 50 55 60 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 65 70 75 80 Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 85 90 95 Lys Val 246294DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 246gcctctacca agggccccag tgtgtttccc ctggctcctt ctagtaaatc cacctctgga 60gggacagccg ctctgggatg tctggtgaag gactatttcc ccgagcctgt gaccgtgagt 120tggaactcag gcgccctgac aagcggagtg cacacttttc ctgctgtgct gcagtcaagc 180gggctgtact ccctgtcctc tgtggtgaca gtgccaagtt caagcctggg cacacagact 240tatatctgca acgtgaatca taagccctca aatacaaaag tggacaagaa agtg 294247110PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 247Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 1 5 10 15 Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val 20 25 30 Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr 35 40 45 Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu 50 55 60 Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His 65 70 75 80 Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys 85 90 95 Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys 100 105 110 248330DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 248gctccagaac tgctgggagg acctagcgtg ttcctgtttc cccctaagcc aaaagacact 60ctgatgattt ccaggactcc cgaggtgacc tgcgtggtgg tggacgtgtc tcacgaggac 120cccgaagtga agttcaactg gtacgtggat ggcgtggaag tgcataatgc taagacaaaa 180ccaagagagg aacagtacaa ctccacttat cgcgtcgtga gcgtgctgac cgtgctgcac 240caggactggc tgaacgggaa ggagtataag tgcaaagtca gtaataaggc cctgcctgct 300ccaatcgaaa aaaccatctc taaggccaaa 330249106PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 249Gly Gln Pro Arg Glu Pro Gln Val Tyr Val Tyr Pro Pro Ser Arg Asp 1 5 10 15 Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe 20 25 30 Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu 35 40 45 Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe 50 55 60 Ala Leu Val Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly 65 70 75 80 Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr 85 90 95 Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 100 105 250318DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 250ggccagccaa gggagcccca ggtgtacgtg tacccaccca gcagagacga actgaccaag 60aaccaggtgt ccctgacatg tctggtgaaa ggcttctatc ctagtgatat tgctgtggag 120tgggaatcaa atggacagcc agagaacaat tacaagacca cacctccagt gctggacagc 180gatggcagct tcgccctggt gtccaagctg acagtggata aatctcgatg gcagcagggg 240aacgtgttta gttgttcagt gatgcatgaa gccctgcaca atcattacac tcagaagagc 300ctgtccctgt ctcccggc 318251232PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 251Glu Pro Lys Ser Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 1 5 10 15 Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 20 25 30 Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val 35 40 45 Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val 50 55 60 Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln 65 70 75 80 Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln 85 90 95 Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala 100 105 110 Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro 115 120 125 Arg Glu Pro Gln Val Tyr Val Leu Pro Pro Ser Arg Asp Glu Leu Thr 130 135 140 Lys Asn Gln Val Ser Leu Leu Cys Leu Val Lys Gly Phe Tyr Pro Ser 145 150 155 160 Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr 165 170 175 Leu Thr Trp Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr 180 185 190 Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe 195 200 205 Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys 210 215 220 Ser Leu Ser Leu Ser Pro Gly Lys 225 230 252696DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 252gaacctaaaa gcagcgacaa gacccacaca tgcccccctt gtccagctcc agaactgctg 60ggaggaccaa gcgtgttcct gtttccaccc aagcccaaag atacactgat gatcagccga 120actcccgagg tcacctgcgt ggtcgtggac gtgtcccacg aggaccccga agtcaagttc 180aactggtacg tggacggcgt cgaagtgcat aatgcaaaga ctaaaccacg ggaggaacag 240tacaactcta catatagagt cgtgagtgtc ctgactgtgc tgcatcagga ttggctgaac 300ggcaaagagt ataagtgcaa agtgtctaat aaggccctgc ctgctccaat cgagaaaact 360attagtaagg caaaagggca gcccagggaa cctcaggtct acgtgctgcc tccaagtcgc 420gacgagctga ccaagaacca ggtctcactg ctgtgtctgg tgaaaggatt ctatccttcc 480gatattgccg tggagtggga atctaatggc cagccagaga acaattacct gacctggccc 540cctgtgctgg acagcgatgg gtccttcttt ctgtattcaa agctgacagt ggacaaaagc 600agatggcagc agggaaacgt ctttagctgt tccgtgatgc acgaagccct gcacaatcat 660tacacccaga agtctctgag tctgtcacct ggcaaa 696253110PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 253Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 1 5 10 15 Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val 20 25 30 Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr 35 40 45 Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu 50 55 60 Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His 65 70 75 80 Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys 85 90 95 Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys 100 105 110 254330DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 254gctccagaac tgctgggagg accaagcgtg ttcctgtttc cacccaagcc caaagataca 60ctgatgatca gccgaactcc cgaggtcacc tgcgtggtcg tggacgtgtc ccacgaggac 120cccgaagtca agttcaactg gtacgtggac ggcgtcgaag tgcataatgc aaagactaaa 180ccacgggagg aacagtacaa ctctacatat agagtcgtga gtgtcctgac tgtgctgcat 240caggattggc tgaacggcaa agagtataag tgcaaagtgt ctaataaggc cctgcctgct 300ccaatcgaga aaactattag taaggcaaaa 330255106PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 255Gly Gln Pro Arg Glu Pro Gln Val Tyr Val Leu Pro Pro Ser Arg Asp 1 5 10 15 Glu Leu Thr Lys Asn Gln Val Ser Leu Leu Cys Leu Val Lys Gly Phe 20 25 30 Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu 35 40 45 Asn Asn Tyr Leu Thr Trp Pro Pro Val Leu Asp Ser Asp Gly Ser Phe 50 55 60 Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly 65 70 75 80 Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr 85 90 95 Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 100 105 256318DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 256gggcagccca gggaacctca ggtctacgtg ctgcctccaa gtcgcgacga gctgaccaag 60aaccaggtct cactgctgtg tctggtgaaa ggattctatc cttccgatat tgccgtggag 120tgggaatcta atggccagcc agagaacaat tacctgacct ggccccctgt gctggacagc 180gatgggtcct tctttctgta ttcaaagctg acagtggaca aaagcagatg gcagcaggga 240aacgtcttta gctgttccgt gatgcacgaa gccctgcaca atcattacac ccagaagtct 300ctgagtctgt cacctggc 318257475PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 257Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Val Ser Ile Gly 20 25 30 Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ser Ala Ser Tyr Arg Tyr Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Tyr Ile Tyr Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gly Gly Gly Gly Ser 100 105 110 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu 115 120 125 Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys 130 135 140 Ala Ala Ser Gly Phe Thr Phe Thr Asp Tyr Thr Met Asp Trp Val Arg 145 150 155 160 Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Asp Val Asn Pro Asn 165 170 175 Ser Gly Gly Ser Ile Tyr Asn Gln Arg Phe Lys Gly Arg Phe Thr Leu 180 185 190 Ser Val Asp Arg Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu 195 200 205 Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asn Leu Gly Pro 210 215 220 Ser Phe Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser 225 230 235 240 Ser Ala Ala Glu Pro Lys Ser Ser Asp Lys Thr His Thr Cys Pro Pro 245 250 255 Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro 260 265 270 Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr 275 280 285 Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn 290 295 300 Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg 305 310 315 320 Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val 325 330 335 Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser 340 345 350 Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys 355 360 365 Gly Gln Pro Arg Glu Pro Gln Val Tyr Val Tyr Pro Pro Ser Arg Asp 370 375 380 Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe 385 390 395 400 Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu 405 410 415 Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe 420 425 430 Ala Leu Val Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly 435 440 445 Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr 450 455 460 Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 465 470 475 2581425DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 258gacattcaga tgacccagag ccctagctcc ctgagtgcct cagtcgggga cagggtgact 60atcacctgca aggcttcaca ggatgtcagc attggcgtgg catggtacca gcagaagcca 120gggaaagcac

ccaagctgct gatctatagc gcctcctaca ggtatacagg cgtgccatcc 180cgcttctctg gcagtgggtc aggaactgac tttacactga ctatttctag tctgcagccc 240gaagatttcg ccacatacta ttgccagcag tactatatct acccttatac ttttggccag 300gggaccaaag tggagattaa gggcggagga ggctccggag gaggagggtc tggaggagga 360ggaagtgagg tccagctggt ggaatctgga ggaggactgg tgcagccagg agggtccctg 420aggctgtctt gtgccgctag tggcttcacc tttacagact acacaatgga ttgggtgcgc 480caggcaccag gaaagggact ggaatgggtc gctgatgtga accctaatag cggaggctcc 540atctacaacc agcggttcaa aggacggttc accctgtcag tggaccggag caagaacacc 600ctgtatctgc agatgaacag cctgagagcc gaggatactg ctgtgtacta ttgcgccagg 660aatctgggcc caagcttcta ctttgactat tgggggcagg gaacactggt cactgtgtca 720agcgcagccg aacccaaatc ctctgataag actcacacct gcccaccttg tccagctcca 780gagctgctgg gaggacctag cgtgttcctg tttccaccca agccaaaaga cactctgatg 840atttctagaa cccctgaagt gacatgtgtg gtcgtggacg tcagtcacga ggaccccgaa 900gtcaaattca actggtacgt ggatggcgtc gaggtgcata atgccaagac caaaccccga 960gaggaacagt acaactcaac ctatcgggtc gtgagcgtcc tgacagtgct gcatcaggac 1020tggctgaacg gcaaggagta taagtgcaaa gtgagcaaca aggctctgcc tgcaccaatc 1080gagaagacca tttccaaggc taaagggcag ccccgcgaac ctcaggtcta cgtgtatcct 1140ccaagccgag atgagctgac aaaaaaccag gtctccctga cttgtctggt gaagggattt 1200tacccaagtg acatcgcagt ggagtgggaa tcaaatggcc agcccgaaaa caattataag 1260accacacccc ctgtgctgga ctctgatggg agtttcgcac tggtctccaa actgaccgtg 1320gacaagtctc ggtggcagca gggaaacgtc tttagctgtt ccgtgatgca cgaggccctg 1380cacaatcatt acacacagaa atctctgagt ctgtcacctg gcaag 1425259107PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 259Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Val Ser Ile Gly 20 25 30 Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ser Ala Ser Tyr Arg Tyr Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Tyr Ile Tyr Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 260321DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 260gacattcaga tgacccagag ccctagctcc ctgagtgcct cagtcgggga cagggtgact 60atcacctgca aggcttcaca ggatgtcagc attggcgtgg catggtacca gcagaagcca 120gggaaagcac ccaagctgct gatctatagc gcctcctaca ggtatacagg cgtgccatcc 180cgcttctctg gcagtgggtc aggaactgac tttacactga ctatttctag tctgcagccc 240gaagatttcg ccacatacta ttgccagcag tactatatct acccttatac ttttggccag 300gggaccaaag tggagattaa g 3212616PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 261Gln Asp Val Ser Ile Gly 1 5 26218DNAArtificial SequenceDescription of Artificial Sequence Synthetic oligonucleotide 262caggatgtca gcattggc 182639PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 263Gln Gln Tyr Tyr Ile Tyr Pro Tyr Thr 1 5 26427DNAArtificial SequenceDescription of Artificial Sequence Synthetic oligonucleotide 264cagcagtact atatctaccc ttatact 272653PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 265Ser Ala Ser 1 2669DNAArtificial SequenceDescription of Artificial Sequence Synthetic oligonucleotide 266agcgcctcc 9267119PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 267Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Thr Asp Tyr 20 25 30 Thr Met Asp Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Asp Val Asn Pro Asn Ser Gly Gly Ser Ile Tyr Asn Gln Arg Phe 50 55 60 Lys Gly Arg Phe Thr Leu Ser Val Asp Arg Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asn Leu Gly Pro Ser Phe Tyr Phe Asp Tyr Trp Gly Gln Gly 100 105 110 Thr Leu Val Thr Val Ser Ser 115 268357DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 268gaggtccagc tggtggaatc tggaggagga ctggtgcagc caggagggtc cctgaggctg 60tcttgtgccg ctagtggctt cacctttaca gactacacaa tggattgggt gcgccaggca 120ccaggaaagg gactggaatg ggtcgctgat gtgaacccta atagcggagg ctccatctac 180aaccagcggt tcaaaggacg gttcaccctg tcagtggacc ggagcaagaa caccctgtat 240ctgcagatga acagcctgag agccgaggat actgctgtgt actattgcgc caggaatctg 300ggcccaagct tctactttga ctattggggg cagggaacac tggtcactgt gtcaagc 3572698PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 269Gly Phe Thr Phe Thr Asp Tyr Thr 1 5 27024DNAArtificial SequenceDescription of Artificial Sequence Synthetic oligonucleotide 270ggcttcacct ttacagacta caca 2427112PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 271Ala Arg Asn Leu Gly Pro Ser Phe Tyr Phe Asp Tyr 1 5 10 27236DNAArtificial SequenceDescription of Artificial Sequence Synthetic oligonucleotide 272gccaggaatc tgggcccaag cttctacttt gactat 362738PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 273Val Asn Pro Asn Ser Gly Gly Ser 1 5 27424DNAArtificial SequenceDescription of Artificial Sequence Synthetic oligonucleotide 274gtgaacccta atagcggagg ctcc 24275110PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 275Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 1 5 10 15 Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val 20 25 30 Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr 35 40 45 Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu 50 55 60 Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His 65 70 75 80 Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys 85 90 95 Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys 100 105 110 276330DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 276gctccagagc tgctgggagg acctagcgtg ttcctgtttc cacccaagcc aaaagacact 60ctgatgattt ctagaacccc tgaagtgaca tgtgtggtcg tggacgtcag tcacgaggac 120cccgaagtca aattcaactg gtacgtggat ggcgtcgagg tgcataatgc caagaccaaa 180ccccgagagg aacagtacaa ctcaacctat cgggtcgtga gcgtcctgac agtgctgcat 240caggactggc tgaacggcaa ggagtataag tgcaaagtga gcaacaaggc tctgcctgca 300ccaatcgaga agaccatttc caaggctaaa 330277106PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 277Gly Gln Pro Arg Glu Pro Gln Val Tyr Val Tyr Pro Pro Ser Arg Asp 1 5 10 15 Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe 20 25 30 Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu 35 40 45 Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe 50 55 60 Ala Leu Val Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly 65 70 75 80 Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr 85 90 95 Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 100 105 278318DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 278gggcagcccc gcgaacctca ggtctacgtg tatcctccaa gccgagatga gctgacaaaa 60aaccaggtct ccctgacttg tctggtgaag ggattttacc caagtgacat cgcagtggag 120tgggaatcaa atggccagcc cgaaaacaat tataagacca caccccctgt gctggactct 180gatgggagtt tcgcactggt ctccaaactg accgtggaca agtctcggtg gcagcaggga 240aacgtcttta gctgttccgt gatgcacgag gccctgcaca atcattacac acagaaatct 300ctgagtctgt cacctggc 318279450PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 279Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Ile Lys Asp Thr 20 25 30 Tyr Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Arg Ile Tyr Pro Thr Asn Gly Tyr Thr Arg Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ser Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125 Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala 130 135 140 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190 Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys 195 200 205 Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp 210 215 220 Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 225 230 235 240 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 245 250 255 Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 260 265 270 Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 275 280 285 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg 290 295 300 Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys 305 310 315 320 Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 325 330 335 Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 340 345 350 Val Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu 355 360 365 Leu Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 370 375 380 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Leu Thr Trp Pro Pro Val 385 390 395 400 Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 405 410 415 Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His 420 425 430 Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 435 440 445 Gly Lys 450 2801350DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 280gaggtgcagc tggtggaaag cggaggagga ctggtgcagc caggaggatc tctgcgactg 60agttgcgccg cttcaggatt caacatcaag gacacctaca ttcactgggt gcgacaggct 120ccaggaaaag gactggagtg ggtggctcga atctatccca ctaatggata cacccggtat 180gccgactccg tgaaggggag gtttactatt agcgccgata catccaaaaa cactgcttac 240ctgcagatga acagcctgcg agccgaagat accgctgtgt actattgcag tcgatgggga 300ggagacggat tctacgctat ggattattgg ggacagggga ccctggtgac agtgagctcc 360gcctctacca agggccccag tgtgtttccc ctggctcctt ctagtaaatc cacctctgga 420gggacagccg ctctgggatg tctggtgaag gactatttcc ccgagcctgt gaccgtgagt 480tggaactcag gcgccctgac aagcggagtg cacacttttc ctgctgtgct gcagtcaagc 540gggctgtact ccctgtcctc tgtggtgaca gtgccaagtt caagcctggg cacacagact 600tatatctgca acgtgaatca taagccctca aatacaaaag tggacaagaa agtggagccc 660aagagctgtg ataagaccca cacctgccct ccctgtccag ctccagaact gctgggagga 720cctagcgtgt tcctgtttcc ccctaagcca aaagacactc tgatgatttc caggactccc 780gaggtgacct gcgtggtggt ggacgtgtct cacgaggacc ccgaagtgaa gttcaactgg 840tacgtggatg gcgtggaagt gcataatgct aagacaaaac caagagagga acagtacaac 900tccacttatc gcgtcgtgag cgtgctgacc gtgctgcacc aggactggct gaacgggaag 960gagtataagt gcaaagtcag taataaggcc ctgcctgctc caatcgaaaa aaccatctct 1020aaggccaaag gccagccaag ggagccccag gtgtacgtgc tgccacccag cagagacgaa 1080ctgaccaaga accaggtgtc cctgctgtgt ctggtgaaag gcttctatcc tagtgatatt 1140gctgtggagt gggaatcaaa tggacagcca gagaacaatt acctgacctg gcctccagtg 1200ctggacagcg atggcagctt cttcctgtat tccaagctga cagtggataa atctcgatgg 1260cagcagggga acgtgtttag ttgttcagtg atgcatgaag ccctgcacaa tcattacact 1320cagaagagcc tgtccctgtc tcccggcaaa 1350281120PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 281Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Ile Lys Asp Thr 20 25 30 Tyr Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Arg Ile Tyr Pro Thr Asn Gly Tyr Thr Arg Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ser Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser 115 120 282360DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 282gaggtgcagc tggtggaaag cggaggagga ctggtgcagc caggaggatc tctgcgactg 60agttgcgccg cttcaggatt caacatcaag gacacctaca ttcactgggt gcgacaggct 120ccaggaaaag gactggagtg ggtggctcga atctatccca ctaatggata cacccggtat 180gccgactccg tgaaggggag gtttactatt agcgccgata catccaaaaa cactgcttac 240ctgcagatga acagcctgcg agccgaagat accgctgtgt actattgcag tcgatgggga 300ggagacggat tctacgctat ggattattgg ggacagggga ccctggtgac agtgagctcc 3602838PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 283Gly Phe Asn Ile Lys Asp Thr Tyr 1 5 28424DNAArtificial SequenceDescription of Artificial Sequence Synthetic oligonucleotide 284ggattcaaca tcaaggacac ctac 2428513PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 285Ser Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr 1 5 10 28639DNAArtificial SequenceDescription of Artificial Sequence Synthetic oligonucleotide 286agtcgatggg gaggagacgg attctacgct atggattat 392878PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 287Ile Tyr Pro Thr Asn Gly Tyr Thr 1 5 28824DNAArtificial SequenceDescription of Artificial Sequence Synthetic oligonucleotide 288atctatccca ctaatggata cacc 2428998PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 289Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 1 5 10 15 Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 25 30 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40 45 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 50 55

60 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 65 70 75 80 Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 85 90 95 Lys Val 290294DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 290gcctctacca agggccccag tgtgtttccc ctggctcctt ctagtaaatc cacctctgga 60gggacagccg ctctgggatg tctggtgaag gactatttcc ccgagcctgt gaccgtgagt 120tggaactcag gcgccctgac aagcggagtg cacacttttc ctgctgtgct gcagtcaagc 180gggctgtact ccctgtcctc tgtggtgaca gtgccaagtt caagcctggg cacacagact 240tatatctgca acgtgaatca taagccctca aatacaaaag tggacaagaa agtg 294291110PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 291Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 1 5 10 15 Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val 20 25 30 Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr 35 40 45 Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu 50 55 60 Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His 65 70 75 80 Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys 85 90 95 Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys 100 105 110 292330DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 292gctccagaac tgctgggagg acctagcgtg ttcctgtttc cccctaagcc aaaagacact 60ctgatgattt ccaggactcc cgaggtgacc tgcgtggtgg tggacgtgtc tcacgaggac 120cccgaagtga agttcaactg gtacgtggat ggcgtggaag tgcataatgc taagacaaaa 180ccaagagagg aacagtacaa ctccacttat cgcgtcgtga gcgtgctgac cgtgctgcac 240caggactggc tgaacgggaa ggagtataag tgcaaagtca gtaataaggc cctgcctgct 300ccaatcgaaa aaaccatctc taaggccaaa 330293106PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 293Gly Gln Pro Arg Glu Pro Gln Val Tyr Val Leu Pro Pro Ser Arg Asp 1 5 10 15 Glu Leu Thr Lys Asn Gln Val Ser Leu Leu Cys Leu Val Lys Gly Phe 20 25 30 Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu 35 40 45 Asn Asn Tyr Leu Thr Trp Pro Pro Val Leu Asp Ser Asp Gly Ser Phe 50 55 60 Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly 65 70 75 80 Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr 85 90 95 Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 100 105 294318DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 294ggccagccaa gggagcccca ggtgtacgtg ctgccaccca gcagagacga actgaccaag 60aaccaggtgt ccctgctgtg tctggtgaaa ggcttctatc ctagtgatat tgctgtggag 120tgggaatcaa atggacagcc agagaacaat tacctgacct ggcctccagt gctggacagc 180gatggcagct tcttcctgta ttccaagctg acagtggata aatctcgatg gcagcagggg 240aacgtgttta gttgttcagt gatgcatgaa gccctgcaca atcattacac tcagaagagc 300ctgtccctgt ctcccggc 318295480PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 295Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Val Asn Thr Ala 20 25 30 Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Arg Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gly Gly Ser Gly Gly 100 105 110 Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Glu 115 120 125 Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser 130 135 140 Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Ile Lys Asp Thr Tyr 145 150 155 160 Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala 165 170 175 Arg Ile Tyr Pro Thr Asn Gly Tyr Thr Arg Tyr Ala Asp Ser Val Lys 180 185 190 Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr Leu 195 200 205 Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ser 210 215 220 Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr Trp Gly Gln Gly 225 230 235 240 Thr Leu Val Thr Val Ser Ser Ala Ala Glu Pro Lys Ser Ser Asp Lys 245 250 255 Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro 260 265 270 Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser 275 280 285 Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp 290 295 300 Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn 305 310 315 320 Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val 325 330 335 Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu 340 345 350 Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys 355 360 365 Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Val 370 375 380 Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Leu 385 390 395 400 Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu 405 410 415 Ser Asn Gly Gln Pro Glu Asn Asn Tyr Leu Thr Trp Pro Pro Val Leu 420 425 430 Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys 435 440 445 Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu 450 455 460 Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 465 470 475 480 2961440DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 296gacattcaga tgacacagag ccccagctcc ctgagtgctt cagtcggcga cagggtgact 60atcacctgcc gcgcatccca ggatgtcaac accgctgtgg catggtacca gcagaagcct 120ggaaaagccc caaagctgct gatctacagc gcttccttcc tgtattctgg cgtgccaagt 180cggttttctg gaagtagatc aggcactgac ttcacactga ctatctctag tctgcagccc 240gaagattttg ccacctacta ttgccagcag cactatacca caccccctac attcggacag 300ggcactaaag tggagattaa gggcgggtca ggcggaggga gcggaggagg gtccggagga 360gggtctggag gagggagtgg agaggtccag ctggtggaat ctggaggagg actggtgcag 420cctggaggct cactgcgact gagctgtgcc gcttccggct ttaacatcaa agacacatac 480attcattggg tcaggcaggc accagggaag ggactggaat gggtggcccg catctatccc 540acaaatgggt acactcgata tgccgacagc gtgaaaggac ggtttaccat ttctgctgat 600accagtaaga acacagcata cctgcagatg aacagcctgc gcgcagagga tacagccgtg 660tactattgca gtcgatgggg gggagacggc ttctacgcca tggattattg gggccagggg 720actctggtca ccgtgtcaag cgcagccgaa cctaaatcct ctgacaagac ccacacatgc 780ccaccctgtc ctgctccaga gctgctggga ggaccatccg tgttcctgtt tcctccaaag 840cctaaagata cactgatgat tagccgcact cccgaagtca cctgtgtggt cgtggacgtg 900tcccacgagg accccgaagt caagttcaac tggtacgtgg acggcgtcga ggtgcataat 960gccaagacta aaccaagaga ggaacagtac aattcaacct atagggtcgt gagcgtcctg 1020acagtgctgc atcaggattg gctgaacggc aaggagtata agtgcaaagt gtctaacaag 1080gccctgcccg ctcctatcga gaagactatt agcaaggcaa aagggcagcc acgggaaccc 1140caggtctacg tgctgccccc tagcagagac gagctgacca aaaaccaggt ctccctgctg 1200tgtctggtga agggctttta tcctagtgat atcgctgtgg agtgggaatc aaatgggcag 1260ccagaaaaca attacctgac atggccaccc gtgctggaca gcgatgggtc cttctttctg 1320tattccaaac tgactgtgga caagtctaga tggcagcagg gaaacgtctt cagctgttcc 1380gtgatgcacg aggccctgca caatcattac acccagaagt ctctgagtct gtcacccggc 1440297107PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 297Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Val Asn Thr Ala 20 25 30 Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Arg Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 298321DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 298gacattcaga tgacacagag ccccagctcc ctgagtgctt cagtcggcga cagggtgact 60atcacctgcc gcgcatccca ggatgtcaac accgctgtgg catggtacca gcagaagcct 120ggaaaagccc caaagctgct gatctacagc gcttccttcc tgtattctgg cgtgccaagt 180cggttttctg gaagtagatc aggcactgac ttcacactga ctatctctag tctgcagccc 240gaagattttg ccacctacta ttgccagcag cactatacca caccccctac attcggacag 300ggcactaaag tggagattaa g 3212996PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 299Gln Asp Val Asn Thr Ala 1 5 30018DNAArtificial SequenceDescription of Artificial Sequence Synthetic oligonucleotide 300caggatgtca acaccgct 183019PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 301Gln Gln His Tyr Thr Thr Pro Pro Thr 1 5 30227DNAArtificial SequenceDescription of Artificial Sequence Synthetic oligonucleotide 302cagcagcact ataccacacc ccctaca 273033PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 303Ser Ala Ser 1 3049DNAArtificial SequenceDescription of Artificial Sequence Synthetic oligonucleotide 304agcgcttcc 9305120PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 305Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Ile Lys Asp Thr 20 25 30 Tyr Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Arg Ile Tyr Pro Thr Asn Gly Tyr Thr Arg Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ser Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser 115 120 306360DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 306gaggtccagc tggtggaatc tggaggagga ctggtgcagc ctggaggctc actgcgactg 60agctgtgccg cttccggctt taacatcaaa gacacataca ttcattgggt caggcaggca 120ccagggaagg gactggaatg ggtggcccgc atctatccca caaatgggta cactcgatat 180gccgacagcg tgaaaggacg gtttaccatt tctgctgata ccagtaagaa cacagcatac 240ctgcagatga acagcctgcg cgcagaggat acagccgtgt actattgcag tcgatggggg 300ggagacggct tctacgccat ggattattgg ggccagggga ctctggtcac cgtgtcaagc 3603078PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 307Gly Phe Asn Ile Lys Asp Thr Tyr 1 5 30824DNAArtificial SequenceDescription of Artificial Sequence Synthetic oligonucleotide 308ggctttaaca tcaaagacac atac 2430913PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 309Ser Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr 1 5 10 31039DNAArtificial SequenceDescription of Artificial Sequence Synthetic oligonucleotide 310agtcgatggg ggggagacgg cttctacgcc atggattat 393118PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 311Ile Tyr Pro Thr Asn Gly Tyr Thr 1 5 31224DNAArtificial SequenceDescription of Artificial Sequence Synthetic oligonucleotide 312atctatccca caaatgggta cact 24313110PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 313Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 1 5 10 15 Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val 20 25 30 Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr 35 40 45 Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu 50 55 60 Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His 65 70 75 80 Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys 85 90 95 Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys 100 105 110 314330DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 314gctccagagc tgctgggagg accatccgtg ttcctgtttc ctccaaagcc taaagataca 60ctgatgatta gccgcactcc cgaagtcacc tgtgtggtcg tggacgtgtc ccacgaggac 120cccgaagtca agttcaactg gtacgtggac ggcgtcgagg tgcataatgc caagactaaa 180ccaagagagg aacagtacaa ttcaacctat agggtcgtga gcgtcctgac agtgctgcat 240caggattggc tgaacggcaa ggagtataag tgcaaagtgt ctaacaaggc cctgcccgct 300cctatcgaga agactattag caaggcaaaa 330315106PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 315Gly Gln Pro Arg Glu Pro Gln Val Tyr Val Leu Pro Pro Ser Arg Asp 1 5 10 15 Glu Leu Thr Lys Asn Gln Val Ser Leu Leu Cys Leu Val Lys Gly Phe 20 25 30 Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu 35 40 45 Asn Asn Tyr Leu Thr Trp Pro Pro Val Leu Asp Ser Asp Gly Ser Phe 50 55 60 Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly 65 70 75 80 Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr 85 90 95 Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 100 105 316318DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 316gggcagccac gggaacccca ggtctacgtg ctgcccccta gcagagacga gctgaccaaa 60aaccaggtct ccctgctgtg tctggtgaag ggcttttatc ctagtgatat cgctgtggag 120tgggaatcaa atgggcagcc agaaaacaat tacctgacat ggccacccgt gctggacagc 180gatgggtcct tctttctgta ttccaaactg actgtggaca agtctagatg gcagcaggga 240aacgtcttca gctgttccgt gatgcacgag gccctgcaca atcattacac ccagaagtct 300ctgagtctgt cacccggc 318317214PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 317Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Val Asn Thr Ala 20 25 30 Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Arg Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70

75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 318642DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 318gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60atcacttgcc gggcaagtca ggacgttaac accgctgtag cttggtatca gcagaaacca 120gggaaagccc ctaagctcct gatctattct gcatcctttt tgtacagtgg ggtcccatca 180aggttcagtg gcagtcgatc tgggacagat ttcactctca ccatcagcag tctgcaacct 240gaagattttg caacttacta ctgtcaacag cattacacta ccccacccac tttcggccaa 300gggaccaaag tggagatcaa acgaactgtg gctgcaccat ctgtcttcat cttcccgcca 360tctgatgagc agttgaaatc tggaactgcc tctgttgtgt gcctgctgaa taacttctat 420cccagagagg ccaaagtaca gtggaaggtg gataacgccc tccaatcggg taactcccaa 480gagagtgtca cagagcagga cagcaaggac agcacctaca gcctcagcag caccctgacg 540ctgagcaaag cagactacga gaaacacaaa gtctacgcct gcgaagtcac ccatcagggc 600ctgagctcgc ccgtcacaaa gagcttcaac aggggagagt gt 642319107PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 319Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Val Asn Thr Ala 20 25 30 Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Arg Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 320321DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 320gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60atcacttgcc gggcaagtca ggacgttaac accgctgtag cttggtatca gcagaaacca 120gggaaagccc ctaagctcct gatctattct gcatcctttt tgtacagtgg ggtcccatca 180aggttcagtg gcagtcgatc tgggacagat ttcactctca ccatcagcag tctgcaacct 240gaagattttg caacttacta ctgtcaacag cattacacta ccccacccac tttcggccaa 300gggaccaaag tggagatcaa a 3213216PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 321Gln Asp Val Asn Thr Ala 1 5 32218DNAArtificial SequenceDescription of Artificial Sequence Synthetic oligonucleotide 322caggacgtta acaccgct 183239PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 323Gln Gln His Tyr Thr Thr Pro Pro Thr 1 5 32427DNAArtificial SequenceDescription of Artificial Sequence Synthetic oligonucleotide 324caacagcatt acactacccc acccact 273253PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 325Ser Ala Ser 1 3269DNAArtificial SequenceDescription of Artificial Sequence Synthetic oligonucleotide 326tctgcatcc 9327107PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 327Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 1 5 10 15 Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 20 25 30 Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 35 40 45 Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 50 55 60 Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 65 70 75 80 Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 85 90 95 Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 100 105 328321DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 328cgaactgtgg ctgcaccatc tgtcttcatc ttcccgccat ctgatgagca gttgaaatct 60ggaactgcct ctgttgtgtg cctgctgaat aacttctatc ccagagaggc caaagtacag 120tggaaggtgg ataacgccct ccaatcgggt aactcccaag agagtgtcac agagcaggac 180agcaaggaca gcacctacag cctcagcagc accctgacgc tgagcaaagc agactacgag 240aaacacaaag tctacgcctg cgaagtcacc catcagggcc tgagctcgcc cgtcacaaag 300agcttcaaca ggggagagtg t 321329231PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 329Glu Pro Lys Ser Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 1 5 10 15 Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 20 25 30 Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val 35 40 45 Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val 50 55 60 Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln 65 70 75 80 Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln 85 90 95 Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala 100 105 110 Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro 115 120 125 Arg Glu Pro Gln Val Tyr Val Leu Pro Pro Ser Arg Asp Glu Leu Thr 130 135 140 Lys Asn Gln Val Ser Leu Leu Cys Leu Val Lys Gly Phe Tyr Pro Ser 145 150 155 160 Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr 165 170 175 Leu Thr Trp Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr 180 185 190 Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe 195 200 205 Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys 210 215 220 Ser Leu Ser Leu Ser Pro Gly 225 230 330693DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 330gaacctaaat ccagcgacaa gacccacaca tgcccccctt gtccagctcc agaactgctg 60ggaggaccaa gcgtgttcct gtttccaccc aagcccaaag atacactgat gatcagccga 120actcccgagg tcacctgcgt ggtcgtggac gtgtcccacg aggaccccga agtcaagttc 180aactggtacg tggacggcgt cgaagtgcat aatgcaaaga ctaaaccacg ggaggaacag 240tacaactcta catatagagt cgtgagtgtc ctgactgtgc tgcatcagga ttggctgaac 300ggcaaagagt ataagtgcaa agtgtctaat aaggccctgc ctgctccaat cgagaaaact 360attagtaagg caaaagggca gcccagggaa cctcaggtct acgtgctgcc tccaagtcgc 420gacgagctga ccaagaacca ggtctcactg ctgtgtctgg tgaaaggatt ctatccttcc 480gatattgccg tggagtggga atctaatggc cagccagaga acaattacct gacctggccc 540cctgtgctgg acagcgatgg gtccttcttt ctgtattcaa agctgacagt ggacaaaagc 600agatggcagc agggaaacgt ctttagctgt tccgtgatgc acgaagccct gcacaatcat 660tacacccaga agtctctgag tctgtcacct ggc 693331110PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 331Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 1 5 10 15 Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val 20 25 30 Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr 35 40 45 Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu 50 55 60 Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His 65 70 75 80 Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys 85 90 95 Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys 100 105 110 332330DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 332gctccagaac tgctgggagg accaagcgtg ttcctgtttc cacccaagcc caaagataca 60ctgatgatca gccgaactcc cgaggtcacc tgcgtggtcg tggacgtgtc ccacgaggac 120cccgaagtca agttcaactg gtacgtggac ggcgtcgaag tgcataatgc aaagactaaa 180ccacgggagg aacagtacaa ctctacatat agagtcgtga gtgtcctgac tgtgctgcat 240caggattggc tgaacggcaa agagtataag tgcaaagtgt ctaataaggc cctgcctgct 300ccaatcgaga aaactattag taaggcaaaa 330333106PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 333Gly Gln Pro Arg Glu Pro Gln Val Tyr Val Leu Pro Pro Ser Arg Asp 1 5 10 15 Glu Leu Thr Lys Asn Gln Val Ser Leu Leu Cys Leu Val Lys Gly Phe 20 25 30 Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu 35 40 45 Asn Asn Tyr Leu Thr Trp Pro Pro Val Leu Asp Ser Asp Gly Ser Phe 50 55 60 Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly 65 70 75 80 Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr 85 90 95 Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 100 105 334318DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 334gggcagccca gggaacctca ggtctacgtg ctgcctccaa gtcgcgacga gctgaccaag 60aaccaggtct cactgctgtg tctggtgaaa ggattctatc cttccgatat tgccgtggag 120tgggaatcta atggccagcc agagaacaat tacctgacct ggccccctgt gctggacagc 180gatgggtcct tctttctgta ttcaaagctg acagtggaca aaagcagatg gcagcaggga 240aacgtcttta gctgttccgt gatgcacgaa gccctgcaca atcattacac ccagaagtct 300ctgagtctgt cacctggc 3183358PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 335Val Asn Pro Asn Ser Gly Gly Ser 1 5 33612PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 336Ala Arg Asn Leu Gly Pro Ser Phe Tyr Phe Asp Tyr 1 5 10 3378PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 337Gly Phe Thr Phe Thr Asp Tyr Thr 1 5 3383PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 338Ser Ala Ser 1 3399PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 339Gln Gln Tyr Tyr Ile Tyr Pro Tyr Thr 1 5 3406PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 340Gln Asp Val Ser Ile Gly 1 5 3418PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 341Ile Tyr Pro Thr Asn Gly Tyr Thr 1 5 34213PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 342Ser Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr 1 5 10 3438PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 343Gly Phe Asn Ile Lys Asp Thr Tyr 1 5 3443PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 344Ser Ala Ser 1 3459PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 345Gln Gln His Tyr Thr Thr Pro Pro Thr 1 5 3466PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 346Gln Asp Val Asn Thr Ala 1 5 3479PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 347Gln Gln Tyr Tyr Ile Tyr Pro Ala Thr 1 5 3488PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 348Gly Phe Thr Phe Ala Asp Tyr Thr 1 5 349607PRTHomo sapiens 349Thr Gln Val Cys Thr Gly Thr Asp Met Lys Leu Arg Leu Pro Ala Ser 1 5 10 15 Pro Glu Thr His Leu Asp Met Leu Arg His Leu Tyr Gln Gly Cys Gln 20 25 30 Val Val Gln Gly Asn Leu Glu Leu Thr Tyr Leu Pro Thr Asn Ala Ser 35 40 45 Leu Ser Phe Leu Gln Asp Ile Gln Glu Val Gln Gly Tyr Val Leu Ile 50 55 60 Ala His Asn Gln Val Arg Gln Val Pro Leu Gln Arg Leu Arg Ile Val 65 70 75 80 Arg Gly Thr Gln Leu Phe Glu Asp Asn Tyr Ala Leu Ala Val Leu Asp 85 90 95 Asn Gly Asp Pro Leu Asn Asn Thr Thr Pro Val Thr Gly Ala Ser Pro 100 105 110 Gly Gly Leu Arg Glu Leu Gln Leu Arg Ser Leu Thr Glu Ile Leu Lys 115 120 125 Gly Gly Val Leu Ile Gln Arg Asn Pro Gln Leu Cys Tyr Gln Asp Thr 130 135 140 Ile Leu Trp Lys Asp Ile Phe His Lys Asn Asn Gln Leu Ala Leu Thr 145 150 155 160 Leu Ile Asp Thr Asn Arg Ser Arg Ala Cys His Pro Cys Ser Pro Met 165 170 175 Cys Lys Gly Ser Arg Cys Trp Gly Glu Ser Ser Glu Asp Cys Gln Ser 180 185 190 Leu Thr Arg Thr Val Cys Ala Gly Gly Cys Ala Arg Cys Lys Gly Pro 195 200 205 Leu Pro Thr Asp Cys Cys His Glu Gln Cys Ala Ala Gly Cys Thr Gly 210 215 220 Pro Lys His Ser Asp Cys Leu Ala Cys Leu His Phe Asn His Ser Gly 225 230 235 240 Ile Cys Glu Leu His Cys Pro Ala Leu Val Thr Tyr Asn Thr Asp Thr 245 250 255 Phe Glu Ser Met Pro Asn Pro Glu Gly Arg Tyr Thr Phe Gly Ala Ser 260 265 270 Cys Val Thr Ala Cys Pro Tyr Asn Tyr Leu Ser Thr Asp Val Gly Ser 275 280 285 Cys Thr Leu Val Cys Pro Leu His Asn Gln Glu Val Thr Ala Glu Asp 290 295 300 Gly Thr Gln Arg Cys Glu Lys Cys Ser Lys Pro Cys Ala Arg Val Cys 305 310 315 320 Tyr Gly Leu Gly Met Glu His Leu Arg Glu Val Arg Ala Val Thr Ser 325 330 335 Ala Asn Ile Gln Glu Phe Ala Gly Cys Lys Lys Ile Phe Gly Ser Leu 340 345 350 Ala Phe Leu Pro Glu Ser Phe Asp Gly Asp Pro Ala Ser Asn Thr Ala 355 360 365 Pro Leu Gln Pro Glu Gln Leu Gln Val Phe Glu Thr Leu Glu Glu Ile 370 375 380 Thr Gly Tyr Leu Tyr Ile Ser Ala Trp Pro Asp Ser Leu Pro Asp Leu 385 390 395 400 Ser Val Phe Gln Asn Leu Gln Val Ile Arg Gly Arg Ile Leu His Asn 405 410 415 Gly Ala Tyr Ser Leu Thr Leu Gln Gly Leu Gly Ile Ser Trp Leu Gly 420 425 430 Leu Arg Ser Leu Arg Glu Leu Gly Ser Gly Leu Ala Leu Ile His His 435 440 445 Asn Thr His Leu Cys Phe Val His Thr Val Pro Trp Asp Gln Leu Phe 450 455 460 Arg Asn Pro His Gln Ala Leu Leu His Thr Ala Asn Arg Pro Glu Asp 465 470 475 480 Glu Cys Val Gly Glu Gly Leu Ala Cys His Gln Leu Cys Ala Arg Gly 485 490 495 His Cys Trp Gly Pro Gly Pro Thr Gln Cys Val Asn Cys Ser Gln Phe 500 505 510 Leu Arg Gly Gln Glu Cys Val Glu Glu Cys Arg Val Leu Gln Gly Leu 515 520 525 Pro Arg Glu Tyr Val Asn Ala Arg His Cys Leu Pro Cys His Pro Glu 530

535 540 Cys Gln Pro Gln Asn Gly Ser Val Thr Cys Phe Gly Pro Glu Ala Asp 545 550 555 560 Gln Cys Val Ala Cys Ala His Tyr Lys Asp Pro Pro Phe Cys Val Ala 565 570 575 Arg Cys Pro Ser Gly Val Lys Pro Asp Leu Ser Tyr Met Pro Ile Trp 580 585 590 Lys Phe Pro Asp Glu Glu Gly Ala Cys Gln Pro Cys Pro Ile Asn 595 600 605 350217PRTHomo sapiens 350Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 1 5 10 15 Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val 20 25 30 Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr 35 40 45 Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu 50 55 60 Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His 65 70 75 80 Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys 85 90 95 Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln 100 105 110 Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu 115 120 125 Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro 130 135 140 Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn 145 150 155 160 Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu 165 170 175 Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val 180 185 190 Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln 195 200 205 Lys Ser Leu Ser Leu Ser Pro Gly Lys 210 215

Claims

1. A method of treating a subject having a tumor; inhibiting, reducing or blocking HER2 signaling; or killing or inhibiting the growth of a HER2-expressing tumor cell, the method comprising administering an effective amount of an antigen binding construct comprising: a first antigen-binding polypeptide construct which monovalently and specifically binds a HER2 (human epidermal growth factor receptor 2) ECD2 (extracellular domain 2) antigen on a HER2-expressing cell; a second antigen-binding polypeptide construct which monovalently and specifically binds a HER2 ECD4 (extracellular domain 4) antigen on a HER2-expressing cell; first and second linker polypeptides, wherein the first linker polypeptide is operably linked to the first antigen-binding polypeptide construct, and the second linker polypeptide is operably linked to the second antigen-binding polypeptide construct; wherein the linker polypeptides are capable of forming a covalent linkage with each other, wherein one or both of the first or the second antigen binding polypeptide construct is an scFv, wherein the dissociation constant (K.sub.D) of the antigen binding construct to murine HER2 extracellular domain as measured by surface plasmon resonance (SPR) is equal to or less than the dissociation constant of a monospecific anti-HER2 ECD4 antibody (v506; SEQ ID NO:1 and SEQ ID NO:317) to murine HER2 extracellular domain as measured by surface plasmon resonance (SPR), and wherein tumor growth is decreased as compared to a control receiving an equivalent amount of a non-specific control antibody, as compared to a control receiving an equivalent amount of Herceptin/trastuzumab, or as compared to a control not receiving treatment.

2. The method of claim 1 wherein the antigen binding construct comprises the full length sequences set forth in SEQ ID NOs 97, 295, and 69 (v10000), and optionally wherein the dissociation constant (K.sub.D) of the construct to murine HER2 extracellular domain as measured by surface plasmon resonance (SPR) is approximately 0.6 nM.

3. A method of treating a subject having a tumor; inhibiting, reducing or blocking HER2 signaling; or killing or inhibiting the growth of a HER2-expressing tumor cell, the method comprising administering an effective amount of an antigen binding construct comprising: a first antigen-binding polypeptide construct which monovalently and specifically binds a HER2 (human epidermal growth factor receptor 2) ECD2 (extracellular domain 2) antigen on a HER2-expressing cell, wherein the first antigen-binding polypeptide construct comprises a first variable light-chain (VL1) domain and a first variable heavy-chain (VH1) domain, wherein the first antigen-binding polypeptide construct comprises VH1 and VL1 CDR sequences that are at least 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to the VH1 and VL1 CDR sequences of v7091 (SEQ ID NOs 223, 225, 227, 37, 39, and 41), and wherein the VL1 domain comprises 1, 2, 3, 4, or 5 amino acid substitutions and/or the VH1 domain comprises 1, 2, 3, 4, or 5 amino acid substitutions; a second antigen-binding polypeptide construct which monovalently and specifically binds a HER2 ECD4 (extracellular domain 4) antigen on a HER2-expressing cell; first and second linker polypeptides, wherein the first linker polypeptide is operably linked to the first antigen-binding polypeptide construct, and the second linker polypeptide is operably linked to the second antigen-binding polypeptide construct; wherein one or both of the first or the second antigen binding polypeptide construct is an scFv, wherein the linker polypeptides are capable of forming a covalent linkage with each other, and wherein tumor growth is decreased as compared to a control receiving an equivalent amount of a non-specific control antibody, as compared to a control receiving an equivalent amount of Herceptin/trastuzumab, or as compared to a control not receiving treatment.

4. The method of any of the above claims, wherein the binding affinity of the antigen binding construct to murine HER2 extracellular domain as measured by surface plasmon resonance (SPR) is greater than the binding affinity of v7091 (SEQ ID NOs 33, 219, and 295) to murine HER2 extracellular domain as measured by surface plasmon resonance (SPR), optionally wherein the antigen binding construct and v7091 bind the same epitope, optionally wherein the antigen binding construct binds the same epitope as pertuzamab, optionally wherein the antigen binding construct has a greater Bmax than v7091, and optionally wherein the antigen binding construct is internalized to a greater extent upon cell surface binding relative to v7091.

5. The method of any of the above claims, wherein the binding affinity of the antigen binding construct to murine HER2 extracellular domain as measured by surface plasmon resonance (SPR) is equal to or greater than the binding affinity of a monospecific anti-HER2 ECD4 antibody (v506; SEQ ID NO:1 and SEQ ID NO:317) to murine HER2 extracellular domain as measured by surface plasmon resonance (SPR).

6. The method of any of the above claims, wherein the first antigen-binding polypeptide construct comprises the VH1 and VL1 CDR sequences of v7091 (SEQ ID NOs 223, 225, 227, 37, 39, and 41), wherein the VL1 domain comprises 1, 2, 3, 4, or 5 amino acid substitutions and/or the VH1 domain comprises 1, 2, 3, 4, or 5 amino acid substitutions, optionally wherein the first antigen-binding polypeptide construct comprises a substitution at Y96 in the VL1 domain (SEQ ID NO:35), optionally wherein the first antigen-binding polypeptide construct comprises a Y96A substitution in the VL1 domain (SEQ ID NO:35), optionally wherein the first antigen-binding polypeptide construct comprises substitutions at T30, A49, and/or L69 in the VH1 domain (SEQ ID NO:221), optionally wherein the first antigen-binding polypeptide construct comprises T30A, A49G, and/or L69F substitution(s) in the VH1 domain (SEQ ID NO:221), and optionally wherein the first antigen-binding polypeptide construct comprises T30A, A49G, and L69F substitution(s) in the VH1 domain (SEQ ID NO:221).

7. The method of any of the above claims, wherein the second antigen-binding polypeptide construct comprises VH2 and VL2 CDR sequences that are at least 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to the VH2 and VL2 CDR sequences of v10000 (SEQ ID NOs 299, 301, 303, 307, 309, and 311), optionally wherein the second antigen-binding polypeptide construct comprises the VH2 and VL2 CDR sequences of v10000 (SEQ ID NOs 299, 301, 303, 307, 309, and 311).

8. The method of any of the above claims, wherein the antigen binding construct comprises the variable domain sequences set forth in SEQ ID NOs 71 and/or 99, the variable domain sequences set forth in SEQ ID NOs 297 and/or 305, or the variable domain sequences set forth in SEQ ID NOs 71, 99, 297, and 305.

9. The method of any of the above claims, wherein the antigen binding construct comprises the full length sequence set forth in SEQ ID NO 97, the full length sequence set forth in SEQ ID NO 295, the full length sequence set forth in SEQ ID NO 69, or the full length sequences set forth in SEQ ID NOs 97, 295, and 69 (v10000).

10. The method of any of the above claims, wherein the first and second linker polypeptide each comprise an immunoglobulin hinge region polypeptide selected from an IgG1, IgG2 or IgG4 hinge region.

11. The method of any of the above claims, wherein the first and second linker polypeptides are operably linked to a scaffold, optionally an Fc.

12. The method of any of the above claims, wherein the first and second linker polypeptides are operably linked to a dimeric Fc comprising first and second Fc polypeptides each comprising a CH3 sequence, wherein the first Fc polypeptide is operably linked to the first linker polypeptide and the second Fc polypeptide is operably linked to the second linker polypeptide.

13. The method of any of the above claims, wherein (i) the first antigen binding polypeptide construct is an scFv and the second antigen binding polypeptide construct is a Fab; or (ii) the first antigen binding polypeptide construct is a Fab and the second antigen binding polypeptide construct is an scFv; or (iii) both the first antigen binding polypeptide construct and the second antigen binding polypeptide construct are scFvs.

14. The method of any of the above claims, wherein i. the first antigen-binding polypeptide construct is a Fab and comprises a. a first heavy chain variable polypeptide VH1 comprising the VH of the pertuzumab arm of v5019, v 5020 v7091, v6717 or v10000 (SEQ ID NOs 221, 149, 221, 259, and 99, respectively), and b. a first variable light chain polypeptide VL1 comprising the VL of the pertuzumab arm of v5019, v 5020 v7091, v6717 or v10000 (SEQ ID NOs 35, 35, and 71 for v5019, v7091, and v10000, respectively); and the second antigen-binding polypeptide construct is an scFv and comprises (a) a second variable heavy chain polypeptide VH2 comprising the VH of the trastuzumab arm of v5019, v 5020 v7091, v6717 or v10000 (SEQ ID NOs 171, 205, 297, 171, and 297, respectively), and (b) a second variable light chain polypeptide VL2 comprising the VL of the trastzumab arm of v5019, v 5020 v7091, v6717 or v10000 (SEQ ID NO:35 for v5020); or ii. the first antigen-binding polypeptide construct is an scFv and comprises (a) a first variable heavy chain polypeptide VH1 comprising the VH of the pertuzumab arm of v5019, v 5020 v7091, v6717 or v10000 (SEQ ID NOs 221, 149, 221, 259, and 99, respectively), and (b) a first variable light chain polypeptide VL1 comprising the VL of the pertuzumab arm of v5019, v 5020 v7091, v6717 or v10000 (SEQ ID NOs 35, 35, and 71 for v5019, v7091, and v10000, respectively), and the second antigen-binding polypeptide construct is an Fab and comprises (a) a second heavy chain variable polypeptide VH2 comprising the VH of the trastuzumab arm of v5019, v 5020 v7091, v6717 or v10000 (SEQ ID NOs 171, 205, 297, 171, and 297, respectively), and (b) a second variable light chain polypeptide VL2 comprising the VL of the trastuzumab arm of v5019, v 5020 v7091, v6717 or v10000 (SEQ ID NO:35 for v5020); or iii. the first antigen-binding polypeptide construct is an scFv and comprises (a) a first heavy chain variable polypeptide VH1 comprising the VH of the pertuzumab arm of v5019, v 5020 v7091, v6717 or v10000 (SEQ ID NOs 221, 149, 221, 259, and 99, respectively), and (b) a first variable light chain polypeptide VL1 comprising the VL of the pertuzumab arm of v5019, v 5020 v7091, v6717 or v10000 (SEQ ID NOs 35, 35, and 71 for v5019, v7091, and v10000, respectively), and the second antigen-binding polypeptide construct is an scFv and comprises (a) a second heavy chain variable polypeptide VH2 comprising the VH of the trastuzumab arm of v5019, v 5020 v7091, v6717 or v10000 (SEQ ID NOs 171, 205, 297, 171, and 297, respectively), and (b) a second variable light chain polypeptide VL2 comprising the VL of the trastuzumab arm of v5019, v 5020 v7091, v6717 or v10000 (SEQ ID NO:35 for v5020).

15. The method of any of the above claims, wherein the first antigen-binding polypeptide construct is selected from: i. a polypeptide construct comprising three VH CDR sequences comprising the amino acid sequences SEQ ID NO: 335, SEQ ID NO:336 and SEQ ID NO:337, or SEQ ID NO:335, SEQ ID NO:336, and SEQ ID NO:348; ii. a polypeptide construct comprising three VH CDR sequences comprising amino acid sequences that are at least 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to the three VH CDR sequences of SEQ ID NO: 335, SEQ ID NO:336 and SEQ ID NO:337, or SEQ ID NO:335, SEQ ID NO:336, and SEQ ID NO:348; iii. a polypeptide construct comprising three VL CDR sequences comprising the amino acid sequences of the three VL CDR sequences of SEQ ID NO: 338, SEQ ID NO:339 and SEQ ID NO:340, or SEQ ID NO:338, SEQ ID NO:347, and SEQ ID NO:340; iv. a polypeptide construct comprising three VL CDR sequences that are at least 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to the amino acid sequences of the three VL CDR sequences are at least 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to SEQ ID NO: 338, SEQ ID NO:339 and SEQ ID NO:340, or SEQ ID NO:338, SEQ ID NO:347, and SEQ ID NO:340; v. a polypeptide construct comprising six CDR sequences comprising the amino acid sequences of the six CDR sequences of SEQ ID NO: 335, SEQ ID NO:336, SEQ ID NO:337, SEQ ID NO: 338, SEQ ID NO:339 and SEQ ID NO:340; or SEQ ID NO:335, SEQ ID NO:336, SEQ ID NO:348, SEQ ID NO:338, SEQ ID NO:347, and SEQ ID NO:340; or vi. a polypeptide construct comprising six CDR sequences comprising the amino acid sequences that are at least 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to the six CDR sequences of SEQ ID NO: 335, SEQ ID NO:336, SEQ ID NO:337, SEQ ID NO: 338, SEQ ID NO:339 and SEQ ID NO:340; or SEQ ID NO:335, SEQ ID NO:336, SEQ ID NO:348, SEQ ID NO:338, SEQ ID NO:347, and SEQ ID NO:340; and the second antigen-binding polypeptide is selected from vii. a polypeptide construct comprising three VH CDR sequences comprising the amino acid sequences of the three VH CDR sequences of SEQ ID NO: 341, SEQ ID NO:342 and SEQ ID NO:343; viii. a polypeptide construct comprising three VH CDR sequences comprising amino acids sequences that are at least 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to the three VH CDR sequences of SEQ ID NO: 341, SEQ ID NO:342 and SEQ ID NO:343; ix. a polypeptide construct comprising three VL CDR sequences comprising the amino acid sequences of the three VL CDR sequences of SEQ ID NO: 344, SEQ ID NO:345 and SEQ ID NO:346; x. a polypeptide construct comprising three VL CDR sequences that are at least 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to the amino acid sequences of the three VL CDR sequences of SEQ ID NO: 344, SEQ ID NO:345 and SEQ ID NO:346; xi. a polypeptide construct comprising six CDR sequences comprising the amino acid sequences of the six CDR sequences of SEQ ID NO: 341, SEQ ID NO:342, SEQ ID NO:343, SEQ ID NO: 344, SEQ ID NO:345 and SEQ ID NO:346; or xii. a polypeptide construct comprising six CDR sequences comprising the amino acid sequences that are at least 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to the six CDR sequences of SEQ ID NO: 341, SEQ ID NO:342, SEQ ID NO:343, SEQ ID NO: 344, SEQ ID NO:345 and SEQ ID NO:346.

16. The method of any of the above claims wherein the first antigen binding polypeptide construct: (i) blocks by 50% or greater the binding of pertuzumab to ECD2, and/or (ii) the second antigen binding polypeptide blocks by 50% or greater the binding of trastuzumab to ECD4.

17. The method according to any preceding claim wherein the first antigen binding polypeptide construct comprises one of the v5019, v10000, v7091, v5020 or v6717 antigen binding polypeptide constructs specific for HER2 ECD2, and the second antigen binding polypeptide construct comprises one of the v5019, v10000, v7091, v5020 or v6717 antigen-binding polypeptide constructs specific for HER2 ECD4.

18. The method according to any preceding claim, wherein the first antigen-binding polypeptide construct comprises an amino acid sequence at least 80%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the v5019, v10000, v7091, v5020 or v6717 antigen-binding polypeptide construct specific for HER2 ECD2 and the second antigen-binding polypeptide construct comprises an amino acid sequence at least 80%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the v5019, v10000, v7091, v5020 or v6717 antigen-binding polypeptide construct specific for HER2 ECD4.

19. The method according to any preceding claim, selected from v5019, v10000, v7091, v5020 and v6717.

20. The method according to any preceding claim, wherein the first antigen binding polypeptide construct is an Fab and the second antigen binding polypeptide construct is an scFv, and wherein the antigen binding construct (i) induces increased receptor internalization in HER2 3+ cells and/or (ii) displays higher potency in an ADCC (antibody directed cellular cytotoxicity) assay against HER2 1+ cells, and/or (iii) comprises one or more of the characteristics described in one or more of the Examples, Tables, and Figures, as compared to a reference biparatopic antigen binding construct having two Fabs.

21. The method according to according to any preceding claim, wherein the first and second antigen binding polypeptide constructs are scFvs, and wherein the antigen binding construct induces increased receptor internalization in HER2 1+, 2+ and 3+ cells as compared to a reference antigen binding construct having two Fabs.

22. The method according to any preceding claim, wherein the antigen-binding construct comprises an Fc, optionally wherein the Fc is a heterodimeric Fc.

23. The method according to any preceding claim, wherein the antigen-binding construct comprises a heterodimeric Fc, wherein the dimerized CH3 sequences have a melting temperature (Tm) of about 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 77.5, 78, 79, 80, 81, 82, 83, 84, or 85.degree. C. or higher.

24. The method according to any preceding claim, wherein the antigen-binding construct comprises a heterodimeric Fc formed with a purity greater than about 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% when expressed.

25. The method according to any preceding claim, wherein the antigen-binding construct comprises a heterodimeric Fc formed with a purity greater than about 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% when expressed via a single cell.

26. The method according to any preceding claim, wherein the antigen-binding construct comprises a heterodimeric Fc comprising one or more modifications in at least one of the CH3 sequences.

27. The method according to any preceding claim, wherein the antigen-binding construct comprises a heterodimeric Fc comprising one or more modifications in at least one of the CH3 sequences that promote the formation of a heterodimer with stability comparable to a wild-type homodimeric Fc.

28. The method according to any preceding claim, wherein the antigen-binding construct comprises: i. a heterodimeric IgG1 Fc having the modifications L351Y_F405A_Y407V in the first Fc polypeptide, and the modifications T366L_K392M_T394W in the second polypeptide; ii. a heterodimeric IgG1 Fc having the modifications L351Y_F405A_Y407V in the first Fc polypeptide, and the modifications T366L_K392L_T394W in the second Fc polypeptide; iii. a heterodimeric IgG1 Fc having the modifications T350V_L351Y_F405A_Y407V in the first Fc polypeptide, and the modifications T350V_T366L_K392L_T394W in the second Fc polypeptide; iv. a heterodimeric IgG1 Fc having the modifications T350V_L351Y_F405A_Y407V in the first Fc polypeptide, and the modifications T350V_T366L_K392M_T394W in the second Fc polypeptide; v. a heterodimeric IgG1 Fc having the modifications T350V_L351Y_S400E_F405A_Y407V in the first Fc polypeptide, and the modifications T350V_T366L_N390R_K392M_T394W in the second Fc polypeptide, vi. a heterodimeric IgG1 Fc having the modifications T350V_L351Y_F405A_Y407V in the first Fc polypeptide, and the modifications T366I_N390R_K392M_T394W in the second Fc polypeptide; or vii. a heterodimeric IgG1 Fc having the modifications L351Y_S400E_F405A_Y405V in the first Fc polypeptide, and the modifications T350V_T366L_K392L_T394W in the second Fc polypeptide; according to EU numbering compared to a wild-type homodimeric Fc.

29. The method according to any preceding claim, wherein the antigen-binding construct comprises a heterodimeric Fc comprising at least one CH2 domain.

30. The method according to claim 29, wherein the CH2 domain(s) of the heterodimeric Fc comprises one or more modifications.

31. The method according to any preceding claim, wherein the antigen-binding construct comprises a heterodimeric Fc comprising one or more modifications to promote selective binding of Fc-gamma receptors.

32. The method according to any preceding claim, wherein the antigen-binding construct comprises at least one modification, and wherein the modification is afucosylation.

33. The method according to any preceding claim, wherein the antigen-binding construct is conjugated to a drug.

34. The method construct according to claim 33, wherein the drug is maytansine (DM1).

35. The method according to claim 34, wherein the construct is conjugated to DM1 through an SMCC linker.

36. The method according to any preceding claim, wherein the antigen-binding construct is formulated in a pharmaceutical composition with a pharmaceutical carrier.

37. The method claim 36, wherein the pharmaceutical carrier comprises a buffer, an antioxidant, a low molecular weight molecule, a drug, a protein, an amino acid, a carbohydrate, a lipid, a chelating agent, a stabilizer, or an excipient.

38. The method according to any preceding claim, wherein the result of the treatment is shrinking the tumor, inhibiting growth of the tumor, increasing time to progression of the tumor, prolonging disease-free survival of the subject, decreasing metastases, increasing the progression-free survival of the subject, or increasing overall survival of the subject.

39. The method according to any preceding claim, wherein the tumor comprises cells that express an average of 10,000 or more copies of HER2 per tumor cell, optionally wherein the tumor is HER2 gene-amplified.

40. The method according to any preceding claim, wherein the tumor is HER2 1+, HER2 2+ or HER2 3+ as determined by immunohistochemistry (IHC).

41. The method according to any preceding claim, wherein the tumor expresses HER2 at a level of 2+ or lower as determined by IHC.

42. The method according to any preceding claim, wherein the HER2+ tumor is a breast cancer that expresses HER2 at a 2+ level or lower, as determined by immunohistochemistry (IHC).

43. The method according to any preceding claim, wherein the tumor is a lung tumor, optionally wherein the tumor is a non-squamous non-small cell lung tumor that is HER2-low, non-HER2 gene amplified.

44. The method of claim 43, wherein the tumor is HER3+.

45. The method of claim 43 or 44, wherein the tumor is EGFR low.

46. The method of claim 43, 44, or 45, wherein the tumor is moderately sensitive to Cisplatin at the MTD.

47. The method according to any preceding claim, wherein the tumor is a head and neck tumor, optionally wherein the tumor is a squamous cell tumor of the head and neck that is HER2 low, non-HER2 gene amplified.

48. The method of claim 47, wherein the tumor is HER3+ low.

49. The method of claim 47 or 48, wherein the tumor is EGFR+.

50. The method of claim 47, 48, or 49, wherein the tumor is highly sensitive to Cisplatin at the MTD.

51. The method according to any preceding claim, wherein the tumor is a breast tumor, optionally wherein the tumor is a ER+/PR- breast cancer with a luminal B molecular classification.

52. The method according to any preceding claim, wherein the tumor is a pancreatic tumor, optionally wherein the pancreatic tumor is HER2 negative as determined by IHC.

53. The method according to any preceding claim, wherein the tumor is a gastric tumor, optionally wherein the gastric tumor is HER2 3+.

54. The method according to any preceding claim, wherein the subject has not previously been treated with an anti-HER2 antibody.

55. The method according to any preceding claim, wherein the tumor is resistant or refractory to pertuzumab, trastuzumab and/or TDM1.

56. The method according to any preceding claim, wherein the subject has previously been treated with pertuzumab, trastuzumab and/or TDM1.

57. The method of any one of claims 1-41, wherein the tumor is (i) a HER2 3+ estrogen receptor negative (ER-), progesterone receptor negative (PR-), trastuzumab resistant, chemotherapy resistant invasive ductal breast cancer, (ii) a HER2 3+ ER-, PR-, trastuzumab resistant inflammatory breast cancer, (iii) a HER2 3+, ER-, PR-, invasive ductal carcinoma or (iv) a HER2 2+ HER2 gene amplified trastuzumab and pertuzumab resistant breast cancer.

58. The method any one of claims 1-41 wherein the tumor cell is a HER2 1+ or 2+ human pancreatic carcinoma cell, a HER2 3+ human lung carcinoma cell, a HER2 2+ human Caucasian bronchioaveolar carcinoma cell, a human pharyngeal carcinoma cell, a HER2 2+ human tongue squamous cell carcinoma cell, a HER2 2+ squamous cell carcinoma cell of the pharynx, a HER2 1+ or 2+ human colorectal carcinoma cell, a HER2 3+ human gastric carcinoma cell, a HER2 1+ human breast ductal ER+ (estrogen receptor-positive) carcinoma cell, a HER2 2+/3+ human ER+, HER2-amplified breast carcinoma cell, a HER2 0+/1+ human triple negative breast carcinoma cell, a HER2 2+ human endometrioid carcinoma cell, a HER2 1+ lung-metastatic malignant melanoma cell, a HER2 1+ human cervix carcinoma cell, Her2 1+ human renal cell carcinoma cell, or a HER2 1+ human ovary carcinoma cell.

59. The method of any one of claims 1-41 wherein the tumor cell is a HER2 1+ or 2+ or 3+ human pancreatic carcinoma cell, a HER2 2+ metastatic pancreatic carcinoma cell, a HER2 0+/1+, +3+ human lung carcinoma cell, a HER2 2+ human Caucasian bronchioaveolar carcinoma cell, a HER2 0+ anaplastic lung carcinoma, a human non-small cell lung carcinoma cell, a human pharyngeal carcinoma cell, a HER2 2+ human tongue squamous cell carcinoma cell, a HER2 2+ squamous cell carcinoma cell of the pharynx, a HER2 1+ or 2+ human colorectal carcinoma cell, a HER2 0+, 1+ or 3+ human gastric carcinoma cell, a HER2 1+ human breast ductal ER+ (estrogen receptor-positive) carcinoma cell, a HER2 2+/3+ human ER+, HER2-amplified breast carcinoma cell, a HER2 0+/1+ human triple negative breast carcinoma cell, a HER2 0+ human breast ductal carcinoma (Basal B, Mesenchymal-like triple negative) cell, a HER2 2+ER+ breast carcinoma, a HER2 0+ human metastatic breast carcinoma cell (ER-, HER2- amplified, luminal A, TN), a human uterus mesodermal tumor (mixed grade III) cell, a 2+ human endometrioid carcinoma cell, a HER2 1+ human skin epidermoid carcinoma cell, a HER2 1+ lung-metastatic malignant melanoma cell, a HER2 1+ malignant melanoma cell, a human cervix epidermoid carcinoma vcell, a HER2 1+ human urinary bladder carcinoma cell, a HER2 1+ human cervix carcinoma cell, Her2 1+ human renal cell carcinoma cell, or a HER2 1+, 2+ or 3+ human ovary carcinoma cell, and wherein the antigen-binding construct is conjugated to maytansine (DM1).

60. The method of any one of claims 1-41 wherein the tumor cell is selected from a HER2 2/3+, gene amplified ovarian cancer cell, a HER2 0+/1+ triple negative breast cancer cell; an ER+, HER2 1+ breast cancer cell; a trastuzumab resistant HER2 2+ breast cancer cell; an ER+, HER2+ breast cancer cell; or a HER2 3+ breast cancer cell.

61. The method according to any preceding claim, wherein the construct is selected from v5019, v10000, v7091, v5020 or v6717.

62. The method according to any preceding claim, wherein administering is done by injection or infusion, optionally wherein the administering is intravenous.

63. The method according to any preceding claim, further comprising administering to the subject an additional agent, optionally a chemotherapeutic agent.

64. The method of claim 63, wherein the additional agent is one or more of bleomycin, carboplatin, cisplatin, nab-paclitaxel, docetaxel, doxorubicin, erlotinib, fluorouracil, gemcitabine, methotrexate, pemetrexed, topotecan, vinorelbine, capecitabine, navelbine, or paclitaxel.

65. The method of claim 63, wherein i. the tumor is non-small cell lung cancer, and the additional agent is one or more of cisplatin, carboplatin, paclitaxel, albumin-bound paclitaxel, nab-paclitaxel, docetaxel, gemcitabine, vinorelbine, irinotecan, etoposide, vinblastine, capecitabine, navelbine or pemetrexed; or ii. the tumor is head and neck cancer, and the additional agent is one or more of paclitaxel, carboplatin, doxorubicin or cisplatin; or iii. the tumor is a estrogen and/or progesterone positive breast cancer, and the additional agent is one or more of doxorubicin, epirubicin, paclitaxel, nab-paclitaxel, docetaxel, fluorouracil, cyclophosphamide, carboplatin, letrozole, mifepristone, capecitabine, gemcitabine, vinorelbine or tamoxifen; or iv. the tumor is a pancreatic tumor and the additional agent is nab-paclitaxel, capecitabine, gemcitabine, navelbine or paclitaxel.

66. The method according to any preceding claim, wherein the subject is a human.

67. The method according to any preceding claim, wherein the method comprises inhibiting, reducing or blocking HER2 signaling.

68. The method according to any preceding claim, wherein the method comprises killing or inhibiting the growth of a HER2-expressing tumor cell.

69. The method according to any preceding claim, wherein the subject is administered at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 doses.

70. The method according to any preceding claim, wherein the amount of at least one of the plurality of doses is at least 0.3, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 mg/kg.

71. The method according to any preceding claim, wherein the amount of each of the plurality of doses is at least 0.3, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 mg/kg.

72. The method according to any preceding claim, wherein each dose is administered at least daily, weekly, or monthly.

73. The method according to any preceding claim, wherein each dose is administered at least every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 days.

74. The method according to any preceding claim, wherein treatment continues for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, or 31 days; at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 weeks; or at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 months.

75. The method according to any preceding claim, wherein the mean tumor volume in the subject after receiving at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 doses is less than the mean tumor volume of a control subject receiving an equivalent amount of trastuzumab.

76. The method according to any preceding claim, wherein overall survival of the subject is significantly increased as compared to a control subject receiving an equivalent amount of a non-specific control antibody or as compared to a control subject not receiving treatment; or wherein the growth of tumor is significantly decreased as compared to a control subject receiving an equivalent amount of a non-specific control antibody, as compared to a control subject receiving an equivalent amount of Herceptin, or as compared to a control subject not receiving treatment.

77. The method of claim 76, wherein the significance is measured by a log rank test.

78. The method of claim 76, wherein the p value is less than 0.5, 0.01, or 0.001.

79. The method according to any preceding claim, wherein overall survival of the subject is more significantly increased as compared to a control subject receiving an equivalent amount of trastuzumab.

80. The method of claim 79, wherein the antigen-binding construct p value is less than 0.001 and wherein the trastuzumab p value is greater than 0.001.

81. The method according to any preceding claim, wherein the p value of the significance of the increase relative to the control subject receiving an equivalent amount of a non-specific control antibody is less than the p value of an increase in survival of a second control receiving an equivalent amount of trastuzumab as compared to the control subject receiving an equivalent amount of a non-specific control antibody.

82. The method of claim 81, wherein the antigen-binding construct p value is less than 0.001 and wherein the trastuzumab p value is greater than 0.001.

83. The method according to any preceding claim, wherein overall survival of the subject after receiving a combination of the antigen-binding construct and an additional agent is significantly increased as compared to a control subject receiving an equivalent amount of trastuzumab alone.

84. The method according to any preceding claim, wherein overall survival of the subject is significantly increased as compared to a control subject receiving a lesser amount of trastuzumab.